

Executive Vice President, Directory Services: David Duplay

Vice President, Sales and Marketing: Dikran N. Barsamian Senior Director of Pharmaceutical Sales: Anthony Sorce National Account Manager: Marion Reid, RPh Senior Account Manager: Frank Karkowsky Account Managers: Marjorie A. Jaxel, Denise Kelley, Eileen Sullivan, Suzanne E. Yarrow, RN Director of Trade Sales: Bill Gaffney Senior Director, Marketing and Product Management: Valerie E. Berger Senior Product Manager: Jeffrey D. Dubin Finance Director: Mark S. Ritchin Senior Director, Publishing Sales and Marketing: Michael Bennett Senior Marketing Manager: Jennifer M. Fronzaglia Direct Mail Manager: Lorraine M. Loening Manager of Marketing Analysis: Dina A. Maeder Promotion Manager: Linda Levine Vice President, Regulatory Affairs: Mukesh Mehta, RPh Editorial Director: Lisette Bralow Manager, Professional Data Services: Thomas Fleming, PharmD Manager, Editorial Services: Bette LaGow

Manager, Concise Data Content: Tammy Chernin, RPh

Drug Information Specialists: Greg Tallis, RPh; Min Ko, PharmD Project Editor: Harris Fleming Senior Editor: Lori Murray Production Editor: Gwynned L. Kelly Senior Director, Operations: Brian Holland Director of PDR Operations: Jeffrey D. Schaefer Manager of Production Operations: Thomas Westburgh PDR Production Manager: Joseph F. Rizzo Senior Production Coordinators: Gianna Caradonna, Christina Klinger Production Coordinator: Yasmin Hernández Senior Index Editor: Shannon Reilly Index Editor: Noel Deloughery Format Editor: Michelle S. Guzman Production Associate: Joan K. Akerlind Production Design Supervisor: Adeline Rich. Electronic Publishing Designers: Bryan Dix, Rosalia Sberna, Livio Udina Digital Imaging Coordinator: Michael Labruyere Director of Client Services: Stephanie Struble Fulfillment Manager: Louis J. Bolcik

Copyright © 2004 and published by Thomson PDR at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication
 may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical,
 photocopyring, recording, or otherwise) without the prior written permission of the publisher. Physicians' Desk Reference*, PDR*, PDR Family Guide to Prescription Drugs*, PDR Family Guide to Women's Health and Prescription Drugs*, and PDR* PDR Family Guide to Prescription Drugs*, PDR Family Guide to Women's Health and Prescription Drugs*, and PDR* PMR Family Guide to Prescription Drugs*, PDR* for Nonprescription Drugs and Dietary Supplements, PDR*
 Nurse's Dictionary, PDR* Pharmacopoeia, PDR* for Herbal Medicines, PDR* for Nutritional Supplements, PDR* Medical Dictionary, PDR* Nurse's Drug Handbook, PDR*
 Nurse's Dictionary, PDR* Family Guide to Over-the-Counter Drugs, PDR* Family Guide to Nutritional Supplements, and 'PDR* Earling Guide to Common
 Aliments, PDR* Family Guide to Over-the-Counter Drugs, PDR* Family Guide to Nutritional Supplements, and 'PDR* Electronic Library are trademarks used herein under
 license.

Officers of Thomson Healthcare,: President and Chief Executive Officer: Richard Noble; Chief Financial Officer: Paul Hilger; Executive Vice President, Clinical Trials: Tom Kelly; Executive Vice President, Medical Education: Jeff MacDonald; Executive Vice President, Clinical Solutions: Jeff Reihl; Executive Vice President, Directory Services: David Duplay; Senior Vice President, Business Development: William Gole; Vice President, Human Resources: Pamela M. Bilash; President, Physician's World: Marty Ceamal

ISBN: 1-56363-471-6

Lilly Exhibit 1255, Page 1 of 39

470/ABBOTT

Gengraf-Cont.

Patients generally show some improvement in the clinical manifestations of psoriasis in 2 weeks. Satisfactory control and stabilization of the disease may take 12-16 weeks to and stabilization of the dose-titration clinical trial with Gengraf indicate that an improvement of psoriasis by 75% or more (based on PASI) was achieved in 51% of the patients or more toased on FASJ was achieved in 01% of the patients after 8 weeks and in 79% of the patients after 16 weeks. Treatment should be discontinued if satisfactory response cannot be achieved after 6 weeks at 4 mg/kg/day or the pa-tient's maximum tolerated dose. Once a patient is adequately controlled and appears stable the dose of Gengraf[®] should be lowered, and the patient treated with the lowest dose that maintains an adequate response (this should not necessarily be total clearing of the patient). In clinical tri-als, cyclosporine doses at the lower end of the recommended

als, cyclosporne doses at the lower end of the recommended dosage range were effective in maintaining a satisfactory re-sponse in 60% of the patients. Doses below 2.5 mg/kg/day may also be equally effective. Upon stopping treatment with cyclosporine, relapse will oc-cur in approximately six weeks (50% of the patients) to 16 weeks (75% of the patients). In the majority of patients rebound does not occur after cessation of treatment with cyclosporine. Thirteen cases of transformation of chronic plaque psoriasis to more severe forms of psoriasis have been reported. There were 9 cases of pustular and 4 cases of erythrodermic psoriasis. Long term experience with Gengraf[®] in psoriasis patients is limited and continuous treatment for extended periods greater than one year is not recommended. Alternation with other forms of treatment should be considered in the long term management of pa-

tients with this life long disease. Blood Concentration Monitoring in Transplant Patients: Transplant centers have found blood concentration monitor Transplant centers have found bloot concentration innot-ing of cyclosporine to be an essential component of patient management. Of importance to blood concentration analysis are the type of assay used, the transplanted organ, and other immunosuppressent agents being administered. While no fixed relationship has been established, blood con-centration monitoring may assist in the clinical evaluation of monitoring and exciting the assess. of rejection and toxicity, dose adjustments, and the assess ment of compliance. Various assays have been used to measure blood concentr:

tions of cyclosporine. Older studies using a non-specific say often ited concentrations that were roughly twice those of the specific assays. Therefore, comparison between con-centrations in the published literature and an individual of the specine assays. Interview, comparison between Con-centrations in the published literature and an individual patient concentration using current assays multi be imäde with detailed knowledge of the assay methods employed. Current assay results are also not interchangeable and their use should be guided by their approved labeling. A dis-cussion of the different assay methods is contained in An-rats of Clinical Biochemistry 1994;31:420-446. While sev-eral assays and assay matrices are available, there is a consensus that parent-compound-specific assays correlate best with clinical events. Of these, HPLC is the standard reference, but the monocional antibody RIA's and the mono-clonal antibody PPIA offer sensitivity, reproducibility, and convenience. Most clinicians base their monitoring (1992) contains a broad discussion of evolosporine formationing (1992) contains a broad discussion of evolosporine framacontine-tics and drug monitoring techniques. Blood concentration monitoring is not a replacement for renal function monitor-ing or tissue biopsies. ing or tissue biopsies.

HOW SUPPLIED

Gengraf[®] Capsules (cyclosporine capsules, USP [MODI-FIED)

25 mg³ /48 Packages of 30 unit-dose blisters. (NDC 0074-6463-32).

Oval, white, with two blue stripes, imprinted in blue, the

corporate logo ⊇, 100 mg, and Abbo-Code OT. Packages of 30 unit-dose blisters. (NDC 0074-6479-32).

Store and Dispense: In the original unit-dose container at controlled room temperature 15°-30°C (59°-86°F). (See

*Sandimmune[®] is a registered trademark of Novartis Phar-maceuticals Corporation.

C Abbott Manufactured by: Abbott Laboratories North Chicago, IL 60064, U.S.A. Distributed by: SangStat Medical Corporation Fremont, CA

94555, U.S.A 03-5242-R4

Revised: January, 2003 ABBOTT LABORATORIES

NORTH CHICAGO, IL 60064, U.S.A.

SANGSTAT

The Transplant Company®

Fremont, CA 94555, U.S.A. Shown in Product Identification Guide, page 303

Information will be superseded by supplements and subsequent edition

HUMIRATM (adalimumab)

Rx only

WARNING

WARDING RISK OF INFECTIONS Cases of tuberculosis (frequently disseminated or ex-trapulmonary at clinical presentation) have been ob-served in patients receiving HUMIRA.

Patients should be evaluated for latent tuberculosis in-fection with a tuberculin skin test. Treatment of latent tuberculosis infection should be initiated prior to ther-apy with HUMIRA.

DESCRIPTION

DESCRIPTION HUMIRA (adalimumab) is a recombinant human lgG1 monocional antibody specific for human tumor necrosis fac-tor (TNF). HUMIRA was created using phage display tech-nology resulting in an antibody with human derived heavy and light tchain variable regions and human lgG1: k con-stant regions. HUMIRA is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 aming acids and has a molecular weight of approximately 148 kilodaltons. HUMIRA is supplied in single-use, 1 mL pre-filled glass sy-ringes as a sterile, preservative-free solution for subcutane-ous administration. The solution of HUMIRA is clear and colorless, with a pH of about 5.2. Each syringe delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL HUMIRA con-tains 40 mg adalimumah, 4.93 mg sodium chloride, 0.69 mg monobasis sodium phosphate dihydrate, 1.22 mg dibasic sodium phosphate dihydrate, 0.24 mg sodium chloritate, 1.04 mg citric acid monohydrate, 9.6 mg manitol, 0.8 mg polysorbate. 80 and Water. for Injection, USP. Sodium hy-droxide added as necessary to adjust pH: CLINICAL PHARMACOLOGY

CUNICAL PHARMACOLOGY

General

General Adalimiumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimiumab illso lyses surface TNF expressing cells in *vitro* in the presence of complement. Adalimiumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of rhoumatoid atthirties patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of rhoumatoid ar-thirtis. thritis

inclus. Malimumaly also modulates biological responses that are induced or regulated by TNF, including changes in the lev-els of adhesion molecules responsible for leukocyte migra-tion (ELAM-1, VCAM-1, and ICAM-1 with an IC₅₀ of 1-2 \times tion (EL 10⁻¹⁰M).

Pharmacodynamics After freatment with HUMIRA, a rapid decrease in levels of acute phase reactants of inflammation (C-reactive protein (CRP) and erythrocytle sedimentation rate (ESR)) and serum cytokines (IL-6) was observed compared to baseline in patients with rheumatoid arthritis. Serum levels of ma-trix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodeling responsible for cartilage destruction were also decreased after HUMIRA administration. Pharmacokinetics The maximum serum concentration (C-read the size

The maximum serum concentration (C_{max}) and the time to reach the maximum concentration (C_{max}) and the time to reach the maximum concentration (T_{max}) were 4.7 ± 1.6 µg/mL and 131 ± 56 hours respectively, following a sin-gle 40 mg subcutaneous administration of HUMIRA to healthy adult subjects. The average absolute bioavailability of adalimumab estimated from three studies following a sin-gle 40 mg subcutaneous does was 64%. The pharmacokinet-ics of adalimumab were linear over the dose range of 0.5 to 10.0 mg/kg, following a single intravenous dose. The single dose pharmacokinetics of adalimumab were de-termined in several studies with intravenous doses.

The single dose pharmacokinetics of adalmumb were de-termined in several studies with intravenous doses ranging from 0.25 to 10 mg/kg. The distribution volume (V_{gs}) ranged from 4.7 to 6.0 L. The systemic clearance of adalmumb is approximately 12 mL/hr. The mean terminal half-life was approximately 12 weeks, ranging from 10 to 20 days across studies. Adalmumb concentrations in the synovial fluid from five rheumatoid arthritis patients ranged from 31-96% of those in serum. Adalmumb mean steady-state trough concentrations of

Adalimumab mean steady-state trough concentrations of Adalimumab mean steady-state trough concentrations of approximately 5 uy/mL, were observed without and, with methotrexate. (MTX) respectively. The serum adalimumab-trough levels, at steady increased ap-proximately proportionally with. dogs following: 20, 40 and 80 mg every, other week and every week subcutaneous dos-ing. In long-term studies with dosing more than two, years, there was no evidence of changes in clearance over time. Population pharmacokinetic analyses revealed that there was .a: trend toward. higher-apparent clearance of adalimumab in the presence of anti-adalimumab antibod-ies, and lower, clearance with increasing age in patients

adaimmination in the presence of anti-adaimmination antioxi-ies, and lower, clearance with increasing age in patients aged 40 to >75 years. Minor increases in apparent clearance were also predicted in patients receiving doses lower than the recommended dose and in patients with high rheumatoid factor or CRP concentrations. These increases are not likely to be clinically important.

PHYSICIANS' DESK REFERENCE®

No gender-related pharmacokinetic differences were ob-served after correction for a patient's body weight. Healthy volunteers and patients with rheumatoid arthritis displayed similar adalimumab pharmacokinetics. No pharmacokinetic data are available in patients with he-

patic or renal impairment HUMIRA has not been studied in children.

Drug Interactions MTX reduced adalimumab apparent clearance after single and multiple dosing by 29% and 44% respectively.

CLINICAL STUDIES

CLINICAL STUDIES The efficacy and safety of HUMIRA were, assessed in four randomized, double-blind studies in patients ≥ age 18 with active rheumatoid arthritis diagnosed according to Ameri-can College of Rheumatology (ACR) oriteria. Patients had at least 6 swollen and 9 tender joints. HUMIRA was adminis-tered subcutaneously in combination with MTX (12.5 to 25 mg, Studies L and III) or as monotherapy (Study II), or with other disease-modifying anti-rheumatic drugs (DMARDs) (Study IV). Study I evaluated 271 patients who had failed therapy with at least one but no more than four DMARDs and had inad-equate response to MTX. Doses of 20, 40 or 80 mg of HUMIRA or placebo were given every other week for 24 weeks.

weeks Study II evaluated 544 patients who had failed therapy with at least one DMARD. Doses of placebo, 20 or 40 mg of HUMIRA were given as monotherapy, every other week or weekly for 26 weeks. Study III evaluated 619 patients who had an inadequate re-sponse to MTX. Patients, received placebo, 40. mg of HUMIRA every other, week with placebo injections on alter-nate weeks, or 20 mg of HUMIRA weekly for up to 52 weeks. Study III had an additional primary endpoint at 52 weeks of inhibition of disease progression (as detected by X-ray re-sults). sults).


sults). Study IV assessed safety in 536 patients who were either DMARD-naive or were permitted to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a minimum of 28 days. Exitents were randomized to 40 mg of HUMIRA or placebo every other week for 24 weeks.

The percent of HUMIRA treated patients achieving ACR 20, 50 and 70 responses in Studies II and III are shown in Table

See table 1 at top of next page] The results of Study I were similar to Study III; patients receiving HUMIRA 40 mg every other week in Study I also achieved ACR 20, 50 and 70 response rates of 65%, 52% and

achieved ACR 20, 50 and 70 response rates of 65%, 52% and 24%, respectively, compared, to placebo responses, of 13%, 7% and 3% respectively, at 6 months (p<001). The results of the components of the ACR response criteria for Studies II and III are shown in Table 2, Improvement was seen in all components and was maintained to week 52. [See table 2 at top of next page] The time course of ACR 20 response for Study III is shown in Figure 1. In Study III, 85% of patients with ACR 20 re-sponses at week 24 maintained the response at 52 weeks. The time course of ACR 20 response for Study I and Study II were similar. were similar.

Figure 1: Study III ACR 20 Responses over 52 Weeks



In Study IV, 53% of patients treated with HUMIRA 40 mig every other week plus standard of care had an ACR 20 re-sponse at week 24 compared to 35% on placebo plus stan-dard of care (p<0.001). No unique adverse reactions related to the combination of HUMIRA and other DMARDs were

observed. In all four studies, HUMIRA showed significantly greater improvement than placebo in the disability index of Health Assessment Questionnaire (HAQ) from baseline to the end Assessment Questionnaire (IAAQ) from Datemie to the rate of study, and significantly greater improvement than pla-cebo in the health-outcomes as assessed by The Short Form Health Survey (SF 36). Improvement was seen in both the Physical Component Summary (PCS) and the Mental Com-ponent Summary (MCS).

ponent Summary (MCS). Radiographic Response In Study III, structural joint damage was assessed radio-graphically and expressed as change in Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score, at month 12 compared to baseline At baseline, the median TSS was approximately 55 in the

Lilly Exhibit 1255, Page 2 of 39

R

see coand 40 mg every other week groups. The results are monimum fable 3. HUMIRA/MTX treated patients demon-monimum failing applied progression than patients receiv-ted less radiographic progression than patients receiv-ter a second second second second second second second terms and the second seco

table 3 abovel INDICATIONS AND USAGE

NDICATIONS AND USAGE TOMIRA is indicated for, reducing signs and symptoms and minimize the progression of structural damage in adult pa-cents with moderately to severely active rheumatoid arthri-terits with moderately to severely active rheumatoid arthri-terity in the severely active rheumatoid arthri-terity have had an inadequate response to one or more DYARDS. HUMIRA can be used alone or in combination DYARDS. HUMIRA can be used alone or in combination CONTRAINDICATIONS CONTRAINDICATIONS

CONTRAINDICATIONS HUMIRA should not be administered to patients with known hypersensitivity to HUMIRA or any of its compo-Loontalli WARNINGS

WARNINGS WARNINGS SERIOUS INFECTIONS AND SEPSIS, INCLUDING FÄTALI-TIES. HAVE BEEN REPORTED WITH THE USE OF TNF BLOCKING AGENTS INCLUDING HUMIRA. MANY OF THE BLOCKING AGENTS INCLUDING HUMIRA. MANY OF THE SERIOUS INFECTIONS HAVE OCCURRED IN PATIENTS ON SERIOUS INFECTIONS HAVE OCCURRED IN PATIENTS ON CONCOMITANT IMMUNOSUPPRESSIVE THERAPY THAT, CONCOMITANT IMMUNOSUPPRESSIVE THERAPY THAT, CONCOMITANT IMMUNOSUPPRESSIVE THERAPY THAT, IN ADDITION TO THEIR RHEUMATOID ARTHRITIS, COULD REDISPOSE THEM TO INFECTIONS. TUBERCULOSIS AND INVASIVE OPPORTUNISTIC FUNGAL INFECTIONS HAVE BEEN OBSERVED IN PATIENTS, TREATED, WITH TNF BLOCKING AGENTS INCLUDING THOMIAL TREATMENT WITH HUMIRA SHOULD NOT BE INITIATED IN PATIENTS WITH ACTIVE 'INFECTIONS' INCLUDING CHRONIC OR LOCALIZED INFECTIONS' PATIENTS WHO DEVELOP A NEW INFECTION WHILE UNDERGOING TREAT-MENT WITH HUMIRA SHOULD BE MONITORED CLOSELY ADMINISTRATION OF HUMIRA SHOULD BE DISCONTIN-LUED IF A PATIENT DEVEVLOPS A SERIOUS INFECTION, HYSICIANS SHOULD EXERCISE CAUTION WHEN CON-SIDERING THE USE OF HUMIRA IN PATIENTS WHEN CON-SIDERING THE USE OF HUMIRA IN PATIENTS WHEN CON-SIDERING THE USE OF HUMIRA IN PATIENTS WITH A HIS TORY OF RECURRENT INFECTION OR UNDERLYING CON-DITIONS WHICH MAY PREDISPOSE THEM TO INFECTIONS, OR'PATIENTS WHO HAVE RESIDED IN REGIONS WHERE TUBERCULOSIS' AND HISTOPLASMOSIS' ARE ENDEMIC (See PRECAUTIONS' - Infercions), THE BENEFITS AND RISKS OF HUMIRA TREATMENT SHOULD DE CAREFULY CONSID ERED BEFORE INITIATION OF HUMIRA THERAPY. NEWRIGING EVENTS USE OT THE BIOKCING AGENTS, INCLUDING HUMIRA, HAS BEENT

Neurologic Events Use of TNF blocking agents, including HUMIRA, has been Use of TNF blocking agents, including HUMIRA, has been associated with rare cases of exacerbation of clinical symp-toms and/or radiographic evidence of demyelinating dis-ease. Prescribers should exercise caution in considering the use of HUMIRA in patients with preexisting or recent-onset central nervous system demyelinating disorders. Malignancies

Unapproved by the set of the set Judicius treated with HOMITA had a mgner incidence of Jymphoma than the expected rate in the general population (see ADVERSE REACTIONS Malignancies). While pa-tients with 'rheumatoid arthritis, particularly those with highly active disease, may be at a higher risk (up to several fold) for the development of lymphoma, the role of TNF blockers in the development of malignancy is not known.⁴⁵ PRECAUTIONS

General General Allergic reactions have been observed in approximately 1% of patients receiving HUMIRA, If an anaphylactic reaction or other serious allergic reaction occurs, administration of HUMIRA should be discontinued immediately and appro-

Information in the discontinued immediately and appre-priate therapy initiated. Information to Patients The first injection should be performed under the supervi-sion of a qualified health care professional. If a patient or caregiver is to administer HUMIRA, he/she should be in-Caregiver is to administer HUMIRA, he/she should be in-structed in injection techniques and their ability to inject subcutaneously should be assessed to ensure the proper ad-ministration of HUMIRA (see HUMIRA, PATIENT INFORMA-ION LEAFLET). A puncture-resistant container for disposal of needles and syringes should be used. Patients or caregiv-ers should be instructed in the technique as well as proper syringe and needle disposal, and be cautioned against reuse of these itemis: Tuberculosis

of these items: **Tuberculosis** As observed with other TNF blocking agents, tuberculosis associated with the administration of HUMIRA in clinical trials has been reported (see **WARNINGS**). While cases were observed at all doses, the incidence of tuberculosis re-activations was particularly increased at doses of HUMIRA that were higher than the recommended doses of All patients recovered after standard antimicrobial therapy. No deaths due to tuberculosis occurred during the clinical trials. Before initiation of therapy with HUMIRA, patients should be evaluated for active or latent tuberculosis indection with a tuberculin skin test. If latent infection is diagnosed, ap-propriate prophylaxis in accordance with the Centers for Disease Control and Prevention guidelines⁶ should be insti-tuted. Patients should be instructed to seek medical advice if signal/symptoms (e.g., persistent cough, wasting/weight

if signs/symptoms (e.g., persistent cough, wasting/weight loss, low grade fever) suggestive of a tuberculosis infection

Immunosuppression The possibility exists for TNF blocking agents, including HUMIRA, to affect host defenses against infections and ma-lignancies since TNF mediates inflammation and modulates

Table 1: ACR Responses in Placebo-Controlled Trials (Percent of Patients)

ABBOTT/471

		en for des statementes	5.2°.5	1		
n an Arrana An Arrana Arrana Arrana		Study IJ Monotherapy (26.weeks)		in a sub-	Methotrexa	tudy III ate Combination 1 52 weeks)
Response	Placebo	HUMIRA 40 mg every other	n in Film Age	HUMIRA 40 mg weekly	Placebo/MTX	HUMIRA/MTX 40 mg every other week
a later i	N=110	week N=113	200 197	N=103	N=200	⇔©≉ 1. 6 N≟207 . 1840€.
ACR20	n an Agus (122 - 1995) Al 1913 - Al 1917 - Angus (1917)	an in the second we be the second second second		and a start	1 and all the Arridge	a nda ang ar ar a
Month 6	19%	46%*	6 GS	53%*	30%	63%*
Month 12	NA	NA	ook T	NA	24%	59%*
ACR50	, har the second Araben taken i	Buerren Autourne (* 1995) Neitzen Autourne (* 1996)	ia. s	a ang palwara a	giot befor top of your Brain Flag man (N. 193	1.5 Sector States States and
Month 6	8%	22%*	Дж К	35%*	10%	39%*
Month 12	NALEDB	NA	s.	NA Street		
ACR70	SPACALCOST : SIGNAL AND A STATE	en an traite an traite a	5 5	1 - 1 - Managaran Analasi - Analasi - A		na tratiti en p
Month 6		12%** 13.4	14			21%* : base
Month 12 is X	C yr cNAssofi e.	NA STA		NA. soon	et griften5%. Geo	23%*
	IRA vs. placebo		L		t in the second s	<u>hanna den para</u> Ai handen na 260
	,			solon - Mai		is share beind i seekas

Table 2: Components of ACR Response in Studies II and III. Study II Study III Parameter (median) Placebo N=110 HUMIRA⁴ Placebo/MTX HUMIRA*/MTX N=113 N=200 N=207 Baseline ... Wk 26 Baseline Wk 26 Baseline Wk 24 Baseline Wk 24 Number of tender joints (0-68) 35 26 31 16* 26 15 -24 8* Number of swollen joints (0-66) Physician global assessment^b Patient global assessment^b 19 16 10* 17 11 18 6.5 7.0 7.5 7.3 6.1 3.7* 4.5* 2.0* 6:6 7.5 6.3 5.4 3.5 6.3 - 3.9 5 2 2.0* 2.0* 2.1* 0.8* 0.4* 6.0 1.5 5.8 Pain $6.1 \\ 1.9$ 73 4.1* 3.8 1.3 Disability index (HAQ)^c CRP (mg/dL) 2.0 1.9 4.6 3.9 4.3 1.8* 1.0 0.9 1.0

^a 40 mg HUMIRA administered every other week
^b Visual analogue scale; 0 = best, 10 = worst
^c Disability Index of the Health Assessment Questionnaire²; 0 = best, 3 = worst, measures the patient's ability to perform the following: (ress/grom, arise, eat, walk, reach, irrip, maintain hygiene, and maintain daily activity
^{*} p<0.001, HUMIRA vs. placebo, based on mean change from baseline:

1	Table 3: Radiographic N	lean Changes Over 12	Months in Study III	an ann ann an
	Placebo/MTX ;	other week	Interval*)	P-value**
Total Sharp score	2.7	0.1		<0.001
Erosion score	1.6	0.0	1.6 (0.9, 2.2)	<0.001
JSN score	1.0	·	0.9 (0.3, 1.4)	0.002

s for the differences in change scores between MTX and HUMIRA o ki z u luk Tamu Akging am **Based on rank analysis

cellular immune responses. In a study of 64 patients with rheumatoid arthritis treated with HUMIRA, there was no evidence of depression of delayed-type hypersensitivity, de-pression of immunoglobulit levels, or change in enumera-tion of effector T- and B-cells and NK-cells, monocyte/mac-rophages, and neutrophils. The impact of treatment with HUMIRA on the development and course of malignancies, as well as active and/or chronic infections is not fully under-stood (see WARNINGS, ADVERSE REACTIONS, Infec-tions and Malignancies). The safety and efficacy of HUMIRA in patients with immunosuppression have not been evaluated. been evaluated.

Immunizations

Immunizations No data are available on the effects of vaccination in pa-tients receiving HUMIRA. Live vaccines should not be given concurrently with HUMIRA. No data are, available on the secondary transmission, of infection by live vaccines in pa-tients receiving HUMIRA. Autoimmunity

Autoimmunity Treatment with HUMIRA may result in the formation of au-toantibodies and, rarely, in the development of a lupus-like syndrome. If a patient develops symptoms suggestive of a lupus-like syndrome.following treatment with HUMIRA, treatment should be discontinued (see ADVERSE REAC-TIONS, Autoantibodies).

TIONS, Autoantibodies). Drug Interactions HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX (see CLINICAL PHARMACOL-OGY: Drug Interactions). The data do not suggest the need for dose adjustment of either HUMIRA or MTX. Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies of HUMIRA have not been con-ducted to evaluate the carcinogenic potential or its effect on

fertility. No clastogenic or mutagenic effects of HUMIRA were observed in the *in vivo* mouse micronucleus test or the Stilmonella-Escherichia coli (Ames) assay, respectively.

Pregnancy Pregnancy Category B—An embryo-fetal perinatal develop-Pregnancy Category B—An embryo-letal perinatal develop-ment toxicity study has been performed in cyromolgus inon-keys at dosages up to 100 mg/kg (266 times human AUC when given 40 mg subcutaneous with MTX every week or 373 times human AUC when given 40 mg subcutaneous without MTX) and has revealed no evidence of harm to the fortune due to additionate marks. fetuses due to adalimumab. There are, however, no ade quate and well-controlled studies in pregnant women. Be-cause animal réproduction and developmental studies are not always predictive of human résponse, HUMIRA (adalimumab) should be used during pregnancy only if

clearly needed. Nursing Mothers It is not known whether adalimumab is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for serious adverse reac-tions in nursing infants from HUMIRA, a decision should be made whether to discart into anymics or to discritions able made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the

mother. Pediatric Use Safety and effectiveness of HUMIRA in pediatric patients have not been established. Geriatric Use

A total of 519 patients 65 years of age and older, including 107 patients 75 years and older, received HUMIRA in clin-

Continued on next page

Consult 2004 PDR[®] supplements and future editions for revisions

Lilly Exhibit 1255, Page 3 of 39

Humira—Cont.	The data sults we
ical studies. No overall difference in effectiven served between these subjects and younger su frequency of serious infection and maligna	abjects. The incidence

HUMIRA treated subjects over age 65 was higher than for those under age 65. Because there is a higher incidence of infections and malignancies in the elderly population in general, caution should be used when treating the elderly. ADVERSE REACTIONS

neral

The most serious adverse reactions were (see WARNINGS): Serious Infections

- Neurologic Events
- Malignancies

The most common adverse reaction with HUMIRA was in-jection site reactions. In placebo-controlled trials, 20% of pa-tients treated with HUMIRA developed injection site reactions (erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of patients receiving placebo. Most injection site reactions were described as mild and

Most injection site reactions were described as mild and generally did not necessitate drug discontinuation. The proportion of patients who discontinued treatment due to adverse events during the double-blind, placebo-con-trolled portion of Studies I, II, III and IV was 7% for pa-tients taking HUMIRA and 4% for placebo-treated patients. The most common adverse events leading to discontinua-tion of HUMIRA-were clinical flare reaction (0.7%), rash-(0.3%) and pneumonia (0.3%). Because clinical trials are conducted under widely verying

Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in a broader patient population in clinical practice. Infections

In placebo-controlled trials, the rate of infection was 1 per patient year in the HUMIRA treated patients and 0.9 per patient year in the HUMIRA treated, patients and 0.9 per-patient year in the placebo-treated patients. The infections consisted primarily of upper respiratory tract infections, bronchitis and urinary tract infections. Most patients con-tinued on HUMIRA after the infection resolved. The inci-dence of serious infections was 0.04 per patient year in HUMIRA treated patients and 0.02 per patient year in placebo-treated patients. Serious infections observed in-cluded pneumonia, septic arthritis, prosthetic and post-surgical infections, erysipelas, cellultis, diverticulitis, and pyelonephritis (see WARNINGS). Thirteen cases of tuberculosis, including miliary lymphatic

Thirteen cases of tuberculosis, including miliary, lymphatic, peritoneal, and pulmonary were reported in clinical trials. Most of the cases of tuberculosis occurred within the first eight months after initiation of therapy and may reflect re-crudescence of latent disease. Six cases of invasive opportunistic infections caused by histoplasma, aspergillus, and no-cardia were also reported in clinical trials (see WARNINGS).

Malignancies

Among 2468 rheumatoid arthritis patients treated in clinical trials with HUMIRA for a median of 24 months, 45 milliganacies of various types were observed, including 10 patients with lymphoma. The Standardized Incidence Ratio (SIR) (ratio of observed rate to age-adjusted expected frequency in the general population) for malignancies was 1.0 (95% CI, 0.7, 1.3) and for lymphomas was 5.4 (95% CI, 2.6, 10.0). An increase of up to several fold in the rate of lymphomas has been reported in the rheumatoid arthritis patient population⁴, and we be further increased in patients with more severe disease activity⁹ (see WARNINGS-Malgnancies). The other malignancies observed during use of HUMIRA were breast, colon-rectum, uterine-cervical, prostate, melanoma, gallbladder-bile ducts, and other carcinomas. Among 2468 rheumatoid arthritis patients treated in clinimas.

Autoantibodies

In the controlled trials, 12% of patients treated with HUMIRA and 7% of placebo-treated patients that had neg-Alter have have been apprecised parameter parameter for the first at week 24. One patient out of 2334 treated with HUMIRA devel-oped clinical signs suggestive of new-moset hupus-like syn-drome. The patient improved following discontinuation of therapy. No patients developed lupus nephritis or central nervous system symptoms. The impact of long-term treat-ment with HUMIRA on the development of autoimmune disease is unknown. diseases is unknown Immunogenicity

Patients in Studies I, II, and III were tested at multiple time points for antibodies to adalimumab during the 6 to 12 month period. Approximately 5% (58 of 1,062) of adult rheu-matoid arthritis patients receiving HUMIRA developed low-titer antibodies to adalimumab at least once during treatther antibodies to adalimumab at least once during treat-ment, which were neutralizing in *vitro*. Patients treated with concomitant MTX had a lower rate of antibody devel-opment than patients on HUMIRA monotherapy (1% versus 12%). No apparent correlation of antibody development to adverse events was observed. With monotherapy, patients receiving every other week dosing may develop antibodies more frequently than those receiving weekly dosing. In pa-tients receiving the recommended dosage of 40 mg every other week as monotherapy, the ACR 20 response was lower among antibody-positive patients than among antibody. among antibody-positive patients than among antibody-negative patients. The long-term immunogenicity of HUMIRA is unknown.

Information will be superseded by supplements and subsequent editions

a reflect the percentage of patients whose test rea renext the proteinage of patients whose the re considered positive for antibodies to adalimumab LISA assay, and are highly dependent on the sensi-ad specificity of the assay. Additionally the observed e of antibody positivity in an assay may be influ-y several factors including sample handling, timing of sample collection, concomitant medications, and underly ing disease. For these reasons, comparison of the incidence of antibodies to adalimumab with the incidence of antibodies to other products may be misleading.

ies to other products may be misleading. Other Adverse Reactions The data described below reflect exposure to HUMIRA in 2334 patients, including 2073 exposed for 6 months, 1497 exposed for greater than one year and 1380 in adequate and well-controlled studies (Studies I, II, III, and IV). HUMIRA was studied primarily in placebo-controlled trials and in long-term follow up studies for up to 36 months duration. The population had a mean age of 54 years, 77% were fo-male, 91% were Caucasian and had moderately to severely active theumatoid arthritis. Most nations received 40 mp

active rheumatoid arthritis. Most patients received 40 mg HUMIRA every other week. Table 4 summarizes events reported at a rate of at least 5% in patients treated with HUMIRA 40 mg every other week compared to placebo and with an incidence higher than pla-cebo. Adverse event rates in patients treated with HUMIRA 0 mo weakly were similar to rates in patients treated with HUMIRA 40 mg weekly were similar to rates in patients treated with HUMIRA 40 mg every other week.

Table 4: Adverse Events Reported by ≥5% of Patients Treated with HUMIRA During Placebo-Controlled Period of Rheumatoid Arthritis Studies

a & Çompinistina (A A)	HUMIRA 40 mg subcutaneous Every Other	Placebo		
ortical/1 ortical	Week (N=705)	(N=690)		
Adverse Event				
(Preferred Term)	Percentage	Percentage		
01	(id - j) and i	indens la tota la la		
Respiratory Upper		itari lafida nogli O viziri vitteza		
respiratory infection	17	13		
Sinusitis				
Flu syndrome	100 017-0000000	9		
Gastrointestinal	01 (Jaci) - (Jaci)	8		
Nausea	9	8		
Abdominal pain	7	4		
Laboratory Tests*	diversity (1)	10211110		
Laboratory test				
abnormal	8	7		
Hypercholesterolemia	6	4		
Hyperlipidemia	7	5		
Hematuria Alkaline phosphatase	5	4		
increased .	5	3		
Other		THE REAL		
Injection site		di seri carici		
pain	12	- 12		
Headache	12	8		
Rash	12	6		
Accidental	-			
	10	8		
Injection site		alana na himpi		
reaction**	8	Similar 1		
Back pain	6	4		
Urinary tract				
infection	8	5		
Hypertension	5	3		

* Laboratory test abnormalities were reported as adverse events in European trials ** Does not include erythema and/or itching, hemorrhage, prince are multica.

pain or swelling

Other Adverse Events

Other infrequent serious adverse events occurring at an in-cidence of less than 5% in patients treated with HUMIRA

Body As A Whole: Fever, infection, pain in extremity, pel-vic pain, sepsis, surgery, thorax pain, tuberculosis reactivated

Cardiovascular System: Arrhythmia, atrial fibrillation, cardiovascular disorder, chest pain, congestive heart failure, coronary artery disorder, heart arrest, hypertensive encephcoronary artery disorder, heart arrest, hypertensive enceph-alopathy, myocardial infarct, palpitation, pericardial effu-sion, pericarditis, syncope, tachycardia, vascular disorder Collagen Disorder: Lupus erythematosus syndrome Digestive System: Cholecystitis, cholelithiasis, esophagi-tis, gastroenteritis, gastrointestinal disorder; gastrointesti-nal hemorrhage, hepatic necrosis, vomiting Endocrine System: Parathyroid disorder Hemic And Lymphistic System: Agranulocytosis, granulo-cytopenia, leukopenia, lymphoma like reaction, pancytope-nia, nolverthemia

Metabolic And Nutritional Disorders: Dehydration, heal-ing abnormal, ketosis, paraproteinemia, peripheral edema

Musculo—Skeletal System: Arthritis, bone disorder, bone fracture (not spontaneous), bone necrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, tendon disorder

Neoplasia: Adenoma, carcinomas such as breast, gastroin-testinal, skin, urogenital, and others; lymphoma, and melaoma

noma. Nervous System: Confusion, multiple sclerosis, paresthe-sia, subdural hematoma, tremor Respiratory System: Asthma, bronchospasm, dyspnea, lung disorder, lung function decreased, pleural effusion,

Skin And Appendages: Cellulitis, erysipelas, herpes

zoster Special Senses: Cataract Thrombosis: Thrombosis leg Urogenital System: Cystitis, kidney calculus, menstrual disorder, pyelonephritis OVERDOSAGE

The maximum tolerated dose of HUMIRA has not been es-tablished in humans. Multiple doses up to 10 mg/kg have been administered to patients in clinical trials without evi-dence of dose-limiting toxicities. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately.

DOSAGE AND ADMINISTRATION

The recommended dose of HUMIRA for adult patients with rheumatoid arthritis is 40 mg administered every other week as a subcutaneous injection. MTX, glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics or other DMARDs may be continued during treatment with HUMIRA. Some patients not taking concomitant MTX may derive additional benefit from in-creasing the dosing frequency of HUMIRA to 40 mg every

HUMIRA is intended for use under the guidance and super-vision of a physician. Patients may self-inject HUMIRA if Value of a physician rate that it is appropriate and with medical follow-up, as necessary, after proper training in in-jection technique. The solution in the syringe should be carefully inspected vi-

sually for particulate matter and discoloration prior to sub-cutaneous administration. If particulates and discolorations are noted, the product should not be used. HUMIRA does

are noted, us preservatives; therefore, unused portions of drug remaining from the syringe should be discarded. NOTE: The needle cover of the syringe contains dry rubber (latex), which should not be handled by persons sensitive to this substance.

Patients using the pre-filled syringes should be instructed to inject the full amount in the syringe (0.8 mL), which pro-There is using the pre-lines symples should be instructed to inject the full amount in the symple (0.8 mL), which pro-vides 40 mg of HUMIRA, according to the directions pro-vided in the Patient Information Leaflet. Injection sites should be rotated and injections should never be given into areas where the skin is tender, bruised, red or hard (see PATIENT INFORMATION LEAFLET). Instructions for Activation the Neadle Scient Patient. Con-

Instructions For Activating the Needle Stick Device: Cartons for institutional use contain a syringe and needle with a needle protection device (see HOW SUPPLIED). To activate the needle stick protection device after injection, hold the syringe in one hand and, with the other hand, slide the outer protective shield over the exposed needle until it locks into place

into place. Storage and Stability Do not use beyond the expiration date on the container. HUMIRA must be refrigerated at 2-8° C (36-46° F). DO NOT FREEZE Protect the pre-filled syringe from exposure to light. Store in original carton until time of administra-

HOW SUPPLIED

HUMIRATM (adalimumab) is supplied in pre-filled syringes as a preservative-free, sterile solution for subcutaneous ad-ministration. The following packaging configurations are available:

Patient Use Syringe Carton

HumiRA is dispensed in a carton containing two alcohol preps and two dose trays. Each dose tray consists of a sin-gle-use, 1 mL pre-filled glass syringe with a fixed 27 gauge % inch needle, providing 40 mg (0.8 mL) of HUMIRA. The NDC number is 0074-3799-02.

Institutional Use Syringe Carton Each carton contains two alcohol preps and one tray. Each dose tray consists of a single use, 1 mL pre-filled glass sy-ringe with a fixed 27 gauge ½ inch needle (with a needle stick protection device) providing 40 mg (0.8 mL) of HUMIRA. The NDC number is 0074-3799-01.

REFERENCES

- 1. Arnett FC, Edworthy SM, Bloch DA, et. al. The American Rheumatology Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum 1988; 31:315–24.

1988; 31:315-24.
 Ramey DR, Fries JF, Singh G. The Health Assessment Questionaire 1995 - Status and Review. In: Spilker B, ed. "Quality of Life and Pharmacoeconomics in Clinical Trials." 2^{ed} ed. Philadelphia, PA. Lippinott-Raven 1996.
 Ware JE, Gandek B. Overview of the SF-36 Health Sur-vey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51(11):903-12.
 Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid Arthritis and Cancer Risk, European Journal of Cancer 1996; 32A (10): 1753-1757.

Lilly Exhibit 1255, Page 4 of 39

5. Baecklund E, Ekbom A, Sparen P, et al. Disease Activity and Risk of Lymphoma in Patients With Rheumatoid Arthritis: Nested Case-Control Study, BMJ 1998; 317; 180-181

6. Centers for Disease Control and Prevention. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. MMWR 2000; 49(No. RR-6):26-38.

Revised: January, 2003 ABBOTT LABORATORIES

NORTH CHICAGO, IL 60064, U.S.A. U.S. Govt. Lic. No. 0043

HUMIRAT (adalimumab)

(adalimumab) Patient Information Read this leaflet carefully before you start taking HUMIRA (hu-mare-ah). You, should also read this leaflet each time you get your prescription refilled, in case something has changed. The information in this leaflet does not take the placebo of talking with your doctor before you start taking this medicine and at check ups. Talk to your doctor if you have any questions about your treatment with HUMIRA. What is HUMIRA? have any questions What is HUMIRA?

What is HUMIRA? HUMIRA is a medicine that is used in people with moderate to severe rheumatoid arthritis (RA). RA is an inflammatory disease of the joints. People with RA are usually given other medicines for their disease before they are given HUMIRA. HUMIRA is for people with RA who have not responded well enough to these other medicines.

How does HUMIRA work?

HUMIRA is a medicine called a *TNF blocker*, that is a type of protein that blocks the action of a substance your body makes called TNF-alpha. TNF-alpha (tumor necrosis factor alpha) is made by your body's immune system. People with RA have too much of it in their bodies. The extra TNF-alpha in your body can attack normal healthy body tissues and cause inflammation especially in the tissues in your bones, cartilage, and joints. HUMIRA helps reduce the signs and symptoms of RA (such as pain and swollen joints) and may

symptoms of RA (such as pain and swollen joints) and may help prevent further damage to your bones and joints. HUMIRA can block the damage that too much TNF-alpha can cause, and it can also lower your body's ability to fight infections. Taking HUMIRA can make your more prone to getting infections or make any infection you have worse. Who should not take HUMIRA?

Violo should not take HUMIRA? You should not take HUMIRA if you have an allergy to any of the ingredients in HUMIRA (sodium phosphate, sodium citrate, citric acid, mannitol, and polysorbate 80). The nee-dle cover on the pre-filled syringe contains dry natural rub-ber. Tell your doctor if you have any allergies to rubber or later

- Before you start taking HUMIRA you should tell your
- doctor if you have or have had any of the following:
 Any kind of infection including an infection that is in only one place in your body (such as an open cut or sore), or an infection that is in your whole body (such as the flu). Hav-ing an infection could put you at risk for serious side ef-fects from HUMIRA. If you are unsure, please ask your doctor
- doctor.
 A history of infections that keep coming back or other conditions that might increase your risk of infections.
 If you have ever had tuberculosis (TB), or if you have been in close contact with someone who has had tuberculosis. If you develop any of the symptoms of tuberculosis (a dry cough that doesn't go away, weight loss, fever, night sweats) call your doctor right away. Your doctor will need to examine you for TB and perform a skin test.
 If you errience any numbers or tineling or have or
- . If you experience any numbness or tingling or have or have ever had a disease that affects your nervous system like multiple sclerosis. • If you are scheduled to have major surgery.

 If you are scheduled to be vaccinated for anything. If you are not sure or have any questions about any of this

information ask your doctor

What important information do I need to know about side effects with HUMIRA?

Any medicine can have side effects. Like all medicines that affect your immune system, HUMIRA can cause serious side effects. The possible serious side effects include:

Serious infections: There have been rare cases where pa-tients taking HUMIRA or other TNF-blocking agents have developed serious infections, including tuberculosis (TB) and infections caused by bacteria or fungi. Some patients have died when the bacteria that cause infections have

have died when the bacteria that cause infections have spread throughout their body (sepsis). Nervous system diseases: There have been rare cases of disorders that affect the nervous system of people taking HUMIRA or other TNF blockers. Signs that you could be experiencing a problem affecting your nervous system in-clude: numbness or tingling, problems with your vision, weakness in your legs and dizziness. <u>Malignancies</u>: There have been very rare cases of certain kinds of cancer in patients taking HUMIRA or other TNF blockers. People with more serious RA that have had the disease for a long time may have a higher than average risk of getting, a kind of cancer that affects the lymph system, called lymphoma. If you take HUMIRA or other TNF block-ers, your risk may increase.

called lymphoma. If you take HUMIRA or other TNF block-ers, your risk may increase. <u>Lupus-like symptoms</u>: Some patients have developed lu-pus-like symptoms that got better after their treatment was stopped. If you have chest pains that do not go away, short-ness of breath, joint pain or a rash on your cheeks or arms that is sensitive to the sun, call your doctor right away. Your doctor may decide to stop your treatment. Allergic reactions: If you develop a severe rash, swollen face or difficulty breathing while taking HUMIRA, call your doctor right away. What are the other more common side effects with HUMIRA?

Many patients experience a reaction where the injection was given. These reactions are usually mild and include redness, rash, swelling, itching or bruising. Usually, the rash will go away within a few days. If the skin around the area where you injected HUMIRA still hurts or is swollen, try using a towel soaked with cold water on the injection site. If you have pain, redness or swelling around the injec-tion site that doesn't go away within a few days or gets worse, call your doctor right away. Other side effects are upper respiratory infections (sinus infections), headache and

nausea. Can I take HUMIRA if I am pregnant or breast-feeding? HUMIRA has not been studied in pregnant women or nursi-ing mothers, so we don't know what the effects are on preg-nant women or nursing babies. You should tell your doctor if you are pregnant, become pregnant or are thinking about becoming pregnant. Can I take HUMIRA If I am taking other medicines for my

Can I take HUMIRA II I am taking other medicines for my RA or other conditions? Yes, you can take other medicines provided your doctor has prescribed them, or has told you it is ok to take them while you are taking HUMIRA. It is important that you tell your doctor about any other medicines you are taking for other conditions (for example, high blood pressure medicine) be-fore you start taking HUMIRA. You should also tell your doctor about any over-the-counter

You should also tell your doctor about any over-the-counter drugs, herbal medicines and vitamin and mineral supple You should not take HUMIRA with other TNF blockers. If

You have questions, ask your doctor. How do I take HUMIRA? You take HUMIRA by giving yourself an injection under the

Tou take HUMIRA by giving yourseit an injection under the skin once every other week, or more frequently (severy week) if your doctor tells you to. If you accidentally take more HUMIRA than you were told to take, you should call your doctor. Make sure you have been shown how to inject HUMIRA before you do it yourself. You can call your doctor or the HUMIRA Patient Resource Center at 1-800 4HUMIRA (448-6472) if you have any questions about giv-ing vaurself an injection. Someone we throw ensu leab hole ing yourself an injection. Someone you know can also help you with your injection. Remember to take this medicine just as your doctor has told you and do not miss any doses.

Use as your docur has one you and up not have any upset. What should i do if i miss a dose of HUMIRA? If you forgot to take HUMIRA when you are supposed to, inject the next dose right away. Then, take your next dose when your next scheduled dose is due. This will put you schedule back

Is one time better than another for taking HUMIRA?

Always follow your doctor's instructions about when and how often to take HUMIRA. To help you remember when to take HUMIRA, you can mark your calendar ahead of time with the stickers provided in the back of the patient information booklet. For other information and ideas you can en-roll in a patient support program by calling the HUMIRA Patient Resource Center at 1-800-4HUMIRA (448-6472). What do I need to do to prepare and give an injection of HUMIRA?

1) Setting up for an injection

Find a clean flat working surface. Remove one dose tray containing a pre-filled syringe of HUMIRA from the refrigerator. Do not use a pre-filled syringe that is frozen or if it has been left in direct sunlight. You will need the following items for each dose: • A dose tray containing a pre-filled syringe of HUMIRA

- with a fixed needle
- 1 alcohol prep The card with the drawing of the pre-filled syringe




If you do not have all of the pieces you need to give yourself an injection, call your pharmacist. Use only the items proan injection, call your pharmacist. Use only the items pro-vided in the box your HUMIRA comes in. • Check and make sure the name HUMIRA appears on the dose tray and pre-filled syringe label.

- Check the expiration date on the dose tray label and pre-filled syringe to make sure the date has not passed. Do not use a pre-filled syringe if the date has passed.
- Make sure the liquid in the pre-filled syringe is clear and colorless. Do not use a pre-filled syringe if the liquid is cloudy or discolored or has flakes or particles in it.
- Have a puncture proof container nearby for disposing of used needles and syringes. FOR YOUR PROTECTION, IT IS IMPORTANT THAT YOU FOLLOW THESE INSTRUCTIONS.

- Choosing and preparing an injection site
 Wash your hands thoroughly
 Choose a site on the front of your thighs or your abdomen. If you choose your abdomen, you should avoid the area 2 es around your navel.

- Choose a different site each time you give yourself an injection. Each new injection should be given at least one inch from a site you used before. Do NOT inject into areas where the skin is tender, bruised, red or hard or
- where you have scars or stretch marks. You may find it helpful to keep notes on the location of previous injections



- Wipe the site where HUMIRA is to be injected with an alcohol prep, using a circular motion. Do NOT touch this
- area again until you are ready to inject. w to prepare your HUMIRA dose for inju Pre-filled Syringe
- Hold the syringe upright with the needle facing down. Take the card with the drawing of the syringe and hold it next to the real syringe so the drawing and the real sy-ringe are side-by-side. Check to make sure that the amount of liquid in the syringe is the same or very close to the 0.8 mL arrow shown on the card with the drawing of the pre-filled syringe. The top of the liquid may be curved as shown in the drawing. The 0.8 mL arrow should point near the middle of the curved liquid. If the real syringe does not have the correct amount of liquid. DO NOT USE
- THAT SYRINGE. Call your pharmacist. Remove the needle cover taking care not to touch the needle with your fingers or allow it to touch any surface.
- Turn the syringe so the needle is facing up and slowly push the plunger in to push the air in the syringe out through the needle. If a small drop of liquid comes out of the needle that is ok.
- Wine House is ok.
 4) Injecting HUMIRA
 With your other hand, gently pinch the cleaned area of skin and hold it firmly. Hold the syringe like a pencil at about a 45° angle to the skin.



With a quick, short, "dart-like" motion, push the needle into the skin.
After the needle is in, let go of the skin. Pull back slightly

- on the plunger, if blood appears in the syringe it means that you have entered a blood vessel. Do not inject HUMIRA. Withdraw the needle and repeat the steps to choose and clean a new injection site. DO NOT use the same syringe; discard it in your puncture proof container. If no blood appears, slowly push the plunger all the way in until all of the HUMIRA is injected.
- When the syringe is empty, remove the needle from the skin keeping it at the same angle it was when it was inserted.
- · Press a cotton ball over the injection site and hold it for 10 seconds. Do NOT rub the injection site. If you have slight bleeding, do not be alarmed.
- Dispose of the syringe immediately.

5) Disposing of syringes and needles You should always check with your healthcare provider for instructions on how to properly dispose of used needles and syringes. You should follow any special state or local laws regarding the proper disposal of needles and syringes. DO NOT throw the needle or syringe in the household trash or recycle

- recycle.
 Place the used needles and syringes in a container made specially for disposing of used syringes and needles (called a "Sharps" container), or a hard plastic container with a strew-on cap or metal container with a plastic lid labeled "Used Syringes". Do not use glass or clear plastic container is the stress of the s containers.
- Always keep the container out of the reach of children When the container is about two-thirds full, tape the cap or lid down so it does not come off and dispose of it as Instructed by your doctor, nurse or pharmacist. DO NOT THROW THE CONTAINER IN THE HOUSEHOLD TRASH OR RECYCLE.
- TRASH OR RECYCLE. Used preps may be placed in the trash, unless otherwise instructed by your doctor, nurse or pharmacist. The dose tray and cover may be recycled. HOW DO I STORE HUMIRA?

Store at 2°C-8°C/36-46°F (in a refrigerator) in the original container until it is used. Protect from light. DO NOT FREEZE HUMIRA. Refrigerated HUMIRA remains stable until the expiration date printed on the pre-filled syringe. If you need to take it with you, such as when traveling, store it in a cool carrier with an ice pack and protect it from light.

Continued on next page

Consult 2004 PDR® supplements and future editions for revisions

Lilly Exhibit 1255, Page 5 of 39

Humira-Cont.

Keep HUMIRA, injection supplies, and all other medicines out of the reach of children. Revised: January, 2003 Ref: 03-5236-R2 ABBOTT LABORATORIES

NORTH CHICAGO, IL 60064, U.S.A. Shown in Product Identification Guide, page 303


R

HYTRIN®

(terazosin hydrochloride) Capsules

DESCRIPTION

HYTRIN (terazosin hydrochloride), an alpha-1-selective adrenoeptor blocking agent, is a quinazoline derivative represented by the following chemical name and structural formula: (S)-Piperazine, 1-(4-amino-6/7-dimethoxy-2-quinazoliny))-4-((tetra-hydro-2-furany))carbony]², monohydrochloride, dihydrate.



Terazosin hydrochloride is a white, crystalline substance, The account hydrocumonice is a white, trystainte substainte, freely soluble in water and isotonic saline and has a molec-ular: weight of 459.93. HYTRIN capsules' (terazosin hydrochloride čapsules) for oral ingestion are supplied in four dosage strengths containing terazosin hydrochloride equivalent to I mg, 2 mg, 5 img, or 10 mg of terazosin Inactive Ingredients: (1996) for a line are added and the hydrochloride support of the support of the support of the support of the support in metagement of the support of

equivalent to 1 mg, 2 mg, 5 mg, or 10 mg of terazósin Inactive Ingredients: " Itanciue Ingredients: " Itanium dioxide, and vanillin. 2 mg capsules: B&C yellow No. 40, gelatin, glycerin, meth-ylparaben, mineral oil, polyethylene glycol, povidone, pro-pylparaben, titanium dioxide, and vanillin. 5 mg capsules: D&C feld No. 28, FD&C red No. 40, gelatin, glycerin, methylparaben, mineral oil, polyethylene glycol, povidone, propylparaben, titanium dioxide, and vanillin. 10 mg capsules: D&C bule No. 1, gelatin, glycerin, meth-ylparaben, mineral oil, polyethylene glycol, povidone, pro-pylparaben, titanium dioxide, and vanillin.

CLINICAL PHARMACOLOGY

Pharmacodynamics: A. Benign Prostatic Hyperplasia (BPH)... The symptoms associated with BPH are related to bladder outlet obstruction, which is comprised of two underlying components: a static component and a dynamic component. The static component is a consequence of an increase in prostatic size. Over time, the prostate will continue to en-large. However, clinical studies have demonstrated that the size of the prostate does not correlate with the severity of BPH symmotoms or the deeree of universition. The large. However, dinical studies have demonstrated that the size of the prostate does not correlate with the severity of BPH symptoms or the degree of urinary obstruction. The dynamic component is a function of an increase in smooth muscle tone in the prostate and 'bladder neity. Reading to constriction of the bladder outlet. Smooth muscle tone is mediated by sympathetic nervous stimulation of alpha-1 adrenoceptors, which are 'abundant' in the prostate, pro-static capsule and bladder neck. The reduction in symptoms and improvement in urine flow rates following idministra-tion of terizosin' is related to relaxation of smooth muscle produced by blockade of alpha-1 adrenoceptors in the blad-der neck and prostate. Because there are relatively few alpha-1 adrenoceptors in the bladder body terazosin' is able to reduce the bladder outlet obstruction without affecting bladder contractifity. Terizosin has been studied in 1222 men with symptomatic BPH. In three placebo-controlled studies, symptom evalua-

BPH. In three placebo-controlled studies, symptom evalua-tion and uroflowmetric measurements were performed ap-


proximately 24 hours following dosing. Symptoms were quantified using the Boyarsky Index. The questionnaire evaluated both obstructive (hesitancy, intermittency, termi-nal dribbling, impairment of size and force of stream, sen-sation of incomplete bladder emptying) and irritative (noc-turia, daytime frequency, urgency, dysuria) symptoms by rating each of the 9 symptoms from '0-3, for a total score of 27 points. Results from these studies indicated that trearzenis ratificially isoficient information montenation and peak urine flow rates over placebo as follows: [See table below]

In all three studies, both symptom scores and peak urine flow rates showed statistically significant improvement from baseline in patients treated with terazosin from week 2 (or the first clinic visit) and throughout the study duration.

Analysis of the effect of terazosin on individual urinary symptoms demonstrated that compared to placebo, terazosin'significantly improved the symptoms of hesitancy, intermittency, impairment in size and force of urinary stream, sensation of incomplete emptying, terminal drib-

bling, daytime frequency and noctura. Global assessments of overall urinary function and symp-toms were also performed by investigators who were blinded to patient treatment assignment. In studies 1 and 3, patients treated with terazosin had a significantly ($p \le 0.001$) greater overall improvement compared to pla-cebo treated patients.

short term study (Study 1), patients were randomized to either 2, 5 or 10 mg of terazosin or placebo. Patients ran-domized to the 10 mg group achieved a statistically signif-cant response in both symptoms and peak flow rate com-pared to placebo (Figure 1).



In a long-term, open-label, non-placebo controlled clinical trial, 181 men were followed for 2 years and 65 of these men were followed for 30 months. The effect of theracosin on uri-nary symptom scores and peak flow rates was maintained throughout the study düration (Eigures 2 and 3). A See figure 2 at top of next column) a start and [See figure 4 at top of next column] where a start is the figure 3 at top of next column] In this long-term trial, both symptom scores and peak uri-nary flow rates showed statistically significant improve-ment suggesting a relaxation of smooth muscle cells. Although blockade of alpha-1 adrenocaptors also lowers

blood pressure in byperfensive patients with increased pe-ripheral vascular resistance, terazisin treatment of normo-tensive men with BPH did not result in a clinically signifi-cant blood pressure lowering effect.

Symptom Score (Range 0-27) Mean N Baseline	Mean Change (%)	Peak Flow Rate (mL/sec) N Baseline Change (%)
Study 1 (10 mg) ^a Titration to fixed dose (12 wks) Placebo Terazosin 55 9.7 Terazosin 54 10.1	-2.3 (24) -4.5 (45)*	
Study 2 (2, 5, 10, 20 mg) ^b Titration to response (24 wks) Placebo Terazosin 85 12.2	-3.8 (30) -5.3 (43)*	88
Study 3 (1, 2, 5, 10 mg) ^c Titration to response (24 wks) Placebo 74 10.4 Terazosin 73 10.9	-1.1 (11) -4.6 (42)*	าร์ว่า สาราสมาชิงสมชังสุราราชสุราช (ค.ศ. 1977) สายหาราชสุราช (ค.ศ. 1977)

n' mo cui co pra c Carolo às monteresseus

9767-166

Information will be superseded by supplements and subsequent editions

223% of patients on 10 mg. 67% of patients on 10 mg. Significantly ($p \le 0.05$) more improvement than placebo.




Figure 2 Figure 2 Méan Change in Total Symptom Score from Baseline Long-Term, Open-Label, Non-Placebo Controlled Study (N=494)

0

.71 * 1. 41.	Group	an inge	Mean	2011 2 2 5 5 5 1	Mean
SBP mm Hg)	Placebo Terazosin	293 519	-0.1 -3.3*	45 65	-5.8 -14.4*
	Placebo				
mm Hg)	Terazosin	519	-2.2*	65	-15.1*
°p ≤ 0.05	vs. placebo		diterta erreg	en de las	1997 1616
1.15	et avail i n	arna.	consecution	lalia te	é c aig

B. Hypertension

Limited measurements of nous sher using, near trate was unchanged. Limited measurements of peak response (2.3 hours after dosing) during chronic 'terazosin administration' indicate that it is greater than about twice the 'trough' (24 hour) re-sponse, suggesting some attenuation of response at 24 hours, presumably due to a fall in blood terazosin 'concen-trations at the end of the dose interval. This explanation' is not established with 'certainty, however, and is not 'consis-tent with the similarity of blood pressure response to once daily and twice daily dosing and with the absence of an ob-served dose-response relationship over a range of 5-20 mg, i.e., if blood concentrations had fallen to the point of provid-ing less than full effect at '24 hours, a shorter dosing interval or larger dose' should have led to increased response. Further dose' tesponse and dose duration studies are being carried out. Blood pressure should be measured at the end

Lilly Exhibit 1255, Page 6 of 39

the patient's condition, sodium intake, and responsiveness. A decision to change the daily dose should be based on the results of thorough clinical and laboratory evaluations. If	PERCENTAGE OF	Tab PATIENTS WHO ACHIEVED	AN ACR RES	SPONSE AT WEEKS	30 AND 54	2 ceció ·
antihypertensive drugs or diuretics are given concurrently	and the second sec	1997 - <u>1997 - 1997 - 1997 - 1997</u>				
with ZAROXOLYN, more careful dosage adjustment may be	Placebo	3 mg/kg ^a			10 mg/kg ^a	2.686-08-00
ecessary. For patients who tend to experience paroxysmal	Response + MTX	q 8 wks	q 4 wks	q 8 wks		wks ·
octurnal dyspnea, it may be advisable to employ a larger	(n=88)	(n=86)	(n=86)	(n=87)		81)
ose to ensure prolongation of diuresis and saluresis for a	ACR 20	(11-00)	(11-00)	(1-0+)	(11-	
Ill.24-hour period.	Week 30 20%	50%	50%	52%		3%
eatment of Hypertension: The time interval required for	Week 54 17%	42%	48%	59%		9%
e initial dosage regimen to show effect may vary from	ACR 50	12,0	10%	0010	a	
iree or four days to three to six weeks in the treatment of	Week 30 5%	27%	29%	31%	9 (3%
evated blood pressure. Doses should be adjusted at appro-	Week 54 9%	21%				
iate intervals to achieve maximum therapeutic effect.	ACR 70	21%	34%	40%		3%
	Week 30 0%	8%	11%	18%	1	1%
IOW BUTT LIED	Week 54 2%	070	11%	10% 26%		1% : 9% :
AROXOLYN Tablets (metolazone tablets, USP) are shal-			10%	20%	1	970 .
w biconvex, round tablets, and are available in three	* p<0.05 for each outcome compar	ed to placebo		1. A. A. A. A.		
rengths:						
/2 mg, pink, debossed "ZAROXOLYN" on one side, and		n de la case de la case Nota managemente de la case de la c		- 11 alt	. ,	4 11 11
½" on reverse side.	A STREET STREET	Tab	le 2	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		
NDC 53014-975-71 Bottle of 100's		MPONENTS OF ACR 20 A		AND 54 WEEKS		
NDC 53014-975-90 Bottle of 1000's			bo + MTX		REMICADE + M	туа
NDC 53014-975-72 Carton of 100's, unit dose	 A set of the set of		n=88)	21 - C. 199	(n=340)	· · ·
mg, blue, debossed "ZAROXOLYN" on one side, and "5" on	 A state of the sta	1	u=00)		(11=040)	
		Pagalina	Weelr	Ed Day	aolino W	eek 54
NDC 52014 250 71 Rottle of 100's	Parameter (medians)	Baseline	Week			
NDC 53014-850-71 Bottle of 100's	No. of Tender Joints	24 19	16 13		32 20	8 7
NDC 53014-850-90 Bottle of 1000's	No. of Swollen Joints					
NDC 53014-850-72 Carton of 100's, unit dose	Pain ^b	6.7	6.1		6.8	3.3
) mg, yellow, debossed "ZAROXOLYN" on one side, and		6.5	5.2		6.2	2.1
l0" on reverse side.	Patient's Global Assessment ^b	6.2	6.2		6.3	3.2
NDC 53014-835-71 Bottle of 100's	Disability Index (HAQ) ^e	1.8	1.5		1.8	1.3
NDC 53014-835-90 Bottle of 1000's	CRP (mg/dL)	3.0	2.3		2.4	0.6
NDC 53014-835-72 Carton of 100's, unit dose	^a All doses/schedules of REMICAL	DE + MTX				
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-						
86°F) [See USP Controlled Room Temperature]. Protect			ories: dressir	ng and grooming, ar	ising, eating, wall	king.
from light. Keep out of the reach of children.	hygiene, reach, grip, and activit		,	0		0,
Celltech Pharmaceuticals, Inc.						
Rochester, NY 14623 USA						
© Celltech Manufacturing, Inc. Rev. 2/03						
			ile 3			
© Celltech Manufacturing, Inc. Rev. 2/03 © 2003, Celltech Pharmaceuticals, Inc. R522B		Tab ADIOGRAPHIC CHANGE F		E TO WEEK 54		
D Celltech Manufacturing, Inc. Rev. 2/03 2003, Celltech Pharmaceuticals, Inc. R522B					1 1 1	
D Celltech Manufacturing, Inc. Rev. 2/03 2003, Celltech Pharmaceuticals, Inc. R522B	R		ROM BASELIN			
D Celltech Manufacturing, Inc. Rev. 2/03 2003, Celltech Pharmaceuticals, Inc. R522B	R Median	ADIOGRAPHIC CHANGE F	ROM BASELIN	DE + MTX		
 Celltech Manufacturing, Inc. 2003, Celltech Pharmaceuticals, Inc. R522B 	R Median (10, 90 Placebo	ADIOGRAPHIC CHANGE F	ROM BASELIN REMICAT)E + MTX 10 m	ng/kg	-
0 Celltech Manufacturing, Inc. Rev. 2/03 0 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved.	R Median (10, 90 Placebo percentiles) + MTX	ADIOGRAPHIC CHANGE Fr	ROM BASELIN REMICAL)E + MTX 10 m q 8 wks	q 4 wks	<u>p-value</u>
0 Celltech Manufacturing, Inc. Rev. 2/03 0 2003, Celltech Pharmaceuticals, Inc. R522B	$\begin{array}{c} Median \\ (10, 90 \qquad Placebo \\ \underline{percentiles} \qquad + MTX \\ \overline{(n=64)} \end{array}$	ADIOGRAPHIC CHANGE Fr	ROM BASELIN REMICAT)E + MTX 10 m	ng/kg <u>q 4 wks</u> (n=66)	<u>p-value</u>
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score	ADIOGRAPHIC CHANGE Fr	ROM BASELIN REMICAL q 4 wks (n=71)	$\frac{10 \text{ m}}{\frac{\text{g 8 wks}}{(\text{n}=77)}}$	$\frac{q \ 4 \ wks}{(n=66)}$	<u>p-value</u>
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar-	Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188)	ADIOGRAPHIC CHANGE Fr	ROM BASELIN REMICAL)E + MTX 10 m q 8 wks	q 4 wks	<u>p-value</u>
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar-	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score	ADIOGRAPHIC CHANGE Fr	ROM BASELIN REMICAL q 4 wks (n=71)	$\frac{10 \text{ m}}{\frac{\text{g 8 wks}}{(\text{n}=77)}}$	$\frac{q \ 4 \ wks}{(n=66)}$	
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B I rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar-	Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188)	ADIOGRAPHIC CHANGE Ff 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4	ROM BASELIN REMICAL q 4 wks (n=71)	$\frac{10 \text{ m}}{\frac{\text{g 8 wks}}{(\text{n}=77)}}$	$\frac{q \ 4 \ wks}{(n=66)}$	
Celltech Manufacturing, Inc. Rev. 2/03 2003, Celltech Pharmaceuticals, Inc. R522B 1 rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar-	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from	ADIOGRAPHIC CHANGE Ff 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4	ROM BASELIN REMICAL (n=71) 5 (8, 162)	$\frac{10 \text{ m}}{\frac{\text{q 8 wks}}{(\text{n=77})}}$ 56 (6, 143)	$\frac{q \ 4 \ wks}{(n=66)}$ 43 (7, 178) -0.5 (-5.7, 4.0)	
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B I rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603.	R Median (10, 90 Placebo percentiles) + MTX (n=64) <i>Total Score</i> Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) <i>Erosion Score</i>	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1	REMICAL REMICAL (n=71) 5 (8, 162) . (-5.2, 9.0)	$\frac{10 \text{ m}}{\frac{9.8 \text{ wks}}{(n=77)}}$ 56 (6, 143) 0.5 (-4.8, 5.0)	$\frac{q \ 4 \ wks}{(n=66)}$ 43 (7, 178) -0.5 (-5.7, 4.0)	
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc.	R Median (10, 90 Placebo percentiles) + <u>MTX</u> (n=64) Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) <i>Erosion Score</i> Baseline 25 (8, 110)	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1	ROM BASELIN REMICAL (n=71) 5 (8, 162)	$\frac{10 \text{ m}}{\frac{\text{q 8 wks}}{(\text{n=77})}}$ 56 (6, 143)	$\frac{q \ 4 \ wks}{(n=66)}$ 43 (7, 178)	
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B I rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603.	R Median (10, 90 Placebo percentiles) + MTX Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) <i>Frosion Score</i> Baseline 25 (8, 110) Change from	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2	REMICAL REMICAL (n=71) 5 (8, 162) . (-5.2, 9.0) 22 (3, 91)	$\frac{10 \text{ m}}{\frac{q \text{ 8 wks}}{(n=77)}}$ 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80)	$\frac{q \ 4 \ wks}{(n=66)}$ 43 (7, 178) -0.5 (-5.7, 4.0) -26 (4, 104)	p<0.00
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B 1 rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY	$\begin{tabular}{ c c c c c c } \hline R \\ \hline Median \\ (10, 90 & Placebo \\ percentiles) & \pm MTX \\ (n=64) \\ \hline Total Score \\ Baseline & 55 (14, 188) \\ Change from \\ baseline & 4.0 (-1.0, 19.0) \\ Erosion Score \\ Baseline & 25 (8, 110) \\ Change from \\ baseline & 2.0 (-1.0, 9.7) \\ \hline \end{tabular}$	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2	REMICAL REMICAL (n=71) 5 (8, 162) . (-5.2, 9.0)	$\frac{10 \text{ m}}{\frac{9.8 \text{ wks}}{(n=77)}}$ 56 (6, 143) 0.5 (-4.8, 5.0)	$\frac{q \ 4 \ wks}{(n=66)}$ 43 (7, 178) -0.5 (-5.7, 4.0)	p<0.00
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B 1 rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc.	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) <i>Brosion Score</i> Baseline 25 (8, 110) Change from baseline 2.0 (-1.0, 9.7) JSN Score	ADIOGRAPHIC CHANGE FR 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 29 (9, 100) 20 (0, (-3.0, 4.3))	g 4 wks (n=71) 5 (8, 162) 4 (-5.2, 9.0) 22 (3, 91) 3 (-3.1, 2.5)	$\begin{array}{c} 10 \text{ m} \\ \frac{q \ 8 \ wks}{(n=77)} \\ 56 \ (6, 143) \\ 0.5 \ (-4.8, 5.0) \\ 22 \ (3, 80) \\ 0.5 \ (-3.0, 2.5) \end{array}$	$\frac{q 4 \text{ wks}}{(n=66)}$ 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5)	p<0.00
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B i rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355	$\begin{tabular}{ c c c c c } \hline R \\ \hline Median \\ (10, 90 & Placebo \\ percentiles) & + MTX \\ (n=64) \\ \hline Total Score \\ Baseline & 55 (14, 188) \\ Change from \\ baseline & 4.0 (-1.0, 19.0) \\ Erosion Score \\ Baseline & 25 (8, 110) \\ Change from \\ baseline & 2.0 (-1.0, 9.7) \\ JSN Score \\ Baseline & 26 (3, 88) \\ \hline \end{tabular}$	ADIOGRAPHIC CHANGE FR 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 29 (9, 100) 20 (0, (-3.0, 4.3))	REMICAL REMICAL (n=71) 5 (8, 162) . (-5.2, 9.0) 22 (3, 91)	$\frac{10 \text{ m}}{\frac{q \text{ 8 wks}}{(n=77)}}$ 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80)	$\frac{q \ 4 \ wks}{(n=66)}$ 43 (7, 178) -0.5 (-5.7, 4.0) -26 (4, 104)	p<0.00
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B I rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355	Median Placebo (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline baseline 25 (8, 110) Change from baseline baseline 2.0 (-1.0, 9.7) JSN Score Baseline Change from 2.0 (3, 88)	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) -0. 29 (4, 80) 2	q 4 wks (n=71) 5 (8, 162) 4 (-5.2, 9.0) 22 (3, 91) 3 (-3.1, 2.5) 20 (3, 83)	$\begin{array}{c} 10 \text{ m} \\ \frac{98 \text{ wks}}{(\text{n=77})} \\ 56 (6, 143) \\ 0.5 (-4.8, 5.0) \\ 22 (3, 80) \\ 0.5 (-3.0, 2.5) \\ 24 (1, 79) \end{array}$	$\frac{g 4 \text{ wks}}{(n=66)}$ 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2^{z} (3, 77)	p<0.00
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B i rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) <i>Erosion Score</i> Baseline 25 (8, 110) Change from baseline 2.0 (-1.0, 9.7) JSN Score Baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0)	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) -0. 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0	g 4 wks (n=71) 5 (8, 162) 4 (-5.2, 9.0) 22 (3, 91) 3 (-3.1, 2.5)	$\begin{array}{c} 10 \text{ m} \\ \frac{q \ 8 \ wks}{(n=77)} \\ 56 \ (6, 143) \\ 0.5 \ (-4.8, 5.0) \\ 22 \ (3, 80) \\ 0.5 \ (-3.0, 2.5) \end{array}$	$\frac{q 4 \text{ wks}}{(n=66)}$ 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5)	p<0.00
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA	Median Placebo (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline baseline 25 (8, 110) Change from baseline baseline 2.0 (-1.0, 9.7) JSN Score Baseline Change from 2.0 (3, 88)	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) -0. 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0	q 4 wks (n=71) 5 (8, 162) 4 (-5.2, 9.0) 22 (3, 91) 3 (-3.1, 2.5) 20 (3, 83)	$\begin{array}{c} 10 \text{ m} \\ \frac{98 \text{ wks}}{(\text{n=77})} \\ 56 (6, 143) \\ 0.5 (-4.8, 5.0) \\ 22 (3, 80) \\ 0.5 (-3.0, 2.5) \\ 24 (1, 79) \end{array}$	$\frac{g 4 \text{ wks}}{(n=66)}$ 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2^{z} (3, 77)	p<0.00
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) <i>Erosion Score</i> Baseline 25 (8, 110) Change from baseline 2.0 (-1.0, 9.7) JSN Score Baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag	ADIOGRAPHIC CHANGE Ff 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.9 (9, 100) 29 (9, 100) 29 (4, 80) 29 (4, 80) 0.0 (-2.5, 4.5) 0.0 (ainst placebo	q.4 wks (n=71) 5 (8, 162) . (-5.2, 9.0) 12 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) 0 (-3.4, 5.0)	$\begin{array}{c} \text{DE} + \text{MTX} \\ & 10 \text{ m} \\ \frac{\text{g & wks}}{(\text{n}=77)} \\ 56 & (6, 143) \\ 0.5 & (-4.8, 5.0) \\ 22 & (3, 80) \\ 0.5 & (-3.0, 2.5) \\ 24 & (1, 79) \\ 0.0 & (-3.0, 2.5) \end{array}$	$\begin{array}{c} \underline{q} \; \underline{4} \; \underline{wks} \\ \hline (n=66) \\ 43 \; (7, 178) \\ -0.5 \; (-5.7, 4.0) \\ 26 \; (4, 104) \\ -0.5 \; (-2.7, 2.5) \\ 2^{2} \; (3, 77) \\ \underline{v} \\ 0.0 \; (.2, 0, 3.5) \end{array}$	p<0.00 p<0.00 p<0.00
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA	R Median (10, 90 Placebo percentiles) + MTX (m=64) <i>Total Score</i> Baseline 55 (14, 188) Change from baseline 25 (8, 110) Change from baseline 20 (-1.0, 9.7) <i>JSN Score</i> Baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) -0.1 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0 ainst placebo section, USP, the resulting	q 4 wks (n=71) 5 (8, 162) . (-5.2, 9.0) 3 (-3.1, 2.5) 20 (3, 83)) (-3.4, 5.0)	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemose	<u>q 4 wks</u> (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) -0.5 (-2.7, 2.5) 2 ^f (3, 77) -0.0 (-2.0, 3.5) attraction [IL-8 an	p<0.00 p<0.00 p<0.00
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B I rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA irect General Inquiries to: h: (610, 651-6000 (888) 874-3083	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) Erosion Score Baseline 25 (8, 110) Change from baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In pH is approximately 7.2. Each	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) - 0.1 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0 ainst placebo ection, USP, the resulting single-use vial contains	q 4 wks (n=71) 5 (8, 162) (.5.2, 9.0) 22 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) () (-3.4, 5.0)	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)), chemos (MCP-1)]	<u>q 4 wks</u> (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ^f (3, 77) 0.0 (-2.0, 3.5) attraction [IL-8 an and tissue degrad	p<0.0 p<0.0 p<0.0 d monoc; dation [n
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- naceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA birect General Inquiries to: th: (610) 651-6000 (888) 874-3083 'ax: (610) 651-6100	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) Erosion Score Baseline 25 (8, 110) Change from baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In pH is approximately 7.2. Each	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) - 0.1 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0 ainst placebo ection, USP, the resulting single-use vial contains	q 4 wks (n=71) 5 (8, 162)	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1)] oproteinase (MMP)	g 4 wks (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ² (3, 77) 0. (-2.0, 3.5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croh	p<0.0 p<0.0 p<0.0 d monoc lation [n n's disea
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- aceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA irect General Inquiries to: h: (610) 651-6000 (888) 874-3083 ax: (610) 651-6100 ledical Emergency Contact:	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 25 (8, 110) Change from baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In; pH is approximately 7.2. Each 100 mg infiximab, 500 mg sucros	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) -0.1 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0 ainst placebo iection, USP, the resulting single-use vial contains ise, 0.5 mg polysorbate 80,	q 4 wks (n=71) 5 (8, 162)	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)), chemos (MCP-1)]	g 4 wks (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ² (3, 77) 0. (-2.0, 3.5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croh	p<0.0 p<0.0 p<0.0 d monoc: lation [n n's disea
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- iaceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Pricet General Inquiries to: th: (610) 651-6000 (888) 874-5083 3rx: (610) 651-6100 Aedical Emergency Contact: th: 14000-476-6399	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) <i>Erosion Score</i> Baseline 25 (8, 110) Change from baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for Inj pH is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosphate	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) -0.3 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0 ainst placebo lection, USP, the resulting single-use vial contains is, hate, monohydrate, and	q 4 wks (n=71) 5 (8, 162) (-5.2, 9.0) 32 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) 0 (-3.4, 5.0) molecule-1 chemotacti trix metall treatment	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1)] oproteinase (MMP) with REMICADE r	g 4 wks (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) -0.5 (-2.7, 2.5) 2 ^f (3, 77) -0.0 (-2.0, 3.5) attraction [IL-8 an and tissue degran 1 and 3]. In Crob	p<0.0 p<0.0 p<0.0 d monoc dation [n n's disea o fo infla
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- iaceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Pricet General Inquiries to: th: (610) 651-6000 (888) 874-5083 3rx: (610) 651-6100 Aedical Emergency Contact: th: 14000-476-6399	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 25 (8, 110) Change from baseline 26 (3, 88) Change from baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In pH is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosp 6.1 mg dibasic sodium phosp	ADIOGRAPHIC CHANGE FF 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) -0.3 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0 ainst placebo lection, USP, the resulting single-use vial contains is, hate, monohydrate, and	q.4 wks (n=71) 5 (8, 162) (.5.2, 9.0) 12 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) (.4.4, 5.0)	10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemose (protein AMP) oproteinase (MMP) with REMICADE r is and TNFa produ	<u>q 4 wks</u> (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ^f (3, 77) 0.0 (-3.0, 3.5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croh educed infiltration	p<0.0 p<0.0 p<0.0 d monoci lation [n n's disea ı of infla ıreas of t
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B I rights reserved. R522B EDUCATIONAL MATERIAL Or educational information, please write to Celltech Phar- naceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Direct General Inquiries to: th: (610) 661-6000 (888) 874-3083 ax: (610) 661-6100 Addical Emergency Contact: th: 14:00)-457-6399 for Medical Information/Adverse Experience Reporting	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) Erosion Score Baseline 25 (8, 110) Change from baseline 26 (3, 88) Change from baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In pH is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosphate tives are present.	ADIOGRAPHIC CHANGE FI 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 29 (9, 100) 29 (4, 80) 0.0 (-2.5, 4.5) 0.1 29 (4, 80) 29 (5, 4.5) 0.5 mg polysorbate 80, ohate, monohydrate, and, dihydrate. No preserva-	q 4 wks REMICAI q 4 wks (n=71) 5 (8, 162) (.52, 9.0) 22 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) (.3.4, 5.0) I molecule-1 chromatait trix metall treatment matory cell intestine, in	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)), chemore c protein (MCP-1) oproteinase (MMP) with REMICADE r Is and TNFc produ and reduced the pro	g 4 wks (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 [£] (3, 77) 0.0 (-3.0, 3.5) attraction [IL-8 an and tissue degram 1 and 3]. In Croh educed infiltration etion in inflamed 4	p<0.0 p<0.0 p<0.0 d monoc; dation [n n's disea 1 of infla areas of t uclear cc
Cellech Manufacturing, Inc. Rev. 203 2003, Cellech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Cellech Phar- naceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Direct General Inquiries to: the (610) 661-6000 (888) 874-3083 Pax: (610) 651-6100 Medical Emergency Contact: Th: 1(800)-457-6399 or Medical Information/Adverse Experience Reporting Contact:	R Median (10, 90 Placebo percentiles) + MTX (m=64) Total Score Baseline 55 (14, 188) Change from baseline 25 (8, 110) Change from baseline 20 (-1.0, 9.7) JSN Score Baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In Pl is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosphate tives are present. CLINICAL PHARMACOLOGY	ADIOGRAPHIC CHANGE FI 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 29 (9, 100) 29 (4, 80) 0.0 (-2.5, 4.5) 0.1 29 (4, 80) 29 (5, 4.5) 0.5 mg polysorbate 80, ohate, monohydrate, and, dihydrate. No preserva-	q 4 wks (n=71) 5 (8, 162) 1. (-5.2, 9.0) 22 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) 0 (-3.4, 5.0) molecule-1 chemotacti trix metall treatment matory cel intestine, i from the 1	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemose c protein (MCP-1)] oprotein(MCP-1)] oprotein(MCP-1)] s and TNFα produ and reduced the pro- ls and TNFα produ	<u>q 4 wks</u> (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ^f (3, 77) 0.0 (-2.6, 0, 3.5) attraction [IL-8 an and tissue degrad 1 and 3]. In Crob educed infiltration etion in inflamed a oportion of monon	p<0.0 p<0.0 p<0.0 d monoc dation [n n's disea n of infla areas of t uclear ce
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- naceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Direct General Inquiries to: hr: (610) 651-6000 (888) 874-3083 ² ax: (610) 651-6100 Aedical Emergency Contact: hr: 14800-476-8399 for Medical Information/Adverse Experience Reporting Jontact: dedical Information	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 25 (8, 110) Change from baseline 26 (3, 88) Change from baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for Ini pH is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2. mg dinoasic sodium phosp 6.1 mg dibasic sodium phosp 1.5 (-0.100 J Lent Lent Matter 100 J Lent 10	ADIOGRAPHIC CHANGE FI 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) -0.3 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0 ainst placebo iection, USP, the resulting single-use vial contains se, 0.5 mg polysorbate 80, hate, monohydrate, and , dihydrate. No preserva-	q.4 wks REMICAL [n=71] 5 (8, 162) (.5-2, 9.0) [22 (3, 91) 3 (.3.1, 2.5) [20 (3, 83) () (.3.4, 5.0) [3.43, 5.0) Image: trix metall treatment matory calls the m	10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemose c protein (MCP-1)] oproteinase (MMP) with REMICADE r is and TNFa produ and reduced the pro aming propria able er treatment with	<u>q 4 wks</u> (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ⁵ (3, 77) 0.0 (-3.0, 3.5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croh educed infiltration and tissue degrad 1 and 3]. In Croh educed infiltration tion in inflamed 4 opportion of monon to express TNFe REMICADE, pat	p<0.0 p<0.0 p<0.0 d monoce lation [m n's disea n's disea i of infla areas of t uclear cc and int tients w
2 Celltech Manufacturing, Inc. Rev. 203 2 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL For educational information, please write to Celltech Phar- naceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Direct General Inquiries to: hr. (610) 651-6000 (888) 874-3083 Fax: (610) 651-6100 Wedical Emergency Contact: hr. 14800-477-6399 for Medical Information/Adverse Experience Reporting Sontact: Wedical Information	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 25 (8, 110) Change from baseline 26 (3, 88) Change from baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for Ini pH is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2. mg dinoasic sodium phosp 6.1 mg dibasic sodium phosp 1.5 (-0.100 J Lent Lent Matter 100 J Lent 10	ADIOGRAPHIC CHANGE FI 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 2 0.0 (-3.0, 4.3) -0.3 29 (4, 80) 2 0.0 (-2.5, 4.5) 0.0 ainst placebo iection, USP, the resulting single-use vial contains se, 0.5 mg polysorbate 80, hate, monohydrate, and , dihydrate. No preserva-	ROM BASELIN REMICAI q 4 wks (n=71) 5 (8, 162) (-5.2, 9.0) 22 (3, 91) 3 (-3.1, 2.5) 20 (3, 83)) (-3.4, 5.0) molecule-1 chemotacti trix metall treatment intestine, from the 1 from the 1 from the 1 from the 1	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1) oproteinase (MMP) with REMICADE r Is and TNFa produ and reduced the pr amina propria able er treatment with d arthrifs or Crohn	q 4 wks (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-5.7, 2.5) 2 [±] 2.5 (-2.7, 2.5) 2 [±] 0.0 (-3.0, 3.5) attraction [IL-8 an and tissue degrae. attraction [IL-8 an inflamed 1 and 3]. In Croheduced infiltration to express TNFa REMICADE, particular momon to express TNFa Sciences exhibite	p<0.00 p<0.00 p<0.00 d monocy lation [m n's diseau n's
2 Celltech Manufacturing, Inc. Rev. 203 2 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL For educational information, please write to Celltech Phar- naceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Direct General Inquiries to: hr. (610) 651-6000 (888) 874-3083 Fax: (610) 651-6100 Wedical Emergency Contact: hr. 14800-477-6399 for Medical Information/Adverse Experience Reporting Sontact: Wedical Information	Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score 5 Baseline 55 (14, 188) Change from baseline baseline 2.0 (-1.0, 9.0) Erosion Score Baseline Baseline 2.0 (-1.0, 9.7) JSN Score Baseline Baseline 2.6 (3, 88) Change from baseline baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In; pH is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosphate tives are present. CLINICAL PHARMACOLOGY General Infliximab neutralizes the biolog	ADIOGRAPHIC CHANGE FI 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 29 (4, 80) 29 (4, 80) 0.0 (-2.5, 4.5) 0.0 (-2.5, 4.5) 0.0 hate, monohydrate, and, dihydrate. No preserva- fical activity of TNFa by	q.4 wks (n=71) 5 (8, 162) (.5.2, 9.0) 12 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) (.4.4, 5.0) molecule-1 thria matory cell intestine, from AH feron. AH rheumatoi levels of the levels of the intestine, form He levels of the levels of the levels of the levels of the intestine, form AH heron. Th heron. Th heron the heron. Th heron the heron. Th heron the the the the heron the heron the the the the heron the the the the the the the the the the the <td< td=""><td>10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1)] oproteinase (MMP) with REMICADE r is and TNFα produ and reduced the pru amina propria able er treatment with d arthritis or Crohn d C-rea</td><td><u>q 4 wks</u> (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2^f (3, 77) 0.0 (.2, 0, 3.5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croh educed infiltration compared to a structure of the structure results TNFG REMICADE, par 's disease exhibite tive protein (CRR</td><td>p<0.00 p<0.00 p<0.00 d monocy lation [m n's disea n of infla areas of t uclear cce and int tients wi d decreas</td></td<>	10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1)] oproteinase (MMP) with REMICADE r is and TNFα produ and reduced the pru amina propria able er treatment with d arthritis or Crohn d C-rea	<u>q 4 wks</u> (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ^f (3, 77) 0.0 (.2, 0, 3.5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croh educed infiltration compared to a structure of the structure results TNFG REMICADE, par 's disease exhibite tive protein (CRR	p<0.00 p<0.00 p<0.00 d monocy lation [m n's disea n of infla areas of t uclear cce and int tients wi d decreas
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- iaceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Virect General Inquiries to: h: (610) 651-6000 (688) 874-3083 ax: (610) 651-6100 Aedical Emergency Contact: h: 1400/657-6399 or Medical Information Adverse Experience Reporting iontact: dedical Information h: (800) 457-6399	Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score 5 Baseline 55 (14, 188) Change from baseline baseline 2.0 (-1.0, 9.0) Erosion Score Baseline Baseline 2.0 (-1.0, 9.7) JSN Score Baseline Baseline 2.6 (3, 88) Change from baseline baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In; pH is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosphate tives are present. CLINICAL PHARMACOLOGY General Infliximab neutralizes the biolog Infliximab neutralizes the main bibiding with high affinity to the binding with high affinity to the	ADIOGRAPHIC CHANGE Ff 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 29 (4, 80) 29 (4, 80) ection, USP, the resulting single-use vial contains the 0.5 mg polysorbate 80, shate, monohydrate, and , dihydrate. No preserva- rical activity of TNFα by soluble and transmeri-	age 4 wks REMICAL REMICAL (n=71) 5 5 (8, 162) (-5.2, 9.0) 22 22 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) (-3.4, 5.0) molecule-1 rinestine, rinement matory cel intestine, rine feron. Aft rheumatoi levisi of set to basel*	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)), chemos c protein (MCP-1) oproteinase (MMP) with REMICADE r Is and TNFc produ and reduced the pr amina propria able the treatment with d arthritis or Crohn rum IL-6 and Crea	q 4 wks (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ² (3, 77) 0.0 (-2.0, 3.5) attraction [IL-8 an and tissue degras 1 and 3). In Croheduced infiltration edition in inflamed infiltration oportion of monon texperses TNF8 's disease exhibite ctive protein (CRE, pai's disease exhibite blood blood	p<0.00 p<0.00 p<0.00 d monocy lation [m n's disea n of infla areas of t uclear cc and int tients wi d decreas ') compary tytes fir
Celltech Manufacturing, Inc. Rev. 2003 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. EDUCATIONAL MATERIAL or educational information, please write to Celltech Phar- iaceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Virect General Inquiries to: h: (610) 651-6000 (688) 874-3083 ax: (610) 651-6100 Aedical Emergency Contact: h: 1400/657-6399 or Medical Information Adverse Experience Reporting iontact: dedical Information h: (800) 457-6399	R Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline 4.0 (-1.0, 19.0) Erosion Score Baseline 25 (8, 110) Change from baseline 26 (3, 88) Change from baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In pH is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosp 6.1 mg dibasic sodium phosphate tives are present. CLINICAL PHARMACOLOGY General Infliximab neutralizes the biolog binding with high affinity to the brane forms of TNFe and inblints	ADIOGRAPHIC CHANGE FI 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 29 (9, 100) 29 (4, 80) 0.0 (-2.5, 4.5) 0.0 (-2.5, 4.5) 0.0 hate, monohydrate, and, dihydrate. No preserva- rical activity of TNFa by soluble and transmem- binding of TNFa with its	and Australia q 4 wks (n=71) 5 (8, 162) (.5.2, 9.0) 32 (3, 91) (.4.5.2, 9.0) 3 (-3.1, 2.5) (.3, 83) 0 (-3.4, 5.0) (.4.5.0) Intestine, from the 1 feron. After framemation intestine, from the 1 feron. After framemation levels of set to baseling the task of ta	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1)] oproteinase (MMP) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1)] oproteinase (MMP) 15 and TNFa produ and reduced the pra amina propria able er treatment with a dribritis or Crohn rum IL-6 and C-rea ine. Peripheral	<u>q 4 wks</u> (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ^f (3, 77) 0.0 (-g-0, 3.5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croh educed infiltration ction in inflamed d poportion of mornon to express TNPe R'EMicaBe, pair E MicaBe, pair R'EMicaBe, exhibite ctive protein (CRF blood lymphoc; s showed no sign	p<0.00 p<0.00 p<0.00 d monocy dation [m n's disea 1 of infla areas of t uclear cc and int tients wid d decreas 2) compar ytes fro ificant c
Celltech Manufacturing, Inc. Rev. 203 2003, Celltech Pharmaceuticals, Inc. R522B Il rights reserved. R522B EDUCATIONAL MATERIAL Or educational information, please write to Celltech Phar- naceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Virect General Inquiries to: th: (610) 661-6000 (88) 874-3083 2ax: (610) 661-6100 Addical Emergency Contact: th: (610) 457-6399 cor Medical Information/Adverse Experience Reporting Vadical Information the(800) 457-6399 Xetticade®	R Median (10, 90 Placebo percentiles) + MTX (m=64) Total Score Baseline 55 (14, 188) Change from baseline 25 (8, 110) Change from baseline 2.0 (-1.0, 9.7) JSN Score Baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In Pl is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosphate tives are present. CLINCAL PHARMACOLOGY General Infliximab neutralizes the biolog binding with high affinity to the brane forms of TNFc and inhibits receptors. ³¹ Infliximab does not 1	ADIOGRAPHIC CHANGE Ff 3 mg/kg q.8 wks (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 29 (4, 80) 29 (4, 80) ection, USP, the resulting single-use vial contains e.g. 0.5 mg polysorbate 80, obate, monohydrate, and , dihydrate. No preservation dihydrate. No preservation of TNFα with its eutralize TNFα (ymphore) that its eutralize TNFα (ymphore) that its eutralize TNFα (ymphore) that its eutralize TNFα (ymphore)	and Australia q 4 wks (n=71) 5 (8, 162) (.5.2, 9.0) 32 (3, 91) (.4.5.2, 9.0) 3 (-3.1, 2.5) (.3, 83) 0 (-3.4, 5.0) (.4.5.0) Intestine, from the 1 feron. After framemation intestine, from the 1 feron. After framemation levels of set to baseling the set of	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)), chemos c protein (MCP-1) oproteinase (MMP) with REMICADE r Is and TNFc produ and reduced the pr amina propria able the treatment with d arthritis or Crohn rum IL-6 and Crea	<u>q 4 wks</u> (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ^f (3, 77) 0.0 (-g-0, 3.5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croh educed infiltration ction in inflamed d poportion of mornon to express TNPe R'EMicaBe, pair E MicaBe, pair R'EMicaBe, exhibite ctive protein (CRF blood lymphoc; s showed no sign	p<0.00 p<0.00 p<0.00 d monocy dation [m n's disea 1 of infla areas of t uclear cc and int tients wid d decreas 2) compar ytes fro ificant c
0 Celltech Manufacturing, Inc. Rev. 203 2 2003, Celltech Pharmaceuticals, Inc. R522B Ill rights reserved. EDUCATIONAL MATERIAL For educational information, please write to Celltech Phar- naceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Direct General Inquiries to: Ph: (610) 651-6000 (888) 874-3083 Fax: (610) 651-6100 Medical Emergency Contact: Ph: 1(480)-457-6399 For Medical Information Ph: (800) 457-6399 For Medical Information Ph: (800) 457-6399 REMICADE®	Median (10, 90 Placebo percentiles) + MTX (n=64) Total Score Baseline 55 (14, 188) Change from baseline baseline 25 (14, 188) Change from baseline baseline 2.0 (-1.0, 9.7) JSN Score Baseline baseline 2.6 (3, 88) ^* For comparisons of each dose age with 10 mL of Sterile Water for In; pH is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosphate tives are present. CLINICAL PHARMACOLOGY General Infliximab neutralizes the biolog binding with high affinity to the brane forms of TNFc and inhibits receptors. ^{2.3} Infliximab does not r	ADIOGRAPHIC CHANGE FI 3 mg/kg <u>q 8 wks</u> (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 29 (4, 80) 29 (4, 80) 29 (4, 80) 29 (4, 80) ainst placebo rection, USP, the resulting single-use vial contains e, 0.5 mg polysorbate 80, hate, monohydrate, and , dihydrate. No preserva- pical activity of TNFa by = soluble and transmembridizes the ransmembridizes the same receptors	action action q. 4 wks (n=71) g. 4 wks (n=71) 5 (8, 162) (.5.2, 9.0) 2 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) (.3.4, 5.0) (.3.4, 5.0) (.3.4, 5.0) molecule-1 thria metall treatment matory call intestine, from the 1 feron. Aft rheumatoi levels of se to basel REMICAI REMICAI crease in p.	10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1)] oproteinase (MMP) with REMICADE ri is and TNFα produ and reduced the pri amina propria able er treatment with d arthritis or Crohn ine. Peripheral DE-treated patients umber or in prolifer	q 4 wks (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ^f (3, 77) 2 ^f (3, 77) 4.1 (1, 1, 2, 3, 3, 5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croheduced infiltration in infilmed 4 oportion of monon to express TNFG REMICADE, parts diverses results of the end of signative responses to attive responses to atttive responses to att	p<0.00 p<0.00 p<0.00 d monocy dation [m n's diseas areas of t uclear ce and intt tients wi d decreas) compar from the form the f
© Celitech Manufacturing, Inc. Rev. 2003 © 2003, Celitech Pharmaceuticals, Inc. R522B All rights reserved. EDUCATIONAL MATERIAL For educational information, please write to Celitech Phar- maceuticals, Inc., PO Box 31766, Rochester, NY 14603. Centocor, Inc. 200 GREAT VALLEY PARKWAY MALVERN, PA 19355 USA Direct General Inquiries to: Ph: (610) 651-6000 (888) 874-3083 Fax: (610) 651-6100 Medical Emergence 209 For Medical Information/Adverse Experience Reporting Contact: Medical Information Ph: (800) 457-6399	R Median (10, 90 Placebo percentiles) + MTX (m=64) Total Score Baseline 55 (14, 188) Change from baseline 25 (8, 110) Change from baseline 2.0 (-1.0, 9.7) JSN Score Baseline 26 (3, 88) Change from baseline 1.5 (-0.8, 8.0) * For comparisons of each dose ag with 10 mL of Sterile Water for In Pl is approximately 7.2. Each 100 mg infliximab, 500 mg sucros 2.2 mg monobasic sodium phosphate tives are present. CLINCAL PHARMACOLOGY General Infliximab neutralizes the biolog binding with high affinity to the brane forms of TNFc and inhibits receptors. ³¹ Infliximab does not 1	ADIOGRAPHIC CHANGE FI 3 mg/kg q 8 wks (n=71) 57 (15, 187) 4 0.5 (-3.0, 5.5) 0.1 29 (9, 100) 29 (9, 100) 29 (4, 80) 0.0 (-3.0, 4.3) 0.1 29 (4, 80) 0.0 (-2.5, 4.5) 0.0 (-2.5, 4.5) 0.5 mg Dolycorbate 80, ohate, monohydrate, and, dihydrate. No preserva- rical activity of TNFα by soluble and transmembinding of TNFα with its reutralize TNFβ (lympho-tilizes the same receptors rributed to TNFα includes	action action q. 4 wks (n=71) g. 4 wks (n=71) 5 (8, 162) (.5.2, 9.0) 2 (3, 91) 3 (-3.1, 2.5) 20 (3, 83) (.3.4, 5.0) (.3.4, 5.0) (.3.4, 5.0) molecule-1 thria metall treatment matory call intestine, from the 1 feron. Aft rheumatoi levels of se to basel REMICAI REMICAI crease in p.	DE + MTX 10 m <u>q 8 wks</u> (n=77) 56 (6, 143) 0.5 (-4.8, 5.0) 22 (3, 80) 0.5 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) 24 (1, 79) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1)] oproteinase (MMP) 0.0 (-3.0, 2.5) (VCAM-1)], chemos c protein (MCP-1)] oproteinase (MMP) 15 and TNFa produ and reduced the pra amina propria able er treatment with a dribritis or Crohn rum IL-6 and C-rea ine. Peripheral	q 4 wks (n=66) 43 (7, 178) -0.5 (-5.7, 4.0) 26 (4, 104) -0.5 (-2.7, 2.5) 2 ^f (3, 77) 2 ^f (3, 77) 4.1 (1, 1, 2, 3, 3, 5) attraction [IL-8 an and tissue degrad 1 and 3]. In Croheduced infiltration in infilmed 4 oportion of monon to express TNFG REMICADE, parts diverses results of the end of signative responses to attive responses to atttive responses to att	dation [main areas of the second seco

induction of pro-inflammatory cytokines such as interleufunction of pro-imminiatory cytokines such as interec-kins (IL) I and 6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, ac-tivation of neutrophil and eosinophil functional activity, in-

duction of neutrophi and eosimophi influctional activity in-duction of acute phase reactants and other liver proteins, as well as tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Cells expressing transmembrane TNFc bound by infliximab can be lysed in *vitro*³ or in *vivo*.⁴ Infliximab inhibits the functional activity of TNFc in a wide

variety of *in vitro* bioassays utilizing human fibroblasts, endothelial cells, neutrophils, B and T lymphocytes and epithelial cells. Anti-TNF α antibodies reduce disease activity

in the cotton top tamarin colitis model, and decrease syno-vitis and joint erosions in a murine model of collagen-

induced arthritis. Infliximab prevents disease in transgenic mice that develop polyarthritis as a result of constitutive

expression of human $TNF\alpha$, and when administered after disease onset, allows eroded joints to heal.

Elevated concentrations of $TNF\alpha$ have been found in the joints of rheumatoid arthritis patients and the stools of

Crohn's disease patients and correlate with elevated disease activity. In rheumatoid arthritis, treatment with REMICADE reduced infiltration of inflammatory cells into

inflamed areas of the joint as well as expression of mol-

Pharmacodynamics

Pharmacokinetics

Single intravenous (IV) infusions of 3 mg/kg to 20 mg/kg showed a linear relationship between the dose administered and the maximum serum concentration. The volume of distribution at steady state was independent of dose and indi-cated that infliximab was distributed primarily within the vascular compartment. Median pharmacokinetic results for doses of 3 mg/kg to 10 mg/kg in rheumatoid arthritis and 5 mg/kg in Crohn's disease indicate that the terminal halflife of infliximab is 8.0 to 9.5 days.

Following an initial dose of REMICADE, repeated infusions at 2 and 6 weeks resulted in predictable concentration-time profiles following each treatment. No systemic accumulation of infliximab occurred upon continued repeated treat-ment with 3 mg/kg or 10 mg/kg at 4- or 8-week intervals. No major differences in clearance or volume of distribution were observed in patient subgroups defined by age, weight, or gender. It is not known if there are differences in clear ance or volume of distribution in patients with marked im-pairment of hepatic or renal function.

A pediatric Crohn's disease pharmacokinetic study was conducted in 21 patients aged 11 to 17 years old. No notable differences in single-dose pharmacokinetic parameters were observed between pediatric and adult Crohn's disease pa-tients (see PRECAUTIONS, Pediatric Use).

for IV injection

WARNING

RISK OF INFECTIONS TUBERCULOSIS (FREQUENTLY DISSEMINATED OR EX-TRAPULMONARY AT CLINICAL PRESENTATION), INVA-NISTIC INFECTIONS, HAVE BEEN OBSERVED IN PATIENTS RECEIVING REMICADE. SOME OF THESE IN-FECTIONS HAVE BEEN FATAL (SEE WARNINGS). PATIENTS SHOULD BE EVALUATED FOR LATENT TU-BERCULOSIS INFECTION WITH A TUBERCULIN SKIN TEST.¹ TREATMENT OF LATENT TUBERCULOSIS IN-FECTION SHOULD BE INITIATED PRIOR TO THERAPY WITH REMICADE.

DESCRIPTION

REMICADE is a chimeric IgG1k monoclonal antibody with an approximate molecular weight of 149,100 daltons. It is composed of human constant and murine variable regions. Composed to influent Constant Constant and marker regions. Influentab binds specifically to human turnor necrosis factor alpha (TNFa) with an association constant of 10^{10} M⁻¹. In-fluentable produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses. DEMICAT We include the contain white humabilized

Remicade—Cont.

CLINICAL STUDIES

Rheumatoid Arthritis The safety and efficacy of REMICADE when given in conjunction with methotrexate (MTX) were assessed in a multicenter, randomized, double-blind, placebo-controlled study of 428 patients with active rheumatoid arthritis despite treatment with MTX (the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy or ATTRACT). Patients enrolled had a median age of 54 years, median disease du-ration of 8.4 years, median swollen and tender joint count of 20 and 31 respectively, and were on a median dose of 15 mg/wk of MTX. Patients received either placebo + MTX or one of 4 doses/schedules of REMICADE + MTX: 3 mg/kg or 10 mg/kg of REMICADE by IV infusion at weeks 0, 2 and 6 followed by additional infusions every 4 or 8 weeks in com-bination with MTX. Concurrent use of stable doses of folic acid, oral corticosteroids (≤10 mg/dav) and/or nonsteroidal

anti-inflammatory drugs was also permitted. Data on use of REMICADE without concurrent MTX are limited (see ADVERSE REACTIONS, Immunogenicity).^{5,6} Clinical response

All doses/schedules of REMICADE + MTX resulted in im-An obsessemedules of REMIADE + MIA resulted in the provement in signs and symptoms as measured by the American College of Rheumatology response criteria (ACR 20) with a higher percentage of patients achieving an ACR 20, 50 and 70 compared to placebo + MTX (Table 1). This improvement was observed at week 2 and maintained through week 102. Greater effects on each component of the ACR 20. ACR 20 were observed in all patients treated with REMICADE + MTX compared to placebo + MTX (Table 2). Approximately 10% of patients treated with REMICADE achieved a major clinical response, defined as maintenance of an ACR 70 response over a 6-month period compared to

0% of placebo-treated patients ($p\leq0.018$). [See table 1 at top of previous page]

[See table 2 at top of previous page] Radiographic response Structural damage in both hands and feet was assessed radiographically at week 54 by the change from baseline in the van der Heijde-modified Sharp score, a composite score of structural damage that measures the number and size of or structural damage that measures the number and size of joint erosions and the degree of joint space narrowing in hands/wrists and feet.⁷ Approximately 80% of patients had paired x-ray data at 54 weeks and approximately 70% at 102 weeks. The inhibition of progression of structural dam age was observed at 54 weeks (Table 3) and maintained through 102 weeks.

[See table 3 at top of previous page]

Physical function response Physical function and disability were assessed using the

Physical function and disability were assessed using the Health Assessment Questionnaire (HAQ) and the general health-related quality of life questionnaire SF-36. All dosses/ schedules of REMICADE + MTX showed significantly greater improvement from baseline in HAQ and SF-36 physical component "mmary score averaged over time through week 54 compared to placebo + MTX, and no wors-ening in the SF-36 mental component summary score. The median (interquartile range) improvement from base-line to week 54 in HAQ was 0.1 (-0.1, 0.5) for the placebo + MTX group and 0.4 (0.1, 0.9) for REMICADE + MTX (p<-0.001). Both HAQ and SF-36 effects were maintained through week 102. Approximately 80% of patients in all doses/schedules of REMICADE + MTX remained in the trial through 102 weeks. through 102 weeks.

Active Crohn's Disease

Active croins Disease The safety and efficacy of single and multiple doses of REMICADE were assessed in two randomized, double-blind, placebo-controlled clinical studies in 653 patients with moderate to severely active Croin's disease (Croin's Disease Activity Index [CDAI] ≥220 and ≤400) with an inadequate response to prior conventional therapies. Concom-itant stable doses of aminosalicylates, corticosteroids and/or immunomodulatory agents were permitted and 92% of patients continued to receive at least one of these medications.

In the single-dose trial⁸ of 108 patients, 16% (4/25) of pla-cebo patients achieved a clinical response (decrease in CDAI \geq 70 points) at week 4 vs. 81% (22/27) of patients receiving 5 mg/kg REMICADE (v<0.001, two-sided, Fisher's Exact test). Additionally, 4% (1/25) of placebo patients and 48% (13/27) of patients receiving 5 mg/kg REMICADE achieved clinical remission (CDAI <150) at week 4.


In a multidose trial (ACCENT I),9 545 patients received In a multidose trial (ACCENT 1), 545 patients received 5 mg/kg at week 0 and were then randomized to one of three treatment groups; the placebo maintenance group received placebo at weeks 2 and 6, and then every 8 weeks; the 5 mg/kg maintenance group received 5 mg/kg at weeks 2 and 6, and then every 8 weeks, and the 10 mg/kg mainte-ments 2 ms/mg at weeks 2 and 6, and then nance group received 5 mg/kg at weeks 2 and 6, and then 10 mg/kg every 8 weeks. Patients in response at week 2 were randomized and analyzed separately from those not in response at week 2. Corticosteroid taper was permitted after week 6

At week 2, 57% (311/545) of patients were in clinical response. At week 30, a significantly greater proportion of these patients in the 5 mg/kg and 10 mg/kg maintenance groups achieved clinical remission compared to patients in he placebo maintenance group (Table 4).

Additionally, a significantly greater proportion of patients in the 5 mg/kg and 10 mg/kg infliximab maintenance groups were in clinical remission and were able to discontinue corticosteroid use compared to patients in the placebo mainte-nance group at week 54 (Table 4).

[See table 4 below]

Patients in the infliximab maintenance groups (5 mg/kg and 10 mg/kg) had a longer time to loss of response than patients in the placebo maintenance group (Figure 1). At weeks 30 and 54, significant improvement from baseline was seen among the 5 mg/kg and 10 mg/kg infliximab-treated groups compared to the placebo group in the disease specific inflammatory bowel disease questionnaire (IBDQ), particularly the bowel and systemic components, and in the physical component summary score of the general health-related quality of life questionnaire SF-36.



In a subset of 78 patients who had mucosal ulceration at baseline and who participated in an endoscopic substudy, 13 of 43 patients in the infliximab maintenance group had endoscopic evidence of mucosal healing compared to 1 of 28 patients in the placebo group at week 10. Of the infliximab-

treated patients showing mucosal healing at week 10, 9 of 12 patients also showed mucosal healing at week 54 Patients who achieved a response and subsequently lost response were eligible to receive infliximab on an episodic ba-sis at a dose that was 5 mg/kg higher than the dose to which they were randomized. The majority of such patients re-sponded to the higher dose. Among patients who were not in response at week 2, 59% (92/157) of infliximab maintenance patients responded by week 14 compared to 51% (39/77) of placebo maintenance patients. Among patients who did not respond by week 14, additional therapy did not result in significantly more responses (see DOSAGE AND ADMINIS-TRATION).

Fradridy, Fistulizing Crohn's Disease The safety and efficacy of REMICADE were assessed in 2 randomized, double-blind, placebo-controlled studies in pa-tients with fistulizing Crohn's disease with fistulak(s) that were of at least 3 months duration. Concurrent use of stables doses of corticosteroids, 5-ASA, antibiotics; MTX, 6-MP

doses of corticosteroids, 5-ASA, antibiotics, MITA, 5-MP and/or AZA was permitted. In the first trial, ¹⁰ 94 patients received three doses of either placebo or REMICADE at weeks 0, 2 and 6. Fistula re-sponse (>EOW reduction.in number of enterocutaneous fistulas draining upon gentle compression on at least two con-secutive visits without an increase in medication or surgery for Crohn's disease) was seen in 68%~(21/31) of patients in the 5 mg/kg REMICADE group (p=0.002) and 56%~(18/32) of

Table 4

CLINICAL REM	IISSIO	N AND	STEROI	d with	IDRAWA	L	1 - C. 1
						Three Dose	Induction ^b
		Single #	5 mg/kg	Dose ^a		REMICADE Main	tenance q 8 wks
		Placebo	Mainte	nance		5 mg/kg	10 mg/kg
Week 30			25/102			41/104	48/105
Clinical remission			25%			39%	46%
p-value ^c			· · ·			0.022	0.001
Week 54						· •	
Patients in remission able to			6/54	11		14/56	18/53
discontinue corticosteroid use ^d			11%			25%	34%
p-value ^c						0.059	0.005
a REMICADE at week 0						1	
^b REMICADE 5 mg/kg administered at weeks 0,	. 2 and	6		1.10	- S A	·	
c p-values represent pairwise comparisons to pla							100 C
a the second							

patients in the 10 mg/kg REMICADE group (p=0.021) vs. 26% (8/31) of patients in the placebo arm. The median time to onset of response and median duration of response in REMICADE-treated patients was 2 and 12 weeks, respec-tively. Closure of all fistula was achieved in 52% of

tively. Closure of all fistula was achieved in 52% of REMICADE-treated patients compared with 13% of place-bo-treated patients (p<0.001). In the second trial (ACCENT II), patients who were enrolled had to have at least one draining enterocutaneous (peria-nal, abdominal) fistula. All patients received 5 mg/kg REMICADE at weeks 0, 2 and 6. Patients were randomized to placebo or 5 mg/kg REMICADE maintenance at week 14. Patients residued maintenance at week 14. Patients received maintenance doses at week 14 and then every eight weeks through week 46. Patients who were in fistula response (fistula response was defined the same as in the first trial) at both weeks 10 and 14 were randomized separately from those not in response. The primary endamong those patients who were in fistula response.

Among the randomized patients (273 of the 296 initially en-rolled), 87% had perianal fistulas and 14% had abdominal Stulas. Eight percent also had rectovaginal fistulas. Greater than 90% of the patients had received previous im-munosuppressive and antibiotic therapy.

At week 14, 65% (177/273) of patients were in fistula re-sponse. Patients randomized to REMICADE maintenance had a longer time to loss of fistula response compared to the placebo maintenance group (Figure 2). At week 54, 38% (33/ practico mannenance group (right 2). At week 53, 50% etc. 53, 50% etc. 35, 50\% etc talizations.




Figure 2 Life table estimates of the proportion of patients who had lost fistula response through week 54

Patients who achieved a fistula response and subsequently lost response were eligible to receive REMICADE maintethe response were engine to there in Ministry in the second seco

unlikely to respond to additional doses of REMICADE. Similar proportions of patients in either group developed new fistulas (17% overall) and similar numbers developed abscesses (15% overall).

INDICATIONS AND USAGE

Rheumatoid Arthritis

REMICADE, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage and improving historia tra-gression of structural damage and improving physical func-tion in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate Crohn's Disease

REMICADE is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. REMICADE is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and main-taining fistula closure in patients with fistulizing Crohn's

CONTRAINDICATIONS

REMICADE is contraindicated in patients with moderate or severe (NYHA Class III/IV) congestive heart failure (see WARNINGS, Congestive Heart Failure).

REMICADE should not be administered to patients with known hypersensitivity to any murine proteins or other component of the product

WARNINGS

RISK OF INFECTIONS (See boxed WARNING)

SEPONSE INFECTIONS, INCLUDING SEPSIS HAVE BEEN REPORTED IN PATIENTS RECEIVING TNF-BLOCKING AGENTS, SOME OF THESE INFECTIONS HAVE BEEN FA-TAL. MANY OF THE SERIOUS INFECTIONS IN PATIENTS TREATED WITH REMICADE HAVE OCCURRED IN PATIENTS ON CONCOMITANT IMMUNOSUPPRESSIVE THERAPY THAT, IN ADDITION TO THEIR CROHN'S DISEASE OR

PHYSICIANS' DESK REFERENCE®

IPR2018-01710

Lilly Exhibit 1255, Page 8 of 39

REMICADE SHOULD NOT BE GIVEN TO PATIENTS WITH A CLINCALLY IMPORTANT, ACTIVE INFECTION, CAUTION SHOULD BE EXERCISED WHEN CONSIDERING THE USE OF REMICADE IN PATIENTS WITH A CHRONIC INFECTION OR A HISTORY OF RECURRENT INFECTION. PATIENTS SHOULD BE MONITORED FOR SIGNS AND SYMPTOMS OF INFECTION WHILE ON OR AFTER TREATMENT WITH REMICADE. NEW INFECTIONS SHOULD BE CLOSELY MONITORED. IF A PATIENT DEVELOPS A SERIOUS INFECTION, REMICADE THERAPY SHOULD BE DISCONTINUED (see ADVERSE REACTIONS, Infections).

CASES OF HISTOPLASMOSIS, COCCIDIOIDOMYCOSIS, LISTERIOSIS, PNEUMOCYSTOSIS, TUBERCULOSIS, OTHER BACTERIAL, MYCOBACTERIAL AND FUNGAL IN-FECTIONS HAVE BEEN OBSERVED IN PATIENTS RECEIV-ING REMICADE, FOR PATIENTS WHO HAVE RESIDED IN REGIONS WHERE HISTOPLASMOSIS OR COCCIDIODOMY-COSIS IS ENDEMIC, THE BENEFITS AND RISKS OF REMICADE TREATMENT SHOULD BE CAREFULLY CONSID-ERED BEFORE INITIATION OF REMICADE THERAPY. **Congestive Heart Failure**

Doses greater than 5 mg/kg should not be administered to patients with congestive heart failure (CHF). REMICADE should be used with caution in patients with mild heart failure (NYHA Class I/II). Patients should be closely monitored. and REMICADE must not be continued in patients who de velop new or worsening symptoms of heart failure (see CONTRAINDICATIONS and ADVERSE REACTIONS, Congestive Heart Failure).

Hypersensitivity REMICADE has been associated with hypersensitivity reactions that vary in their time of onset. Most hypersensitiv-ity reactions, which include urticaria, dyspnea, and/or hypotension, have occurred during or within 2 hours of REMICADE infusion. However, in some cases, serum sickness-like reactions have been observed in Crohn's disease patients 3 to 12 days after REMICADE therapy stituted following an extended period without REMICADE treatment. Symptoms associated with these reactions in-clude fever, rash, headache, sore throat, myalgias, pol-varthralisies hand and finite divide the source of the sou yarthralgias, hand and facial edema and/or dysphagia. These reactions were associated with marked increase in antibodies to infliximab, loss of detectable serum concentrations of infliximab, and possible loss of drug efficacy. REMICADE should be discontinued for severe reactions. Medications for the treatment of hypersensitivity reactions (e.g., acetaminophen, antihistamines, corticosteroids and/or epinephrine) should be available for immediate use in the event of a reaction (see ADVERSE REACTIONS, Infusion related Reactions)

Neurologic Events

Infliximab and other agents that inhibit TNF have been associated in rare cases with optic neuritis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis. Prescribers should exercise caution in considering the use of REMICADE in patients with pre-existing or recent onset of central nervous system demyelinating or seizure disorders.

PRECAUTIONS

Autoimmunity Treatment with REMICADE may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with REMICADE, treatment should be discontinued (see AD-VERSE REACTIONS, Autoantibodies/Lupus-like Syndrome).

Malignancy

Patients with long duration of Crohn's disease or rheuma-toid arthritis and chronic exposure to immunosuppressant therapies are more prope to develop lymphomas (see AD-VERSE REACTIONS, Malignancies/Lymphoproliferative Disease). The impact of treatment with REMICADE on these phenomena is unknown.

Vaccinations

No data are available on the response to vaccination or on the secondary transmission of infection by live vaccines in patients receiving anti-TNF therapy. It is recommended that live vaccines not be given concurrently. Information for Patients

Patients should be provided the REMICADE Patient Information Sheet and provided an opportunity to read it prior to each treatment infusion session. Because caution should be exercised in administering REMICADE to patients with clinically important active infections, it is important that the patient's overall health be assessed at each treatment visit and any questions resulting from the patient's reading of the Patient Information Sheet be discussed.

Drug Interactions

Specific drug interaction studies, including interactions with MTX, have not been conducted. The majority of pa-tients in rheumatoid arthritis or Crohn's disease clinical studies received one or more concomitant medications. In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics. Concomitant Crohn's disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates. Patients with Crohn's disease who received immunosuppress ratio and to exper-ience fewer infusion reactions compared to patients on no immunosuppressants (see ADVERSE REACTIONS. Immu-

Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn's disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.

Carcinogenesis, Mutagenesis and Impairment of Fertility

A repeat dose toxicity study was conducted with mice given cV1q anti-mouse $TNF\alpha$ to evaluate tumorigenicity. CV1q is an analogous antibody that inhibits the function of TNFs in mice. Animals were assigned to 1 of 3 dose groups: control, 10 mg/kg or 40 mg/kg cV1g given weekly for 6 months. The weekly doses of 10 mg/kg and 40 mg/kg are 2 and 8 times, respectively, the human dose of 5 mg/kg for Crohn's disease: Results indicated that cV1q did not cause tumorigenicity in mice. No clastogenic or mutagenic effects of infliximab were observed in the *in vivo* mouse micronucleus test or the Salmonella-Escherichia coli (Ames) assay, respectively. Chromosomal aberrations were not observed in an assay performed using human lymphocytes. The significance of these findings for human risk is unknown. It is not known whether infliximab can impair fertility in humans. No im-pairment of fertility was observed in a fertility and general eproduction toxicity study with the analogous mouse antibody used in the 6-month chronic toxicity study.

Pregnancy Category B

Since infliximab does not cross-react with TNFa in species other than humans and chimpanzees, animal reproduction studies have not been conducted with REMICADE. No evidence of maternal toxicity, embryotoxicity or teratogenicity was observed in a developmental toxicity study conducted in mice using an analogous antibody that selectively inhib the functional activity of mouse $TNF\alpha$. Doses 15 mg/kg in pharmacodynamic animal models with the anti-TNF analogous antibody produced maximal pharmacologic effectiveness. Doses up to 40 mg/kg were shown to produce no adverse effects in animal reproduction studies. It is not known whether REMICADE can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. REMICADE should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether infliximab is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for adverse reactions in nursing infants from REMICADE, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

Pediatric Use Safety and effectiveness of REMICADE in patients with in

venile rheumatoid arthritis and in pediatric patients with Crohn's disease have not been established. Geriatric Use

In the ATTRACT study, no overall differences were observed in effectiveness or safety in 72 patients aged 65 or older compared to younger patients. In Crohn's disease studies, there were insufficient numbers of patients aged 65 and over to determine whether they respond differently from patients aged 18 to 65. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly (see *ADVERSE RE-*ACTIONS, Infections)

ADVERSE REACTIONS

The data described herein reflect exposure to REMICADE in 1678 patients, including 842 patients exposed beyond 30 weeks and 295 exposed beyond one year. The most common reason for discontinuation of treatment was infusion-related reactions (e.g. dyspneä, flushing, headache and rash). Adverse events have been reported in a higher proportion of rheumatoid arthritis patients receiving the $10~{\rm mg/kg}$ dose than the 3 mg/kg dose, however, no differences were observed in the frequency of adverse events between the 5 mg/kg dose and 10 mg/kg dose in patients with Crohn's disease

Infusion-related Reactions

Acute infusion reactions

An infusion reaction was defined in clinical trials as any adverse event occurring during an infusion or within 1 to 2 hours after an infusion. Approximately 20% of REMICADEtreated patients in all clinical studies experienced an infu-sion reaction compared to approximately 10% of placebo-treated patients. Among all REMICADE infusions, 3% were accompanied by nonspecific symptoms such as fever or chills, 1% were accompanied by cardiopulmonary reactions (primarily chest pain, hypotension, hypotension or dysp-nea), and <1% were accompanied by pruritus, urticaria, or the combined symptoms of pruritus/urticaria and cardiopul-monary reactions. Serious infusion reactions occurred in <1% of patients and included anaphylaxis, convulsions, erythematous rash and hypotension. Approximately 3% of pa-tients discontinued REMICADE because of infusion reactions, and all patients recovered with treatment and/or discontinuation of the infusion. REMICADE infusions bevond the initial infusion were not associated with a higher incidence of reactions.

Patients who became positive for antibodies to infliximal were more likely (approximately 2- to 3-fold) to have an in-fusion reaction than were those who were negative. Use of concomitant immunosuppressant agents appeared to reduce the frequency of antibodies to infliximab and infusion reac-tions (see ADVERSE REACTIONS; Immunogenicity and

In post-marketing experience, cases of anaphylactic like re-actions, including laryngeal/pharyngeal edema and severe bronchospasm, and seizure have been associated with REMICADE administration.

Reactions following readministration

In a study where 37 of 41 patients with Crohn's diseas were retreated with infliximab following a 2 to 4 year period without infliximab treatment, 10 patients experienced ad-verse events manifesting 3 to 12 days following infusion of which 6 were considered serious. Signs and symptoms in-cluded myalgia and/or arthralgia with fever and/or rash, with some patients also experiencing pruritus, facial, hand or lip edema, dysphagia, urticaria, sore throat, and headache. Patients experiencing these adverse events had not experienced infusion-related adverse events associated with their initial infliximab therapy. These adverse events occurred in 39% (9/23) of patients who had received liquid formulation which is no longer in use and 7% (1/14) of pa tients who received lyophilized formulation. The clinical data are not adequate to determine if occurrence of these reactions is due to differences in formulation. Patients' signs and symptoms improved substantially or resolved with treatment in all cases. There are insufficient data on the incidence of these events after drug-free intervals of 1 to 2 years. These events have been observed only infrequently in clinical studies and post-marketing surveillance with retreatment intervals up to 1 year.

Infections

In REMICADE clinical studies, treated infections were re norted in 35% of REMICADE-treated patients (average of 53 weeks of follow-up) and in 26% of placebo-treated patients (average of 41 weeks of follow-up). When longer observation of patients on REMICADE was accounted for, the event rate was similar for both groups. The infections most event rate was similar for both groups. The infections most frequently reported were respiratory tract infections (in-cluding sinusitis, pharyngitis, and bronchitis) and urinary tract infections. No increased risk of serious infections or sepsis was observed with REMICADE compared with pla-cebo in clinical studies. Among REMICADE treated pa-tients, serious infections included pneumonia, cellulitis, ab-scease, skin ulceration, sepsis, and bacterial infection. Three concentrative infections with respect to be infection of the pre-sent series of the pre-spin series of the pre-spin series of the pre-sent series of the pre-spin series of the pre-spin series of the pre-sent series of the pre-spin series of the pre-spin series of the pre-sent series of the pre-spin series of the pre-spin series of the pre-sent series of the pre-spin series of the pre-spin series of the pre-sent series of the pre-spin series of the pre-spin series of the pre-sent series of the pre-spin series of the pre-spin series of the pre-sent series of the pre-spin series of the pre-spin series of the pre-sent series of the pre-spin opportunistic infections were reported, coccidioidomycosis (which resulted in death), nocardiosis and cytomegalovirus. Tuberculosis was reported in two patients, one of whom died due to miliary tuberculosis. Other cases of tuberculosis, including disseminated tuberculosis, also have been reported post-marketing. Most of the cases of tuberculosis occurred within the first two months after initiation of therapy with infliximab and may reflect recrudescence of latent disease (see WARNINGS, RISK OP INFECTIONS). During the 54 week ACCENT II trial, 15% of patients with fistulizing Crohn's disease developed a new fistula-related abscess. In post-marketing experience, infections have been ob served with various pathogens including viral, bacterial, fungal, and protozoal organisms. Infections have been noted in all organ systems and have been reported in patients re-ceiving REMICADE alone or in combination with immuno-

suppressive agents. Autoantibodies/Lupus-like Syndrome

Approximately 52% of 1261 infliximal-treated natients in clinical trials who were antinuclear antibody (ANA) nega-tive at baseline developed a positive ANA during the trial compared with approximately 19% of 129 placebo-treated patients. Anti-dsDNA antibodies were newly detected in approximately 17% of 1507 infliximab-treated patients compared with 0% of 162 placebo-treated patients. Reports of lupus and lupus-like syndromes, however, remain uncom-

Malignancies/Lymphoproliferative Disease

In completed clinical studies of REMICADE for up to 102 weeks, 18 of 1678 patients developed 19 new or recurrent malignancies of various types, such as non-Hodgkin's B-cell lymphoma, breast, melanoma, squamous, rectal and basal There are insufficient data to determine whether REMICADE contributed to the development of these malignancies. The observed rates and incidences were similar to those expected for the populations studied $^{11.12}$ (see PRECAUTIONS, Malignancy).

Immunogenicity

Treatment with REMICADE can be associated with the development of antibodies to infliximab. The incidence of an-tibodies to infliximab in patients given a 3-dose induction regimen followed by maintenance dosing was approxi-mately 10% as assessed through one to two years of REMICADE treatment. A higher incidence of antibodies to infliximab was observed in Crohn's disease patients receiv-ing REMICADE after drug free intervals >16 weeks. The majority of antibody-positive patients had low titers. Pa-tients who were antibody-positive were more likely to exper-ience an infusion reaction (see ADVERSE REACTIONS, Infusion-related Reactions). Antibody development was lower among rheumatoid arthritis and Crohn's disease patients receiving immunosuppressant therapies such as 6-MP/AZA or MTX

The data reflect the percentage of patients whose test re-sults were positive for antibodies to infliximab in an ELISA assay, and are highly dependent on the sensitivity and spec-ificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, timing of sample collec-tion, concomitant medication, and underlying disease. For

Remicade-Cont.

these reasons, comparison of the incidence of antibodies to infliximab with the incidence of antibodies to other products may be misleading.

Congestive Heart Failure

In a phase II study evaluating REMICADE in NYHA Class II/IV CHF patients (left ventricular ejection fraction \$35%), higher incidences of mortality and hospitalization ≤35%), higher incidences of mortality, and hospitalization due to worsening heart failure were seen in REMICADE-treated patients, especially those treated with 10 mg/kg. One hundred and fifty patients were treated with 3 infu-sions of REMICADE 5 mg/kg, 10 mg/kg, or placebo over 6 weeks. At 28 weeks, 4 of 101 patients treated with REMICADE (1 at 5 mg/kg and 3 at 10 mg/kg) died compared with no deaths among the 49 placebo-treated patients. In follow-up, at 38 weeks, 9 patients treated with REMICADE (2 at 5 mg/kg aed 3 at 10 mg/kg) died compared by the set of the follow-up, at 30 weeks, 9 patients treated with REMICADE (2 at 5 mg/kg and 7 at 10 mg/kg) died compared with one death among the placebo-treated patients. At 28 weeks, 14 of 101 patients treated with REMICADE (3 at 5 mg/kg and 11 at 10 mg/kg) were hospitalized for worsening CHF com-pared with 5 of the 49 placebo-treated patients (see CON-TRAINDICATIONS and WARNINGS, Congestive Heart Failure).

Other Adverse Reactions

Safety data are available from 1678 REMICADE-treated patients, including 555 with rheumatoid arthritis, 1106 with Crohn's disease and 17 with conditions other than rheumatoid arthritis or Crohn's disease. Adverse events reported in \geq 5% of all patients with rheumatoid arthritis receiving 4 or more infusions are in Table 5. The types and frequencies of adverse reactions observed were similar in REMICADE-treated rheumatoid arthritis and Crohn's disease patients except for abdominal pain which occurred in 26% of REMICADE-treated patients with Crohn's disease. In the Crohn's disease studies, there were insufficient numbers and duration of follow-up for patients who never re-ceived REMICADE to provide meaningful comparisons.

Table 5 ADVERSE EVENTS OCCURRING IN 5% OR MORE OF PATIENTS RECEIVING 4 OR MORE INFUSIONS FOR RHEUMATOID ARTHRITIS

FOR RHEUMATOID A	RTHRITIS	
	Placebo	REMICADE
	(n=81)	(n=430)
Average weeks of follow-up	73	82
Gastrointestinal		
Abdominal pain	12%	17%
Nausea	23%	24%
Diarrhea	19%	19%
Dyspepsia	9%	10%
Respiratory		
Upper respiratory tract		
infection	35%	40%
Pharyngitis	12%	17%
Sinusitis	7%	20%
Coughing	9%	18%
Rhinitis	14%	14%
Dyspnea	2%	6%
Skin and appendage disorders		
Rash	7%	- 18%
Pruritis	2%	9%
Body as a whole-general disorders		
Fatigue	9%	13%
Chest pain	6%	7%
Resistance mechanism disorders		
Fever	11%	13%
Abscess	5%	6%
Moniliasis	2%	8%
Central and peripheral nervous sys	stëm disor	ders
Headache	21%	29%
Musculoskeletal system disorders		
Arthralgia	7%	13%
Back pain	5%	13%
Psychiatric disorders		· · · ·
Insomnia	4%	6%
Depression	2%	. 8%
Urinary system disorders		
Urinary tract infection	12%	14%
Cardiovascular disorders, general	$(-p') \to 0$	
Hypertension	6%	. 10%
		ta an

Because clinical trials are conducted under widely varying Decause clinical rans are conducted under where where y arying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not predict the rates ob-served in broader patient populations in clinical practice. The most common serious adverse events observed in clinical trials were infections (see ADVERSE REACTIONS, In-fections). Other serious, medically relevant adverse events 20.2% or clinically significant adverse events by body sys-tem were as follows:

Body as a whole: allergic reaction, diaphragmatic hernia, edema, surgical/procedural sequela

Blod: paneytopenia Cardiouascular: circulatory failure, hypotension, syncope Castrointestinal: constipation, gastrointestinal hemor-rhage, ileus, intestinal obstruction, intestinal perforation, intestinal stenosis, pancreatitis, peritonitis, proctalgia Central & Peripheral Nervous: meningitis, neuritis, pe ripheral neuropathy, dizziness

Heart Rate and Rhythm: arrhythmia, bradycardia, cardiac

Liver and Biliary: biliary pain, cholecystitis, cholelithia sis, hepatitis Metabolic and Nutritional: dehydration

Musculoskeletal: intervertebral disk herniation, tendon

disorder Myo-, Endo-, Pericardial and Coronary Value: myocardial infarction

Platelet, Bleeding and Clotting: thrombocytopenia Neoplasms: basal cell, breast, lymphoma Psychiatric: confusion, suicide attempt

Red Blood Cell: anemia, hemolytic anemia Reproductive: menstrual irregularity

Resistance Mechanism: cellulitis, sepsis, serum sickness Resistance Mechanism: cellulitis, sepsis, serum sickness Respiratory: adult respiratory distress syndrome, lower respiratory tract infection, pleural effusion, pleurisy, pulmo-nary edema, respiratory insufficiency Skin and Appendages: increased sweating, ulceration

Urinary: renal calculus, renal failure Vascular (Extracardiac): brain infarction, pulmonary em-bolism, thrombophlebitis

White Cell and Reticuloendothelial: leukopenia, lymphadenopathy

A greater proportion of patients enrolled into the ATTRACT study who received REMICADE + MTX experienced transient mild (<2 times the upper limit of normal) or moderate sent init (-2 times the upper limit of normal) of inductate (e^{2} but <3 times the upper limit of normal) elevations in AST or ALT (49% and 47%, respectively) compared to pa-tients treated with placebo + MTX (27% and 35%, respec-tively). Six (1.8%) patients treated with REMICADE + MTX

experienced more prolonged elevations in their ALT. The following adverse events have been reported during post-approval use of REMICADE: demyelinating disorders (see WARNINGS, Neurologic Events) (such as multiple scle-rosis and optic neuritis), Guillain-Barré syndrome, hemolytic anemia, idiopathic thrombocytic purpura, interstitial pneumonitis/fibrosis, neuropathies, thrombotic thrombocytopenic purpura, and transverse myelitis. Because these events are reported voluntarily from a population of uncer-tain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to REMICADE exposure.

OVERDOSAGE

Single doses up to 20 mg/kg have been administered with-out any direct toxic effect. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately

DOSAGE AND ADMINISTRATION Rheumatoid Arthritis

The recommended dose of REMICADE is 3 mg/kg given as an intravenous infusion followed with additional similar doses at 2 and 6 weeks after the first infusion then every 8 doses at 2 and 6 weeks after the first infusion then every 8 weeks thereafter. REMICADE should be given in combina-tion with methotrexate. For patients who have an incom-plete response, consideration may be given to adjusting the dose up to 10 mg/kg or treating as often as every 4 weeks. **Crohn's Disease or Fistulizing Crohn's Disease** The recommended dose of REMICADE is 5 mg/kg given as an induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of moderately to severely active Crohn's

for the treatment of moderately to severely active Crohn's disease or fistulizing disease. For patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Patients who do not respond by week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue REMICADE in these patients

Preparation and administration instructions

Preparation and administration instructions Use aseptic technique. REMICADE vials do not contain antibacterial preserva-tives. Therefore, the vials after reconstitution should be used immediately, not re-entered or stored. The diluent to be used for reconstitution is 10 mL of Sterile Water for In-jection, USP. The total dose of the reconstituted product must be further diluted to 250 mL with 0.% Sodium Chlo-ride Injection USP. ride Injection, USP. The infusion concentration should range between 0.4 mg/mL and 4 mg/mL. The REMICADE

- infusion should begin within 3 hours of preparation. 1. Calculate the dose and the number of REMICADE vials needed. Each REMICADE vial contains 100 mg of infliximab. Calculate the total volume of reconstituted REMICADE solution required. Reconstitute each REMICADE vial with 10 mL of Sterile
- Water for Injection, USP, using a syringe equipped with a 21-gauge or smaller needle. Remove the flip-top from the vial and wipe the top with an alcohol swab. Insert the syringe needle into the vial through the center of the rub-ber stopper and direct the stream of Sterile Water for Injection, USP, to the glass wall of the vial. Do not use the vial if the vacuum is not present. Gently swirl the solujection tion by rotating the vial to dissolve the lyophilized powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE. Foaming of the solution on reconstitution is not unusual. Allow the reconstituted solution to stand for 5 minutes. The solution should be colorless to light yellow and opalescent, and the solution may develop a few trans-lucent particles as infliximab is a protein. Do not use if opaque particles, discoloration, or other foreign particles re present.
- Dilute the total volume of the reconstituted REMICADE solution dose to 250 mL with 0.9% Sodium Chloride In-iection. USP. by withdrawing a volume of 0.9% Sodium

tuted REMICADE from the 0.9% Sodium Chloride Injec-tion, USP, 250 mL bottle or bag. Slowly add the total vol-ume of reconstituted REMICADE solution to the 250 mL infusion bottle or bag. Gently mix. The infusion solution must be administered over a period of not less than 2 hours and must use an infusion set with print line fulle are musticiped in the full.

- of not less than 2 hours and must use an infusion set with an in-line, sterile, non-pyrogenic, low-protein-binding fil-ter (pore size of 1.2 µm or less). Any unused portion of the infusion solution should not be stored for reuse. 5. No physical biochemical compatibility studies have been conducted to evaluate the co-administration of REMICADE with other agents. REMICADE should not be infused concomitantly in the same intravenous line with other agents. 6. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administra-tion, whenever solution and container permit. If visibly opaque particles, discoloration or other foreign particu-lates are observed, the solution should not be used. Storage Storage

Store the lyophilized product under refrigeration at 2° C to 8° C (36° F to 46° F). Do not freeze. Do not use beyond the expiration date. This product contains no preservative.

HOW SUPPLIED

REMICADE lyophilized concentrate for IV injection is supplied in individually-boxed single-use vials in the following

strength: NDC 57894-030-01 100 mg infliximab in a 20 mL vial

REFERENCES

- American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treat-ment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-S247.
- Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. *Molec Immunol* 1993;30:1443-1453... Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-
- TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions, *Cytokine* 1995;7:251-259.
- ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina pro-pria T lymphocytes in Crohn's disease. *Gut* 2002;50:206-211.
- Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41(9):1552-1563.
- Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) vs. placebo in rheumatoid arthritis. *Lancet* 1994;344(8930):1105-1110. Van der Heijde DM, van Leeuwen MA, van Riel PL, et
- al. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35(1): 26 - 34
- 20-34. Targan SR, Hanauer SR, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J 8 Med 1997;337(15):1029-1035. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Main-
- tenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359:1541-1549.
- randomized trial. Lancet 2002;309:1344-13649.
 10. Present DH, Rutgerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's dis-ease. N Engl J Med 1999;340:1398-1405.
 11. Bernstein C, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease. Cancer
- 2001-91-854-862
- 12. Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malig-nancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheum 1996;35:738-745.

© Centocor, Inc. 2003 Malvern, PA 19355, USA 1-800-457-6399

License #1242 Revised April 1, 2003 IN03175

Shown in Product Identification Guide, page 312

RETAVASE®

(reteplase) recombinant

DESCRIPTION

Retavase⁶ (Reteplase) is a non-glycosylated deletion mutein of tissue plasminogen activator (tPA), containing the kringle 2 and the protease domains of human tPA. Retavase⁶ contains 355 of the 527 amino acids of native tPA (amino acids 1-3 and 176-527). Retavase⁶ is produced by recombinant DNA technology in E. coli. The protein is iso-lated as inactive inclusion bodies from E. coli, converted into its active form by an in vitro folding process and puri-fied by chromatographic separation. The molecular weight of Reteplase is 39,571 daltons.

of Reteplase is 39,5/1 faitons. Potency is expressed in units (U) using a reference standard which is specific for Retavase[®] and is not comparable with units used for other thrombolytic agents. Retavase[®] is a sterile, white, lyophilized powder for intra-vanue holus injection after reconstitution with Sterila Wa.

Lilly Exhibit 1255, Page 10 of 39

 \mathbf{R}

ng moderate to severe cough (24/65, 37% as compared to ing moderate to severe cough (24/bb, 3/% as compared to. (533,18%). Other events tended to be of mild to moderate severity. The number of patients reporting rhinitis was higher in the younger age group as compared to the older age group (23/65, 35% compared to 9/33, 27%) as was the number reporting rash (4/65, 6% as compared to 0/33). The nature of adverse events was similar to that seen in the larger trials of Pulmozyme® (dornase alfa) Inhalation Solution. Allergic Reactions

There have been no reports of anaphylaxis attributed to the administration of Pulmozyme to date. Urticaria, mild to moderate, and mild skin rash have been observed and have hour are and mind skin rash nave been observed and have been transient. Within all of the studies, a small percentage (average of 2.4%) of patients treated with Pulmozyme de-veloped serum antibodies to Pulmozyme. None of these patients developed anaphylaxis, and the clinical significance of serum antibodies to Pulmozyme is unknown.

OVERDOSAGE

Single-dose inhalation studies in rats and monkeys at doses up to 180-times higher than doses routinely used in clinical studies are well tolerated. Single dose oral administration of Pulmozyme in doses up to 200 mg/kg are also well toler ated by rats.

Cystic fibrosis patients have received up to 20 mg BID for up to 6 days and 10 mg BID intermittently (2 weeks on/2 weeks off drug) for 168 days. These doses were well tolerated

DOSAGE AND ADMINISTRATION

The recommended dose for use in most cystic fibrosis pa-The recommended does not use in most open horses paid tients is one 2.5 mg single-use ampule inhaled once daily using a recommended nebulizer. Some patients may benefit from twice daily administraton (see Clinical Experience, Table 1). Clinical trial results and laboratory information are only available to support use of the following nebulizer/ compressor systems (see Table 3).

Table 3 Recommended Nebulizer/Compressor Systems Jet Nebulizer Compressor Hudson T Up-draft II® with Marquest Acorn II® with PARI LC Jet⁺ with *PARI BABY^M with Pulmo-Aíde® Pulmo-Aide® PARI PRONEB® PARI PRONEB® Durable Sidestream® with MOBILAIRETM Durable Sidestream® with Porta-Neb®

*Patients who are unable to inhale or exhale orally throughout the entire nebulization period may use the PARI BABYTM nebulizer.

Patients who use the Sidestream® Nebulizer with the MOBILAIRE[™] compressor should turn the compressor con-trol knoh fully to the right and then turn on the compressor. At this setting, the needle on the pressure gauge should vibrate between 35 and 45 pounds per square inch (highest essure output).

No data are currently available that support the administration of Pulmozyme with other nebulizer systems. The particular systems is the particular system of the particular system of the particular system of the particular system. tient should follow the manufacturer's instructions on the use and maintenance of the equipment. Pulmozyme should not be diluted or mixed with other drugs

in the nebulizer. Mixing of Pulmozyme with other drugs could lead to adverse physicochemical and/or functional changes in Pulmozyme or the admixed compound. Patients should be advised to squeeze each ampule prior to use in order to check for leaks.

HOW SUPPLIED

Pulmozyme® (dornase alfa) Inhalation Solution is supplied in single-use ampules. Each ampule delivers 2.5 mL of a sterile, clear, colorless, aqueous solution containing 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dibydrate and 8.77 mg/mL sodium chloride with no preserva-tive. The nominal pH of the solution is 6.3.

Pulmozyme is supplied in: • 30 unit cartons containing 5 foil pouches of 6 single-use ampules: NDC 50242-100-40. Storage

Pulmozyme® (dornase alfa) Inhalation Solution should be stored under refrigeration (2-8°C/36-46°F). Ampules should be protected from strong light. Do not use beyond the expiration date stamped on the ampule. Unused ampules should be stored in their protective foil pouch under refrigeration.

REFERENCES

- Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87:
- 9188-92
- 2. Boat TF. Cystic Fibrosis. In: Murray JF, Nadel JA, editors, Textbook of respiratory medicine. Philadelphia: Saunders WB, 1988;1:1126-52.
- Collins FS. Cystic Fibrosis: molecular biology and ther apeutic implications. Science 1992;256:774-9.
- 4.
- Potter JL, Spector S, Matthews LW, Lemm J. Studies of pulmonary secretions. Am Rev of Respir Dis 1969;99: 909-15.
- 5. Hubbard RC. McElvanev NG Birror P Shak C

aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Eng J Med 1992:326 812-5.

- 6. Aitken ML, Burke W, McDonald G, Shak S, Montgom ery AB, Smith A. Recombinant buman DNase inhalation in normal subjects and patients with cystic fibrosis. JAMA 1992;267(14):1947-51. ż.
- JANK 1992(20)(14)(1947-51. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respira-tory symptomes and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42.
- McCoy K, Hamilton S, Johnson C. Effects of 12-week ad-ministration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996;110:889-95.

Pulmozyme® (dornase alfa)

Revised January 2001 © 2001 Genentech, Inc. INHALATION SOLUTION

4812405

R

Manufactured by

GENENTECH, Inc. 1 DNA Way

South San Francisco, CA 94080-4990 Shown in Product Identification Guide, page 315

(Rituximab)

WARNINGS

Fatal Infusion Reactions: Deaths within 24 hours of RITUXAN infusion have been reported. These fatal re-actions followed an infusion reaction complex which included hypoxia, pulmoary inflirates, acute respiratory distress syndrome, myocardial infarction, ventricular fi-brillation or cardiogenic shock. Approximately 80% of fatal infusion reactions occurred in association with the. first infusion. (See WARNINGS and ADVERSE REACTIONS.)

Patients who develop severe infusion reactions should have RITUXAN infusion discontinued and receive medical treatment

Tumor Lysis Syndrome (TLS): Acute renal failure re-quiring dialysis with instances of fatal outcome has been reported in the setting of TLS following treatment with RITUXAN. (See WARNINGS.)

Severe Mucocutaneous Reactions: Severe mucocutaneous reactions, some with fatal outcome, have been re-ported in association with RITUXAN treatment. (See WARNINGS and ADVERSE REACTIONS.)

DESCRIPTION

The RITUXAN® (Rituximab) antibody is a genetically engineered chimeric murine/human monoclonal antibody di rected against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an normal and malignant B lymphocytes. The antibody is an IgG_1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino for the CD20 antigen of approximately 8.0 nM. The chimeric anti-CD20 antibody is produced by mammalian cell (Chinese Hamster Ovary) suspension culture in a nutrient medium containing the antibiotic gentamicin. Gen-

tamicin is not detectable in the final product. The anti-CD20 antibody is purified by affinity and ion exchange chro-CD20 antibiody is purned by ammity and ion exchange enro-matography. The purification process includes specific viral inactivation and removal procedures. Rituximab drug prod-uct is manufactured from either bulk drug substance man-ufactured by Genentech, Inc. (US License No. 1048) or uti-lizing formulated bulk. Rituximab supplied by IDEC Pharmaceuticals Corporation (US License No. 1235) under a shared manufacturing arrangement.

a shared manufacturing arrangement. RITUXAN is a sterile, clear, colorless, preservative-free liq-uid concentrate for intravenous (IV) administration. RITUXAN is supplied at a concentration of 10 mg/mL in ei-ther 100 mg (10 mL) or 500 mg (50 mL) single-use vials. The product is formulated for IV administration in 9.0 mg/mL sodium chloride, 7.35 mg/mL sodium citrate dihydrate, 0.7 mg/mL polysorbate 80, and Sterile Water for Injection. The pH is adjusted to 6.5.

CLINICAL PHARMACOLOGY General

Rituximab binds specifically to the antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a B-lymphocyte-restricted differentiation antigen, Bp3S), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre-B and mature B lymphocytes.¹⁴ The antigen is also expressed on > 90% of B-cell non-Hodgkin's lymphomas (NHL),³-but is not found on hematopoietic stem cells, pro-B cells, normal plasma cells or other normal tissues.⁴ CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation,⁴ and possibly functions as a calcium ion channel.⁵ CD20 is not shed from the cell surface and does

Preclinical Pharmacology and Toxicology Mechanism of Action: The Fab domain of Rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in the Descharge of cell being for the state of the sta recruits immune effector functions to mediate B-cell lysis in vitro. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC)⁷ and antibody-dependent cell mediated cytotoxicity (ADCC). The antibody has been shown to induce apoptosis in the DHL-4 human B-cell lym-phoma line.⁸

Normal Tissue Cross-reactivity: Rituximab binding was observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding was observed in the non-lymphoid tissues examined.

Human Pharmacokinetics/Pharmacodynamics

Human Pharmacokinetics/Pharmacodynamics In patients given single doses at 10, 50, 100, 250 or 500 mg/m² as an IV infusion, serum levels and the half-life of Rituximab were proportional to dose.⁹ In 14 patients given 375 mg/m² as an IV infusion for 4 weekly doses, the mean serum half-life way 76.3 hours (range, 31.5 to 152.6 hours) after the first infusion and 205.8 hours (range, 83.9 to 407.0 hours); after the fourth infusion.^{10,112} The wide range of half-lives may reflect the variable tumor burden among patients and the changes in CD20-positive (normal and malignant) B-cell populations upon repeated adminis-

RITUXAN at a dose of 375 mg/m² was administered as an In rotation at a close of 375 mg/m⁻ was administered as an UV infusion at weekly intervals for 4 does to 203 patients naive to RITUXAN. The mean C_{max} following the fourth infusion was 486 pg/mL (range, 77.5 to 996.6 pg/mL). The peak and trough serum levels of Riturixmab were inversely correlated with baseline values for the number of circulation CD00 existing D00 existing D000 existing D000 existing D000 existing D000ing CD20 positive B cells and measures of disease burden. Median steady-state serum levels were higher for respondrection steady-state serum levels were higher for respond-ers compared with nonresponders; however, no difference was found in the rate of elimination as measured by serum half-life. Serum levels were higher in patients with Interna-tional Working Formulation (IWF) subtypes B, C, and D as compared with those with subtype A. Rituximab was detect-ble is the more formulation of the second se able in the serum of patients 3 to 6 months after completion of treatment

RITUXAN at a dose of 375 mg/m² was administered as an We influe at a weekly intervals for 8 does to 37 patients. The mean C_{max} after 8 influeions was 550 µg/mL/crange, 171 to 1177 µg/mL). The mean C_{max} increased with each successive influeion through the eighth influeion (Table 1).

	Table 1 Rituximab C _{max} Valu	1998 (1998)
Infusion Number	Mean C _{max} µg/mL	Range µg/mL
1	242.6	16.1–581.9
2	357.5	106.8–948.6
3	381.3	110:5-731.2
	460.0	138.0-835.8
- 16 ⁻⁵ -5-5-5-5	475.3 515.4	156.0-929.1 152.7-865.2
7	544.6	187.0-936.8
8	550.0	170.6-1177.0

The pharmacokinetic profile of RITUXAN when administered as 6 infusions of 375 mg/m^2 in combination with 6 ycles of CHOP chemotherapy was similar to that seen with RITUXAN alone.

Administration of RITUXAN resulted in a rapid and susained depletion of circulating and tissue-based B cells. Lymph node biopsies performed 14 days after therapy showed a decrease in the percentage of B cells in seven of eight patients who had received single doses of Rituxinab \geq 100 mg/m^{2,9} Among the 166 patients in the pivotal study, circulating B cells (measured as CD19-positive cells) were depleted within the first three does with sustained depletion for up to 6 to 9 months post-treatment in 83% of pa-tionis for up to 6 to 9 months post-treatment in 83% of pa-tients. Of the responding patients assessed (n = 80), 1% failed to show significant depletion of CD19-positive cells after the third infusion of Rituximab as compared to 19% of the nonresponding patients. B-cell recovery began at approximately 6 months following completion of treatment. Median Bicell levels returned to normal by 12 months folowing completion of treatment.

There were sustained and statistically significant reduc-tions in both IgM and IgG serum levels observed from 5 through 11 months following Rituximals administration. However, only 14% of patients had reductions in IgM and/or IgG serum levels, resulting in values below the normal

CLINICAL STUDIES

Studies with a collective enrollment of 296 patients having relapsed or refractory low-grade or follicular B-cell NHL are described below (Table 2). RITUXAN regimens tested in-clude treatment weekly for 4 doses and treatment weekly for 8 doses. Clinical settings studied were initial treatment, initial treatment of bulky disease, and retreatment. [See table 2 at top of next page]

Isee table 2 at top of next page) Initial Treatment, Weekly for 4 doses A multicenter, open-label, single-arm study was conducted in 166 patients with relapsed or refractory low-grade or fol-licular B-cell NHL who received 375 mg/m² of RTTUXAN given as an IV infusion weekly for 4 doses.¹⁹ Patients with

Lilly Exhibit 1255, Page 11 of 39

RITUXAN®

Rituxan-Cont.

tumor masses >10 cm or with >5,000 lymphocytes/ μ L in the peripheral blood were excluded from the study. The overall response rate (ORR) was 48% with 6% complete response (CR) and 42% partial response (PR) rates. The median time to onset of response was 50 days and the median duration of response was 11.2 months (range, 1.9 to 42.1+). Disease-related signs and symptoms (including B-sym toms) were present in 23% (39/166) of patients at study en-try and resolved in 64% (25/39) of those patients.

In a multivariate analysis, the ORR was higher in patients with IWF B, C, and D histologic subtypes as compared to IWF subtype A (55% vs. 12%), higher in patients whose largest lesion was <5 cm vs. >7 cm (maximum, 21 cm) in greatest diameter (53% vs. 38%), and higher in patients with chemosensitive relapse as compared with chemoresistant (defined as duration of response <3 months) relapse (53% vs. 36%). ORR in patients previously treated with autolo-gous bone marrow transplant was 78% (18/23). The following adverse prognostic factors were not associated with lower response rate: age ≥60 years, extranodal disease, prior anthracycline therapy, and bone marrow involvement. Initial Treatment, Weekly for 8 Doses In a multicenter, single-arm study, 37 patients with re

lapsed or refractory, low-grade NHL received 375 mg/m² of RITUXAN weekly for 8 doses. The ORR was 57% (CR 14%, PR 43%) with a projected median duration of response of 13.4 months (range, 2.5 to 36.5+).¹⁴ (For information on the higher incidence of Grade 3 and 4 adverse events, see AD-VERSE REACTIONS, Risk Factors Associated with Increased Rates of Adverse Events.)

Initial Treatment, Bulky Disease, Weekly for 4 Doses

Initial reatment, bulky Usease, weekly for 4 Doses In pooled data from multiple studies of RITUXAN, 39 pa-tients with relapsed or refractory, bulky disease (single le-sion >10 cm in diameter), low-grade NHL received 375 mg/m² of RITUXAN weekly for 4 doses. The ORR was 36% (CR 3%, PR 33%) with a median duration of response of 6.9 months (range 2.8 to 25.0+). (For information of response of higher incidence of Grade 3 and 4 adverse events, see AD-VERSE REACTIONS, Risk Factors Associated with Increased Rates of Adverse Events.) Retreatment, Weekly for 4 Doses

In a multi-center, single-arm study, 60 patients received 375 mg/m² of RITUXAN weekly for 4 doses.¹⁵ All patients had relapsed or refractory, low-grade or follicular B-cell NHL and had achieved an objective clinical response to a prior course of RITUXAN. Of these 60 patients, 55 received prior course of R11 UZAN. Ut these 60 patients, 55 received their second course of R11UXAN. 3 patients received their third course and 2 patients received their second and third courses of R1TUXAN in this study. The ORR was 38% (10% CR and 28% PR) with a projected median duration of re-sponse of 15 months (range, 3.0 to 25.1+ months).

INDICATIONS AND USAGE

RITUXAN is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma.

CONTRAINDICATIONS

RITUXAN is contraindicated in patients with known anaphylaxis or IgE-mediated hypersensitivity to murine pro-teins or to any component of this product. (See WARN-INGS.)

WARNINGS (See BOXED WARNINGS.) Severe Infusion Reactions (See BOXED WARNINGS, AD-VERSE REACTIONS and Hypersensitivity Reactions): RITUXAN has caused severe infusion reactions. In some cases, these reactions were fatal. These severe reactions typically occurred during the first infusion with time to on-set of 30 to 120 minutes. Signs and symptoms of severe infusion reactions may include hypotension, angioedema, hyp-oxia or bronchospasm, and may require interruption of RITUXAN administration. The most severe manifestations and sequelae include pulmonary infiltrates, acute respira-tory distress syndrome, myocardial infarction, ventricular fibrillation, and cardiogenic shock. In the reported cases, the following factors were more frequently associated with fatal outcomes: female gender, pulmonary infiltrates, and

acta outcomes, leinate genoer, purmonary innitrates, and chronic lymphocytic leukemia or mantle cell lymphoma. Management of severe infusion reactions: The RITUXAN infusion should be interrupted for severe reactions and sup-portive care measures instituted as medically indicated (e.g., intravenous fluids, vasopressors, oxygen, bronchodila-tors, diphenhydramine, and acetaminophen). In most cases, the infusion can be resumed at a 50% reduction in rate (e.g., from 100 mg/hr to 50 mg/hr) when symptoms have com-pletely resolved. Patients requiring close monitoring during first and all subsequent infusions include those with preexisting cardiac and pulmonary conditions, those with prior clinically significant cardiopulmonary adverse events and those with high numbers of circulating malignant cells (≥ 25,000/mm³) with or without evidence of high tumor burden

Tumor Lysis Syndrome [TLS] (See BOXED WARNINGS and ADVERSE REACTIONS);

Rapid reduction in tumor volume followed by acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hy-perphosphatasemia, have been reported within 12 to 24 hours after the first RITUXAN infusion. Rare instances of fatal outcome have been reported in the setting of TLS following treatment with RITIVAN The wide of TLS PHYSICIANS' DESK REFERENCE®

Table 2 Summary of RITUXAN Efficacy Data by Schedule and Clinical Setting (See ADVERSE REACTIONS for Risk Factors Associated with Increased Rates of Adverse Events.)

	Initial,	Initial,	Initial, Bulky,	Retreatment,
	Weekly×∞4	Weekly× 8	Weekly × 4	Weekly× 4
	N = 166	N = 37	N = 39 ¹	N = 60
Overall Response Rate Complete Response	48%	57%	36%	38%
Rate Median Duration of	6%	14%	3%	10%
Response ^{2,3,4} (Months)	11.2	13.4	6.9	15.0
[Range]	[1.9 to 42.1+]	[2.5 to 36.5+]	[2.8 to 25.0+]	[3.0 to 25.1+]

Six of these patients are included in the first column. Thus, data from 296 intent to treat patients are provided in this table. ²Kaplan-Meier projected with observed range ³"+" indicates an ongoing response.

⁴Duration of response: interval from the onset of response to disease progression.

lating malignant cells (≥25,000/mm³) or high tumor burden. Prophylaxis for TLS should be considered for patients at high risk. Correction of electrolyte abnormalities, monitoring of renal function and fluid balance, and administra-tion of supportive care, including dialysis, should be initiated as indicated. Following complete resolution of the complications of TLS, RITUXAN has been tolerated when re-administered in conjunction with prophylactic therapy for TLS in a limited number of cases

Hypersensitivity Reactions:

RITUXAN has been associated with hypersensitivity reac tions (non-IgE-mediated reactions) which may respond to adjustments in the infusion rate and in medical manage ment. Hypotension, bronchospasm, and angioedema have occurred in association with RITUXAN infusion (see Severe Infusion Reactions). RITUXAN infusion should be inter Initiation reactions). All OAAN initiation should be inter-rupted for severe hypersensitivity reactions and can be re-sumed at a 50% reduction in rate (e.g., from 100 mg/hr to 50 mg/hr) when symptoms have completely resolved. Treat-ment of these symptoms with diphenhydramine and acetaminophen is recommended; additional treatment with bronchodilators or IV saline may be indicated. In most cases, patients who have experienced non-life-threatening hypersensitivity reactions have been able to complete the full course of therapy. (See DOSAGE and ADMINISTRA-TION.) Medications for the treatment of hypersensitivity reactions, e.g., epinephrine, antihistamines and corticoster-oids, should be available for immediate use in the event of a reaction during administration.

Cardiovascular: Infusions should be discontinued in the event of serious or life-threatening cardiac arrhythmias. Patients who develop clinically significant arrhythmias should undergo cardiac monitoring during and after subsequent infusions of RITUXAN. Patients with pre-existing cardiac conditions including arrhythmias and angina have had recurrences of these events during RITUXAN therapy and should be monitored throughout the infusion and immediate post-infusion period. Renal

RITUXAN administration has been associated with severe renal toxicity including acute renal failure requiring dialy-sis and in some cases, has led to a fatal outcome. Renal toxicity has occurred in patients with high numbers of circulat-ing malignant cells (>25,000/mm³) or high tumor burden who experience tumor lysis syndrome (see Tumor Lysis Syn who experience tumor lysis syndrome (see Tumor Lysis Syn-drome) and in patients administered concomitant isplatin therapy during clinical trials. The combination of cisplatin and RITUXAN is not an approved treatment regimen. If this combination is used in clinical trials extreme caution should be exercised; patients should be monitored closely for signs of renal failure. Discontinuation of RITUXAN should be considered for those with rising serum creatinine or oliguria

Severe Mucocutaneous Reactions (See BOXED WARN INGS and ADVERSE REACTIONS.):

Mucocutaneous reactions, some with fatal outcome, have been reported in patients treated with RITUXAN. These rebeen reported in patients treated with KITUAAN. These re-ports include paraneoplastic pemphigus (an uncommon dis-order which is a manifestation of the patients underlying malignancy).¹⁶ Stevens-Johnson syndrome, lichenoid der-matitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. The onset of the reaction in the reported cases has varied from 1 to 13 weeks following RITUXAN expo sure. Patients experiencing a severe mucocutaneous reaction should not receive any further infusions and seek prompt medical evaluation. Skin biopsy may help to distin-guish among different mucocutaneous reactions and guide subsequent treatment. The safety of readministration of RITUXAN to patients with any of these mucocutaneous reactions has not been determined

PRECAUTIONS

Laboratory Monitoring: Because RITUXAN targets all CD20-positive B lymphocytes, malignant and nonmalig-nant, complete blood counts (CBC) and platelet counts should be obtained at regular intervals during RITUXAN therapy and more frequently in patients who develop cy-topenias (see ADVERSE REACTIONS). The duration of cytopenias caused by RITUXAN can extend well beyond the treatment period.

Drug/Laboratory Interactions: There have been no formal drug interaction studies performed with RITUXAN. HowHACA Formation: Human antichimeric antibody (HACA) was detected in 4 of 356 patients and 3 had an objective clinical response. The data reflect the percentage of patients whose test results were considered positive for antibodies to RITUXAN using an enzyme-linked immunosorbant assay (limit of detection = 7 ng/mL). The observed incidence of antibody positivity in an assay is highly dependent on the sensitivity and specificity of the assay and may be influ-enced by several factors including sample handling, concomitant medications, and underlying disease. For these rea-sons, comparison of the incidence of antibodies to RITUXAN with the incidence of antibodies to other products may be misleading. Immunization: The safety of immunization with live viral

vacines following RITUXIAN therapy has not been studied. The ability to generate a primary or anamnestic humoral response to vaccination is currently being studied. **Carcinogenesis, Mutagenesis, Impairment of Ferliity:** No long-term animal studies have been performed to establish

the carcinogenic or mutagenic potential of RITUXAN, or to determine its effects on fertility in males or females. Indi-viduals of childbearing potential should use effective contraceptive methods during treatment and for up to 12 months following RITUXAN therapy.

Pregnancy Category C: Animal reproduction studies have not been conducted with RITUXAN. It is not known whether RITUXAN can cause fetal harm when administered to a pregnant woman or whether it can affect repro-ductive capacity. Human IgG is known to pass the placental barrier, and thus may potentially cause fetal B-cell deple-tion; therefore, RITUXAN should be given to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether RITUXAN is excreted in human milk. Because human IgG is excreted in human milk and the potential for absorption and immunosuppression in the infant is unknown, women should be advised to discontinue nursing until circulating drug levels are no longer detectable. (See CLINICAL PHARMACOL-OGY.)

Pediatric Use: The safety and effectiveness of RITUXAN in

Pediatric Use: The safety and effectiveness of RITUXAN in pediatric patients have not been established. Geriatric Use: Among the 331 patients enrolled in clinical studies of single agent RITUXAN, 24% were 65 to 75 years old and 5% were 75 years old and older. The overall re-sponse rates were higher in older (age \geq 65 years) vs. younger (age < 65 years) patients (52% vs. 44%, respec-tively). However, the median duration of response, based on Kanlan Meirr astimutes, were about as in older were response. Kaplan-Meier estimates, was shorter in older vs. younger patients: 10.1 months (range, 1.9 to 36.5+) vs. 11.4 months (range, 2.1 to 42.1+), respectively. This shorter duration of response was not statistically significant. Adverse reactions, including incidence, severity and type of adverse reaction were similar between older and younger patients.

ADVERSE REACTIONS

The most serious adverse reactions caused by RITUXAN include infusion reactions, tumor lysis syndrome, mucocutaneous reactions, hypersensitivity reactions, cardiac ar-rhythmias and angina, and renal failure. Please refer to the BOXED WARNINGS and WARNINGS sections for detailed descriptions of these reactions. Infusion reactions and lym-phopenia are the most commonly occurring adverse reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Additional adverse reactions have been identified during postmarketing use of RITUXAN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to RITUXAN exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to RITUXAN

Where specific percentages are noted, these data are based on 356 patients treated in nonrandomized, single-arm studies of RITUXAN administered as a single agent. Most pa-

≥10 cm) and 60 patients who received more than 1 course of RTUXAN. Thirty-seven patients received 375 mg/m² for 8 doses and 25 patients received, doses other than 375 mg/m² for 4 doses and up to 500 mg/m² single dose in the Phase 1 setting. Adverse events of greater severity are referred to as "Grade 3 and 4 events" defined by the commonly used National Cancer Institute Common Toxicity Criteria.¹⁷

Table 3 Incidence of Adverse Events ≥ 5% of Patients in Clinical Trials (N = 356) (Adverse Events were followed for a period of 12 months following RITUXAN therapy.)

24 1	All Grades (%)	Grade 3 and 4 (%)
Any Adverse Events	99	. 57
Body as a Whole	86	10
Fever	- 53	1
Chills	33	3
Infection	31	4
Asthenia	26	1
Headache	19	ĩ
Abdominal Pain	14	1
Pain	12	. 1
Back Pain	10	1
Threat Irritation	9	0
	5	0
Flushing		
Cardiovascular System	25	
Hypotension	10	1
Hypertension	- 6	
Digestive System	37	2
Nausea	23	1
Diarrhea	10	
Vomiting	10	· · · 1 · ·
Hemic and Lymphatic	67	48
System		
Lymphopenia	48	40
Leukopenia	14	4
Neutropenia	14	6 -
Thrombocytopenia	12	2
Anemia	8	. 3
Metabolic and Nutritional		3
Disorders		3
Angioedema	11	
Hyperglycemia	9	1
	8	1
Peripheral Edema	7	0
LDH Increase		0 0
Musculoskeletal System	26	3
Myalgia	10	- 1
Arthralgia	10	1
Nervous System	32	ii ∈ 1° i
Dizziness	10	5.1.1.1.1.4
Anxiety	5	
Respiratory System	38 .	4
Increased Cough	13	1997 - 1 999 -
Rhinitis	12	- 1 I
Bronchospasm	. 8	1
Dyspnea	. 7	· . 1
Sinusitis	6	, Ō
Skin and Appendages	44	2
Night Sweats	15	1
Rash	15	1 .
Pruritus	15	1
Urticaria	8	1
orucaria	8	16.4

Risk Factors Associated with Increased Rates of Adverse Events:

Administration of RITUXAN weekly for 8 doses resulted in higher rates of Grade 3 and 4 adverse events¹⁷ overall (70%) compared with administration weekly for 4 doses (57%). The incidence of Grade 3 or 4 adverse events was similar in patients retreated with RITUXAN compared with initial treatment (58% and 57%, respectively). The incidence of the following clinically significant adverse events was higher in patients with bulky disease (lesions ≥ 10 cm) (N = 39) versus patients with lesions < 10 cm (N = 195); abdominal pain, anemia, dyspnea, hypotension, and neutropenia. Infusion Reactions (See BOXED WARNINGS and WARN-

Infusion Reactions (see DOADD MARTINO and THEM INGS): Mild to moderate infusion reactions consisting of fever and chills/rigors occurred in the majority of patients during the first RITUXAN infusion. Other frequent infusion reaction symptoms included nausea, pruritus, angioedema, asthenia, hypotension, headache, bronchospasm, throat ir-ritation, rhinitis, urticaria, rash, vomiting, myalgia, dizzi-ness, and hypertension. These reactions generally occurred within 30 to 120 minutes of beginning the first infusion, and resolved with slowing or interruption of the RITUXAN inresolved with slowing or interruption of the KITUXAN in-fusion and with supportive care (diphenhydramine, acet-aminophen, IV saline, and vasopressors). In an analysis of data from 356 patients with relapsed or refractory, low-grade NHL who received 4 (N = 319) or 8 (N = 37) weekly infusions of RITUXAN, the incidence of infusion reactions was highest during the first infusion (77%) and decreased with each subsequent infusion (30% with fourth infusion and 14% with eighth infusion) and 14% with eighth infusion).

Infectious Events: RITUXAN induced B-cell depletion in 70% to 80% of patients and was associated with decreased serum immunoglobulins in a minority of patients; the lym-phopenia lasted a median of 14 days (range, 1 to 588 days). Infectious events occurred in 31% of patients: 19% of pa-

had fungal infections, and 6% were unknown infections. Inhad more than one type of infection. Serious infections investigate the type of infection infection infection infection infection in 2% of 2% of 2%patients

Hematologic Events: Grade 3 and 4 cytopenias¹⁷ were reported in 12% of patients treated with RITUXAN; these in-clude: lymphopenia (40%), neutropenia (6%), leukopenia (4%), anemia (3%), and thrombocytopenia (2%). The median duration of lymphopenia was 14 days (range, 1 to 588 days) and of neutropenia was 13 days (range, 2 to 116 days). A single occurrence of transient aplastic anemia (pure red cell aplasia) and two occurrences of hemolytic anemia following RITUXAN therapy were reported. In addition, there have been rare postmarketing reports of prolonged pancytopenia and marrow hypoplasia. Cardiac Events (See BOXED WARNINGS): Grade 3 or 4

cardiac-related events include hypotension. Rare, fatal car-diac failure with symptomatic onset weeks after RITUXAN has also been reported. Patients who develop clinically significant cardiopulmonary events should have RITUXAN infusion discontinued.

Pulmonary Events (See BOXED WARNINGS): 135 pa-tients (38%) experienced pulmonary events. The most common respiratory system adverse events experienced were increased cough, rhinitis, bronchospasm, dyspnea, and sinusitis. Three pulmonary events have been reported in tem poral association with RITUXAN infusion as a single agent: acute bronchospasm, acute pneumonitis presenting 1-4 weeks post-RITUXAN infusion, and bronchiolitis obliterans. One case of bronchiolitis obliterans was associated with progressive pulmonary symptoms and culminated in death several months following the last RITUXAN infusion. The safety of resumption or continued administration of RITUXAN in patients with pneumonitis or bronchiolitis obliterans is unknown.

Immune/Autoimmune Events: Immune/Autoimmune events have been reported, including uveitis, optic neuritis in a patient with systemic vasculitis, pleuritis in a patient with a lupus-like syndrome, serum sickness with polyarticular arthritis, and vasculitis with rash. Less Commonly Observed Events: In clinical trials, <5%

and >1% of the patients experienced the following events regardless of causality assessment: agitation, anorexia, arthritis, conjunctivitis, depression, dyspepsia, edema, hyperkinesia, hypertonia, hypesthesia, hypoglycemia, injection site pain, insomnia, lacrimation disorder, malaise, nervousness, neuritis, neuropathy, paresthesia, somnolence, vertigo, weight decrease.

OVERDOSAGE

There has been no experience with overdosage in human clinical trials. Single doses of up to 500 mg/m² have been given in controlled clinical trials.¹⁰

DOSAGE AND ADMINISTRATION

Initial Therapy: RITUXAN is given at 375 mg/m² IV infusion once weekly for 4 or 8 doses.

Retreatment Therapy:

Patients who subsequently develop progressive disease may be safely retreated with RITUXAN 375 mg/m² IV infusion once weekly for 4 doses. Currently there are limited data concerning more than 2 courses

RITUXAN as a Component of Zevalin™ (Ibritumomab Tiuxetan) Therapeutic Regimen

is a required component of the Zevalin therapeutic regimen, RITUXAN 250 mg/m² should be infused within 4 hours prior to the administration of Indium-111-(In-111-) Zevalin and within 4 hours prior to the administration of Yttrium-90-(Y-90-) Zevalin. Administration of RITUXAN and In-111-Zevalin should precede RITUXAN and Y-90-Zevalin by 7-9 days. Refer to the Zevalin package insert for full prescribing information regarding the Zevalin therapeutic regimen

RITUXAN may be administered in an outpatient setting. DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS. (See Administration.)

Instructions for Administration

Instructions for Administration Preparation for Administration: Use appropriate aseptic technique. Withdraw the necessary amount of RITUXAN and dilute to a final concentration of 1 to 4 mg/mL into an infusion bag containing either 0.9% Sodium Chloride, USP, or 5% Dextrose in Water, USP. Gently invert the bag to mix the solution. Discard any unused portion left in the vial. Parenteral drug products should be inspected visually for articulate matter and discolarizion prior to administra particulate matter and discoloration prior to administra-

RITUXAN solutions for infusion may be stored at 2-8°C (36-46°F) for 24 hours. RITUXAN solutions for infusion have been shown to be stable for an additional 24 hours at room temperature. However, since RITUXAN solutions do not contain a preservative, diluted solutions should be stored refrigerated (2-8°C). No incompatibilities between RITUXAN and polyvinylchloride or polyethylene bags have been observed.

Administration: DO NOT ADMINISTER AS AN INTRAVE-NOUS PUSH OR BOLUS.

Infusion and hypersensitivity reactions may occur. (see BOXED WARNINGS, WARNINGS, and ADVERSE REAC-TIONS). Premedication consisting of acetaminophen and di-phenhydramine should be considered before each infusion of RITUXAN. Premedication may attenuate infusion reacRITUXAN infusion, consideration should be given to with-holding antihypertensive medications 12 hours prior to RITUXAN infusion.

First Infusion: The RITUXAN solution for infusion should administered intravenously at an initial rate of 50 mg/hr. RITUXAN should not be mixed or diluted with other drugs. If hypersensitivity or infusion reactions do not occur, escalate the infusion rate in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr. If a hypersensitiv-ity (non-IgE-mediated) or an infusion reaction develops, the infusion should be temporarily slowed or interrupted (see BOXED WARNINGS and WARNINGS). The infusion can continue at one-half the previous rate upon improvement of patient symptoms.

Subsequent Infusions: If the patient tolerated the first infusion well, subsequent RITUXAN infusions can be adminis-tered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maxi-mum of 400 mg/hr as tolerated. If the patient did not tolerate the first infusion well, follow the guidelines under First Infusion.

Stability and Storage: RITUXAN vials are stable at $2-8^{\circ}C$ (36-46°F). Do not use beyond expiration date stamped on carton. RITUXAN vials should be protected from direct sunlight. Refer to the "Preparation and Administration" section for information on the stability and storage of solutions of RITUXAN diluted for infusior

HOW SUPPLIED

RITUXAN is supplied as 100 mg and 500 mg of sterile, preservative-free, single-use vials. Single unit 100 mg carton: Contains one 10 mL vial of

RITUXAN (10 mg/mL). NDC 50242-051-21

Single unit 500 mg carton: Contains one 50 mL vial of RITUXAN (10 mg/mL). NDC 50242-053-06

REFERENCES

- 1. Valentine MA, Meier KE, Rossie S, et al. Phosphorylation of the CD20 phosphoprotein in resting B lympho-cytes. J Biol Chem: 1989.264(19):11282-11287.
- 2 Einfeld DA Brown JP Valentine MA et al Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. *EMBO J* 1988 7(3):711-717. 3. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Ex-
- pression of human B cell-associated antigens on leuke-mias and lymphomas: A model of human B cell differen-tiation. *Blood* 1984 63(6):1424–1433.
- 4. Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985 135(2):973-979.
- 5. Tedder TF, Zhou LJ, Bell PD, et al. The CD20 surface molecule of B lymphocytes functions as a calcium chan-
- molecule of B symphocytes functions as a calcium channel. J Cell Biochem 1990 14D:195.
 Press OW, Applebaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 1987 69(2):584-591.
- 1307 0302/034-091. Reff ME, Carner C, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chi-meric mouse human monoclonal antibody to CD20. Blood 1994 83(2):435-445.
- 8. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, and Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) mono-Conal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy & Ra-diopharmaceuticals 1997 12(3):177-186.
- 9. Maloney DG, Liles TM, Czerwinski C, Waldichuk J, Rosenberg J, Grillo-López A, et al. Phase I clinical trial ussenserg of Grino Lopez A, et al. raise t clinical trains ing escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. *Blood* 1994 84(8):2457-2466.
- Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology 1998, 9:995-1001.
- Maloney DG, Grillo-López AJ, Bodkin D, White CA, Liles T-M, Royston I, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997 15(10): 3266-3274.
- 12. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lym-phoma. Blood 1997 90(6):2188-2195.
- McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuc-zman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indo-lent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 16(8):2825-2833.
- 14. Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or re-fractory low-grade or follicular non-Hodgkin's lym-phoma. Annals of Oncology 1999 10:655-661.

Lilly Exhibit 1255, Page 13 of 39

Rituxan—Cont.	Mortality Stroke, and Con
15. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczmań MS, Link BK, Maloney DG, Weaver RL, Ro- senberg J, Levy R. Rituxinab'anti-CD20 monoclonal antibody therapy in non-hodgkin's lymphoma: safety	search annaigh a cart à sart. D' a seus 30-day Evérés a sé d'us branch a seus
and efficacy of re-treatment J Clin Oncol 2000 18(17): 3135–3143. 16. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA,	Mortality ¹ - Etc. (2005), and (2005) (Method Level 1 - great study of the second study (2005), and (2005), and (
Kory M, Izumi H, Ratrie H, Mutasim D, Ariss Abdo L, Labib RS: Paraneoplastic Pemphigus, an autoimmune mucocutaneous disease associated with neoplasia.	Intracranial Hemorrhage (ICH)
 NEJM 1990 323(25):1729–1735. 17. National Institutes of Health (US), National Cancer Institute. Common Toxicity Criteria. (Bethesda, MD): National Cancer Institute. 	Any Stroke.
tional Institutes of Health, National Cancer Institute; c1998. 73p.	Death or Nonfatal Stroke
Jointly Marketed by: IDEC Pharmaceuticals Corporation	<u>a Xiya Basa</u> ABagada aya sa
11011 Torreyana Road, Mittal and the Base of the off San Diego, CA 92121 - Genentech, Inc. 1 DNA Way	्यः स्वान्ध्रेयस्य दिन्द्राः दिक्कीयः स्वान्ध्राः स्वान्ध्रः स्वान्ध्रः स्वान्ध्रीः स्वान्ध्रयः स्वान्ध्रः स्वान्ध्रः स्वान्ध्रः
South San Francisco, CA 94080-4990 (4809705 Revised February 2002)	Activase ≤ (n=31
© 2002 IDEC Pharmaceuticals Corporation and Genentech, Inc.	TIMI Grade 3 Flow 63%
Shown in Product Identification Guide, page 315	TIMI Grade 2/3 Flow 82%

 \mathbf{R}

TNKase™

(Tenecteplase) Full Prescribing Information

DESCRIPTION

Tenecteplase is a tissue plasminogen activator (tPA) pro-duced by recombinant DNA technology using an established mammalian cell line (Chinese Hamster Ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by intro-ducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain. Cell culture is carried out in nutrient me dium containing the antibiotic gentamicin (65 mg/L). However, the presence of the antibiotic is not detectable in the final product (limit of detection is 0.67 µg/vial). TNKase is a mai product (unit of detection is 0.67 gb/via). Trykase is a sterile, white 60 off-white, lopohilized powder for single in-travenous (IV) bolus administration after reconstitution with Sterile Water for Injection (SWFI), USP. Each-vial of TNKase nominally contains 52.5 mg Tenecteplase, 0.55 g L-arginine, 0.17 g phosphoric acid, and 4.3 mg polysorbate 20, which includes a 5% overfill. Each vial will deliver 50 mg of Tenecteplace in the state of the sta Tenecteplase.

CLINICAL PHARMACOLOGY

General Tenecteplase is a modified form of human tissue plasminogen activator (tPA) that binds to fibrin and converts plasgen activator (Jr.A) that mines to norm and convertes pas-minoger to plasmin. In the presence of fibrin, in vitro stud-ies demonstrate that Tenecteplase conversion of plasminogén to plasmin is increased relative to its conver-sion in the absence of fibrin. This fibrin specificity decreases systemic activation of plasminogen and the resulting degradation of circulating fibrinogen as compared to a molecule lacking this property. Following administration of 30, 40, or lacking this property. Following administration of 30, 40, or 50 mg of TIMKase, there are decreases in circulating fibrin-ogen (4%-15%) and plasminogen (11%-24%). The clinical significance of fibrin-specificity'on safety (e.g., bleeding) or efficacy has not been established. Biological potency is de-termined by an *in vitro* clot lysis assay and is expressed in Tenecteplase-specific units. The specific activity of Tenect-eplase has been defined as 200 units/mg. Pharmacokinetics

Pharmacokinetics In patients with acute myocardial infarction (AMI), TNKase administered as a single bolus exhibits a biphasic dispo-sition from the plasma. Tenecteplase was cleared from the plasma with an initial half-life of 02 to 24 minutes. The ter-minal phase half-life of Tenecteplase was 90 to 130 minutes.

minar phase nair-ine of renectephase was 50 to 150 minutes 10:90 of 104 patients' treated with Tenéctephase, mean plasma clearance ranged from 99 to 119 mL/min. The initial volume of distribution is weight related and ap-proximates plasma volume. Liver metabolism is the major clearance mechanism for Tenecteplase.

CLINICAL STUDIES

ASSENT-2 was an international, randomized, double-blind trial that compared 30-day mortality rates in 16,949 pa-tients assigned to receive an IV bolus dose of TNKase or an there assigned to reduve an 1v boos does of riverse of an accelerated infusion of Activase® (Alteplase, recombinant).¹ Eligibility criteria included onset of chest pain within 6 hours of randomization and ST-segment elevation or left bundle branch block on electrocardiogram (BCG). Patients were to be excluded from the trial if they received GP llb/ IIIa inhibitors within the previous 12 hours. TNKase was dosed using actual or estimated weight in a weight-tiered fashion as described in DOSAGE AND ADMINISTRATION. fashion as described in Dostob Attention in the administration of the second se administered as a 4000 unit IV bolus followed by infusion at $800~{\rm U/hr};$ for patients weighing $>67~{\rm kg},$ heparin was administered as a 5000 unit IV bolus followed by infusion at 1000 U/hr. Heparin was continued for 48 to 72 hours with infusion adjusted to maintain aPTT at 50-75 seconds. The use of GP IIb/IIIa inhibitors was discouraged for the first 24 use of of Horizan animoto was discontaged of the rise of hours following randomization. The results of the primary endpoint (30-day mortality rates with non-parametric ad-justment for the covariates of age, Killip class, heart rate, systolic blood pressure and infarct location) along with selected other 30-day endpoints are shown in Table 1

[See table 1 above]

Rates of mortality and the combined endpoint of death or stroke among pre-specified subgroups, including age, gen-der, time to treatment, infarct location, and history of previous myocardial infarction, demonstrate consistent relative risks across these subgroups. There was insufficient enrollment of non-Caucasian patients to draw any conclusions re-garding relative efficacy in racial subsets.

Rates of in-hospital procedures, including percutaneous transluminal coronary angioplasty (PTCA), stent place-ment, intra-aortic balloon pump (IABP) use, and coronary artery bypass graft (CABG) surgery, were similar between the TNKase and Activase groups.

the TNKase and Activase groups. TIMI 10B was an open-label, controlled, randomized, dose-ranging, angiography study which utilized a blinded core laboratory for review of coronary arteriograms.² Patients (n =387) presenting within 12 hours of symptom ionset were treated with fixed doses of 30, 40, or 50 mg of TNKase or the accelerated infusion of Activase and underwent coronary ar-teriography at 90 minutes. The results showed that the 40 mg and 50 mg doses were similar to accelerated infusion of Activase in restoring patency. TIMI grade 3 flow and TIMI grade 2/3 flow at 90 minutes are shown in Table 2. The exact relationship between coronary artery patency and clinical activity has not been established.

[See table 2 above] The angiographic results from TIMI 10B and the safety data from ASSENT-1, an additional uncontrolled safety study of 3,235 TNKase-treated patients, provided the framework to develop a weight-tiered TNKase dose regiment² Exploratory analyses suggested that a weight-ad-justed dose of 0.5 mg/kg to 0.6 mg/kg of TNKase resulted in a better patency to bleeding relationship than fixed doses of TNKase across a broad range of patient weights down as a

INDICATIONS AND USAGE

TNKase is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI). Treat-ment should be initiated as soon as possible after the onset of AMI symptoms (see CLINICAL STUDIES).

CONTRAINDICATIONS TNKase therapy in patients with acute myocardial infarc-tion is contraindicated in the following situations because of an increased risk of bleeding (see WARNINGS): Active internal bleeding

- History of cerebrovascular accident
- Intracranial or intraspinal surgery or trauma within 2 months
- Intracranial neoplasm, arteriovenous malformation, or aneurysm Known bleeding diathesis
- Severe uncontrolled hypertension and an analysis Col
- WARNINGS Bleeding

The most common complication encountered during TNKase therapy is bleeding. The type of bleeding associated

in a second second we have a state of the second Table 1 ASSENT-2 mbined Outcome of Death or Stroke Measured at Thirty Days

	TNKase/Activase
E.J. 21	
1 101 101 1 0.9% Low 11080-2	Sec. 16.1 10.99 (44) 11
State States D 1.7% Hondard of State 1.7% Hondard of Market States (Market States)	1.07 (0.86, 1.35)
	come Accelerated Activase - 14- come (N=8488) - 14-05 - 14

Table 2 TIMI 10B Patency Rates TIMI Grade Flow at 90 Minutes

and the second sec				
	Activase ≤ 100 mg (n = 311)	TNKase 30 mg (n = 302)	TNKase 40 mg (n = 148)	TNKase 50 mg (n = 76)
TIMI Grade 3 Flow	the second se		63%	66%
TIMI Grade 2/3 Flow	82%	77%	79%	88%
95% CI (TIMI 2/3 Flow)	(77%, 86%)	(72%, 81%)	(72%, 85%)	(79%, 94%)

Internal bleeding, involving intracranial and retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts. Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, ar-terial punctures) or sites of recent surgical intervention.

Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In clinical studies of TNKase, patients were treated with

In clinical studies of IVIAse, patients were build of the bleeding risks associated with TNKase. The safety of the use of TNKase with other antiplatelet agents has not been adequately studied (see <u>PRECAUTIONS</u>: Drug Interac-tions). Intramuscular injections and nonessential handling of the patient should be avoided for the first few hours fol-lowing treatment with TNKase. Venipunctures should be performed and monitored carefully.

Should an arterial puncture be necessary during the first few hours following TNKase therapy, it is preferable to use an upper extremity vessel that is accessible to manal com-pression. Pressure should be applied for at least 30 minutes. a pressure dressing applied, and the puncture site checked frequently for evidence of bleeding. Each patient being considered for therapy with TNKase

should be carefully evaluated and anticipated benefits weighed against potential risks associated with therapy. In the following conditions, the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits:

- Recent major surgery, e.g., coronary artery bypass graft, obstetrical delivery, organ biopsy, previous puncture of noncompressible vessels
- Cerebrovascular disease
- Recent gastrointestinal or genitourinary bleeding
- Recent trauma • Hypertension: systolic BP ≥ 180 mm Hg and/or diastolic
- BP > 110 mm Hg.
 High likelihood of left heart thrombus, e.g., mitral steno-
- sis with atrial fibrillation Acute pericarditis
- Subacute bacterial endocarditis Hemostatic defects, including those secondary to severe
- hepatic or renal disease Severe, hepatic dysfunction
- Pregnancy
- · Diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions
- · Septic thrombophlebitis or occluded AV cannula at seriously infected site
- Advanced age (see <u>PRECAUTIONS</u>: Geriatric Use) · Patients currently receiving oral anticoagulants, e.g.,
- warfarin sodium
- Recent administration of GP IIb/IIIa inhibitors
- Any other condition in which bleeding constitutes a sig-nificant hazard or would be particularly difficult to manage because of its location Cholesterol Embolization

Cholesteril embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true ind-dence is unknown. This serious condition, which can be le-thal, is also associated with invasive vascular procedures (e.g., cardiac catheterization, angiography, vascular sur-gery) and/or anticoagulant therapy. Clinical features of cho-lesterol embolism may include livedo reticularis, "purple tee" syndrome, acute renal failure, gangrenous digits, hy-pertension, pancreatitis, myocardial infarction, cerebral in-ference renal information, rotinal artery occlusion

Lilly Exhibit 1255, Page 14 of 39

1724/IDEC

Rituxan-Cont.

tions. Since transient hypotension may occur during RITUXAN infusion, consideration should be given to withholding antihypertensive medications 12 hours prior to RITUXAN infusion.

First Infusion: The RITUXAN solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. RITUXAN should not be mixed or diluted with other drugs. If IDAAN should not be mixed of duited with other drugs. If hypersensitivity or influsion reactions do not occur, esca-late the infusion rate in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr. If a hypersensiti-ity (non-IgE-mediated) or an influsion reaction develops, the influsion should be temporarily slowed or interrupted (see BOXED WARNINGS and WARNINGS). The influsion can continue at one-half the previous rate upon improvement of patient symptoms.

Subsequent Infusions: If the patient tolerated the first infusion well, subsequent RITUXAN infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated. If the patient did not tolerate the first infusion well, follow the guidelines under First Infusion

Stability and Storage: RITUXAN vials are stable at 2-8°C (36-46°F). Do not use beyond expiration date stamped on carton. RITUXAN vials should be protected from direct sunlight. Refer to the "Preparation and Admin-istration" section for information on the stability and stor-age of solutions of RITUXAN diluted for infusion.

HOW SUPPLIED

RITUXAN is supplied as 100 mg and 500 mg of sterile, preservative-free, single-use vials

Single unit 100 mg carton: Contains one 10 mL vial of RITUXAN (10 mg/mL).

NDC 50242-051-21 Single unit 500 mg carton: Contains one 50 mL vial of RITUXAN (10 mg/mL).

NDC 50242-053-06 REFERENCES

- Valentine MA, Meier KE, Rossie S, et al. Phosphoryla-tion of the CD20 phosphoprotein in resting B lympho ytes. J Biol Chem 1989 264(19):11282-11287.
- 2. Einfeld DA, Brown JP, Valentine MA, et al. Molecular Janica DA, Divin DJ, Valenzi AL, et al. Indectati cloning of the human B cell CD2 receptor predicts a hydrophobic protein with multiple transmembrane do-mains. EMBO J 1988 7(3):711-717.
- 3. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leuke-mias and lymphomas: A model of human B cell differentiation. Blood 1984 63(6):1424-1433.
- 4. Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985 135(2):973-979
- 5. Tedder TF, Zhou LJ, Bell PD, et al. The CD20 surface molecule of B lymphocytes functions as a calcium channel. J Cell Biochem 1990 14D:195.
 Press OW, Applebaum F, Ledbetter JA, Martin PJ,
- Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. *Blood* 1987 69(2):584-591.
- 7. Reff ME, Carner C, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chi-meric mouse human monoclonal antibody to CD20. Blood 1994 83(2):435-445
- 8. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, and Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) mono-clonal antibody sensitizes a B cell lymphoma cell line to
- clonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy & Ra-diopharmaceuticals 1997 12(3):177-186.
 9. Maloney DG, Liles TM, Czerwinski C, Waldichuk J, Ro-senberg J, Grillo-López A, et al. Phase I clinical trial us-ing escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994 84(8):2457-2466.
- 0405.2407-2400.
 10. Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low grade or follicular non-Hodgkin's lymphoma. Annals of Oncology 1998, 9:995-1001.
- Maloney DG, Grillo-López AJ, Bodkin D, White CA, Liles T-M, Royston I, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997 15(10): 3266-3274
- Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in
- matterist with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997 90(6):2188-2195.
 McLaughin P, Grillo-López AJ, Link BK, Levy R, Czuzzman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indo-

CD20 monoclonal antibody) therapy for relapsed or re-CD20 monoconari antuno0y interapy for respect of re-fractory low-grade or follicular non-Hodgkin's lym-phoma. Annals of Oncology 1999 10:655-661. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Ro-

- 15 senberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000 18(17): 3135-3143
- 16. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Lumi H, Ratrie H, Mutasim D, Ariss-Abdo L, Labib RS. Paraneoplastic Pemphigus, an autoimmune mucocutaneous disease associated with neoplasia. NEJM 1990 323(25):1729-1735
- 17. National Institutes of Health (US), National Cancer Institute. Common Toxicity Criteria. [Bethesda, MD]: Na-tional Institutes of Health, National Cancer Institute; c1998. 73p.

Jointly Marketed by:

IDEC Pharmaceuticals Corporation 11011 Torreyana Road

San Diego, CA 92121 Genentech, Inc.

1 DNA Way

- South San Francisco, CA 94080-4990
- (4809705 Revised February 2002) © 2002 IDEC Pharmaceuticals Corporation and Genentech. Inc.
- Shown in Product Identification Guidé, page 321

ZEVALIN®

[zĕ-vă-lĭn] (Ibritumomab Tiuxetan)

For intravenous use only as part of Zevalin Therapeutic Regimen

Kits for the Preparation of Indium-111 (In-111) Ibritumo mab Tiuxetan (In-111 ZEVALIN) and Yttrium-90 (Y-90) Ibritumomab Tiuxetan (Y-90 ZEVALIN) In-111 Ibritumomab Tiuxetan and Y-90 Ibritumomab Tiuxetan

etan are components of the ZEVALIN therapeutic regimen (See Description).

WARNINGS

Fatal Infusion Reactions: Deaths have occurred within 24 hours of Rituximab infusion, an essential component of the ZEVALIN therapeutic regimen. These fatalities were associated with an infusion reaction symptom complex that included hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction ventricular fibrillation, or cardiogenic shock. Approximately 80% of fatal infusion reactions occurred in asso-ciation with the first Rituximab infusion (See WARN-INGS and ADVERSE REACTIONS). Patients who develop severe infusion reactions should have Ritux-imab, In-111 ZEVALIN, and Y-90 ZEVALIN infusions

discontinued and receive medical treatment. Prolonged and Severe Cytopenias: Y-90 ZEVALIN administration results in severe and prolonged cytopenias in most patients. The ZEVALIN therapeutic regimen should not be administered to patients with $\geq 25\%$ lymphoma marrow involvement and/or impaired bone marrow reserve (See WARNINGS and ADVERSE REACTIONS)

- Dosina The prescribed, measured, and administered dose of Y-90 ZEVALIN should not exceed the absolute maxi-
- mum allowable dose of 32.0 mCi (1184 MBq). Y-90 ZEVALIN should not be administered to patients
- with altered biodistribution as determined by imaging with In-111 ZEVALIN. In-111 ZEVALIN and Y-90 ZEVALIN are radiopharma-

ceuticals and should be used only by physicians and other professionals qualified by training and experienced in the safe use and handling of radionuclides.

DESCRIPTION

ZEVALIN®

ZEVALIN (Ibritumomab Tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator monoclonal antibody Ibritumomab and the linker-chelator tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(p-isothio-cyanatophenyl)-propyl]IN-[2-bis(carboxymethyl)amino]-2-(methyl)-ethyl]glycine. This linker-chelator provides a high affinity, conformationally restricted chelation site for Indium-111 or Yttrium-90. The approximate molecular weight of Ibritumomab Tiuxetan is 148 kD. The antibody moiety of ZEVALIN is Ibritumomab, a murine IG21 kapne monoclonal antibody directed against the CD20.

IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. ZEVALIN Therapeutic Regimen

The ZEVALIN therapeutic regimen is administered in two

ZEVALIN is supplied as two separate and distinctly labeled kits that contain all of the non-radioactive ingredients necessary to produce a single dose of In-111 ZEVALIN and a single dose of Y-90 ZEVALIN, both essential components of the ZEVALIN therapeutic regimen. Indium-111 chloride and Rituximab must be ordered separately from the ZEVALIN kit. Yttrium-90 chloride sterile solution is sup-plied by MDS Nordion when the Y-90 ZEVALIN kit is orlorod

ZEVALIN Kits

Each of the two ZEVALIN kits contains four vials that are used to produce a single dose of either In-111 ZEVALIN or Y-90 ZEVALIN, as indicated on the outer container label: (1) One (1) ZEVALIN Vial containing 3.2 mg of Ibritumo-

- mab Tiuxetan in 2 mL of 0.9% sodium chloride solution: a sterile, pyrogen-free, clear, colorless solution that may contain translucent particles; no preservative present.
- (2) One (1) 50 mM Sodium Acetate Vial containing 13.6 mg of sodium acetate trihydrate in 2 mL of Water for Inject tion; a sterile, pyrogen-free, clear, colorless solution; no preservative present.
- (3) One (1) Formulation Buffer Vial containing 750 mg of Albumin (Human), 76 mg of sodium chloride, 28 mg of sodium phosphate dibasic dodecalydrate, 4 mg of pen-tetic acid, 2 mg of potassium phosphate monobasic and 2 mg of potassium chloride in 10 mL of Water for Injection adjusted to pH 7.1 with either sodium hydroxide or hydrochloric acid; a sterile, pyrogen-free, clear yellow to amber colored solution; no preservative present.
- (4) One (1) empty Reaction Vial, sterile, pyrogen-free.

Physical/Radiochemical Characteristics of In-111

Indium-111 decays by electron capture, with a physical half-life of 67.3 hours (2.81 days)^[1]. The product of radioactive decay is nonradioactive cadmium-111. Radiation emission data for In-111 are summarized in Table 1.

Table 1. Principal In-111 Radiation Emission Data			
Radiation	Mean % per Disintegration	Mean Energy (keV)	
Gamma-2 Gamma-3	90.2 94:0	171.3 245.4	

External Radiation

R

The exposure rate constant for 37 MBq (1 mCi) of In-111 is 3.3×10^{-4} C/kg/hr (3.2 R/hr) at 1 cm. Adequate shielding should be used with this gamma-emitter, in accordance with institutional good radiation safety practices To allow correction for physical decay of In-111, the fractions

that remain at selected intervals before and after the time of calibration are shown in Table 2.

Table 2. Physical Decay Chart: In-111 Half-life 2.81 Days (67.3 Hours)			
Calibration Time (Hrs.)	Fraction Remaining		
-48	1.64		
-42	1.54		
-36	1.45		
-24	1.28		
-12	1.13		
-6	1.06		
0	1.00		
6	0.94		
12	0.88		
24	0.78		
36	0.69		
42	0.65		
48	0.61		
10			

Physical/Radiochemical Characteristics of Y-90

Yttrium-90 decays by emission of beta particles, with a physical half-life of 64.1 hours (2.67 days)^[1]. The product of radioactive decay is non-radioactive zirconium-90. The range of beta particles in soft tissue (χ_{90}) is 5 mm. Radiation emission data for Y-90 are summarized in Table 3.

Table 3. Principal Y-90 Radiation Emission Data				
Radiation	Mean % per Disintegration	Mean Energy (keV)		
Beta minus	100	750-935		

External Radiation

The exposure rate for 37 MBg (1 mCi) of Y-90 is 8.3×10^{-5} C/kg/hr (32 R/hr) at the mouth of an open Y-90 vial. Ade-quate shielding should be used with this beta-emitter, in ac-

Lilly Exhibit 1255, Page 15 of 39

PHYSICIANS' DESK REFERENCE®

PRECAUTIONS

Laboratory Monitoring: Because RITUXAN targets all CD20-positive B lymphocytes, malignant and nonmalig-nant, complete blood counts (CBC) and platelet counts nant, complete blood counts (CBC) and plateiet counts should be obtained at regular intervals during RITUXAN therapy and more frequently in patients who develop cy-topenias (see ADVERSE REACTIONS). The duration of cytopenias caused by RITUXAN can extend well beyond the treatment period.

Drug/Laboratory Interactions: There have been no formal drug interaction studies performed with RITUXAN. However, renal toxicity was seen with this drug in combination with cisplatin in clinical trials. (See WARNINGS, Renal.) HACA Formation: Human antichimeric antibody (HACA) was detected in 4 of 356 patients and 3 had an objective clin-ical response. The data reflect the percentage of patients whose test results were considered positive for antibodies to RITUXAN using an enzyme-linked immunosorbant assay (limit of detection = 7 ng/mL). The observed incidence of antibody positivity in an assay is highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors including sample handling, concom-itant medications, and underlying disease. For these rea-sons, comparison of the incidence of antibodies to RITUXAN with the incidence of antibodies to other products may be misleading.

Immunization: The safety of immunization with live viral vaccines following RITUXAN therapy has not been studied

vaccines following RITUXAN therapy has not been studied. The ability to generate a primary or anamnestic humoral response to vaccination is currently being studied. Carcinogenesis, Mutagenesis, Impairment of Fertility: No long-term animal studies have been performed to establish the carcinogenic or mutagenic-potential of RITUXAN, or to determine its effects on fertility in males or females. Indi-viduals of childbearing potential should use effective contra-centive methods during treatment and for un to 12 months ceptive methods during treatment and for up to 12 months

cepuive methods.during treatment and for up to 12 months following RITUXAN therapy. Pregnancy Category C: Animal reproduction studies have not been conducted with RITUXAN. It is not known whether RITUXAN can cause fetal harm when adminis-tered to a pregnant woman or whether it can affect reproductive capacity. Human IGG is known to pass the placental barrier, and thus may potentially cause fetal B-cell deple-tion; therefore, RITUXAN should be given to a pregnant

woman only if clearly needed. Nursing Mothers: It is not known whether RITUXAN is excreted in human milk. Because human IgG is excreted in human milk and the potential for absorption and immuno-suppression in the infant is unknown, women should be advised to discontinue nursing until circulating drug levels are no longer detectable. (See CLINICAL PHARMACOL-OGY)

Pediatric Use: The safety and effectiveness of RITUXAN in

pediatric patients have not been established. Geriatric Use: Among the 331 patients enrolled in clinical studies of single agent RITUXAN, 24% were 65 to 75 years studies of single agent KII OKAN, 24% were ob to 75 years old and 5% were 75 years old and older. The overall re-sponse rates were higher in older (age \geq 65 years) vs. younger (age < 65 years) patients (52% vs. 44%, respec-tively). However, the median duration of response, based on Kaplan-Meier estimates, was shorter in older vs. younger patients: 10.1 months (range, 1.9 to 36.5+) vs. 11.4 months (range, 2.1 to 42.1+), respectively. This shorter duration of response was not statistically significant. Adverse reactions, including incidence, severity and type of adverse reaction were similar between older and younger patients.

ADVERSE REACTIONS

The most serious adverse reactions caused by RITUXAN in-Ine most serious adverse features duscu by AITOAAN Tolder in clude infusion reactions, tumor lysis syndrome, mucocuta-neous reactions, hypersensitivity reactions, cardiac ar-rhythmias and angina, and renal failure. Please refer to the BOXED WARNINGS and WARNINGS sections for detailed descriptions of these reactions. Infusion reactions and lym-phopenia are the most commonly occurring adverse reactions.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. Additional adverse reactions have been identified during

postmarketing use of RITUXAN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency It is not anways possible to remany estimate unter frequency or establish a causal relationship to KITUXAN exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to RITUXAN.

Where specific percentages are noted, these data are based on 356 patients treated in nonrandomized, single-arm studtion of RITUXAN administered as a single agent. Most pa-tion te received RITUXAN 375 mc/m² waskly for 4 doese

≥10 cm) and 60 patients who received more than 1 course of RITUXAN. Thirty-seven patients received 375 mg/m² for 8 doses and 25 patients received doses other than 375 mg/m² for 4 doses and up to 500 mg/m² single dose in the Phase 1 setting. Adverse events of greater severity are referred to as "Grade 3 and 4 events" defined by the commonly used National Cancer Institute Common Toxicity Criteria.¹⁷

Table 3

Incidence of Adverse Events ≥ 5% of Patients in Clinical Trials (N = 356) (Adverse Events were followed for a period of 12 months following RITUXAN therapy.)

a sa Banifani (Banifani) Banifani (Banifani)	All Grades (%)	Grade.3 and 4 (%)
Any Adverse Events	99	57
Body as a Whole	86	10
Fever	53 (1)	ere stady highly of
Chills	33	
Infection	31	
Asthenia		~ 1 , 1
Headache	19	1
Abdominal Pain	14	2/1 (2)
	12	an testing
Back Pain	10	1
Throat Irritation	9	
Flushing	5	
	25	0 561
Cardiovascular System		3
Hypotension	10	1
Hypertension		1
Digestive System	37	2
Nausea	23	tan i n sin
Diarrhea	10	(1, 1)
Vomiting	10	$(1, \dots, 1, \dots, 1)$
Hemic and Lymphatic	67	av. 3.4 - 48 - 1 - 1
System		a table 1
Lymphopenia	48	40
Leukopenia	tina 14 a -	- 16 10 4 1 k di
Neutropenia Thrombocytopenia	14	6
Thrombocytopenia	12	2
Anemia	8	3
Metabolic and Nutritional	38	3.5 3 .5.55
Disorders		$A_{i}^{(1)} = \{i_{i}, \dots, i_{i}\}$
Angioedema	11	1
Hyperglycemia	9	. 1
Peripheral Edema	8	0
LDH Increase	7 7	- r-0
Musculoskeletal System	26	3
Myalgia	10	1
Arthralgia	10	1
Nervous System	32	natori dhu q hi shek
Dizziness	.10	- 5 me 1 -
Anxiety	5 VT 5 V 4	 Sub1
Respiratory System	38	4
Increased Cough		a at spis
Rhinitis	12	់ភ្នំស្រៀងស
Bronchospasm		1
Dyspnea	7	1 1 1
Sinusitis	6	0
		2
Skin and Appendages	44	2 1
Night Sweats	15 15	1
Rash		
Pruritus Urticaria	14	1
	8	

Risk Factors Associated with Increased Rates of Adverse Events

Administration of RITUXAN weekly for 8 doses resulted in higher rates of Grade 3 and 4 adverse events¹⁷ overall (70%) compared with administration weekly for 4 doses (57%). The incidence of Grade 3 or 4 adverse events was similar in patients retreated with RITUXAN compared with initial treatment (58% and 57%, respectively). The incidence of the following clinically significant adverse events was higher in patients with bulky disease (lesions ≥ 10 cm) (N = 39) versus patients with lesions < 10 cm (N = 195): abdominal pain, anemia, dyspnea, hypotension, and neutropenia.

Infusion Reactions (See BOXED WARNINGS and WARN-INGS): Mild to moderate infusion reactions consisting of fever and chills/rigors occurred in the majority of patients during the first RITUXAN infusion. Other frequent infusion reaction symptoms included nausea, pruritus, angioedema asthenia, hypotension, headache, bronchospasm, throat ir ritation, rhinitis, urticaria, rash, vomiting, myalgia, dizziness, and hypertension. These reactions generally occurred within 30 to 120 minutes of beginning the first infusion, and resolved with slowing or interruption of the RITUXAN in fusion and with supportive care (diphenhydramine, acet-aminophen, IV saline, and vasopressors). In an analysis of data from 356 patients with relapsed or refractory, low-grade NHL who received 4 (N = 319) or 8 (N = 37) weekly infusions of RITUXAN, the incidence of infusion reactions was highest during the first infusion (77%) and decreased with each subsequent infusion (30% with fourth infusion and 14% with eighth infusion)

Infectious Events: RITUXAN induced B-cell depletion in 70% to 80% of patients and was associated with decreased serum immunoglobulins in a minority of patients: the lymphopenia lasted a median of 14 days (range, 1 to 588 days).

had fungal infections, and 6% were unknown infections, Incidence is not additive because a single patient may have had more than one type of infection. Serious infectious events (Grade 3 or 4),¹⁷ including sepsis occurred in 2% of

patients Hematologic Events: Grade 3 and 4 cytopenias¹⁷ were re-Hematologic Events: Grade 3 and 4 cytopenias" were re-ported in 12% of patients treated with RITUXAN; these in-clude: lymphopenia (40%), neutropenia (6%), leukopenia (4%), anemia (3%), and thrombocytopenia (2%). The median duration of lymphopenia was 1,4 days (range, 1 to 588 days) and of neutropenia was 13 days (range, 2 to 116 days). A single occurrence of transient aplastic anemia (pure red cell aplasia) and two occurrences of hemolytic anemia following RITUXAN therapy were reported. In addition, there have been rare postmarketing reports of prolonged pancytopenia

and marrow hypoplasia. Cardiac Events (See BOXED WARNINGS): Grade 3 or 4 cardiac-related events include hypotension. Rare, fatal cardiac failure with symptomatic onset weeks after RITUXAN has also been reported. Patients who develop clinically sig.

has also been reported. Patients who develop clinically sig-nificant cardiopulmonary events should have RITUXAN in-fusion discontinued. Pulmonary Events (See BOXED WARNINGS): 135 pa-tients (38%) experienced pulmonary events. The most com-mon respiratory system adverse events experienced were increased cough, rhinitis, bronchospasm, dyspnea, and si-nusitis. Three pulmonary events have been reported in tem-poral association with RITUXAN infusion as a single agent: events have been event events. acute bronchospasm, acute pneumonitis presenting 1-4 weeks post-RITUXAN infusion, and bronchiolitis obliteras. One case of bronchiolitis obliterans was associated with progressive pulmonary symptoms and culminated in death several months following the last RTPUXAN infusion. The safety of resumption or continued administration of RITUXAN in patients with pneumonitis or bronchiolitis ob literans is unknown. Immune/Autoimmune Events: Immune/autoimmune

events have been reported, including uveitis, optic neuritis in a patient with systemic vasculitis, pleuritis in a patient with a lupus-like syndrome, serum sickness with polyarticular arthritis, and vasculitis with rash. Less Commonly Observed Events: In clinical trials, < 5%

and > 1% of the patients experienced the following events regardless of causality assessment: agitation, anorexia, arthritis, conjunctivitis, depression, dyspepsia, edema, hyper-kinesia, hypertonia, hypesthesia, hypoglycemia, injection site pain, insomnia, lacrimation disorder, malaise, nervousness, neuritis, neuropathy, paresthesia, somnolence, ver-tigo, weight decrease.

OVERDOSAGE

There has been no experience with overdosage in human clinical trials. Single doses of up to 500 $\rm mg/m^2$ have been given in controlled clinical trials.^10

DOSAGE AND ADMINISTRATION

Initial Therapy: RITUXAN is given at 375 mg/m² IV infusion once weekly for 4 or 8 doses

Retreatment Therapy:

Patients who subsequently develop progressive disease may be safely retreated with RITUXAN 375 mg/m² IV infusion once weekly for 4 doses. Currently there are limited data concerning more than 2 courses.

RITUXAN as a Component of Zevalin™ (Ibritumomab Tiuxetan) Therapeutic Regimen:

As a required component of the Zevalin therapeutic regimen, RITUXAN 250 mg/m^2 should be infused within 4 hours prior to the administration of Indium-111-(In-111-) Zevalin and within 4 hours prior to the administration of Yttrium-90-(Y-90-) Zevalin. Administration of RITUXAN peutic regimen. RITUXAN may be administered in an outpatient setting

DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS. (See Administration.)

Instructions for Administration

Preparation for Administration: Use appropriate asepti technique. Withdraw the necessary amount of RITUXAN and dilute to a final concentration of 1 to 4 mg/mL into an infusion bag containing either 0.9% Sodium Chloride, USP, in the solution of the solutio

RITUXAN solutions for infusion may be stored at 2-8°C (36-46°F) for 24 hours. RITUXAN solutions for infusion have been shown to be stable for an additional 24 hours at room temperature. However, since RITUXAN solutions do not contain a preservative, diluted solutions should be stored refrigerated (2-8°C). No incompatibilities between RITUXAN and polyvinylchloride or polyethylene bags have

been observed. Administration: DO NOT ADMINISTER AS AN INTRAVE-NOUS PUSH OR BOLUS.

Infusion and hypersensitivity reactions may occur (see BOXED WARNINGS, WARNINGS, and ADVERSE REAC-TIONS). Premedication consisting of acetaminophen and di-phenhydramine should be considered before each infusion of RITUXAN. Premedication may attenuate infusion reac-

Lilly Exhibit 1255, Page 16 of 39

Table 4. Physical Decay Chart: Y-90 Half-life 2.67 Days (64.1 Hours)				
Calibration Time (Hrs.)	Fraction Remaining		Fraction Remaining	
-36	1.48	0 .	. 1.00	
-24	1.30	1 .	0.99	
-12	1.14	2	0.98	
-8:	1.09	3	0.97	
-7 .	1.08	4	0.96	
-6 .	1.07	5	0.95	
-5	1.06	6	0.94	
-4	1.04	7	0.93	
-3	1.03	8	0.92	
-2	1.02	12	0.88	
-1	1.01	24	0.77	
0	1.00	36	0.68	

CLINICAL PHARMACOLOGY

General Pharmacology Ibritumomab Tiuxetan binds specifically to the CD20 anti-Ibritumomab Tuxetan binds specifically to the CD20 anti-gen (human B-lymphocyte-restricted differentiation anti-gen, Bp35)^{12, 3]}. The apparent affinity (K_D) of Ibritumomab Tiuxetan for the CD20 antigen ranges between approxi-mately 14 to 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin's lymphomas (NHL)^{4, 5]}. The CD20 antigen is not shed from the cell surface and does not internalize upon articled bidraf^{6[]} antibody binding^[6]

Mechanism of Action: The complementarity-determining necimism of britumomab lind to the CD20 antigen on B lym-phocytes. Ibritumomab, like Rituximab, induces apoptosis, in CD20+ B-cell lines in vitro^[6]. The chelate tiuxetan, which tightly binds In-111 or Y-90, is covalently linked to the aming groups of exposed lysines and arginines contained within the antibody. The beta emission from Y-90 induces cellular damage by the formation of free radicals in the tar-get and neighboring cells^[7].

Normal Human Tissue Cross-Reactivity: Ibritumomab Tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleer, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as the large and small intestines. Binding was not observed on the nonlym-phoid tissues or gonadal tissues (see CLINICAL PHAR-MACOLOGY, Radiation Dosimetry)

Pharmacokinetics / Pharmacodynamics // Pharmacokinetics and biodistribution studies were per-formed using In-111 ZEVALIN (5 mCi [185 MBq] In-111, 1.6 mg Ibritumomab Tuxetan). In an early study designed to assess the need for pre-administration of unlabeled anti-body, only 18% of known sites of disease were imaged when In-111 ZEVALIN was administered without unlabeled Ibritumomab. When preceded by unlabeled Ibritumomab (1.0 mg/kg or 2.5 mg/kg), In-111 ZEVALIN detected 56% and 92% of known disease sites, respectively. These studies were conducted with a Zevalin therapeutic regimen that included unlabeled Ibritumomab.

In pharmacokinetic studies of patients receiving the ZEVALIN therapeutic regimen, the mean effective half-life for Y-90 activity in blood was 30 hours, and the mean area under the fraction of injected activity (FIA) vs. time curve in blood was 39 hours. Over 7 days, a median of 7.2% of the injected activity was excreted in urine. In clinical studies, administration of the ZEVALIN thera-

Peutic regimen resulted in sustained depletion of circulating B cells. At four weeks, the median number of circulating B cells was zero (range, 0-1084 cell/mm³). B-cell recovery be-gan at approximately 12 weeks following treatment, and the median level of B cells was within the normal range (32 to 341 cells/mm³) by 9 months after treatment. Median serum levels of IgG and IgA remained within the normal range throughout the period of B-cell depletion. Median IgM serum levels dropped below normal (median 49 mg/dL, range 13-3990 mg/dL) after treatment and recovered to normal values by 6 month post therapy.

Radiation Dosimetry

Estimations of radiation-absorbed doses for In-111 ZEVALIN and Y-90 ZEVALIN were performed using sequential whole body images and the MIRDOSE 3 software program . The estimated radiation absorbed doses to orprogram gans and marrow from a course of the ZEVALIN therapeutic regimen are summarized in Table 5. Absorbed dose estimates for the lower large intestine, upper large intestine and small intestine have been modified from the standard MIRDOSE 3 output to account for the assumption that activity is within the intestine wall rather than the intestine conten [See table 5 above]

CLINICAL STUDIES

The safety and efficacy of the ZEVALIN therapeutic regi-The sates and encary of the Devalue (in the repeated regi-men were evaluated in two multi-enter trials enrolling a total of 197 subjects. The ZEVALIN therapeutic regimen was administered in two steps (see DOSAGE and ADMIN-ISTRATION). The activity and toxicity of a variation of the ZEVALIN therapeutic regimen employing a reduced dose of Y-90 ZEVALIN was further defined in a third study enroll-ing a total of 30 natients who had mild thrombocutonenia

Table 5. Estimated Radiation Absorbed Doses From Y-90 ZEVALIN and In-111 ZEVALIN

երում։ Դիչնելել Հանիչը հայտում։ Հենցելու էլեստելել հայտների։ Դուսի հայտների հետում։	ZEVALIN Gy/MBq	In-111 ZEVA mGy/MB	
Organ Median	Range	Median	Range
Spleen state www.eeroor.com.com.com.com.com.com.com.com.gerup.g.e	1.8-14.4	0.9	0.2-1.2
${ m Testes^1}$. The study of the set of the set of the set of the state 9.1° , 1	5.4-11.4	0.6	0.4-0.8
Liver^1 , and even of preserves to the constant of the 4.8 result.	2.3-8.1	0.7	0.3-1.1
Lower Large Intestinal Wall ¹	6. 3.1-8.2°	0.4	0.2-0.6
Upper Large Intestinal Wall ¹ 3.6	2.0-6.7	0:3	0.2-0.6
Heart Wall ¹ 2.8	1.5-3.2	0.4	0.2-0.5
Lungs ¹ - Contraction of the second state of	1.2-3.4	0.2	0:1-0.4
Small Intestine ¹ 1.4	0.8-2.1	0.2	0:1-0:3
Red Marrow ² 1.3	0.7-1.8	0.2	0.1-0.2
Urinary Bladder Wall ³ 0.9	0.7-2.1	0.2	0.1-0.2
Bone Surfaces ² 0.9	0.5-1.2	0.2	0.1-0.2
Ovaries ³ 0.4	0.3-0.5	0.2	0.2 - 0.2
Uterus ³ 0.4	0.3-0.5	0.2	0.1-0.2
Adrenals ³ 0.3	0.0-0.5	0.2	0.1-0.3
Brain ³ 0.3	0.0-0.5	0.1	0.0-0.1
Breasts ³ 0.3	0.0-0.5	0.1	0.0-0.1
Gallbladder Wall ³ 0.3	0.0-0.5	0.3	0.1-0.4
Muscle ³ 0.3	0.0-0.5	0.1	0.0-0.1
Pancreas ³ 0.3	0.0-0.5	0.2	0.1-0.3
Skin ³ 0.3	0.0-0.5	0.1	0.0-0.1
Stomach ³ 0.3	0.0-0.5	0.1	0.1-0.2
Thymus ³ 0.3	0.0-0.5	0.1	0.1-0.2
Thyroid ³ 0.3	0.0-0.5	0.1	0.0-0,1
Kidneys ¹ 0.1	0.0-0.2	0.2	0.1-0.2
Total Body ³ 0.5	0.2-0.7	0.1	0.1-0.2
¹ Organ region of interest	· · · · · · · · · · · · · · · · · · ·		
² Sacrum region of interest ^[10] ³ Whole body region of interest	un de la chuitemaire Australia	n in india Angli in Angli in Ang	

 International statements and the statement of the statement o		se constanta di anti-entre s ta ¹ interestativenti se neg	en de Marine de Marine
n an an Arthur an Art Arthur an Arthur an A	Study 1	Study 2	
1999年,1995年1日日,1月19日(1997年)。 1995年———————————————————————————————————	IN = 54	ZEVALIN therapeutic regimen N = 73	Rituximab N = 70
Overall Response Rate (%)		1. 1992 (A. 802) (A. 1998) 61 (A. 1903 (B. 802) 61 (A. 1993) (B. 1993) 71 (A. 1993) (4) (A. 1993) (B. 1993)	16
(Months) [Range ⁵]	6.4	13.9 13.9 13.1+]	11.8 [1.2-24.5]
Median TTP ^{3,6} (Months) [Range ⁵]	6.8	11.2 [0.8-31.5+]	10.1 [0.7-26.1]

IWRC: International Workshop response criteria

²CRu: Unconfirmed complete response and the second secon

⁴Duration of response: interval from the onset of response to disease progression. ^{5*+}" indicates an ongoing response.

Time to Disease Progression: interval from the first infusion to disease progression.

Study 1 was a single arm study of 54 patients with relapsed follicular lymphoma refractory to Rituximab treatment. Pa tients were considered refractory if their last prior treat-ment with Rituximab did not result in a complete or partial response, or if time to disease progression (TTP) was < 6 months⁽¹¹⁾. The primary efficacy endpoint of the study was the overall response rate (ORR) using the International Workshop Response Criteria (IWRC)^[12]. Secondary efficacy endpoints included time to disease progression (TTP) and duration of response (DR). In a secondary analysis comparing objective response to the ZEVALIN therapeutic regimen with that observed with the most recent treatment with Rit-uximab, the median duration of response following the ZEVALIN therapeutic regimen was 6 vs. 4 months. Table 6 summarizes efficacy data from this study.

Study 2 was a randomized, controlled, multicenter study comparing the ZEVALIN therapeutic regimen to treatment with Rituximab. The trial was conducted in 143 patients with relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL), or transformed B-cell NHL A total of 73 patients received the ZEVALIN therapeutic reg-imen, and 70 patients received Rituximab given as an IV infusion at 375, mg/m² weekly times 4 doses. The primary efficacy endpoint of the study was to determine the ORR using the IWRC¹¹² (see Table 6). The ORR was significantly higher (80% vs. 56%, p = 0.002)¹³³ for patients treated with the ZEVALIN therapeutic regimen. The secondary endpoints, duration of response and time to progression, were not significantly different between the two treatment arms. [See table 6 above]

Study 3 was a single arm study of 30 patients with relapsed or refractory low-grade, follicular, or transformed B-cell NHL who had mild thrombocytopenia (platelet count 100,000 to 149,000 cells/mm³). Excluded from the study were patients with ≥ 25% lymphoma marrow involvement and/or impaired bone marrow reserve. Patients were considered to have impaired bone marrow reserve if they had tive marrow; a platelet count <100,000 cells/mm³, or neutrophil count < 1,500 cells/mm³. In this study, a modification of the ZEVALIN therapeutic regimen with a lower specific activity Y.90 ZEVALIN dose [(Y-90 ZEVALIN at 0.3 mC/kg (11.1 MBq/kg]) was used. Objective, durable clinical responses were observed [67% ORR (95% CI: 48-85%)¹⁴⁴]. 11.8 months median DR (range: 4-17 months)] and resulted in a greater incidence of hematologic toxicity (see AD-VERSE REACTIONS) than in Studies 1 and 2.

INDICATIONS AND USAGE

ZEVALIN, as part of the ZEVALIN therapeutic regimen (see DOSAGE AND ADMINISTRATION), is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab refractory follicular non-Hodgkin's lymphoma. Determination of the effectiveness of the ZEVALIN therapeutic regimen in a relapsed or refractory patient population is based on overall response rates (see CLINICAL STUDIES). The effects of the ZEVALIN therapeutic regimen on survival are not known.

CONTRAINDICATIONS

The ZEVALIN therapeutic regimen is contraindicated in patients with known Type I hypersensitivity or anaphylactic reactions to murine proteins or to any component of this product, including Rituximab, yttrium chloride, and indium chloride

WARNINGS (SEE BOXED WARNING)

Altered Biodistribution: Y-90 ZEVALIN should not be administered to patients with altered biodistribution of In-111 ZEVALIN. The expected biodistribution of In-111 ZEVALIN includes easily detectable uptake in the blood pool areas on the first day image, with less activity in the blood pool areas on the second or third day image; moderately high to high uptake in normal liver and spleen during the first day and the second or third day image; and moderately low or very low uptake in normal kineps, urinary bladder, and normal bowel on the first day image and the second or third day

IPR2018-01710

Lilly Exhibit 1255, Page 17 of 39

1726/IDEC

Zevalin—Cont.

image. Altered biodistribution of In-111 ZEVALIN can be characterized by diffuse uptake in normal lung more intense than the cardiac blood pool on the first day image or more intense than the liver on the second or third day image, kidneys with greater intensity than the liver on the posterior view of the second or third day image; or intense areas of uptake throughout the normal howel comparable to uptake by the liver on the second or third day images. Severe Infusion Reactions (See PRECAUTIONS, Hypersensitivity):

The ZEVALIN therapeutic regimen may cause severe, and potentially fatal, infusion reactions. These severe reactions typically occur during the first Rituixmab infusion with time to onset of 30 to 120 minutes. Signs and symptoms of severe infusion reaction may include hypotension, angioedema, hypoxia, or bronchospasm, and may require interruption of Rituximab, In-111 ZEVALIN, or Y-90 ZEVALIN administration. The most severe manifestations and sequelae may include pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, and cardiogenic shock. Because the ZEVALIN therapeutic regimen includes the use of Rituximab, see also presoribing information for RITUXAN (Rituximab).

Cytopenias (See ADVERSE REACTIONS, Hematologic Events):

The most common severe adverse events reported with the ZEVALIN therapeutic regimen were thrombocytopenia (61% of patients with platelet counts <50,000 cells/mm³) and neutropenia (57% of patients with absolute neutrophil count (ANC) <1,000 cells/mm³) in patients with $\ge 150,000$ platelets/mm3 prior to treatment. Both incidences of severe thrombocytopenia and neutropenia increase to 78% and 74% for patients with mild thrombocytopenia at baseline (platelet count of 100,000 to 149,000 cells/mm³). For all patients, the median time to nadir was 7-9 weeks and the median duration of cytopenias was 22-35 days. In $<\!5\%$ of cases, patients experienced severe cytopenia that extended beyond the prospectively defined protocol treatment period of 12 weeks following administration of the ZEVALIN ther apeutic regimen. Some of these patients eventually recov ered from cytopenia, while others experienced progressive disease, received further anti-cancer therapy, or died of their lymphoma without having recovered from cytopenia The cytopenias may have influenced subsequent treatment decisions

Hemorrhage, including fatal cerebral hemorrhage, and severe infections have occurred in a minority of patients in clinical studies. Careful monitoring for and management of cytopenias and their complications (e.g., febrile neutropenia, hemorrhage) for up to 3 months after use of the ZEVALIN therapeutic regimen are necessary. Caution should be exercised in treating patients with drugs that interfere with platelet function or coagulation following the ZEVALIN therapeutic regimen and patients receiving such agents should be closely monitored.

The ZEVALIN therapeutic regimen should not be administered to patients with $\geq 25\%$ lymphoma marrow involvement and/or impaired bone marrow reserve, e.g., prior myeloablative therapies; platelet count < 100,000 cells/mm³; neutrophil count < 1,500 cells/mm³; hypocellular bone marrow ($\leq 15\%$ cellularity or marked reduction in bone marrow precursors); or to patients with a history of failed stem cell collection.

Secondary Malignancies: Out of 349 patients treated with the ZEVALIN therapeutic regimen, three cases of acute myelogenous leukemia and two cases of myelodysplastic syndrome have been reported following the ZEVALIN therapeutic regimen (see ADVERSE REACTIONS).

Pregnancy Category D: Y-90 ZEVALIN can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

Creutzfeldt-Jakob disease (CJD): This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.

PRECAUTIONS

The ZEVALIN therapeutic regimen is intended as a single course treatment. The safety and toxicity profile from multiple courses of the ZEVALIN therapeutic regimen or of other forms of therapeutic irradiation preceding, following, or in combination with the ZEVALIN therapeutic regimen have not been established. to minimize radiation exposure to patients and to medical personnel, consistent with institutional good radiation safety practices and patient management procedures.

Hypersensitivity: Anaphylactic and other hypersensitivity reactions have been reported following the intravenous administration of proteins to patients. Medications for the treatment of hypersensitivity reactions, e.g., epinephrine, antihistamines and corticosteroids, should be available for immediate use in the event of an allergic reaction during administration of ZEVALIN. Patients who have received murine proteins should be screened for human anti-mouse antibodies (HAMA). Patients with evidence of HAMA have not been studied and may be at increased risk of allergic or serious hypersensitivity reactions during ZEVALIN therapeutic regimen administrations.

Immunization: The safety of immunization with live viral vaccines following the ZEVALIN therapeutic regimen has not been studied. Also, the ability of patients who received the ZEVALIN therapeutic regimen to generate a primary or anamnestic humoral response to any vaccine has not been studied.

Laboratory Monitoring: Complete blood counts (CBC) and platelet counts should be obtained weekly following the ZEVALIN therapeutic regimen and should continue until levels recover. CBC and platelet counts should be monitored more frequently in patients who develop severe cytopenia, or as clinically indicated.

Drug Interactions: No formal drug interaction studies have been performed with ZEVALIN. Due to the frequent occurrence of severe and prolonged thrombocytopenia, the potential benefits of medications which interfere with platelet function and/or anticoagulation should be weighed against the potential increased risks of bleeding and hemorrhage. Patients receiving medications that interfere with platelet function or cogulation should have more frequent laboratory monitoring for thrombocytopenia. In addition, the transfusion practices for such patients may need to be modified given the increased risk of bleeding. Carcinogenesis, Mutagenesis, Impairment of Fertility: No

Carcinogenesis, Mutagenesis, Impairment of Fertility: No long-term animal studies have been performed to establish the carcinogenic or mutagenic potential of the ZEVALIN therapeutic regimen, or to determine its effects on fertility in males or females. However, radiation is a potential carcinogen and mutagen. The ZEVALIN therapeutic regimen results in a significant radiation dose to the testes. The radiation dose to the ovaries has not been established. There have been no studies to evaluate whether the ZEVALIN therapeutic regimen causes hypogonadism, premature menopause, azoospermia and/or mutagenic alterations to germ cells. There is a potential risk that the ZEVALIN therapeutic regimen could cause toxic effects on the male and female gonads. Effective contraceptive methods should be used during treatment and for up to 12 months following the ZEVALIN therapeutic regimen.

Pregnancy Category D: SEE WARNINGS.

Nursing Mothers: It is not known whether ZEVALIN is excreted in human milk. Because human IgG is excreted in human milk and the potential for ZEVALIN expositer in the infant is unknown, women should be advised to discontinue nursing and formula feeding should be substituted for breast feedings (see CLINICAL PHARMACOLOGY). Geriatric Use: Of 349 patients treated with the ZEVALIN therapeutic regimen in clinical studies, 38% (132 patients) were age 65 years and over, while 12% (41 patients) were age 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

viduals cannot be ruled out. Pediatric Use: The safety and effectiveness of the ZEVALIN therapeutic regimen in children have not been established.

ADVERSE REACTIONS

Safety data, except where indicated, are based upon 349 patients treated in 5 clinical studies with the ZEVALIN therapeutic regimen (see DOSAGE AND ADMINISTRA-TION). Because the ZEVALIN therapeutic regimen includes the use of Rituximab, also see prescribing information for RITUXAN (Rituximab).

The most serious adverse reactions caused by the ZEVALIN therapeutic regimen include infections (predominantly bacterial in origin), allergic reactions (bronchospasm and angioedema), and hemorrhage while thrombocytopenic (resulting in deaths). In addition, patients who have received the ZEVALIN therapeutic regimen have developed myeloid malignancies and dysplasias. Fatal infusion reactions have occurred following the infusion of Rituximab. Please refer to the **BOXED WARNINGS** and **WARNINGS** sections for detailed descriptions of these reactions. The most common toxicities reported were neutropenia,

The most common toxicities reported were neutropenia, htrombocytopenia, anemia, gastrointestinal symptoms (nausea, vomiting, abdominal pain, and diarrhea), increased cough, dyspnea, dizziness, arthralgia, anorexia, anxiety, and ecchymosis. Hematologic toxicity was often severe and prolonged, whereas most non-hematologic toxicity was mild in severity. Table 7 lists adverse events that occurred in 5 6% of patients. A more detailed describition of

Any Adverse Event Body as a Whole Asthenia Infection Chills Fever Abdominal Pain Pain Headache Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	All Grades % 99 80 43 29 24 17 16 16 13 12 10 8 6 6 77 6 48 81 12 9 8 8 5		rade 3/4 % 89 12 3 12 3 5 1 1 1 0 1 1 0 3 1 1 0 -
Body as a Whole Asthenia Infection Cchills Fever Abdominal Pain Fain Headache Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	80 43 29 24 17 16 13 12 10 8 6 7 7 6 48 31 12 9 9 8 8		12 3 5 <1 1 3 1 1 0 1 0 3 1 3 1 1 0 <1
Asthenia Infection Cchills Fever Abdominal Pain Pain Headache Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	43 29 24 17 16 13 12 10 8 6 17 6 48 31 12 9 9 8 8 8		3 5 <1 1 3 1 1 0 1 0 3 1 3 1 1 0 4
Infection Chills Fever Abdominal Pain Pain Headache Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	29 24 17 16 13 12 10 8 6 17 6 48 31 12 9 8 8		5 <1 1 3 1 1 0 1 0 3 1 3 1 3 4 4
Chills Fever Abdominal Pain Pain Headache Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	24 17 16 13 12 10 8 6 17 48 31 12 9 9 8		<1 1 3 1 1 0 1 0 3 1 3 1 0 <1
Fever Abdominal Pain Pain Headache Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	17 16 13 12 10 8 6 17 6 48 8 11 22 9 8		1 3 1 0 1 0 3 1 3 4 0 <1
Abdominal Pain Pain Headache Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	16 13 12 10 8 6 17 6 48 31 12 9 8		3 1 1 0 1 0 3 1 1 0 <1
Pain Headache Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	13 12 10 8 6 17 6 48 31 12 9 8		1 1 0 1 0 3 1 0 <1
Headache Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	12 10 8 6 17 6 48 31 12 9 8		1 0 1 0 3 1 1 0 <1
Throat Irritation Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	10 8 6 17 6 48 31 12 9 8		0 1 0 3 1 3 1 0 <1
Back Pain Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	8 6 48 31 12 9 8		1 0 3 1 3 1 0 <1
Flushing Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	6 17 6 48 31 12 9 8		0 3 1 3 1 0 <1
Cardiovascular System Hypotension Digestive System Nausea Vomiting Diarrhea	17 6 48 31 12 9 8		3 1 3 1 0 <1
System Hypotension Digestive System Nausea Vomiting Diarrhea	6 48 31 12 9 8		1 3 1 0 <1
Hypotension Digestive System Nausea Vomiting Diarrhea	48 31 12 9 8		3 1 0 <1
Nausea Vomiting Diarrhea	31 		
Vomiting Diarrhea	12 9 8		$^{0}_{<1}$
Vomiting Diarrhea	9 8	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	<1
	8	1.2.450	
Anorexia	5	214.14	Ú.
Abdominal			0
enlargement	2 ⁻ 2		1
Constipation	5		0 .
Hemic and Lymphatic System	98		86
Thrombocytopenia	95		63
Neutropenia	.77		60
Anemia	61		17
Ecchymosis	7		<1
Metabolic and	23		3
Nutritional Disorders			
Peripheral Edema	8		i
Angioedema	5		<1
Musculoskeletal	18		1
System	d e		
Arthralgia ,	7		1
Myalgia	7		<1
Nervous System	27		2
Dizziness Insomnia	10 5		<1 0 ·
Respiratory System	36		3
Dyspnea	14		2
Increased Cough	10		õ
Rhinitis	6		0 ···
Bronchospasm	5		Ő
Skin and	28		1
Appendages			
Pruritus Rash	9		<1 <1
Special Senses			<1

Adverse events were followed for a period of 12 weeks following the first Rituximab infusion of the ZEVALIN therapeutic regimen

Note: All adverse events are included, regardless of relationship.

The following adverse events (except for those noted in Table 7) occurred in between 1 and 4% of patients during the treatment period: urticaria (4%), anxiety (4%), dyspepsia (4%), sexests (4%), perchain (3%), epistaxis (3%), allergic reaction (2%), and melena (2%).

Faction (5.%), and meteria (2.%). Severe of life-threatening adverse events occurring in 1-5% of patients (except for those noted in Table 7) consisted of pancytopenia (2%), allerigic reaction (1%), gastrointestinal hemorrhage (1%), mélena (1%), tumor pain (1%), and apnea (1%). The following severe or life threatening events occurred in -3% of patients: angiodema, tachycardia, urticaria, arthritis; lung edema, pulmonary embolus, encephalopathy, hematemesis, subdural hematoma, and vaginal hemorrhage.

Hemotologic Events: Hematologic toxicity was the most frequently observed adverse event in clinical trials. Table 8 presents the incidence and duration of severe hematologic toxicity for patients with normal baseline platelet count ($\geq 150,000$ cells/mm³) treated with the ZEVALIN therapeutic regimen and patients with mild thrombocytopenia (platelet count 100,000 to 149,000 cells/mm³) at baseline who were treated with a modified ZEVALIN therapeutic regimen that included a lower Y-90 ZEVALIN dose at 0.3 mCi/W (111 MBo/W)

Lilly Exhibit 1255, Page 18 of 39

PHYSICIANS' DESK REFERENCE®

mation on growth factor use and platelet transfusions is based on 211 patients for whom data were collected. Filgrastim was given to 13% of patients and erythropoietin to 8%. Platelet transfusions were given to 22% of patients and red blood cell transfusions to 20%.

and red blood cell transfusions to 20%. Infectious Events: During the first 3 months after initiat-ing the ZEVALIN therapeutic regimen, 29% of patients de-veloped infections. Three percent of patients developed se-rious infections comprising urinary tract infection, febrile neutropenia, sepsis, pneumonia, cellulitis, colitis, diarrhea, osteomyelitis, and upper respiratory tract infection. Life threatening infections were reported for 2% of patients that included sepsis, empyema, pneumonia, febrile neutropenia, fever, and biliary stent-associated cholangitis. During follow-up from 3 months to 4 years after the start of freatment with ZEVALIN, 6% of patients developed infections. Two percent of patients had serious infections comprising uripercent of parents hav serious mechanisms drift nary tract infection, bacterial or viral pneumonia, febrile neutropenia, perihilar infiltrate, pericarditis, and intrave-nous drug-associated viral hepatitis. One percent of pa-tients had life threatening infections that included bacterial

pneumonia, respiratory disease, and sepsis. Secondary Malignancies: A total of 2% of patients devel-oped secondary malignancies following the ZEVALIN therapeutic regimen. One patient developed a Grade 1 meningi-oma, three developed acute myelogenous leukemia, and two developed a myelodysplastic syndrome. The onset of a sec-ond cancer was 8-34 months following the ZEVALIN therapeutic regimen and 4 to 14 years following the patients' diagnosis of NHL.

Immunogenicity: Of 211 patients who received the ZEVALIN therapeutic regimen in clinical trials and who were followed for 90 days, there were eight (3.8%) patients with evidence of human anti-mouse antibody (HAMA) (n=5) or human anti-chimeric antibody (HACA) (n=4) at any time during the course of the study. Two patients had low, titers of HAMA prior to initiation of the ZEVALIN therapeutic regi-men; one remained positive without an increase in titer while the other had a negative titer post-treatment. Three patients had evidence of HACA responses prior to initiation of the ZEVALIN therapeutic regimen; one had a marked in-crease in HACA titer while the other two had negative titers post-treatment. Of the three patients who had negative HAMA or HACA titers prior to the ZEVALIN therapeutic regimen, two developed HAMA in absence of HACA titers, and one had both HAMA and HACA positive titers post-treatment. Evidence of immunogenicity may be masked in during the course of the study. Two patients had low titers of and one had both HAMA and HACA positive titers post-treatment. Evidence of inmunogenicity may be masked in patients who are lymphopenic. There has not been adequate evaluation of HAMA and HACA at delayed timepoints, con-current with the recovery from lymphopenia at 6-12 months, to establish whether masking of the immunogenic-ity at early timepoints occurs. The data reflect the percent-age of patients whose test results were considered positive or astibodies to Instruments on Rituring burges this dis for antibodies to Ibritumomab or Rituximab using kinetic enzyme immunoassays to Ibritumomab and Rituximab. The observed incidence of antibody positivity in an assay is highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors including sam ple handling and concomitant medications. Comparisons of the incidence of HAMA/HACA to the ZEVALIN therapeutic regimen with the incidence of antibodies to other products may be misleading.

OVERDOSAGE

Doses as high as 0.52 mCi/kg (19.2 MBq/kg) of Y-90 ZEVALIN were administered in ZEVALIN therapeutic regimen clinical trials and severe hematological toxicities were observed. No fatalities or second organ injury resulting from overdosage administrations were documented. However single doses up to 50 mCl (1880 MBq) of Y-90 ZEVALIN, and multiple doses of 20 mCl (740 MBq) followed by 40 mCl (1480 MBq) of Y-90 ZEVALIN were studied in a limited number of subjects. In these trials, some patients required autologous stem cell support to manage hematological toxicity.

DOSAGE AND ADMINISTRATION

The ZEVALIN therapeutic regimen is administered in two The ZEVALIN therapeutic regimen is administered in two steps: Step 1 includes a single infusion of 250 mg/m² Ritux-imab (not included in the ZEVALIN kits) preceding a fixed dose of 5.0 mCi (1.6 mg total antibody dose) of In-111 ZEVALIN administered as a 10 minute IV push. Step 2 fol-lows step 1 by seven to nine days and consists of a second infusion of 250 mg/m² of Rituximab prior to 0.4 mC/Rg of Y=00 ZEVALIN administered as a 10 minute IV push. Rituximab Administeration: NOTE THAT THE DOSE OF RIT-IV PARTY IN CONTROL OF ADMINISTRATION OF THAT THE DOSE OF RIT-IV PARTY IN CONTROL OF ADMINISTRATION OF THAT THE DOSE OF RIT-

UXIMAB IS LOWER WHEN USED AS PART OF THE ZEVALIN THERAPEUTIC REGIMEN, AS COMPARED TO THE DOSE OF RITUXIMAB WHEN USED AS A SINGLE AGENT. DO NOT ADMINISTER RITUXIMAB AS AN INTRAVENOUS PUSH OR BOLUS. Hypersensitivity reactions may occur (see WARNINGS). Premedication, consisting of acetamino-phen and diphenhydramine, should be considered before each infusion of Rituximab.

ZEVALIN Therapeutic Regimen Dose Modification in Pa tients with Mild Thrombocytopenia: The Y-90 ZEVALIN dose should be reduced to 0.3 mCi/kg (11.1 MBq/kg) for patients with a baseline platelet count between 100,000 and 149,000 cells/mm³

Two separate and distinctly-labeled kits are ordered for the Preparation of a single dose each of In-111 ZEVALIN and Y-90 ZEVALIN. In-111 ZEVALIN and Y-90 ZEVALIN are radiopharmaceuticals and should be used only by physicians

and the second secon	Table 8. matologic Toxicity	s a tha an an a
Sasta thera guilden agus thera the sasta the sasta the sasta the sasta	peutic regimen mCi/kg Y-90 Dose	Modified ZEVALIN therapeutic regimen using 0.3 mCi/kg Y-90 dose (11.1 MBq/kg)
ANC Median nadir (cells/mm ³) Per Patient Incidence ANC <1000 cells/mm ³ Per Patient Incidence ANC <500 cells/mm ³	800 57% 30%	600 74%
ANC <1000 cells/mm ³	22 to the case of a second sec	29
Platelets Median nadir (cells/mm ³) Fer Patient Incidence Platelets <50,000 cells/mm ³ Per Patient Incidence Platelets <10,000 cells/mm ³	41,000 61% 10%	24,000 78% 14%

24 35 Platelets <50,000 cells/mm³ *Median duration of neutropenia for patients with ANC <1000 cells/mm³ (Date from last laboratory value showing ANC ≥1000 cells/mm³ to date of first laboratory value following nadir showing ANC ≥1000 cells/mm³, censored at initiation of

next treatment or death) Median duration of thrombocytopenia for patients with platelets <50,000 cells/mm³ (Date from last laboratory value show-ing platelet count ≥50,000 cells/mm³ to date of first laboratory value following nadir showing platelet count ≥50,000

enced in the safe use and handling of radionuclides. Changing the ratio of any of the reactants in the radiolabeling process may adversely impact therapeutic results. In-111 ZEVALIN and Y-90 ZEVALIN should not be used in the absence of the Rituximab pre-dose.

cells/mm3, censored at initiation of next treatment or death)

Median Duration (Davs)

	(a) (a) (b) (b) (b) (b) (b) (b) (b) (b) (b) (b
Overview of D	osing Schedule:
	 and example AD in the index pro-
	Day 1
	IV infusion of 250 mg/m of Rituximab
	Within 4 hours
na na stra Tan a stra	IV injection of In-111 ZEVALIN over 10 minutes
	 adjusters (paters of an
10 A	Assess Blodistribution 1º image 2 to 24 hours effer In 113 ZEVALIN 2º image 48 to 72 hours after In 111 ZEVALIN ORTIONAL: 3º image 90 to 120 hours after In 111 ZEVALIN
and a start of the	many the second se
	さん しんら大の みつとうたい
	Biodistribution No DO NOT Acceptable? No PROCEED
30.00	Acceptable? PROCEED
	n na ginna de da 🗸 de seu e 🗤 este da com
	The start of Yester and the start of the
	and the state of the
1.0	Day 7 - 9 IV infusion of 250 mg/m of Rituximab
	Within 4 hours
0.4.mCi/kg (Y-90 ZEVALIN over 10 m/hutes as follows: 14.8 MBq/kg) for patients with normal platelet count 11.1 MBq/kg) for patients with platelet count of 100,000 - 149,000cells/mi
	TREAT PATIENTS WITH DOSE OF Y 90 ZEVALIN IS S2.0 mCi (1184 MEq)

ZEVALIN Therapeutic Regimen Administration

First Rituximab Infusion: Rituximab at a dose of 250 mg/m² should be administered intravenously at an initial rate of 50 mg/hr. Rituximab should not be mixed or diluted with other drugs. If hypersensitivity or infusion-related events do not occur, escalate the infusion rate in 50 mg/hr incre-ments every 30 minutes, to a maximum of 400 mg/hr. If hypersensitivity or an infusion-related event develops, the in-fusion should be temporarily slowed or interrupted (see WARNINGS). The infusion can continue at one-half the previous rate upon improvement of patient symptoms. In-111 ZEVALIN Injection: Within 4 hours following com-

pletion of the Rituximab dose, 5.0 mCi (1.6 mg total anti-body dose) of In-111 ZEVALIN is injected intravenously (I.V.) over a period of 10 minutes. A 0.22 micrometer low protein-binding filter should be in-line between the syring and the infusion port prior to injection of In-111 ZEVALIN. After injection, the line should be flushed with at least 10 mL of normal saline. Step 2:

Step 2 of the ZEVALIN therapeutic regimen is initiated seven to nine days following Step 1 administrations. Second Rituximab Infusion: Rituximab at a dose of 250 mg/m² is administered I.V. at an initial rate of 100 mg/hr (50 mg/hr if infusion related events were docu-mented during the first Rituximab administration) and increased by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr, as tolerated. Y-90 ZEVALIN Injection;

Within 4 hours following completion of the Rituximab dose, Y-90 ZEVALIN at a dose of 0.4 mCi/kg (14.8 MBq/kg) actual body weight for patients with a platelet count ≥150,000 cells/mm³ and 0.3 mCi/kg (11.1 MBc/kg) actual body weight

mm³ is injected intravenously (I.V.) over a period of 10 minmm" is injected intravenously (1.V.) over a period of 10 min-utes. A 0.22 micrometer low-protein-binding filter should be in-line between the syringe and the infusion port prior to injection of In-111 ZEVALIN. After injection, the line should be flushed with at least 10 mL of normal saline. Precautions should be taken to avoid extravasation. A free flowing I.V. line should be established prior to Y-90 ZEVALIN injection. Close monitoring for evidence of extravasation during the injection of Y-90 ZEVALIN is required. If any signs or symp-toms of extravasetion back converted the infinite should be toms of extravasation have occurred, the infusion should be immediately terminated and restarted in another vein. The prescribed, measured, and administered dose of Y-90 2EVALIN must not exceed the absolute maximum allow-able dose of 32.0 mCi (1184 MBq), regardless of the pa-tient's body weight. Do not give Y-90 ZEVALIN to patients with a platelet count 100,000/mm² isee WARNINGS). DIRECTIONS FOR PREPARATION OF RADIOLABELED ZEVALIN

A. PREPARATION OF THE IN-111 ZEVALIN DOSE

GENERAL

Read all directions thoroughly and assemble all materials before starting the radiolabeling procedure. Important, significant differences exist in the preparation of the In-111 ZEVALIN dose and the Y-90 ZEVALIN dose.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. The dose calibrator must be operated in accord dance with the manufacturer's specifications and quality control for the measurement of In-111.

Proper aseptic technique and precautions for handling radi-oactive materials should be employed. Waterproof gloves should be utilized in the preparation and during the deter-mination of radiochemical purity of In-111 ZEVALIN Ap-propriate shielding should be used during radiolabeling, and use of a syringe shield is recommended during admin-istration to the patient. The radiolabeling of ZEVALIN shall be done according to the following directions Required materials not supplied in the kit:

- A. Indium-111 Chloride Sterile Solution (In-111 Chlo-ride) from Amersham Health, Inc. or Mallinckrodt,
- B. Three sterile 1 mL syringes
- C. One sterile 3 mL syringe
- D. Two sterile 10 mL syringes with 18-20 G needles E. Instant thin-layer chromatographic silica gel strips
- F. 0.9% sodium chloride aqueous solution for the chro-
- matography solvent
- G. Developing chamber for chromatography
- H. Suitable radioactivity counting apparatus
 I. Filter, 0.22 micrometer, low-protein-binding (see DOSAGE AND ADMINISTRATION, Zevalin Therapeutic Regimen Administration) Vial and syringe shield

Method:

- 1. Sterile, pyrogen-free In-111 chloride must be used for the preparation of In-111 ZEVALIN. The use of high purity In-111 chloride manufactured by Amersham
- Health, Inc. or Mallinckrodt, Inc. is required. Health, Inc. or Mallinckrodt, Inc. is required. Before radiolabeling, allow contents of the refriger-ated carton to reach room temperature. Note: The ZEVALIM, vial contains a protein solution that may develop translucent particulates. These particulates will be removed by filtration prior to administration
- Clean the rubber stoppers of all of the vials in the kit and the In-111 chloride vial with a suitable alcohol
- swab and allow to air dry. Place the empty Reaction Vial in a suitable dispens-4
- ing shield (pre-warmed to room temperature). To

Lilly Exhibit 1255, Page 19 of 39

Zevalin-Cont.

avoid the buildup of excessive pressure during the procedure, use a 10 mL syringe to withdraw 10 mL of air from the Reaction Vial.

- Prior to initiating the radiolabeling reaction, determine the amount of each component needed according to the directions below:
- a. Calculate the volume of In-111 chloride that is equivalent to 5.5 mCi based on the activity concentration of the In-111 chloride stock.
- b. The volume of 50 mM sodium acetate solution needed is 1.2 times the volume of In-111 chloride solution determined in step 5.a., above. (The 50 mM sodium acetate is used to adjust the pH for the radiolabeling reaction.)
- c. Calculate the volume of Formulation Buffer needed to bring the Reaction Vial contents to a final volume of 10 mL. This is the volume of Formu lation Buffer needed to protect the labeled product lation built needed to protect the indeled product from radiolysis and to terminate the labeling reac-tion. For example, if volumes of 0.5 mL of In-111 chloride, 0.6 mL of sodium acetate and 1.0 mL of ZEVALIN were used, then the amount of formula-tion buffer would be $10 \cdot (0.5 + 0.6 + 1.0) = 7.9$ mL.
- With a sterile 1 mL syringe, transfer the calculated volume of 50 mM of sodium acetate to the empty Re-
- action Vial. Coat the entire inner surface of the Re-action Vial by gentle inversion or rolling. Transfer 5.5 mCi of In-111 chloride to the Reaction Vial with a sterile 1 mL syringe. Mix the two solu-
- tions and coat the entire inner surface of the Reaction Vial by gentle inversion or rolling. 8
- With a sterile 3 mL syringe, transfer 1.0 mL of ZEVALIN (Ibritumomab Tiuxetan) to the Reaction Vial. Coat the entire surface of the Reaction Vial by gentle inversion or rolling. Do not shake or agitate the vial contents, since this will cause foaming and denaturation of the protein.
- 9. Allow the labeling reaction to proceed at room tem perature for 30 minutes. Allowing the labeling read tion to proceed for a longer or shorter time may result in inadequate labeling.
- in inadequate labeling. 10. Immediately after the 30-minute incubation period, using a sterile 10 mL syringe with a large bore needle (18 G 20 G), transfer the calculated volume of For-mulation Buffer from step 5c. to the Reaction Vial. Gently add the Formulation Buffer down the side of the Reaction Vial. If necessary, to normalize air pres-sure, withdraw an equal volume of air. Coat the entire inner surface of the Reaction Vial by gentle in version or rolling. Do not shake or agitate the vial contents. Avoid foaming.
- Using the supplied labels, record the patient identi-fication, the date and time of preparation, the total activity and volume, and the date and time of expira-tion, and affix these labels to the reaction vial and shielded reaction vial container.
- shielded reaction vial container. 12. Calculate the volume required for an In-111 ZEVALIN dose of 5 mCi. Withdraw the required vol-ume from the Reaction Vial contents into a sterile 10 mL syringe with a large bore needle (18 G 20 G). Assay the syringe and contents in a dose calibrator. The syringe should contain the dose of In-111 ZEVALIN to be administered to the patient. Using the supplied labels, record the patient identification, the dote and time of perspection. the date and time of preparation, the total activity and volume added, and the date and time of expira-tion, and affix these labels to the syringe and shielded unit dose container.
- 13. Determine Radiochemical purity. See Section C: Procedure for Determining Radiochemical Purity Section that follows DIRECTIONS FOR PREPARATION OF THE Y-90 ZEVALIN DOSE.
- 14. Indium-111 ZEVALIN should be stored at 2 8°C (36 - 46°F) until use and administered within 12 hours of radiolabeling.
- 15. See DOSAGE AND ADMINISTRATION: ZEVALIN
- Therapeutic Regimen Administration: Step 1 16. Discard vials, needles and syringes in accordance with local, state, and federal regulations governing radioactive and biohazardous waste:
- B. PREPARATION OF THE Y-90 ZEVALIN DOSE

GENERAL:

Read all directions thoroughly and assemble all materials before starting the radiolabeling procedure. Important, sig-nificant differences exist in the preparation of the In-111 ZEVALIN dose and the Y-90 ZEVALIN dose.

The patient dose should be measured by a suitable radio activity calibration system immediately prior to adminis-tration. The dose calibrator must be operated in accordance with the manufacturer's specifications and quality control for the measurement of Y-90.

Proper aseptic technique and precations for handling radi-oactive materials should be employed. Waterproof gloves should be utilized in the preparation and during the deter-mination of radiochemical purity of Y-90 ZEVALIN. Appropriate shielding should be used during radiolabeling, and use of a syringe shield is recommended during administra-tion to the patient. The radiolabeling of ZEVALIN shall be

- Required materials not supplied in the kit: A. Yttrium-90 Chloride Sterile Solution from MDS Nor-dion (shipped directly from MDS Nordion upon place-
- ment of an order for the Y-90 ZEVALIN kit) Three sterile 1 mL syringes One sterile 3 mL syringe
- D. Two sterile 10 mL syringes with 18-20 G needles E. Instant thin-layer chromatographic silica gel strips (ITLC-SG)
- F. 0.9% sodium chloride aqueous solution for the chro matography solvent
- G. Suitable radioactivity counting apparatus H. Developing chamber for chromatography
- Filter, 0.22 micrometer, low-protein-binding (see DOSAGE AND ADMINISTRATION, Zevalin Thera-I. peutic Regimen Administration) Vial and syringe shield

Method:

- Sterile, pyrogen-free Y-90 chloride must be used for the preparation of Y-90 ZEVALIN. The use of high 1. purity Y-90 chloride manufactured by MDS Nordion required
- Before radiolabeling, allow the contents of the refrigerated carton to reach room temperature. Note: The ZEVALIN vial contains a protein solution that may develop translucent particulates. These particulates will be removed by filtration prior to administration.
- Clean the rubber stoppers of all of the vials in the kit and the Y-90 chloride vial with a suitable alcohol
- swab and allow to air dry. Place the empty Reaction Vial in a suitable dispens-
- ing shield (pre-warmed to room temperature). To avoid the buildup of excessive pressure during the procedure, use a 10 mL syringe to withdraw 10 mL of air from the Reaction Vial.
- Prior to initiating the radiolabeling reaction, determine the amount of each component needed accord ing to the directions below
- Calculate the volume of Y-90 chloride that is equiv-alent to 40 mCi based on the activity concentration of the Y-90 chloride stock.
- b. The volume of 50 mM sodium acetate solution needed is 1.2 times the volume of Y-90 chloride so-lution determined in step 5.a., above. (The 50 mM sodium acetate is used to adjust the pH for the ra diolabeling reaction.)
- c. Calculate the volume of Formulation Buffer needed to bring the Reaction Vial contents to a fi-nal volume of 10 mL. This is the volume of Formulation Buffer needed to protect the labeled product from radiolysis and to terminate the labeling reaction. For example if the volumes were 0.5 mL of 5.00 chloride, 0.6 mL of sodium acetate and 1.3 mL of ZEVALIN, then the amount of formulation buffer would be 10 - (0.5 + 0.6 + 1.3) = 7.6 mL.
- With a sterile 1 mL syringe, transfer the calculated volume of 50 mM sodium acetate to the empty Reaction Vial. Coat the entire inner surface of the Reac
- tion Vial by gentle inversion or rolling. Transfer 40 mCi of Y-90 chloride to the Reaction Vial with a sterile 1 mL syringe. Mix the two solutions and coat the entire inner surface of the Reaction Vial by gentle inversion or rolling.
- With a sterile 3 mL syringe, transfer 1.3 mL of ZEVALIN (Ibritumomab Tiuxetan) to the Reaction Vial. Coat the entire surface of the Reaction Vial by gentle inversion or rolling. Do not shake or agitate the vial contents, since this will cause foaming and denaturation of the protein.
- 9. Allow the labeling reaction to proceed at room temperature for 5 minutes. Allowing the labeling reac-tion to proceed for a longer or shorter time may result
- tion to proceed for a longer or shorter time may result in inadequate labeling.
 10. Immediately after the 5-minute incubation period, using a sterile 10 mL syringe with a large bore needle (18 G 20 G), transfer the calculated volume of For-mulation Buffer from step 5c. to the Reaction. Vial, terminating incubation. Gently add the Formulation Buffer down the side of the Reaction Vial. If neces-count is emerging a improvement with down an equal. sary to normalize air pressure, withdraw an equal volume of air. Coat the entire inner surface of the Reaction Vial by gentle inversion or rolling. Do not shake or agitate the vial contents. Avoid foaming.
- 11. Using the supplied labels, record the patient identi-fication, the date and time of preparation, the total activity and volume, and the date and time of expiration and affix these labels to the reaction vial and shielded reaction vial container.
- Calculate the volume required for a Y-90 ZEVALIN dose of 0.4 mCi/kg (14.8 MBq/kg) actual body weight for patients with normal platelet count, and 0.3 mCi/kg (11.1 MBq/kg) actual body weight for pa-tients with platelet count of 100,000 - 149,000 cells/ mm^3 . The prescribed, measured, and administered dose of V-90 ZEVALIN must not exceed the absolute maximum allowable dose of 32.0 mCi (1184 MBq), regardless of the patient's body weight. Withdraw the required volume from the Reaction Vial contents into a sterile 10 mL syringe with a large bore needle (18 G - 20 G). Assay the syringe and contents in a dose calibrator. The dose calibrator must be operated

- syringe should contain the dose of Y-90 ZEVALIN to be administered to the patient, and should be within
- 10% of the actual prescribed dose of Y-90 ZEVALIN, not to exceed a maximum dose of 32.0 mCi. Do not
- exceed \pm 10% of the prescribed dose. Using the supplied labels, record the patient identification, the date and time of preparation, the total activity and volume added, and the date and time of expiration and affix these labels to the syringe and shielded unit dose container.
- 13. Determine Radiochemical Purity. See Section C: Pro cedure for Determining Radiochemical Purity Section that follows these DIRECTIONS FOR PREPARA-
- TION OF THE Y-90 ZEVALIN DOSE.
- 14. Yttrium-90 ZEVALIN should be stored at 2 8°C (36 - 46°F) until use and administered within 8 ho of radiolabeling. 15. See DOSAGE AND ADMINISTRATION: ZEVALIN
- Therapeutic Regimen Administration: Step 2.
- 16. Discard vials, needles and syringes in accordance with local, state, and federal regulations governing radioactive and biohazardous waste.

Yttrium-90 ZEVALIN is suitable for administration on an outpatient basis. Beyond the use of vial and syringe shields for preparation and injection, no special shielding is

C. PROCEDURE FOR DETERMINING RADIOCHEMICAL PU-RITY (RCP)

The following procedure should be used for both In-111 ZEVALIN and Y-90 ZEVALIN:

- A. At room temperature, place a small drop of either In-111 ZEVALIN or Y-90 ZEVALIN at the origin of an ITLC-SG strip. B. Place the ITLC-SG strip into a chromatography cham-
- ber with the origin at the bottom and the solvent front at the top. Allow the solvent (0.9% NaCl) to migrate at
- least 5 cm from the bottom of the strip. Remove the strip from the chamber and cut the strip in half. Count each half of the ITLC-SG strip for one minute (CPM) with a suitable counting apparatus.
- C. Calculate the percent RCP as follows:

% RCP = CPM bottom half CPM bottom half + CPM top half $\times 100$

D. If the radiochemical purity is <95%, the ITLC procedure should be repeated. If repeat testing confirms that radiochemical purity is < 95%, the preparation should not be administered.

IMAGE ACQUISITION AND INTERPRETATION

The biodistribution of In-111 ZEVALIN should be assessed by a visual evaluation of whole body planar view anterior and posterior gamma images at 2 - 24 hours and 48 - 72 hours after injection. To resolve ambiguities, a third image at 90 - 120 hours may be necessary. Images should be ac-quired using a large field of view gamma camera equipped with a medium energy collimator. Whole body anterior/ posterior planar images should be acquired using a large field-of-view gamma camera and medium energy collina tors. Suggested gamma camera settings: 256 × 1024 ma trix; dual energy photopeaks set at 172 and 247 keV; 15% symmetric window; scan speed of 10 cm/min for the 2-24 hour scan, 7-10 cm/min for the 48-72 hour scan and 5 cm/

min for the optional 90-120 hour scan. The radiopharmaceutical is expected to be easily detectable in the blood pool areas at the first time point, with less ac-tivity in the blood pool on later images. Moderately high to high uptake is seen in the normal liver and spleen, with low uptake in the lungs, kidneys, and urinary bladder. Localiza-tion to lymphoid aggregates in the bowel wall has been reported. Tumor uptake may be visualized in soft tissue as areas of increased intensity, and tumor-bearing areas in normal organs may be seen as areas of increased or de-creased intensity.

If a visual inspection of the gamma images reveals an al-tered biodistribution, the patient should not proceed to the Y-90 ZEVALIN dose. The patient may be considered to have an altered biodistribution if the blood pool is not visualized on the first image indicating rapid clearance of the radiopharmaceutical by the reticuloendothelial system to the liver, spleen, and/or marrow. Other potential examples of al-tered biodistribution may include diffuse uptake in the normal lungs or kidneys more intense than the liver on the second or third image. During ZEVALIN clinical development, individual tumor

radiation absorbed dose estimates as high as 778 cGy/mCi have been reported. Although solid organ toxicity has not have been reported. Although solid organ botchy has not been directly attributed to radiation from adjacent tumors, careful consideration should be applied before proceeding with treatment in patients with very high tumor uptake next to critical organs or structures.

HOW SUPPLIED

The In-111 ZEVALIN kit provides for the radiolabeling of Ibritumomab Tiuxetan with In-111. The Y-90 ZEVALIN kit provides for the radiolabeling of Ibritumomab Tiuxetan rith Y-90.

The kit for the preparation of a single dose of In-111 ZEVALIN includes four vials: one ZEVALIN vial containing 3.2 mg of Dritumomah Thurston in 2 mJ of 0.9% sodium

PHYSICIANS' DESK REFERENCE®

mulation Buffer vial; one empty Reaction vial and four identification labels.

The kit for the preparation of a single dose of Y-90 ZEVALIN includes four vials: one ZEVALIN vial containing 3.2 mg of Ibritumomab Tiuxetan in 2 mL of 0.9% sodium chloride solution; one 50 mM Sodium Acetate vial; one Formulation Buffer vial; one empty Reaction vial and four identification labels.

The contents of all vials are sterile, pyrogen-free and contain no preservatives.

The Indium-111 Chloride Sterile Solution (In-111 Chloride) must be ordered separately from either Amersham Health, Inc. or Mallinckrodt, Inc. at the time the In-111 ZEVALIN kit is ordered. The Yttrium-90 chloride sterile solution will be shipped directly from MDS Nordion upon placement of an order for the Y-90 ZEVALIN kit.

Storage Store at 2 - 8°C (36 - 46°F). Do not freeze.

REFERENCES

- 1. Kocher DC. Radioactive Decay Data Tables A Handbook of Decay Data for Application to Radiation Dosim-etry and Radiological Assessments: U.S. Department of Energy 1981: DOE/TIC-11026.
- 2. Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem Binfeld D, Brown J, Valentine M, Clark E, Ledbetter J.
- Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmem-brane domains. EMBO J 1988;7(3):711-7.
- 4. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63(6): 1424-33
- 5. Tedder T, Boyd A, Freedman A, Nadler L, Schlossman S The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985:135(2):973-9.
- Press O, Appelbaum F, Ledbetter J, Martin P, Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) se rotherapy of human B-cell lymphomas. Blood 1987;69(2):584-91. 7. Chakrabarti MC, Le N, Paik CH, De Graff WG;
- Carrasquillo JA. Prevention of radiolysis of monoclonal antibody during labeling. J Nucl Med 1996; 37(8):1384-8
- Wiseman GA; White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II 90Y Zevalin™ (90yttrium ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27(7); 766-77.
- Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica DA, et al. Biodistribution and dosim etry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001;39(1-2): 181-94.
- 10. Siegel J, Lee R, Pawlyk D, Horowitz J, Sharkey R, Goldenberg D. Sacral scintigraphy for bone marrow dosime-try in radioimmunotherapy. Int J Appl Radiat Instr 1989:16(Part B):553-9.
- 11. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN; et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's Lym-phoma. J. Clin Oncol 2002;20(15);3262-9.
- 12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international work-shop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999;17(4):1244-53. 13. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Em-
- manouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radio immunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicu-lar, or transformed B-cell non-Hodgkins lymphoma. J
- Clin Oncol 2002;20(10):2453-63. 14. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmu notherapy for relapsed or refractory non-Hodgkins lym phoma patients with mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99(12):4336-42.

3-665-1820

Rx Only In-111 ZEVALIN kit, NDC 64406-104-04

Y-90 ZEVALIN kit, NDC 64406-103-03 © 2002 IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego, CA 92121 U.S. License Number 1235 Protected by one or more U.S. Patents.

Issue Date: January 2003

Immunotec Research Ltd. 292 ADRIEN PATENAUDE VAUDREUIL-DORION (QUEBEC)

CANADA J7V 5V5

For Direct Inquiries Contact: 1-800-440-6250

IMMUNOCAL® 2003

NUTRACEUTICAL (Bonded cysteine supplement) Powder Sachets

DESCRIPTION and CLINICAL PHARMACOLOGY

IMMUNOCAL® is a U.S. patented natural food protein concentrate in the FDA category of GRAS (generally recognized as safe) which assists the body in maintaining optimal con-centrations of glutathione (GSH) by supplying the precur-sors required for intracellular glutathione synthesis. It is clinically proven to raise glutathione values (Lands et al, 1999).

Glutathione is a tripeptide made intracellularly from its constituent amino acids Leglutamate, Legsteine, and gly-cine. The sulfhydryl (thiol) group (SH) of cysteine serves as a proton donor and is responsible for the biological activity of glutathione. Provision of this amino acid is the rate-limiting factor in glutathione synthesis by the cells since cysteine is relatively rare in foodstuffs and furthermore, if released as the free amino acid, is toxic and spontaneously catabolized in the gastrointestinal tract and blood plasma. Immunocal® is a bovine whey protein isolate specially pre-pared so as to provide a rich source of bioavailable cysteine. Following digestion, the cysteine remains as the stable form cysteine (2 molecules of cysteine linked by disulfide bond) and glutamylcystine. After absorption, these dipeptides travel safely in the blod stream and readily enter the cells to release free cysteine for intracellular glutathione synthesis. Immunocal® can thus be viewed as a cysteine de livery system.

The disulphide bond in cystine is pepsin and trypsin resis-tant but may be split by heat low pH or mechanical stress releasing free cysteine. When subject to heat or shearing forces (inherent in most extraction processes), the fragile di-sulfide bonds within the peptides are broken and the bio-availability of cysteine is greatly diminished.

Glutathione is a tightly regulated intracellular constituent and is limited in its production by negative feedback inhibition of its own synthesis through the enzyme gammaglutamylcysteine synthetase, thus greatly minimizing any possibility of overdosage.

Glutathione has multiple functions: I. It is the major endogenous antioxidant produced by the cells, participating directly in the neutralization of free radicals and reactive oxygen compounds, as well as main taining exogenous antioxidants such as vitamins C and E in their reduced (active) forms. 2. Through direct conjugation, it detoxifies many xenobiot-

ics (foreign compounds) and carcinogens, both organic and inorganic. 3. It is essential for the immune system to exert its full po-

5. It is essential tor the immune system to exert its full po-tential, e.g. (1) modulating antigen presentation to lympho-cytes, thereby influencing cytokine production and type of response (cellular or humoral) that develops, (2) enhancing proliferation of lymphocytes thereby increasing magnitude of response, (3) enhancing killing activity of cytotoxic T cells and NK cells, and (4) regulating apoptosis, thereby main-taining control of the immune response.

4. It plays a fundamental role in numerous metabolic and biochemical reactions such as DNA synthesis and repair, protein synthesis, prostaglandin synthesis, amino acid transport and enzyme activation. Thus, every system in the body can be affected by the state of the glutathione system, especially the immune system; the nervous system, the gas trointestinal system and the lungs.

INDICATIONS AND USAGE

IMMUNOCAL® is a natural food supplement and as such is limited from stating medical claims per se. Statements have not been evaluated by the FDA. As such, this product is thus not intended to diagnose, cure, prevent or treat any disease. Glutathione augmentation is a strategy developed to address states of glutathione deficiency, high oxidative stress, immune deficiency, and xenobiotic overload in which glutathione plays a part in the detoxification of the xenobiotic in question. Glutathione deficiency states include, but are not limited to: HIV/AIDS, chemical and infectious hepattis, prostate and other cancers, channel and intercloug nep-attis, prostate and other cancers, cataracts, Allaheimer's, Parkinsons, chronic obstructive pulmonary disease, asthma, radiation poisoning, malnutritive states, arduous physical stress, aging, and has been associated with sub-optimal immune response. Many clinical pathologies are associated with oxidative stress and are elaborated upon in numerous medical references.

Low glutathione is also strongly implicated in wasting and negative nitrogen balance (Droge and Holm, 1997), notably as seen in cancer, AIDS, sepsis, trauma, burns and even athletic overtraining. Glutathione supplementation can op-nose this monose and in AIDS for anamole result in im-

CONTRAINDICATIONS

IMMUNOCAL® is contraindicated in individuals who develop or have known hypersensitivity to specific milk proteins.

PRECAUTIONS

Each sachet of IMMUNOCAL® contains nine grams of protein. Patients on a protein-restricted diet need to take this into account when calculating their daily protein load. Al-though a bovine milk derivative, IMMUNOCAL® contains less than 1% lactose and therefore is generally well tolerated by lactose-intolerant individuals.

WARNINGS

OTC

Patients undergoing immunosuppressive therapy should discuss the use of this product with their health professional.

ADVERSE REACTIONS

Gastrointestinal bloating and cramps if not sufficiently rehydrated. Transient urticarial-like rash in rare individuals undergoing severe detoxification reaction. Rash abates when product intake stopped or reduced. OVERDOSAGE

Overdosing on IMMUNOCAL® has not been reported.

DOSAGE AND ADMINISTRATION

For mild to moderate health challenges, 20 grams per day is recommended. Clinical trials in patients with AIDS, COPD, cancer and chronic fatigue syndrome have used 30-40 grams per day without ill effect. IMMUNOCAL® is best administered on an empty stomach or with a light meal. Con-comitant intake of another high protein load may adversely affect absorption. RECONSTITUTION

RECONSTITUTION IMMUNOCALOW is a dehydrated powdered protein isolate. It must be appropriately rehydrated before use. Remains bioactive up to 12 hours after mixing. DO NOT heat or use a hot liquid to rehydrate the product. DO NOT use a high-speed blender for reconstitution. These methods will decrease the activity of the product. Proper mixing is imperative. Consult instructions included

in packaging.

HOW SUPPLIED

10 grams of bovine milk protein isolate powder per sachet. 30 sachets per box. STORAGE

Store in a cool dry environment. Refrigeration is not neces-

- Patent no.'s: 5,230,902 5,290,571 5,456,924 5,451,412 -5,888,552
- REFERENCES Baruchel S, Viau G, Olivier R. et al. Nutraceutical mod-1: ulation of glutathione with a humanized native milk serum protein isolate, Immunocal®: application in AIDS
- and cancer. In: Oxidative Stress in Cancer AIDS and Neurodegenerative Diseases. Ed.; Montagnier L, Olivier R, Pasquier C. Marcel Dekker Inc. New York, 447-461, 1998
- Bounous G, Kongshavn P. Influence of protein type in nutritionally adequate diets on the development of im-munity. <u>In</u> Absorption and Utilization of Amino Acids Vol.II. Ed. M. Friedman. CRC Press, Inc., Fla. 2:219-32, 1989
- Bounous G, Gold P. The biological activity of undenatured whey proteins: role of glutathione. Clin Invest Med 14:296-309, 1991 Bounous G, Baruchel S, Falutz J. Gold P. Whey proteins
- Boundous C, Baruchel S, Faitt 2, Gold P. Whey proteins as a food supplement in HIV-seropositive individuals. Clin Invest Med. 16.3; 204–209, 1992 Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 20:4785–4792,2000
- Bounous G. Immunoenhancing properties of undena-tured milk serum protein isolate in HIV patients. Int. Diary Fed: Whey: 293-305, 1998
- Droge W, Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle Marinectoria dina dina di anti di associate di associate di muscle wasting and immunological dysfunction. FASEB J: 11(13):1077-1089, 1997 Herzenberg LA, De Rosa SC, Dubs JG et al. Glutathione
- deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci 94:1967-72,1997
- Kennedy R, Konok G, Bounous G et al.. The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: A phase 1-II clinical study Anticancer Res. 15:2643-50,1995 Lands LC, Grey VL, Smountas AA. Effect of supplemen-
- Lands LC, Grey VL, Smountas AA. Effect of supplemen-tation with a cysteine donor on muscular performance. J. Appl. Physiol. 87:1381–1385, 1999 Locigno R, Castronovo V. Reduced glutathione System: Role in cancer development, prevention and treatment. International Journal of Oncology 19:221–236, 2001 11
- Lomaestro B, Malone M. Glutathione in health and dis-12. ease: pharmacotherapeutic issues. Ann Pharmacother 29: 1263–73,1995
- Lothian B, Grey V, Kimoff RJ, Lands. Treatment of ob structive airway disease with a cysteine donor protein supplement: a case report. Chest 117:914-916, 2000.
- Meister A. Glutathione. Ann Rev Biochem 52:711-60,1983

Lilly Exhibit 1255, Page 21 of 39

fined as those occurring on 1 or more occasions in at least 100 patients; infrequent adverse events are those occur-ring in 1/100 to 1/1000 patients; rare events are those occur-ring in less than 1/1000 patients.

Body as a Whole—Frequent: chest pain, chills; Infrequent: chills and fever, face edema, intentional overdose, malaise, claus and level, lace edema, intentional overdose, malaise, pelvic pain, suicide attempt, *Rare:* abdominal syndrome acute, hypothermia, intentional injury, neuroleptic malig-nant syndrome⁴, photosensitivity reaction. **Cardiovascula: System**-*Prequent:* hemorrhage, hyperten-sion, palpitation; *Infrequent:* angina pectoris, arrhythmia, converting theory follower foll

congestive heart failure, hypotension, migraine, myocardial infarct, postural hypotension, syncope, tachycardia, vascu-lar headache; Rare: atrial fibrillation, bradycardia; cerebral ian neatacute, fure' atrial normation, pracycardia, cerebral embolism, cerebral ischemia, cerebravsacular accident, ex-trasystoles, heart arrest, heart block, pallor, peripheral vas-cular disorder, phlebitis, shock, thrombophlebitis, thrombo-sis, vasospasm, ventricular arrhythmia, ventricular extrasystoles, ventricular fibrillation.

Digestive System—Frequent: increased appetite, nausea and vomiting; Infrequent: aphthous stomatitis, cholelithiasis, colitis, dysphagia, eructation, esophagitis, gastritis, gas-troenteritis, glossitis, gum hemorrhage, hyperchlorhydria, increased salivation, liver function tests abnormal, melena mouth ulceration, nausea/vomiting/diarrhea, stomach ulcer, stomatitis, thirst; Rare: biliary pain, bloody diarrhea, cholecystitis, duodenal ulcer, enteritis, esophageal ulcer, fecal in-continence, gastrointestinal hemorrhage, hematemesis. hemorrhage of colon, hepatitis, intestinal obstruction, liver fatty deposit, pancreatitis, peptic ulcer, rectal hemorrhage, salivary gland enlargement, stomach ulcer hemorrhage, tongue edema.

Endocrine System-Infrequent: hypothyroidism; Rare: dia-

betic acidosis, diabetes mellitus. Hemic and Lymphatic System—Infrequent: anemia, ecchy-mosis; Rare: blood dyscrasia, hypochromic anemia, leukope-

mossi, Aure. buod dyscrasia, hypochromic anemia, leukope-nia, lymphedema, lymphocytosis, petechia, purpura, throm-bocythemia, thrombocytopenia. Metabolic and Nutritional—Frequent: weight gain; Infre-quent: dehydration, generalized edema, gout, hyperholes-teremia, hyperlipenia, hypokalemia, peripheral edema; Brass clebal intriuma. Rare: alcohol intolerance, alkaline phosphatase increased BUN increased, creatine phosphokinase increased, hyperkalemia, hyperuricemia, hypocalcemia, iron deficiency

mia, SGPT increased. Musculoskeletal System-Infrequent: arthritis, bone pain, bursitis, leg cramps, tenosynovitis; Rare: arthrosis, chon-drodystrophy, myasthenia, myopathy, myositis, osteomyelitis, osteoporosis, rheumatoid arthritis

Is, osteoporosis, rheumatoid artinrits. Nervous System—Frequent: agitation, amnesia, confusion, emotional lability, sleep disorder; Infrequent: abnormal gait, acute brain syndrome, akathisia, apathy, ataxia, bucceglos-sal syndrome, CNS depression, CNS stimulation, depersonalization, euphoria, hallucinations, hostility, hyperkinesia, hypertonia, hypesthesia, incoordination, libido increased, invocionus, neuralgia, neuropathy, neurosis, paranoid reac-tion, personality disorder², psychosis, vertigo, *Rare*: abnor-mal electroencephalogram, antisocial reaction, circumoral paresthesia, coma, delusions, dysarthria, dystonia, extrapy-ramidal syndrome, foot drop, hyperesthesia, neuritis, paralysis, reflexes decreased, reflexes increased, stupor.

Respiratory System—Infraquent: asthma, epistaxis, hiccup, hyperventilation; Rare: apnea, atelectasis, cough decreased, emphysema, hemoptysis, hypoventilation, hypoxia, larynx edema, lung edema, pneumothorax, stridor. Skin and Appendages—Infrequent: acne, alopecia, contact

dermatitis, eczema, maculopapular rash, skin discoloration, skin ulcer, vesiculopullous rash; Rare: furunculosis, herpes zoster, hirsutism, petechial rash, psoriasis, purpuric rash pustular rash, seborrhea.

puscutar rash, secorrinea. Special Senses—Frequent: ear pain, taste perversion, tinni-tus; Infrequent: conjunctivitis, dry eyes, mydriasis, photo-phobia; Rare: blepharitis, deafness, diplopia, exophthalmos, eye hemorrhage, glaucoma, hyperacusis, iritis, parosmia, scleritis, strabismus, taste loss, visual field defect.

scleritis, strabismus, taste loss, visual field defect. Urogenital System—Frequent: urinary frequency; Infre-quent; abortion³, albuminuria, amenorrhea³, anorgasmia, versati autori, autoriniaria, amenorinea, anorgasmia, breast enlargement, breast pain, cystitis, dysuria, female lactation³, fibrocystic breast³, hematuria, leukorrhea³, met-orrhagia³, metrorrhagia³, nocturia, polyuria, urinary incontinence, urinary retention, urinary urgency, vaginal hemor-thance³, Rare: breast engorgement, glycosuria, hypomenorrhage³, uterine fibroids enlarged⁴.

¹Neuroleptic malignant syndrome is the COSTART term hich best captures serotonin syndrome

² Personality disorder is the COSTART term for designating non-aggressive objectionable behavior.

³ Adjusted for gender. Postintroduction Reports

Voluntary reports of adverse events temporally associated with Prozac that have been received since market introduction and that may have no causal relationship with the drug include the following: aplastic anemia, atrial fibrillation, cataract, cerebral vascular accident, cholestatic jaundice. catarat, dereoran vascular accident, choiestatic jaunnice, confusion, dyskinesia (including, for example, a case of buccal-lingual-masticatory syndrome with involuntary tongue protrusion reported to develop in a 77-year-old fe-male after 5 weeks of floxetine therapy and which com-pletely resolved over the next few months following drug discontinuity) accidentation discontinuation), eosinophilic pneumonia, epidermal necrolysis, erythema nodosum, exfoliative dermatitis, gyne-

lactinemia, hypoglycemia, immune-related hemolytic anehachineme, nypogycema, minume-reaten nemotyuc ane-mia, kidney failure, misuse/abuse, movement disorders developing in patients with risk factors including drugs as sociated with such events and worsening of preexisting movement disorders, neuroleptic malignant syndrome-like events, optic neuritis, pancreatitis, pancytopenia, priapism, pulmonary embolism, pulmonary hypertension, QT prolongation, serotonin syndrome (a range of signs and symptoms that can rarely, in its most severe form, resemble neuroleptic malignant syndrome), Stevens-Johnson syndrome, sud-den unexpected death, suicidal ideation, thrombocytopenia, thrombocytopenic purpura, vaginal bleeding after drug withdrawal, ventricular tachycardia (including torsades de pointes-type arrhythmias), and violent behaviors.

DRUG ABUSE AND DEPENDENCE

Controlled substance class-Prozac is not a controlled substance

Physical and psychological dependence-Prozac has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical dependence. While the premarketing clinical experience with Prozac did not reveal any tendency for a withdrawal syndrome or any drug seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this lim-ited experience the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of Prozac (e.g., development of tolerance, incrementation of dose, drugseeking behavior).

OVERDOSAGE Human Experience

Worldwide exposure to fluoxetine hydrochloride is esti-mated to be over 38 million patients (circa 1999). Of the 1578 cases of overdose involving fluoxetine hydrochloride, alone or with other drugs, reported from this population

there were 195 deaths. Among 633 adult patients who overdosed on fluoreting Among 653 adult patients who overdosed on fluoxetine hydrochloride alone, 34 resulted in a fatal outcome, 378 completely recovered, and 15 patients experienced sequelae after overdosage, including abnormal accommodation, ab-normal gait, confusion, unresponsiveness, nervousness, pulmonary dysfunction, vertigo, tremor, elevated blood pres-sure, impotence, movement disorder, and hypomania. The remaining 206 patients had an unknown outcome. The mos common signs and symptoms associated with non-fatal overdosage were seizures, somnolence, nausea, tachycardia. and vomiting. The largest known ingestion of fluoxetine hydrochloride in adult patients was 8 grams in a patient who took fluoxetine alone and who subsequently recovered. However, in an adult patient who took fluoxetine alone, an ingestion as low as 520 mg has been associated with lethal

outcome, but causality has not been established. Among pediatric patients (ages 3 months to 17 years), there were 156 cases of overdose involving fluoxetine alone or in combination with other drugs. Six patients died, 127 pa-tients completely recovered, 1 patient experienced renal failure, and 22 patients had an unknown outcome. One of the six fatalities was a 9-year-old boy who had a history of OCD. The state of the size OCD, Tourette's syndrome with tics, attention deficit disorder, and fetal alcohol syndrome. He had been receiving 100 mg of fluoxetine daily for 6 months in addition to clonidine, methylphenidate, and promethazine. Mixed drug in-gestion or other methods of suicide complicated all 6 overdoses in children that resulted in fatalities. The largest ingestion in pediatric patients was 3 grams which was nonlethal

Other important adverse events reported with fluoxetine verdose (single or multiple drugs) include coma, delirium. ECG abnormalities (such as QT interval prolongation and ventricular tachycardia, including torsades de pointes-type arrhythmias), hypotension, mania, neuroleptic malignant syndrome-like events, pyrexia, stupor, and syncope.

Animal Experience Studies in animals do not provide precise or necessarily studies in animals do not provide precise or necessarily valid information about the treatment of human overdose. However, animal experiments can provide useful insights into possible treatment strategies. The oral median lethal dose in rats and mice was found to

be 452 and 248 mg/kg, respectively. Acute high oral doses produced hyperirritability and convulsions in several animal species

Among 6 dogs purposely overdosed with oral fluoxetine, 5 experienced grand mal seizures. Seizures stopped immedi-ately upon the bolus intravenous administration of a standard veterinary dose of diazepam. In this short-term study, the lowest plasma concentration at which a seizure occurred was only twice the maximum plasma concentration seen in humans taking 80 mg/day, chronically. In a separate single-dose study, the ECG of dogs given high

doses did not reveal prolongation of the PR, QRS, or QT in-tervals. Tachycardia and an increase in blood pressure were observed. Consequently, the value of the ECG in predicting cardiac toxicity is unknown. Nonetheless, the ECG should ordinarily be monitored in cases of human overdose (see Management of Overdose). Management of Overdose

Treatment should consist of those general measures em ployed in the management of overdosage with any drug effective in the treatment of major depressive disorder. Ensure an adequate airway, oxygenation and ventile

and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protec-tion, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to the large

volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for fluoxetine are known. A specific caution involves patients who are taking or have recently taken fluoxetine and might ingest excessive quantities of a TCA. In such a case, accumulation of the parent tricyclic and/or an active metabolite may increase the possibility of clinically significant sequelae and extend the time needed for close medical observation (see Other drugs effec-tive in the treatment of major depressive disorder under PRECAUTIONS).

Based on experience in animals, which may not be relevant to humans, fluoxetine-induced seizures that fail to remit spontaneously may respond to diazepam.

In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the *Physicians' Desk Ref*erence (PDR).

DOSAGE AND ADMINISTRATION Major Depressive Disorder

Initial Treatment

Adult-In controlled trials used to support the efficacy of fluoxetine, patients were administered morning doses rang-ing from 20 to 80 mg/day. Studies comparing fluoxetine 20, 40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in major depressive disorder in most cases. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose.

A dose increase may be considered after several weeks if insufficient clinical improvement is observed. Doses above 20 mg/day may be administered on a once-a-day (morning) or BID schedule (i.e., morning and noon) and should not ex-ceed a maximum dose of 80 mg/day.

Pediatric (children and adolescents)—In the short-term (8 to 9 week) controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of major depressive disor-der, patients were administered fluozetine doses of 10 to 20 mg/day (see CLINICAL TRIALS). Treatment should be initiated with a dose of 10 or 20 mg/day. After 1 week at 10 mg/day, the dose should be increased to 20 mg/day.

However, due to higher plasma levels in lower weight children, the starting and target dose in this group may be 10 mg/day. A dose increase to 20 mg/day may be considered after several weeks if insufficient clinical improvement is observed;

All patients—As with other drugs effective in the treatment of major depressive disorder, the full effect may be delayed until 4 weeks of treatment or longer.

As with many other medications, a lower or less frequent dosage should be used in patients with hepatic impairment. A lower or less frequent dosage should also be considered for the elderly (see Geriatric Use under PRECAUTIONS), and for patients with concurrent disease or on multiple concom itant medications. Dosage adjustments for renal impairment are not routinely necessary (see Liver disease and Renal disease under CLINICAL PHARMACOLOGY in patients with concomitant illness under PRECAU-TIONS).

Maintenance/Continuation/Extended Treatment

It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Whether the dose needed to induce remission is identical to the dose needed to maintain and/or sustain euthymia is unknown Daily Dosing

Systematic evaluation of Prozac in adult patients has shown that its efficacy in major depressive disorder is main-tained for periods of up to 38 weeks following 12 weeks of open-label acute treatment (50 weeks total) at a dose of 20 mg/day (see CLINICAL TRIALS).

Weekly Dosing

Systematic evaluation of Prozac Weekly in adult patients has shown that its efficacy in major depressive disorder is maintained for periods of up to 25 weeks with once-weekly dosing following 13 weeks of open-label treatment with Prozac 20 mg once daily. However, therapeutic equivalence of Prozac Weekly given on a once-weekly basis with Prozac 20 mg given daily for delaying time to relayse has not been established (see CLINICAL TRIALS).

Weekly dosing with Prozac Weekly capsules is recommended to be initiated 7 days after the last daily dose of Prozac 20 mg (see Weekly dosing under CLINICAL PHAR-MACOLOGY).

Continued on next page

* Identi-Code® symbol. This product information was prepared in June 2002. Current information on these and other products of Eli Lilly and Company may be obtained by direct inquiry to Lilly Research Laboratories, Lilly Corporate Center, If satisfactory response is not maintained with Prozac Weekly, consider reestablishing a daily dosing regimen (see CLINICAL TRIALS).

Switching Patients to a Tricyclic Antidepressant (TCA) Dosage of a TCA may need to be reduced, and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued (see Other drugs effective in the treatment of major de-pressive disorder *under* Drug Interactions).

Switching Patients to or from a Monoamine Oxidase Inhib-itor (MAOI)

Information of the set of the

Obsessive-Compulsive Disorder

Initial Treatment

Adult-In the controlled clinical trials of fluoxetine support ing its effectiveness in the treatment of OCD, patients were administered fixed daily doses of 20, 40, or 60 mg of fluox-etine or placebo (see CLINICAL TRIALS). In 1 of these studies, no dose-response relationship for effectiveness was dem-onstrated. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Since there was a suggestion of a possible dose-response relation ship for effectiveness in the second study, a dose increase may be considered after several weeks if insufficient clinical improvement is observed. The full therapeutic effect may be delayed until 5 weeks of treatment or longer.

Doses above 20 mg/day may be administered on a once-aday (i.e., morning) or BID schedule (i.e., morning and noon). A dose range of 20 to 60 mg/day is recommended; however, doses of up to 80 mg/day have been well tolerated in open studies of OCD. The maximum fluoxetine dose should not exceed 80 mg/day.

Pediatric (children and adolescents)-In the controlled cli ical trial of fluoxetine supporting its effectiveness in the treatment of OCD, patients were administered fluoxetine doses in the range of 10 to 60 mg/day (see CLINICAL TRIALS)

In adolescents and higher weight children, treatment should be initiated with a dose of 10 mg/day. After 2 weeks, the dose should be increased to 20 mg/day. Additional dose increases may be considered after several more weeks if in-sufficient clinical improvement is observed. A dose range of 20 to 60 mg/day is recommended.

In lower weight children, treatment should be initiated with dose of 10 mg/day. Additional dose increases may be consid-ered after several more weeks if insufficient clinical improvement is observed. A dose range of 20 to 30 mg/day is recommended. Experience with daily doses greater than 20 mg is very minimal, and there is no experience with doses greater than 60 mg.

<u>All patients</u>—As with the use of Prozac in the treatment of major depressive disorder, a lower or less frequent dosage should be used in patients with hepatic impairment. A lower or less frequent dosage should also be considered for the el-derly (see Geriatric Use *under* PRECAUTIONS), and for patients with concurrent disease or on multiple concomitant medications. Dosage adjustments for renal impairment are not routinely necessary (see Liver disease and Renal disease under CLINICAL PHARMACOLOGY, and Use in patients with concomitant illness under PRECAUTIONS).

Maintenance/Continuation Treatment

While there are no systematic studies that answer the ques tion of how long to continue Prozac, OCD is a chronic condition and it is reasonable to consider continuation for a re sponding patient. Although the efficacy of Prozac after 13 weeks has not been documented in controlled trials, adult patients have been continued in therapy under double-blind conditions for up to an additional 6 months without loss of benefit. However, dosage adjustments should be made to maintain the patient on the lowest effective dosage, and pa-tients should be periodically reassessed to determine the

need for treatment Bulimia Nervosa

Initial Treatment

In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of bulimia nervosa, patients were administered fixed daily fluoxetine doses of 20 or 60 mg, or placebo (see CLUM) Hubichills). Only the 60 mg dose was statistically significantly superior to placebo in re-ducing the frequency of bingre-ating and vomiting. Conse-quently, the recommended dose is 60 mg/day, administered in the morning. For some patients it may be advisable to titrate up to this target dose over several days. Fluoxetine doses above 60 mg/day have not been systematically studied

in patients with bulimia. As with the use of Prozac in the treatment of major depressive disorder and OCD, a lower or less frequent dosage should be used in patients with hepatic impairment. A lower or less frequent dosage should also be considered for the el-derly (see Geriatric Use under PRECAUTIONS), and for pa-tients with concurrent disease or on multiple concomitant medications. Dosage adjustments for renal impairment are not routinely necessary (see Liver disease and Renal disease under CUDUCAL PHAPMACOLOGY and Use in patients

Maintenance/Continuation Treatment

Systematic evaluation of continuing Prozac 60 mg/day for periods of up to 52 weeks in patients with bulimia who have responded while taking Prozac 60 mg/day during an 8-week acute treatment phase has demonstrated a benefit of such maintenance treatment (see CLINICAL TRIALS). Nevertheless; patients should be periodically reassessed to deter mine the need for maintenance treatment. Panic Disorder

Initial Treatment

In the controlled clinical trials of fluoxetine supporting its effectiveness in the treatment of panic disorder, patients were administered fluoxetine doses in the range of 10 to 60 mg/day (see CLINICAL TRIALS). Treatment should be initiated with a dose of 10 mg/day. After 1 week, the dose should be increased to 20 mg/day. The most frequently ad-ministered dose in the 2 flexible-dose clinical trials was 20 mg/day.

A dose increase may be considered after several weeks if no clinical improvement is observed. Fluoxetine doses above 60 mg/day have not been systematically evaluated in pa tients with panic disorder. As with the use of Prozac in other indications, a lower

less frequent dosage should be used in patients with hepatic impairment. A lower or less frequent dosage should also be considered for the elderly (see Geriatric Use under PRE-CAUTIONS), and for patients with concurrent disease or on multiple concomitant medications. Dosage adjustments for renal impairment are not routinely necessary (see Liver dis-ease and Renal disease *ünder* CLINICAL PHARMACOL-OGY, and Use in patients with concomitant illness under PRECAUTIONS)

Maintenance/Continuation Treatment

While there are no systematic studies that answer the question of how long to continue Prozac, panic disorder is a chronic condition and it is reasonable to consider continuation for a responding patient. Nevertheless, patients should be periodically reassessed to determine the need for continued treatment

HOW SUPPLIED

The following products are manufactured by Eli Lilly and Company for Dista Products Company. Prozac[®] Pulvules[®], USP, are available in:

The 10-mg1 Pulvule is opaque green and green, imprinted with DISTA 3104 on the cap and Prozac 10 mg on the body: NDC 0777-3104-02 (PU3104²) – Bottles of 100

NDC 0777-3104-07 (PU3104²) - Bottles of 2000 NDC 0777-3104-82 (PU3104²) - 20 FlexPak^{TM3} blister

cards of 31

The 20-mg¹ Pulvule is an opaque green cap and off-white body, imprinted with DISTA 3105 on the cap and Prozac 20 mg on the body: NDC 0777-3105-30 (PU3105²) - Bottles of 30.

NDC 0777-3105-02 (PU31052) - Bottles of 100

NDC 0777-3105-07 (PU3105²) - Bottles of 2000

NDC 0777-3105-33 (PU3105²) - (ID⁴100) Blisters

NDC 0777-3105-82 (PU3105²) - 20 FlexPak^{TM3} blister cards of 31

The 40-mg¹ Pulvule is an opaque green cap and opaque orange body, imprinted with DISTA 3107 on the cap and Prozac 40 mg on the body:

NDC 0777-3107-30 (PU31072) - Bottles of 30

Liquid, Oral Solution is available in: 20 mg¹ per 5 mL with mint flavor:

NDC 0777-5120-58 (MS-5120⁵) - Bottles of 120 mL

The following products are manufactured and distributed by Eli Lilly and Company.

Prozac[®] Tablets are available in:

The 10-mg¹ tablet is green, elliptical shaped, and scored, with PROZAC 10 debossed on opposite side of score. NDC 0002-4006-30 (TA4006) - Bottles of 30

NDC 0002-4006-02 (TA4006) - Bottles of 100

Prozac[®] Weekly™ Capsules are available in:

The 90-mg¹ capsule is an opaque green cap and clear body containing discretely visible white pellets through the clear body of the capsule, imprinted with Lilly on the cap and 3004 and 90 mg on the body.

NDC 0002-3004-75 (PU3004) - Blister package of 4

¹Fluoxetine base equivalent.

²Protect from light.

³FlexPak[™] (flexible blister card, Lilly).

⁴Identi-Dose® (unit dose medication, Lilly).

⁵Dispense in a tight, light resistant container. Store at Controlled Room Temperature, 15° to 30°C (59° to

ANIMAL TOXICOLOGY

Phospholipids are increased in some tissues of mice, rats, and dogs given fluoxetine chronically. This effect is revers-ible after cessation of fluoxetine treatment. Phospholipid ac-cumulation in animals has been observed with many cationic amphiphilic drugs, including fenfluramine, imipramine, and ranitidine. The significance of this effect in humans is unknown. Literature revised January 3, 2003

PV 3453 DPP

[*rē-ō-prō*] (abciximab) For intravenous administration

DESCRIPTION

Abciximab, ReoPro®, is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin $(\alpha_{\nu}\beta_{3})$ receptor found on platelets and vessel

wall endothelial and smooth muscle cells. The chimeric 7E3 antibody is produced by continuous per-fusion in mammalian cell culture. The 47,615 dalton Fab fragment is purified from cell culture supernatant by a se-ries of steps involving specific viral inactivation and removal procedures, digestion with papain and column chromatography. ReoPro® is a clear, colorless, sterile, non-pyrogenic solution

for intravenous (IV) use. Each single use vial contains 2 mg/mL of Abciximab in a buffered solution (pH 7.2) of 0.01 M sodium phosphate, 0.15 M sodium chloride and 0.001% polysorbate 80 in Water for Injection. No preservatives are added.

CLINICAL PHARMACOLOGY

General- Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhe-sion receptors and the major platelet surface receptor involved in platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/ Illa receptor sites on activated platelets. The mechanism of action is thought to involve steric hindrance and/or conformational effects to block access of large molecules to the receptor rather than direct interaction with the RGD arginine-glycine-aspartic acid) binding site of GPIIb/IIIa. (argnine-giycne-aspartic acid) binding site of GP110111a. Abcixinab binds with similar affinity to the vitronectin re-ceptor, also known as the $\alpha_s \beta_3$ integrin. The vitronectin re-ceptor mediates the proceagulant properties of platelets and the proliferative properties of vascular endothetial and smooth muscle cells. In *in vitro* studies using a model cell smooth muscle cents. In *the ouro* studies using a house data line derived from melanoma cells, Abduximab blocked $\alpha_s \beta_3^-$ mediated effects including cell adhesion (ICs₅₀ = 0.34 µg/mL). At concentrations which, *in vitro*, provide > 80% efflb/IIIa receptor blockade, but above the *in vito* therapeutic range, Abciximab more effectively blocked the burst of thrombin accumulation that followed platelet activation than select com-parator antibodies which inhibit GPIIb/IIIa alone (1). The relationship of these *in vitro* data to clinical efficacy is unknown.

Abciximab also binds to the activated Mac-1 receptor on monocytes and neutrophils (2). In *in vitro* studies, Abciximab and 7E3 IgG blocked Mac-1 receptor function as evidenced by inhibition of monocyte adhesion (3). In addition, the degree of activated Mac-1 expression on circulating leukocytes and the numbers of circulating leukocyte-platelet complexes has been shown to be reduced in patients treated with Abciximab compared to control patients (4). The relationship of these *in vitro* data to clinical efficacy is uncertain

Pre-clinical experience- Maximal inhibition of platelet ag-gregation was observed when \ge 80% of GPIIb/IIIa receptors were blocked by Abciximab. In non-human primates, Abciximab bolus doses of 0.25 mg/kg generally achieved a Abciximab holus doses of 0.25 mg/kg generally achieved a blockade of at least 80% of platelet receptors and fully in-hibited platelet aggregation. Inhibition of platelet function was temporary following a bolus dose, but receptor blockade could be sustained at \gtrsim 80% by continuous intravenous in-fusion. The inhibitory effects of Abciximab were substan-tially reversed by the transfusion of platelets in monkeys. The antithrombotic efficacy of prototype antibodies [nurrine 172 Teb and Yeb/L] and Abrivings by we evaluated in dog 7E3 Fab and F(ab')₂] and Abciximab was evaluated in dog, monkey and baboon models of coronary, carotid, and femoral artery thrombosis. Doses of the murine version of 7E3 or Abiximab sufficient to produce high-grade ($\geq 80\%$) GPIIb IIIa receptor blockade prevented acute thrombosis and yielded lower rates of thrombosis compared with aspirin and/or heparin.

Pharmacokinetics- Following intravenous bolus administra-Pharmacokinetus: Poliowing intravenous bolus administra-tion, free plasma concentrations of Abckiximab decrease rap-idly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors. Platelet function generally recovers over the course of 48 hours (5,6), although Abciximab remains in the circulation for 15 days or more in a platelet-bound state. Intravenous adminmays of more in a platelectronic state. Intraventies activities istration of a 0.25 mg/kg/bolus dose of Abcxinnah followed by continuous infusion of 10 pg/min (or a weight-adjusted in-fusion of 0.125 µg/kg/min to a maximum of 10 µg/min) pro-duces approximately constant free plasma concentrations throughout the infusion. At the termination of the infusion period, free plasma concentrations fall rapidly for approxi-mately six hours then decline at a slower rate.

Pharmacodynamics- Intravenous administration in hu-mans of single bolus doses of Abciximab from 0.15 mg/kg to 0.30 mg/kg produced rapid dose-dependent inhibition of platelet function as measured by *ex vivo* platelet aggrega-tion in response to adenosine diphosphate (ADP) or by protion in response to auctivitie. At the two highest does (0.25 and 0.30 mg/kg) at two hours post injection (the first time point evaluated), over 80% of the GPIIb/III a receptors were blocked and platelet agreegation in restorms to 20 1M ADP

Lilly Exhibit 1255, Page 23 of 39

PHYSICIANS' DESK REFERENCE®

Ŗ

to over 30 minutes at both doses compared with a baseline value of approximately five minutes. The second state of the second

minutes after treatment initiation. Low levels of GPIDs/IIIa receptor blockade are present for more than 10 days following cessation of the infusion. After discontinuation of Abeiximab infusion, platelet function returns gradually to normal. Bleeding time returned to ≤ 12 minutes within 12 hours following the end of infusion in 15 of 20 patients (75%), and within 24 hours in 18 of 20 patients (90%). Ex vivo platelet aggregation in response to 5 µM ADP returned to $\geq 50\%$ of baseline within 24 hours following the end of infusion in 11 of 32 patients (34%) and within 48 hours in 23 of 32 patients (72%). In response to 20 µM ADP, ex vivo platelet aggregation returned to $\geq 50\%$ of baseline within 24 hours in 20 of 32 patients (62%) and within 48 hours in 23 of 32 patients (62%) and

CLINICAL STUDIES

Abciximab has been studied in four Phase 3 clinical trials, all of which evaluated the effect of Abciximab in patients undergoing percutaneous coronary intervention (PCI): in patients at high risk for abrupt closure of the treated coronary vessel (EPIC); in a broader group of patients (EPILOG), in unstable angina patients not responding to conventional medical therapy (CAPTURE), and in patients suitable for either conventional angiopalsty/atherectomy or primary istent implantation (EPILOG Stent; EPISTENT). Percutaneous intervention included balloon angioplasty, atherectomy/or stent placement. All trials involved the use of various, concomitant heparin dose regimens and, unless contraindicated, aspirin '0325 mg) was administered orally two hours prior to the planned procedure and then once daily.

EPIC was a multicenter, double-blind, placebo-controlled trial of Abciximab in patients undergoing percutaneous transluminal coronary angioplasty or atherectomy (PTCA) who were at high risk for abrupt closure of the treated coronary vessel (7). Patients were allocated to treatment with. 1) Abciximab bolus plus infusion for 12 hours; 2) Abciximab bolus plus placebo infusion, or; 3) placebo bolus plus infusion. All patients received concomitant heparin (10,000 th 0.000 II has followed by an information for 12 hours).

2000 TU bolus followed by an infusion for 12 hours). The primary endpoint was the composite of death, myocardial infarction (MI); or urgent intervention for recurrent ischemia within 30 days of randomization. The primary endpoint event rates in the Abciximab bolus plus infusion group were reduced mostly in the first 48 hours and this benefit was sustained through 30 days (7), 6 months (8), and three years (9).

EPILOG was a randomized, double-blind, multicenter, placebo-controlled trial which evaluated Abciximab in a broad population of patients undergoing PCI (excluding patients with myocardial infarction and unstable angina meeting the EPIC high risk criteria) (10). Study procedures emphasized discontinuation of heparin after the procedure with early femoral arterial sheath removal and careful access site management (see PRECAUTIONS). EPILOG was a three-arm trial comparing Abciximab plus standard-dose heparin, Abciximab plus low-dose heparin infusions standard-dose heparin. Abciximab blus plus infusion regimen was: 0.25 mg/kg bolus followed by a 0.125 pg/kg/min infusion (to a maximum of 10 ig/min) for 12 hours. The heparin regimen was either a standard-dose regimen (initial 100 U/kg bolus, target ACT \geq 300 seconds).

The primary endpoint of the EPILOG trial was the composite of death or MI occurring within 30 days of PCI. The composite of death, MI, or urgent intervention was an important secondary endpoint. The endpoint events in the Abaximab treatment group were reduced mostly in the first 48 hours and this benefit was sustained through 30 days and six months (10) and one year (11). The (Kaplan-Meier) endpoint event rates at 30 days are shown in Table 1. [See table 1 above]

At the six-month follow up visit, the event rate for death, MI, or repeat (urgent or non-urgent) intervention remained lower: in the Abciximab treatment arms (22.3% and 22.8%, respectively, for the standard- and low-dose heparin arms) than in the placebo, arm (25.8%) and the event rate for death, MI, or urgent intervention was substantially lower in the Abciximab treatment arms (8.3% and 8.4%, respectively, for the standard- and low-dose heparin arms) than in the valuebe arm (14.7%). The treatment areasociated affects com-

	Table 1		a secondaria de
ENDPOINT EVEN	RATES AT 30 D/	AYS - EPILOG TRIAL	
services and the service services	Placebo +	Abciximab +	Abciximab +
	' Standard Dose	Standard Dose	Low Dose
	Heparin	Heparin	Heparin
	(n=939)	(n=918)	<u>(n=935)</u>
 A second sec second second sec	(11=000)		
	1 A.	Number of Patients (%)	ka shi bada se
Death or MI ^a	85 (9.1)	38 (4:2)	i 🗠 🗉 35 (3.8) 👘 🗤
p-value vs. placebo		< 0.001	< 0.001
Death, MI, or urgent intervention ^a	109 (11.7)	49 (5.4)	48 (5.2)
p-value vs. placebo		<0.001	<0.001
Components of Composite Endpoints ^b		phillipper sector and a sector of	in hereine eine eine eine eine eine eine ein
Death		4 (0.4)	
Acute myocardial infarctions	1 (010)		ant Brancisco
	78 (8.4)		
		04(0.17	
Urgent interventions in surviving patients			
without an acute myocardial infarction	24 (2.6)	11.(1.2)	13 (1.4)
^a Patients who experienced more than one event in	the first 30 days	are counted only once.	
r unchilo milo capericitette metre unen one orene m			A MARCHAELEN CONTRACTOR OF A MARCHAELEN CONTRACTOR OF A MARCHAELEN CONTRACTOR OF A MARCHAELEN CONTRACTOR OF A M

^bPatients are counted only once under the most serious component (death > acute MI > urgent intervention).

PRIMARY ENDPOINT EVI	Table 2 ENT BATE AT 30	DAYS - EPISTENT TRIAL	
i nega silan sina karang dari suran silan suran. 1917 - Barris Barris, Barris, nega silan silan si 1917 - Barris Mandalah, Karaga Addi Danda sa silan si	Placebo + Stent (n=809)	Abciximab + Stent (n=794)	Abciximab + PTCA (n=796)
Death, MI, or urgent intervention ⁸ p-value vs. placebo	87 (10.8%)	Number of Patients (%) 42 (5.3%) <0.001	55 (6.9%) 0.007
Death	5 (0.6%)	2 (0.3%)	6 (0.8%)
Acute myocardial infarctions in surviving patients	77 (9.6%)	35 (4.4%)	40 (5.0%)
Urgent interventions in surviving patients without an acute myocardial infarction	5 (0.6%)	5 (0.6%)	9 (1.1%)

Patients who experienced note than one event in the most of days are counted only once. Patients are counted only once under the most serious component (death > acute MI > urgent intervention).

tionate reductions in endpoint event rates were similar irrespective of the type of coronary intervention used (balloon angioplasty, atherectomy, or stent placement). Risk assessment using the American College of Cardiology/American Heart Association clinical /morphological criteria had large inter-observer variability. Consequently, a low risk subgroup could not be reproducibly identified in which to evaluate efficacy. The EPISTENT trial was a randomized, multicenter trial

The EPISTENT trial was a randomized, multicenter trial evaluating three different treatment strategies in patients undergoing PCI: conventional PTCA with Abciximab plus low-dose heparin, primary intracoronary stent implantation with Abciximab plus low-dose heparin, and primary intracoronary stent implantation with placebo plus standarddose heparin (12). The heparin dose was weight-adjusted in all arms. The JJIS Palmaz-Schatz stent was used in over 90% of the patients receiving stents. The two stent arms were blinded with respect to study agent (Abciximab or placebo) and heparin dose; the PCI arm with Abčiximab was open-label. The Abciximab bolus plus infusion regimen was the same as that used in the EPILOG trial. The standarddose and low-dose heparin regimens were the same as those used in the EPILOG trial. All patients were to receive aspirin; ticlopidine, if given, was to be started prior to study agent. Patient and access site management guidelines were the same as those for EPILOG, including a strong recommendation for early sheath removal. The results demonstrated benefit in both Abciximab arms

The results demonstrated benefit in both Abciximab arms (i.e., with and without stents) compared with stenting alone on the composite of death, MI, or urgent intervention (repeat PCI or CABG) within 30 days of PCI (12). The (Kaplan-Meier) endpoint event rates at 30 days are shown in Table 2. [See table 2 above]

[See table 2.above] This benefit was maintained at 6 months: 12.1% of patients in the placebo/stent group experienced death, MI, or urgent revascularization compared with 6.4% of patients in the Abcixinab/stent group (\sim 0.001 vs placebo/stent) and 9.2% in the Abciximab/PTCA group (p=0.051 vs placebo/stent). At 6 months, a reduction in the composite of death, MI, or all repeat (urgent or non-urgent) intervention was observed in the Abciximab/stent group compared with the placebo/stent group (15.4% vs 20.4%, p=0.060; the rate of this composite endpoint was similar in the Abciximab/PTCA and placebo/ stent groups (22.4% vs 20.4%, p=0.467). (13)

CAPTURE was a randomized, double-blind, multicenter, placebo-controlled trial of the use of Abciximab in unstable angina patients not responding to conventional medical therapy for whom PCL was planned, but not immediately performed (14). The CAPTURE trial involved the administration of placebo or Abciximab starting 18 to 24 hours prior to PCI and continuing until one hour after completion of the intervention.

Intervention. Patients were assessed as having unstable angina not responding to, conventional medical therapy if they had at least one episode of myocardial ischemia despite bed rest and at least two hours of therapy with intravenous heparin and eral or intravenous nitrates. These patients were enrolled into the CAPTURE trial, if during a screening angiogram, they were determined to have a coronary lesion amenable to PCI. Patients received a bolus dose and intravenous infusion of placebo or Abciximab for 18 to 24 hours. At the end of the infusion period, the intervention was performed The Abeirimab kor placebo infusion was discontintreated with intravenous heparin and oral or intravenous nitrates throughout the 18- to 24-hour Abeiximab infusion period prior to the PCI.

The Abeiximab dose was a 0.25 mg/kg bolus followed by a continuous infusion at a rate of 10 µg/min. The CAPTURE trial incorporated weight adjustment of the standard heparin dose only during the performance of the intervention, but did not investigate the effect of a lower heparin dose, and arterial sheaths were left in place for approximately 40 hours. The primary endpoint of the CAPTURE trial was the occurrence of any of the following events within 30 days of PCI: death, MI, or urgent intervention. The 30-day (Kaplan-Meier) primary endpoint event tates are shown in Table 3. [See table 3 at too of next base]

[See table 3 at top of next page] The 30-day results are consistent with the results of the other three trials, with the greatest effects on the myocardial infarction and urgent intervention components of the composite endpoint. As secondary endpoints, the components of the composite endpoint were analyzed separately for the period prior to the PCI and the period from the beginning of the intervention through Day 30. The greatest difference in MI occurred in the post-intervention period the rates of MI were lower in the Abciximab group compared with placebo (Abciximab 3.6%, placebo 6.1%). There was also a reduction in MI occurring prior to the PCI (Abciximáb 0.6%, placebo 2.0%). An Abciximab-associate reduction in the incidence of urgent intervention occurred in the post-intervention period. No effect on mortality was observed in either period. At six months of follow up, the composite endpoint of death, MI, or all repeat intervention (urgent or non-urgent) was not different between the Abciximab and placebo groups (Abciximab 31.0%, placebo 30.8%, p=0.77).

Mortahity was uncommon in all four trials. Similar mortahity rates were observed in all arms within each trial. Patient follow-up through one year of the EFISTENT trial suggested decreased mortality among patients treated with Abciximab and stent placement compared to patients treated with stent alone (8/784 vs. 19/809, p=0.037). Data from earlier studies with balloon angioplasty were not suggestive of the same benefit. In all four trials, the rates of acute MI were significantly lower in the groups treated with Abciximab. Most of the Abciximab treatment effect was seen in reduction in the rate of acute non-Qwave MI. Urgent intervention rates were also lower in Abciximab-treated groups in these trials.

EPILOG and EPISTENT: Weight-adjusted low dose heparin, weight-adjusted Abciximab, careful vascular access site management and discontinuation of heparin after the procedure with early femoral arterial sheath removal were used.

The initial heparin bolus was based upon the results of the baseline ACT, according to the following regimen:

Continued on next page

* Identi-Code® symbol. This product information was prepared in June 2002. Current information on these and other products of EII Lilly and Company may be obtained by direct inquiry to Lilly Research Laboratories, Lilly Corporate Center,

1848/ELI LILLY

PHYSICIANS' DESK REFERENCE®

ReoPro-Cont.

ACT < 150 seconds: administer 70 U/kg heparin ACT 150-199 seconds: administer 50 U/kg heparin

ACT ≥ 200 seconds: administer no heparin Additional 20 U/kg heparin boluses were given to achieve and maintain an ACT of ≥ 200 seconds during the

De Co

procedure." Discontinuation of heparin immediately after the procedure and remioval of the arterial sheath within six hours were strongly-recommended in the trials. If prolonged heparin therapy or delayed sheath removal was clinically indicated. therapy or delayed sneath removal was chinically indicated heparin was adjusted to keep the APTT at a target of 60 to 85 seconds (EPILOG) or 55 to 75 seconds (EPISTENT). CAPTURE trial: Anticoagulation was initiated prior to the administration of Abciximab. Anticoagulation was initiated administration of Addiximal. Anticoogunation was initiated with an intravenous heparin infusion to achieve a target APTT of 60 to 85 seconds. The heparin infusion was not uni-formly weight adjusted in this trial. The heparin infusion was maintained during the Abciximab infusion and was ad-justed to achieve an ACT of 300 seconds or an APTT of 70

seconds during the PCI. Following the intervention, heparin management was as outlined above for the EPILOG trial. INDICATIONS AND USAGE

Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications

- · in patients undergoing percutaneous coronary intervention
- · in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours
- Abciximab use in patients not undergoing percutaneous cor-onary intervention has not been studied.

Abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in CLIN-ICAL STUDIES.

CONTRAINDICATIONS

Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:

- Active internal bleeding
 Recent (within six weeks) gastrointestinal (GI) or genito
- recent (within six weeks) gastrointestinal (GI) or genito-urinary (GU) bleeding of clinical significance.
 History of cerebrovascular accident (CVA) within two years, or CVA with a significant residual neurological deficit
- Bleeding diathesis
- Bleeding diathesis
 Administration of oral anticoagulants within seven days unless prothrombin time is ≤ 1.2 times control
 Thrombocytopenia (< 100,000 cells/pL)
 Recent (within six weeks) major surgery or trauma
 Intracranial neoplasm, arteriovenous malformation, or

- aneurvsm
- Severe uncontrolled hypertension
- · Presumed or documented history of vasculitis
- Use of intravenous dextran before PCI, or intent to use it

during an intervention Abciximab is also contraindicated in patients with known hypersensitivity to any component of this product or to arine proteins

WARNINGS

Abciximab has the potential to increase the risk of bleeding, particularly in the presence of anticoagulation, e.g., from heparin, other anticoagulants, or thrombolytics (see AD-VERSE REACTIONS: Bleeding). The risk of major bleeds due to Abciximab therapy may

increased in patients receiving thrombolytics and should be weighed against the anticipated benefits.

Should serious bleeding occur that is not controllable with pressure, the infusion of Abciximab and any concomitant heparin should be stopped.

PRECAUTIONS

Bleeding Precautions- To minimize the risk of bleeding with Abciximab, it is important to use a low-dose, weight-adjusted heparin regimen, a weight-adjusted Abciximab bolus and infusion, strict anticoagulation guidelines, careful vas-

cular access site management, discontinuation of heparin after the procedure and early femoral arterial sheath removal. Therapy with Abciximab requires careful attention to all po-

tential bleeding sites (including catheter insertion sites, arterial and venous puncture sites, cutdown sites, needle puncture sites, and gastrointestinal, genitourinary, and retroperitoneal sites).

Arterial and venous punctures, intramuscular injections, and use of urinary catheters, nasotracheal intubation. na sogastric tubes and automatic blood pressure cuffs should be minimized. When obtaining intravenous access, noncompressible sites (e.g., subclavian or jugular veins) should be avoided. Saline or heparin locks should be considered for blood drawing. Vascular puncture sites should be docu-mented and monitored. Gentle care should be provided when removing dressings.

Femoral artery access site: Arterial access site care is im-portant to prevent bleeding. Care should be taken when attempting vascular access that only the anterior wall of the femoral artery is punctured, avoiding a Seldinger (through

PRIMARY ENDPOINT EVENT R	ATE AT 30 DAYS - CAPTURE TRIAI Placebo	Abciximab
	(n=635)	(n=630)
	Number of P	atients (%)
eath, MI, or urgent intervention ^a p-value vs. placebo	101 (15.9)	71 (11.3) 0.012
omponents of Primary Endpoint ^b Death MI in surviving patients	8 (1.3) 49 (7.7)	6 (1.0) 24 (3.8)
Urgent intervention in surviving patients without an acute MI	44 (6.9)	41 (6.6)

^a Patients who experienced more than one event in the first 30 days are counted only once. Urgent interventions included any unplanned PCI after the planned intervention, as well as any stent placement for immediate patency and any

upplaned CABC or use of an intra-aortic balloon pump. ^b Patients are counted only once under the most serious component (death > acute MI > urgent intervention).

maintained on complete bed rest with the head of the bed ≤ 30° and the affected limb restrained in a straight position. Patients may be medicated for back/groin pain as necessary. Discontinuation of heparin immediately upon completion of the procedure and removal of the arterial sheath within six hours is strongly recommended if APTT \leq 50 sec or ACT \leq 175 sec (See PRECAUTIONS: Laboratory Tests). In all is the set (see rule of the rule). In all circumstances, heparin should be discontinued at least two hours prior to arterial sheath removal.

hours prior to arternal sheath removal. Following sheath removal, pressure should be applied to the femoral artery for at least 30 minutes using either manual compression or a mechanical device for hemostasis. A pres-sure dressing should be applied following hemostasis. The patient should be maintained on bed rest for six to eight hours following sheath removal or discontinuation of Abciximab, or four hours following discontinuation of heparin, whichever is later. The pressure dressing should be re-moved prior to ambulation. The sheath insertion site and distal pulses of affected leg(s) should be frequently checked while the femoral artery sheath is in place and for six hours after femoral artery sheath removal. Any hematoma should be measured and monitored for enlargement.

The following conditions have been associated with an increased risk of bleeding and may be additive with the effect of Abciximab in the angioplasty setting: PCI within 12 hours of the onset of symptoms for acute myocardial infarction, prolonged PCI (lasting more than 70 minutes) and failed PCI.

Use of Thrombolytics, Anticoagulants and Other Antiplate-let Agents- In the EPIC, EPILOG, CAPTURE, and EPISTENT trials, Abciximab was used concomitantly with heparin and aspirin. For details of the anticoagulation algo-rithms used in these clinical trials, see CLINICAL STUD-IES: Anticoagulation. Because Abciximab inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostasis, including throm-bolytics, oral anticoagulants, non-steroidal anti-inflammatory drugs, dipyridamole, and ticlopidine.

In the EPIC trial, there was limited experience with the ad-ministration of Abciximab with low molecular weight dexministration of Abersimab with low molecular weight dext tran. Low molecular weight dextran was usually given for the deployment of a coronary stent, for which oral antico-agulants were also given. In the 11 patients who received low molecular weight dextran with Abeiximab, five had major bleeding events and four had minor bleeding events. None of the five placebo patients treated with low molecular weight dextran had a major or minor bleeding event (see CONTRAINDICATIONS).

There are limited data on the use of Abciximab in patients receiving thrombolytic agents. Because of concern about synergistic effects on bleeding, systemic thrombolytic therapy should be used judiciously. Thrombocytopenia- Platelet counts should be monitored

prior to treatment, two to four hours following the bolus dose of Abciximab and at 24 hours or prior to discharge, whichever is first. If a patient experiences an acute platelet decrease (e.g., a platelet decrease to less than 100,000 cells/pL and a decrease of at least 25% from pre-treatment value), additional platelet counts should be determined. These platelet counts should be drawn in three separate tubes containing ethylenediaminetetraacetic acid (EDTA), citrate and heparin, respectively, to exclude pseudothrombocytopenia due to in vitro anticoagulant interaction. If true thrombocytopenia is 'verified, Abciximab should be immediately discontinued and the condition appropriately immediately discontinued and the control appropriately monitored and treated. For patients with thrombocytopenia in the clinical trials, a daily platelet count was obtained un-til it returned to normal. If a patient's platelet count dropped to 60,000 cells/µL, heparin and aspirin were discontinued. If a patient's platelet count dropped below 50,000 cells/L, platelets were transfused. Most cases of severe thrombocytopenia (< 50,000 cells/µL) occurred within the first 24 hours of Abciximab administration.

Restoration of Platelet Function- In the event of serious uncontrolled bleeding or the need for emergency surgery, Abciximab should be discontinued. If platelet function does not return to normal, it may be restored, at least in part, with platelet transfusions.

Laboratory Tests- Before infusion of Abciximab, platelet count, prothrombin time, ACT and APTT should be mea-sured to identify pre-existing hemostatic abnormalities. rated analysis of data from all studies, the

When Abciximab is initiated 18 to 24 hours before PCI, the APTT should be maintained between 60 and 85 seconds during the Abciximab and heparin infusion period. During PCI the ACT should be maintained between 200 and 300 seconds.

If anticoagulation is continued in these patients following PCI, the APTT should be maintained between 55 and 75

The APTT or ACT should be checked prior to arterial sheath removal. The sheath should not be removed unless APTT ≤ 50 seconds or ACT ≤ 175 seconds.

Readministration Administration of Abciximab may result in human anti-chimeric antibody (HACA) formation that (including anaphylaxis), thrombocytopenia or diminished Uncluding anapyyaaks, automoto openia of uninusory benefit upon readministration of Abciximab. In the EPIC, EPILOG, and CAPTURE trials, positive HACA responses occurred in approximately 5.8% of the Abciximab-treated patients. There was no excess of hypersensitivity or allergic reactions related to Abciximab treatment.

Readministration of Abciximab to 29 healthy volunteers who had not developed a HACA response after first adminwho had not developed a FACA response and first admini-istration has not led to any change in Abciximab pharmaco-kinetics or to any reduction in antiplatelet potency. How-ever, results in this small group of patients suggest that the incidence of HACA response may be increased after read-ministration. Readministration to patients who have devel-oped a positive HACA response after initial administration becaute the unbetted in a binefed trial. has not been evaluated in clinical trials. Allergic Reactions- Anaphylaxis has not been reported for

Abiximab-treated patients in any of the Phase 3 clinical trials. However, anaphylaxis may occur. If it does, adminis-tration of Abiximab should be immediately stopped and standard appropriate resuscitative measures should be initiated.

Drug Interactions- Although drug interactions with Abciximab have not been studied systematically, Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medica-tions used in the treatment of angina, myocardial infarction and hypertension. These medications have included hepa-rin, warfarin; beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibi tors, intravenous and oral nitrates, ticlopidine, and aspirin. Heparin, other anticoagulants, thrombolytics, and antiplatelet agents may be associated with an increase in bleed-ing. Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.

Carcinogenesis, Mutagenesis and Impairment of Fertility In vitro and in vivo mutagenicity studies have not demon-strated any mutagenic effect. Long-term studies in animals

strated any mutagence enect. Long-term scottes in animatic have not been performed to evaluate the carcinogenic poten-tial or effects on fertility in male or female animals. **Pregnancy Category C** Animal reproduction studies have not been conducted with Abeiximab. It is also not known whether Abeiximab can cause fetal harm when administered to a pregnant woman or can affect reproduction capac-ity. Abciximab should be given to a pregnant woman only if clearly needed.

Nursing Mothers- It is not known whether this drug is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, cau-tion should be exercised when Abciximab is administered to a nursing woman

Pediatric Use- Safety and effectiveness in pediatric patients have not been studied.

Geriatric Use- Of the total number of 7860 patients in the four Phase 3 trials, 2933 (37%) were 65 and over, while 653 (8%) were 75 and over. No overall differences in safety or efficacy were observed between patients of age 65 to less than 75 as compared to younger patients. The clinical exper-ience is not adequate to determine whether patients of age 75 or greater respond differently than younger patients.

ADVERSE REACTIONS

Bleeding-Abciximab has the potential to increase the risk of bleeding, particularly in the presence of anticoagulation, e.g., from heparin, other anticoagulants or thrombolytics. Bleeding in the Phase 3 trials was classified as major, minor or insignificant by the criteria of the Thrombolysis in Myo-cardial Infarction study group (15). Major bleeding events were defined as either an intracranial hemorrhage or a de-

hematemesis, observed blood loss with a hemoglobin denematerizes, observed bloot loss with a nemoglobin of a crease of more than 3 g/dL, or a decrease in hemoglobin of at least 4 g/dL without an identified bleeding site. Insignificant bleeding events were defined as a decrease in hemoglobin between 3.4 g/dL without observed bleeding. In patients who received transfusions, the number of units of blood lost was estimated through an adaptation of the method of Landefeld, et

al. (16). In the EPIC trial, in which a non-weight adjusted, longer-In the BPIC trial, in which a non-weight-adjusted, longer-duration heparin dose regimen was used, the most common complication during Abciximab therapy was bleeding during the first 36 hours. The incidences of major bleeding, minor bleeding and transfosion of blood products were sig-nificantly increased. Major bleeding occurred in 10.6% of patients in the Abciximab bolus plus infusion arm compared with 3.3% of patients in the placebo arm. Minor bleeding was seen in 16.8% of Abciximab bolus plus infusion patients and 9.2% of placebo patients (7). Approximately 70% of Abciximab-treated natients with maior bleeding bleed hold in the state of the state bleeding b Abciximab-treated patients with major bleeding had bleed-ing at the arterial access site in the groin. Abciximabtreated patients also had a higher incidence of major bleed.

ing events from gastrointestinal, genitourinary, retroperitoneal, and other sites. Bleeding rates were reduced in the CAPTURE trial, and further reduced in the EPILOG and EPISTENT trials by use of modified dosing regimens and specific patient man-agement techniques. In EPILOG and EPISTENT, using the agoment termingtes. In EFIDOS and EFISIEN1, using the heparin and Abciximab dosing, sheath removal and arterial access site guidelines described under PRECAUTIONS, the incidence of major bleeding in patients treated with Abciximab and low-dose, weight-adjusted heparin was not significantly different from that in patients receiving placebo.

Subgroup analyses in the EPIC and CAPTURE trials Subjector analyses in the LFIC and CAFICKE trails showed that non-CABG major bleeding was more common in Abciximab patients weighing \leq 75 kg. In the EPILOG and EPISTENT trials, which used weight-adjusted heparin dosing, the non-CABG major bleeding rates for Abciximab-treated patients did not differ substantially by weight subgroup. Although data are limited, Abciximab treatment was not as-

sociated with excess major bleeding in patients who under-went CABG surgery. (The range among all treatment arms was 3-5% in EPIC, and 1-2% in the CAPTURE, EPILOG, and EPISTENT trials.) Some patients with prolonged bleed-ing times received platelet transfusions to correct the bleeding time prior to surgery. (See PRECAUTIONS: Restoration of Platelet Function.)

on Fracted Function.) The rates of major bleeding, minor bleeding and bleeding events requiring transfusions in the CAPTURE, EPILOG, and EPISTENT trials are shown in Table 4. The rates of insignificant bleeding events are not included in Table 4. [See table 4 at right]

Intracranial Hemorrhage and Stroke- The total incidence of intracranial hemorrhage and non-hemorrhagic stroke across all four trials was not significantly different, 9/3023 across an lot trans was not significantly unferent, 9/3/023 for placebo patients and 15/4680 for Aboiximab-treated pa-tients. The incidence of intracranial hemorrhage was 3/3023 for placebo patients and 7/4680 for Aboiximab patients. Thrombocytopenia- In the clinical trials, patients treated with Aboiximab were more likely than patients treated with

placebo to experience decreases in platelet counts. Among patients in the EPILOG and EPISTENT trials who

were treated with Abciximab plus low-dose heparin, the pro-portion of patients with any thrombocytopenia (platelets less than 100,000 cells/µL) ranged from 2.5 to 3.0%. The incidence of severe thrombooytopenia (platelets less than 50,000 cells/µL) ranged from 0.4 to 1.0% and platelet transfusions were required in 0.9 to 1.1%, respectively. Modestly lower rates were observed among patients treated with pla-cebo plus standard-dose heparin. Overall higher rates were observed among patients in the EPIC and CAPTURE trials treated with Abciximab plus longer duration heparin: 2.6 to 5.2% were found to have any thrombocytopenia, 0.9 to 1.7% had severe thrombocytopenia, and 2.1 to 5.5% required platelet transfusion, respectively.

Other Adverse Reactions- Table 5 shows adverse events other than bleeding and thrombocytopenia from the com-bined EPIC, EPILOG and CAPTURE trials which occurred in patients in the bolus plus infusion arm at an incidence of more than 0.5% higher than in those treated with placebo.

Note that 0.5% inguer than in toose treated with piacetor. (See table 5 at right) The following additional adverse events from the EPIC, EPILOG and CAPTURE trials were reported by investiga-tors for patients treated with a bolus plus infusion of Aboximab at incidences which were less than 0.5% higher

Auximatic at incidences which were less than 0.5% higher than for patients in the placebo arm. Cardiovascular System: ventricular tachycardia (1.4%), pseudoaneurysm (0.8%), palpitation (0.5%), arteriovenous fistula (0.4%), incomplete AV block (0.3%), nodal arrhythmia (0.2%), complete AV block (0.1%), embolism (limb)(0.1%); theoreberliktic (0.1%) thrombophlebitis (0.1%):

Gastrointestinal System: dyspepsia (2.1%), diarrhea (1.1%), ileus (0.1%), gastroesophogeal reflux (0.1%); Hemic and Lymphatic System: anemia (1.3%), leukocyto-sis (0.5%), petechiae (0.2%);

Nervous System: dizziness (2.9%), anxiety (1.7%), abnor mal thinking (1.3%), agitation (0.7%), hypesthesia (0.6%), confusion (0.5%) muscle contractions (0.4%), coma (0.2%), hypertonia (0.2%), diplopia (0.1%);

Respiratory System: pneumonia (0.4%), rales (0.4%), pleural effusion (0.3%), bronchitis (0.3%) bronchospasm (0.3%), pleurisy (0.2%), pulmonary embolism (0.2%), rhon-

	Table 4 NON-CABG BLEEDING IN TRIALS OF PERCUTANEOUS CORONARY INTERVENTION (EPILOG, EPISTENT and CAPTURE) Number of Patients with Bleeds (%)
	EPILOG and EPISTENT:
	Abciximab + Abciximab +
	Placebo ^c Low-dose Heparin ^d Standard-dose Heparin ^e (n = 1748) (n=2525) (n=918)
	Major ^a $\frac{(n = 1748)}{18 (1.0)}$ $\frac{(n = 2525)}{21 (0.8)}$ $\frac{(n = 918)}{17 (1.9)}$
	Minor 46 (2,6) 82 (3,2) 70 (7.6)
	Requiring transfusion ^b 15 (0.9) 13 (0.5) 7 (0.8)
	CAPTURE: A second se
.	Placebo ^f Abciximab ^f
	(n=635) (n=630)
	Major ^a . <u>12 (1.9)</u> Minor 13 (2.0)
	Requiring transfusion ^b 9 (1.4) 30 (4.8) 15 (2.4)
	^a Patients who had blooding in more than an elemistic and a line is a line of the second se

more than one classification are counted only once according to the most sever classification. Patients with multiple bleeding events of the same classification are also counted once within that lassification

Patients with major non-CABG bleeding who received packed red blood cells or whole blood transfusion Standard-dose heparin with or without stent (EPILOG and EPISTENT)

^d Low-dose heparin with or without stent (EPILOG and EPISTENT)

^e Standard-dose heparin (EPILOG) ^f Standard-dose heparin (CAPTURE)

	ble 5	11
ADVERSE EVENTS AMONG TREATED PATIENT	S IN THE EPIC, EPILOG, AND CAPTURE TRIALS	5
Event	Placebo Bolus + 1 (n=2226) (n=31	
0	Number of Patients (%)	
Cardiovascular system Hypotension Bradycardia	230 (10.3) 447 (1 79 (3.5) 140 (
Gastrointestinal system		
Nausea Vomiting	255 (11.5) 423 (1 152 (6.8) 226 (1	
Abdominal pain Miscellaneous	49 (2.2) 97 (3	3.1)
Back pain Chest pain	304 (13.7) 208 (9.3) 546 (1 356 (1	
Headache	122 (5.5) 200 (6.4)
Puncture site pain Peripheral edema	58 (2.6) 113 (25 (1.1) 49 (1	

Musculoskeletal System: myalgia (0.2%); Urogenital System: urinary retention (0.7%), dysuria (0.4%), abnormal renal function (0.4%), frequent micturition (0.1%), cystalgia (0.1%), urinary incontinence (0.1%), prostatitis (0.1%)

Miscellaneous: pain (5.4%), sweating increased (1.0%), as-Miscentaneous: pain (3.4%), sweating increased (1.0%), as-thenia (0.7%), incisional pain (0.6%), pruritus (0.5%), abnor-mal vision (0.3%), edéma (0.3%), wound (0.2%), abscess (0.2%), cellulitis (0.2%), peripheral coldness (0.2%), injection site pain (0.1%), dry mouth (0.1%), pallor (0.1%), diabetes mellitus (0.1%), hyperkalemia (0.1%), enlarged abdomen (0.1%), bullous eruption (0.1%), inflammation (0.1%), drug toxicity (0.1%).

OVERDOSAGE

There has been no experience of overdosage in human clinical trials.

DOSAGE AND ADMINISTRATION

The safety and efficacy of Abciximab have only been investigated with concomitant administration of heparin and as-

prin as described in CLINICAL STUDIES. In patients with failed PCIs, the continuous infusion of

Abciximab should be stopped because there is no evidence for Abciximab efficacy in that setting. In the event of serious bleeding that cannot be controlled by compression, Abciximab and heparin should be discontin-

ued immediately.

The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus administered 10-60 minutes before the start of PCI, followed by a continuous intrave-nous infusion of 0.125 µg/kg/min (to a maximum of 10 µg/ min) for 12 hours.

Patients with unstable angina not responding to conven-tional medical therapy and who are planned to undergo PCI within 24 hours may be treated with an Abciximab 0.25 mg/kg intravenous bolus followed by an 18. to 24-hour intravenous infusion of 10 µg/min, concluding one hour after the PCL

Instructions for Administration

1. Parenteral drug products should be inspected visually for particulate matter prior to administration. Preparations of Abciximab containing visibly opaque particles should NOT be used .

Hypersensitivity reactions should be anticipated whenever protein solutions such as Abciximab are adminiswhenever protein southous such as Apeximan are adminis-tered. Epinephrine, dopamine, theophylline, antihista-mines and corticosteroids should be available for immediate use. If symptoms of an allergic reaction or ana-phylaxis appear, the infusion should be stopped and appropriate treatment given.

3. As with all parenteral drug products, aseptic procedures should be used during the administration of Abciximab. 4. Withdraw the necessary amount of Abciximab for bolus injection into a syringe. Filter the bolus injection using a sterile, non-pyrogenic, low protein-binding 0.2 or 0.22 µm

5. Withdraw the necessary amount of Abciximab for the continuous infusion into a syringe. Inject into an appropriate container of sterile 0.9% saline or 5% dextrose and infuse at the calculated rate via a continuous infusion pump at the calculated rate via a continuous musion pump. The continuous infusion should be filtered either upon admixture using a sterile, non-pyrogenic, low protein-binding 0.2 vm 9.22 µm syringe filter (Millipore SLGV025LS or equivalent) or upon administration using an in-line, sterile, non-pyrogenic, low protein-binding 0.2 or 0.22 µm filter (Abbott #4524 or equivalent). Discard the unused portion at the end of the infusion.

6. No incompatibilities have been shown with intravenous infusion fluids or commonly used cardiovascular drugs. Nevertheless. Abciximab should be administered in a sep rate intravenous line whenever possible and not mixed with other medications.

7. No incompatibilities have been observed with glass bottles or polyvinyl chloride bags and administration sets.

HOW SUPPLIED

Abciximab (ReoPro®) 2 mg/mL is supplied in 5 mL vials containing 10 mg (NDC 0002-7140-01). Vials should be stored at 2 to 8°C (36 to 46°F). Do not freeze. Do not shake. Do not use beyond the expiration date. Dis-

card any unused portion left in the vial. REFERENCES

- Reverter JC, Beguin S, Kessels H, Kumar R, Hemmer HC, Coller BS. Inhibition of platelet-mediated, tissue-factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody; potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest. 1996;**98**:863-874.
- Alteri D, Edgington T, A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). The Journal of Immunology. 1988;141:2656-2660.
- 3. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997;17:528-535
- Mickelson JK, Ali MN, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ. Chimeric TES Tab (ReoPro) decreases detectable CD11b on neutrophils from patients undergo-ing coronary angioplasty. J Am Coll Cardiol. 1999;33: 97-106

Continued on next page

* Identi-Code® symbol. This product information was prepared in June 2002, Current information on these and other products of Eli Lilly and Company may be obtained by direct inquiry to Lilly Research Laboratories, Lilly Corporate Center,

PHYSICIANS' DESK REFERENCE®

ReoPro-Cont.

Tcheng J, Ellis SG, George BS. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet anti-body Fab 7E3 in high risk coronary angioplasty. *Circu-lation*. 1994;**30**:1757-1764.

Simons ML; de Boer MJ, van der Brand MJBM, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. *Circulation*. 1994-89-596-603

- EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961
- 8. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against
- platelet III/III integrin for reduction of clinical reste-nosis: results at six months. *Lancet.* 1994;343:861-866. Topol EJ, Ferguson JJ, Weisman HF, et al. for the EPIC Investigators. Long-term protection from myocardial is-chemic events in a randomized trial of brief integrin blockade with percutaneous coronary intervention. JAMA 1997;278:479-484.
- CONTRACT 103 (JUNO 197404. 10. EPILOG Investigators. Platelet glycoprotein IIb/III a receptor blockade and low dose heparin during percutaneous coronary revascularization. N Eng J Med. 1997;336:1689-1696.
- 11. Lincoff AM, Tcheng JE, Califf RM, et al. for the EPILOG Investigators. Sustained suppression of ischneit com-plications of coronary intervention by platelet GP IIb/ IIIa blockade with abciximab. *Circ.* 1999;99:1951-1958.
- 12. EPISTENT Investigators. Randomised placebo-con-trolled and balloon angioplasty-controlled trial to assess
- trolled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycopro-tein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
 Lincoff AM, Califf RM, Moliterno DJ, et al. for the EPIS-TENT Investigator. Complementary clinical benefits of coronary stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999;341:319-327.
 CAPTURE Investigators. Randomised placebo-con-tentied in a factorizable for coro.
- CAPTORE Investigators. Kandonneau practoo-con-trolled trial of abcitmab before, during and after coro-nary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
 Rao, AK, Pratt C, Berke A, et al. Thrombolysis in Myo-cardial Infarction (TIMI) Trial Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolatic avoid min national transformed with the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and strepto kinase.

J Am Coll Cardiol, 1988:11:1-11.

16. Landefeld, CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleed-ing in hospitalized patients starting anticoagulant ther-apy. Am J Med. 1987;82:703-713.

Manufactured by: Centocor B.V.

Leiden, The Netherlands U.S. License Number: 1178

Distributed by:

Eli Lilly and Co Indianapolis, IN 46285

Revision Date: May 14, 2001 Shown in Product Identification Guide, page 322


Ŗ

STRATTERAM [stră-těr-ă]

(atomoxetine HCI)

DESCRIPTION

STRATTERA™ (atomoxetine HCl) is a selective norepi STRATTERA¹⁰ (atomoxetine HCI) is a selective norepine nephrine requirates inhibitor. Atomoxetine HCI is the R(-) isomer as determined by x-ray diffraction. The chemical designation is (-)-N-methyl-3-phenyl-3-(o-tohyloxy)-propylamine hydrochloride. The molecular formula is $C_{17}H_{21}NO$ -HCl, which corresponds to a molecular weight of 291.82. The chemical structure is:



Atomoxetine HCl is a white to practically white solid, which has a solubility of 27.8 mg/mL in water. STRATTERA capsules are intended for oral administration

Each capsule contains atomoxetine HCl equivalent to 10, Bach capsule contains a common the fore quarter to or-tain pregelatinized starch and dimethicone. The capsules also con-tain pregelatinized starch and dimethicone. The capsule shells contain gelatin, sodium lauryl sulfate, and other in-active ingredients. The capsule shells also contain one or more of the following: FD&C Blue No. 2, synthetic yellow iron gxide, titanium dioxide. The capsules are imprinted with edible black ink.

CLINICAL PHARMACOLOGY

Pharmacodynamics and Mechanism of Action

der (ADHD) is unknown, but is thought to be related to se-lective inhibition of the pre-synaptic norepinephrine trans-porter, as determined in ex vivo uptake and neurotransmitter depletion studies.

Human Pharmacokinetics

Atomoxetine is well-absorbed after oral administration and is minimally affected by food. It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway and subsequent glucuronida-tion. Atomoxetine has a half-life of about 5 hours. A fraction of the population (about 7% of Caucasians and 2% of African Americans) are poor metabolizers (PMs) of CYP2D6 metab-olized drugs. These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabo-lizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure.

The pharmacokinetics of atomoxetine have been evaluated in more than 400 children and adolescents in selected clinical trials, primarily using population pharmacokinetic studies. Single-dose and steady-state indivídual pharmaco-kinetic data were also obtained in children, adolescents, and adults. When doses were normalized to a mg/kg basis, similar half-life, C_{max}, and AUC values were observed in children, adolescents, and adults. Clearance and volume of distribution after adjustment for body weight were also similar.

Absorption and Distribution—Atomoxetine is rapidly ab-sorbed after oral administration, with absolute bioavailabil-ity of about 63% in EMs and 94% in PMs. Maximal plasma concentrations (C_{max}) are reached approximately 1 to 2 hours after desing hours after dosing. STRATTERA can be administered with or without food, Ad

ministration of STRATTERA with a standard high-fat meal in adults did not affect the extent of oral absorption of atomoxetine (AUC), but did decrease the rate of absorption, resulting in a 37% lower C_{max} , and delayed T_{max} by 3 hours. In clinical trials with children and adolescents, administra-It in not STRATTERA with food resulted in a 9% lower $C_{\rm max}$. The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water. Volume of distribu tion is similar across the patient weight range after normalizing for body weight.

At therapeutic concentrations, 98% of atomoxetine in

At therapeutic concentrations, 90% of acomotechne in plasma is bound to protein, primarily albumin. <u>Metabolism and Elimination</u>—Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway. People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with pasma concentrations of acomovenine compared with people with normal activity (EMs). For PMs, AUC of atomoxetine is approximately 10-fold and $C_{ss,max}$ is about 5-fold greater than EMs. Laboratory tests are available to identify CYP2D6 PMs. Coadministration of STRATTERA with potent inhibitors of CYP2D6, such as fluxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may

atomoxetine plasma exposure, and dosing adjustment may be necessary (see Drug-Drug Interactions). Atomoxetine did not inhibit or induce the CYP2D6 pathway. The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine trans-porter but circulates in plasma at much lower concentraporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes. N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs).

Mean apparent plasma clearance of atomoxetine after oral istration in adult EMs is 0.35 L/hr/kg and the mean half-life is 5.2 hours. Following oral administration of atomoxetine to PMs; mean apparent plasma clearance is 0.03 L/hr/kg and mean half-life is 21.6 hours. For PMs, AUC of atomoxetine is approximately 10-fold and $C_{ss,max}$ is about 5-fold greater than EMs. The elimination half-life of 4-hydroxyatomoxetine is similar to that of N-desmethylato-moxetine (6 to 8 hours) in EM subjects, while the half-life of N-desmethylatomoxetine is much longer in PM subjects (34 to 40 hours)

Atomoxetine is excreted primarily as 4-hydroxyatomoxet ine-O-glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose). Only a small fraction of the STRATTERA dose is excreted as unchanged atomoxétine (less than 3% of the dose), indicating extensive biotransformation. Special Populations

Special Populations Hepatic insufficiency—Atomoxetine exposure (AUC) is in-creased, compared with normal subjects, in EM subjects with moderate (Child-Pugh Class B) (2-fold increase) and severe (Child-Pugh Class C) (4-fold increase) hand ficiency. Dosage adjustment is recommended for patients

with moderate or severe hepatic insufficiency (see DOSAGE AND ADMINISTRATION).

healthy subjects (about a 65% increase), but there was no difference when exposure was corrected for mg/kg dose. STRATTERA can therefore be administered to ADHD pa tients with end stage renal disease or lesser degrees of renal insufficiency using the normal dosing regimen.

Geriatric—The pharmacokinetics of atomoxetine have not been evaluated in the geriatric population.

Pediatric-The pharmacokinetics of atomoxetine in children and adolescents are similar to those in adults. The phar-macokinetics of atomoxetine have not been evaluated in

children under 6 years of age. <u>Gender</u>—Gender did not influence atomoxetine disposition. <u>Ethnic origin—Ethnic origin did not influence atomoxetine</u> <u>disposition</u> (except that PMs are more common in Caucasians).

Caucasians). Drug-Drug Interactions CYP2D6 activity and atomoxetine plasma concentration— Atomoxetine is primarily metabolized by the CYP2D6 path-way to 4-hydroxyatomoxetine. In EMs, inhibitors of CYP2D6 increase atomoxetine steady-state plasma concen-trations to exposures similar to those observed in PMs. Dos-age adjustment of STRATTERA in EMs may be necessary when coadministered with CYP2D6 inhibitors, e.g., parox-tice flowating and ministers. etine, fluoxetine, and quinidine (see Drug Interactions un-der PRECAUTIONS). In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.

Effect of atomoxetine on P450 enzymes—Atomoxetine did not cause clinically important inhibition or induction of cy-tochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9. Albuterol—Albuterol (600 mcg iv over 2 hours) induced in-

creases in heart rate and blood pressure. These effects were potentiated by atomoxetine (60 mg BID for 5 days) and were most marked after the initial coadministration of albuterol and atomoxetine (see Drug-Drug Interactions under PRECAUTIONS).

PRECAUTIONS). Alcohol—Consumption of ethanol with STRATTERA did not change the intoxicating effects of ethanol. Desipramine—Coadministration of STRATTERA (40 or 60 mg BID for 13 days) with desipramine, a model com-pound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended for drugs metabolized by CYPOPG CŸP2D6

Methylphenidate-Coadministration of methylphenidate with STRATTERA did not increase cardiovascular effects beyond those seen with methylphenidate alone. Midazolam—Coadministration of STRATTERA (60 mg BID

Midazolam—Coadministration of STRATTERA (60 mg BID for 12 days) with midazolam, a model compound for CYP3A metabolized drugs, (single dose of 5 mg), resulted in 15% increase in AUC of midazolam. No dose adjustment is recommended for drugs metabolized by CYP3A. Drugs highly bound to plasma protein—In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations. Atomoxetine did not affect the binding of warfarin, acetyl-salicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin. Drugs that affect gastric pH—Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on STRATTERA bioavailability. CLINICAL STIDIES

CLINICAL STUDIES

The effectiveness of STRATTERA in the treatment of ADHD was established in 6 randomized, double-blind, placebocontrolled studies in children, adolescents, and adults who met Diagnostic and Statistical Manual 4th edition (DSM-IV) criteria for ADHD (see INDICATIONS AND USAGE). Children and Adolescents

The effectiveness of STRATTERA in the treatment of ADHD was established in 4 randomized, double-blind, placebo-controlled studies of pediatric patients (ages 6 to 18). Approximately one-third of the patients met DSM-IV criteria for inattentive subtype and two-thirds met criteria for both inattentive and hyperactive/impulsive subtypes (see INDI-CATIONS AND USAGE).

Signs and symptoms of ADHD were evaluated by a compar-ison of mean change from baseline to endpoint for STRATTERA- and placebo-treated patients using an intentto treat analysis of the primary outcome measure, the in-vestigator administered and scored ADHD Rating Scale IV-Parent Version (ADHDRS) total score including hyperactive/impulsive and inattentive subscales. Each item on the ADHDRS maps directly to one symptom criterion for ADHD in the DSM-IV.

In Study 1, an 8-week randomized, double-blind, placebo In Study I, an 8-week randomized, double-bind, placebo-controlled, dose-response, acute treatment study of children and adolescents aged 8 to 18 (N=297), patients received ei-ther a fixed dose of STRATTERA (0.5, 1.2, or 1.8 mg/kg/day) or placebo. STRATTERA was administered as a divided dose in the early morning and late aftermoon/early evening. dose in the early morning and late atternoon/early evening. At the 2 higher doses, improvements in ADHD symptoms were statistically significantly superior in STRATTERA-treated patients compared with placebo-treated patients as measured on the ADHDRS scale. The 1.8-mg/kg/day STRATTERA dose did not provide any additional benefit over that observed with the 1.2-mg/kg/day dose. The 0.5-mg/ kg/day STRATTERA dose was not superior to placebo. In Study 2. a 6-weak randomized double-blind placebo.

In Study 2, a 6-week randomized, double-blind, placebocontrolled, acute treatment study of children and adoles-controlled, acute treatment study of children and adoles-

Lilly Exhibit 1255, Page 27 of 39

Sandostatin LAR® Depot vials are manufactured by: Biochemie GmbH, Schaftenau, Austria (Subsidiary of Novartis Pharma AG, Basle, Switzerland). The diluent vials are manufactured by: Novartis Pharma AG, Basle, Switzerland Distributed by: Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936 vartis Shown in Product Identification Guide, page 327

SIMULECT[®] [sĭm ew lĕkt] (basiliximab) For Injection Bx only

The following prescribing information is based on official labeling in effect July 2003. Prescribing Information

WARNING

WARNING Only physicians experienced in immunosuppression therapy and management of organ transplantation pa-tients should prescribe Simulect[®] (basiliximab). The physician responsible for Simulect[®] administration should have complete information requisite for the follow-up of the patient. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical receivent resources.

DESCRIPTION

Simulect[®] (basiliximab) is a chimeric (murine/human) Similect, (basinthab) is a clinical cumulate function monoclonal antibody (Ig_{1a}), produced by recombinant DNA technology, that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2Ra, also known as CD25 antigen) on the surface of activated T-lymphocytes. Based on the amino acid sequence, the calculated molecular weight of the pro-tein is 144 kilodaltons. It is a glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL- $2R\alpha$.

The active ingredient, basiliximab, is water soluble. The drug product, Simulect[®], is a sterile lyophilisate which is available in 6 mL colorless glass vials and is available in 10 mg and 20 mg strengths.

Each 10 mg vial contains 10 mg basiliximab, 3.61 mg monobasic potassium phosphate, 0.50 mg disodium hydrogen phosphate (anhydrous), 0.80 sodium chloride, 10 mg sucrose, 40 mg mannitol and 20 mg glycine, to be reconsti-tuted in 2.5 mL of Sterile Water for Injection, USP. No pre-

titled in 2.5 int of oberne water in trajectory portrained and servatives are added.
Each 20 mg vial contains 20 mg basiliximab, 7.21 mg mono-basic potassium phosphate, 0.99 mg disodium hydrogen phosphate (anhydrous), 1.61 mg sodium chloride, 20 mg su-crose, 80 mg mannitol and 40 mg glycine, to be reconsti-tuted in 5 mL of Sterile Water for Injection, USP. No preser-ting are added vatives are added.

CLINICAL PHARMACOLOGY

General

Mechanism of action: Basiliximab functions as an IL-2 re Mechanism of action: Basinximab functions as an IL-2 re-ceptor antagonist by binding with high affinity ($K_a = 1 \times 10^{-9} M^{-1}$) to the alpha chain of the high affinity IL-2 receptor complex and inhibiting IL-2 binding. Basiliximab is specifi-cally targeted against IL-2Ra, which is selectively ex-pressed on the surface of activated T-lymphocytes. This spe-cific high affinity binding of Simulect to IL-2Ra competitively inhibits IL-2-mediated activation of lympho-cates a critical pathway in the cellular immune response cytes, a critical pathway in the cellular immune response

while in the circulation, Simulect[®] impairs the response of while in the circulation, Simulett' impairs the response of the immune system to antigenic challenges. Whether the ability to respond to repeated or ongoing challenges with those antigens returns to normal after Simulett[®] is cleared is unknown (See PRECAUTIONS).

Pharmacokinetics

Adults: Single-dose and multiple-dose pharmacokinetic studies have been conducted in patients undergoing first kidney transplantation. Cumulative doses ranged from 15 ng up to 150 mg. Peak mean ± SD serum concentration following intravenous infusion of 20 mg over 30 minutes is 7.1 ± 5.1 mg/L. There is a dose-proportional increase in C_{max} and AUC up to the highest tested single dose of 60 mg. C_{\max} and AUC up to the highest tested single dose of 60 mg. The volume of distribution at steady state is 8.6 \pm 4.1 L. The extent and degree of distribution to various body compartments have not been fully studied. The terminal halfbar unerts have not been ruly status. This is the minimum life is 7.2 ± 3.2 days. Total body clearance is 41 ± 19 mL/h. No clinically relevant influence of body weight or gender on distribution volume or clearance has been observed in adult attention of the second second

ADMINISTRATION). Pediatric: "The pharmacokinetics of Simulect[®] have been assessed in 39 pediatric patients undergoing renal trans-plantation. In infants and children (1-11 years of age, n=25), the distribution volume and clearance were reduced by

Table 1 Efficacy Parameters (Percentage of Patients) Dual-therapy Regimen (cyclosporine* and corticosteroids) Study 1 bo Sir Study 2 Placebo Placebo ulect® (N=173) (N=173) p-value (N=185) (N=190) p-value Primary endpoint Death, graft loss or acute rejection episode (0-6 months) 38% 0:002 42% 0.003 55% Secondary endpoints Death, graft loss or acute rejection episode (0-12 months) 41% 0.001 0.007 58% 46% Biopsy-confirmed rejection episode (0-6 months) 46% 33% 0.015 0.007 44% 30% Biopsy-confirmed rejection episode (0-12 months) 35% 0.009 46% 32% 0.005 49% Patient survival (12 months) 97% 95% 0:29 96% 97% 0.56 Patients with functioning graft (12 months) 87% 88% 0 70 93% 95% 0.50

USP (MODIFIED)

R

2.1 L. half-life was 9.5 \pm 4.5 days and clearance was 17 \pm 2.1 L, hait-life was 9.5 ± 4.5 usys and using a more since was 1 = 6 mLh. Disposition parameters were not influenced to a clinically relevant extent by age (1-11 years of age), body weight (9-37 kg) or body surface area (0.44-1.20 m²) in this age group. In adolescents (12-16 years of age, n=14), disposition was similar to that in adult renal transplantation patients. The volume of distribution at steady state was 7.8 \pm 5.1 L half-life was 9.1 \pm 3.9 days and clearance was 31 \pm 19 mL/h (See DOSAGE AND ADMINISTRATION). Pharmacodynamics

Complete and consistent binding to IL-2Ra in adults is maintained as long as serum Simulect[®] levels exceed 0.2 µg/ mL. As concentrations fall below this threshold, the IL-2Ro mb, as concentrations can be work and the number of T-cells sites are no longer fully bound and the number of T-cells expressing unbound IL-2R α returns to pretherapy values within 1-2 weeks. The relationship between serum concentration and receptor saturation was assessed in 13 pediatric patients and was similar to that characterized in adult renal transplantation patients. In vitro studies using human tissues indicate that Simulect[®] binds only to lymphocytes. The duration of clinically relevant L-2 receptor blockade after the recommended course of Simulect[®] is not known. When basiliximab was added to a regimen of cyclosporine, USP (MODIFIED) and corticosteroids in adult patients, the USP (MODIFIED) and corticosteroids in adult patients, the duration of IL-2Rα saturation was 36 ± 14 days (mean \pm SD), similar to that observed in pediatric patients (36 ± 14 days) (See DOSAGE AND ADMINISTRATION). When bas-iliximab was added to a triple therapy regimen consisting of cyclosporine, USP (MODIFIED), corticosteroids, and aza-thioprine in adults, the duration was 50 ± 20 days and when added to cyclosporine, USP (MODIFIED), corticoster-oids, and mycophenolate mofetil in adults, the duration was 59 ± 17 days (See PRECAUTIONS-DRUG INTERAC-TIONS). No significant changes to circulating Immhocyte TIONS). No significant changes to circulating lymphocyte numbers or cell phenotypes were observed by flow cytome-

CLINICAL STUDIES


The safety and efficacy of Simulect[®] for the prophylaxis of acute organ rejection in adults following cadaveric- or acute organ rejection in adults following cataveries (living-donor renal transplantation were assessed in four randomized, double-blind, placebo-controlled clinical stud-ies (1184 patients). Of these four, two studies [Study 1 (EU/ CAN) and Study 2 (US study)] compared two 20 mg doses of Simulect[®] with placebo, each administered intravenously as an infusion, as part of a standard immunosuppressive reg imen comprised of cyclosporine, USP (MODIFIED) and cor iticsteroids. The other two controlled studies compared two 20 mg doses of Simulect[®] with placebo, each administered intravenously as a bolus injection, as part of a standard tri-De immunosuppressive regimen comprised of cyclosporine, USP (MODIFIED), corticosteroids and either azathioprine or mycophenolate mofetil (Study 3 and Study 4, respectively). The first dose of Simulect[®] or placebo was adminis treely). The first dose of Simulect² or placebo was adminis-tered within 2 hours prior to transplantation surgery (Day 0) and the second dose administered on Day 4 post-transplantation. The regimen of Simulect[®] was chosen to provide 30-45 days of L-2Rs asturation. 729 patients were enrolled in the two studies using a dual


maintenance immunosuppressive regimen comprised of cyclosporine, USP (MODIFIED) and corticosteroids, of which 363 patients were treated with Simulect[®] and 358 patients were placebo-treated. Study 1 was conducted at 21 sites in Europe and Canada (EU/CAN Study); Study 2 was conducted at 21 sites in the USA (US Study). Patients 18-75 years of age undergoing first cadaveric (Study, 1 and Study 2) or living-donor (Study 2 only) renal transplantation, with

2) or nving-donor (scudy 2 only) renal transplantation, with 21 HLA mismatch, were enrolled.^{1,2} The primary efficacy endpoint in both studies was the inci-dence of death, graft loss or an episode of acute rejection during the first 6 months post-transplantation. Secondary efficacy endpoints included the primary efficacy variable measured during the first 12 months post-transplantation, the incidence of biopsy-confirmed acute rejection during the first 6 and 12 months post-transplantation, and patient survival and graft survival, each measured at 12 months post-transplantation. Table 1 summarizes the results of these studies. Figure 1 displays the Kaplan-Meier estimates of

post-transplantation for Study 2. Patients in both studies receiving Simulect[®] experienced a significantly lower inci-dence of biopsy-confirmed rejection episodes at both 6 and 12 months post-transplantation. There was no difference in the rate of delayed graft function, patient survival, or graft survival between Simulect[®]-treated patients and placebotreated patients in either study. There was no evidence that the clinical benefit of Simulect®

was limited to specific subpopulations based on age, gender, race, donor type (cadaveric or living-donor allograft) or history of diabetes mellitus. [See table 1 above]





Two double-blind, randomized, placebo-controlled studies Two double-blind, randomized, placebo-controlled studies (Study 3 and Study 4) assessed the safety and efficacy of Simulect[®] for the prophylaxis of acute renal transplant re-jection in adults when used in combination with a triple im-munosuppressive regimen. In Study 3, 340 patients were concomitantly treated with cyclosporine, USP (MODIFIED), corticosteroids and azathioprine (AZA), of which 168 pa-tients were treated with Simulect[®] and 172 patients were tients were treated with Simulect" and 1/2 patients were treated with placebo. In Study 4, 128 patients were concom-itantly treated with cyclosporine, USP (MODIFIED), corti-costeroids and mycophenolate mofetil (MMF), of which 59 patients were treated with Simulect[®] and 64 patients were treated with placebo. Patients 18-70 years of age undergo ing first or second cadaveric or living-donor (related or un-related) renal transplantation were enrolled in both studies. The results of Study 3 are shown in Table 2. These results are consistent with the findings from Study 1 and Study 2. [See table 2 at top of next page]

The study 4 the percentage of patients experiencing biopsy-proven acute rejection by 6 months was 15% (9 of 59 pa-tients) in the Simulect[®] group and 27% (17 of 64 patients) in the placebo group. Although numerically lower, the differ-ence in acute rejection was not significant.

In a multicenter, randomized, double-blind, placebo-controlled trial of Simulet[®] for the prevention of allograft rejection in liver transplant recipients (n=381) receiving concomitant cyclosporine, USP (MODIFIED) and steroids, the incidence of the combined endpoint of death, graft loss, or first biopsy-confirmed rejection episode at either 6 or 12 months was similar between patients randomized to receive Simulect[®] and those randomized to receive placebo.

The efficacy of Simulect[®] for the prophylaxis of acute rejec-tion in recipients of a second renal allograft has not been demonstrated.

INDICATIONS AND USAGE

Simulect® is indicated for the prophylaxis of acute organ re-Simulate is indicated of the prophysics of active organ ice jection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that in-cludes cyclosporine, USP (MODIFIED) and corticosteridis. The efficacy of Simulate[®] for the prophylaxis of acute rejection in recipients of other solid organ allografts has not been demonstrated.

Simulect-Cont.

CONTRAINDICATIONS

Simulect[®] is contraindicated in patients with known hypersensitivity to basiliximab or any other component of the formulation. See composition of Simulect[®] under DESCRIPTION.

WARNINGS. See Boxed WARNING

General Simulect[®] should be administered under qualified medical supervision. Patients should be informed of the potential benefits of therapy and the risks associated with administration of immunosuppressive therapy.

While neither the incidence of lymphoproliferative disorders nor opportunistic infections was higher in Simulect[®]treated patients than in placebo-treated patients, patients on immunosuppressive therapy are at increased risk for developing these complications and should be monitored accordingly.

Hypersensitivity

rypersensitivity Severe acute (onset within 24 hours) hypersensitivity reac-tions including anaphylaxis have been observed both on in-itial exposure to Simulect[®] and/or following re-exposure af ter several months. These reactions may include hypotension, tachycardia, cardiae failure, dyspnea, wheezhypotension, tachycarna, carnuar lanne, utspinea, whece ing, bronchospasm, pulmorary edema, respiratory failure, urticaria, rash, pruritus, and/or šneezing, if a severe hyper-sensitivity reaction occurs, therapy with Simuled[®] should be permanently discontinued. Medications for the treatment of severe hypersensitivity reactions including anaphy-laxis should be available for immediate use. Patients previ-ously administered Simulect[®] should only be re-exposed to a subsequent course of therapy with extreme caution. The potential risks of such re-administration, specifically those associated with immunosuppression, are not known.

PRECAUTIONS

General It is not known whether Simulect[®] use will have a long-term effect on the ability of the immune system to respond to an-tigens first encountered during Simulect[®]-induced immunosuppression.

Immunogenicity

Of renal transplantation patients treated with Simulect® and tested for anti-idiotype antibodies, 4/339 developed an anti-idiotype antibody response, with no deleterious clinical effect upon the patient. In none of these cases was there ev-idence that the presence of anti-idiotype antibody acceler-ated Simulect[®] clearance or decreased the period of receptor saturation. In Study 2, the incidence of human anti-murine antibody (HAMA) in renal transplantation patients treated antibody (HAAN) in refin transplantation patients tracked with Simulett[®] was 21/138 in patients not exposed to muromonab-CD3 and 4/34 in patients who subsequently re-ceived muromonab-CD3. The available clinical data on the use of muromonab-CD3 in patients previously treated with Simulect[®] suggest that subsequent use of muromonab-CD3 or other murine anti-lymphocytic antibody preparations is not precluded.

These data reflect the percentage of patients whose test results were considered positive for antibodies to Simulect[®] in an ELISA assay, and are highly dependent on the sensitiv-ity and specificity of the assay. Additionally the observed inity and specificity of the assay. Additionally use observed in-cidence of antibody positivity in an assay may be influenced by several factors including sample handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Simulect[®] with the incidence of antibodies to other products may be milledding. misleading.

Drug Interactions

Drug interactions No dose adjustment is necessary when Simulect[®] is added to triple immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or my-cophenolate mofetil. Three clinical trials have investigated cophenolate motetil. Three clinical trials have investigated Simulect[®] use in combination with triple therapy regimens. Pharimacokinetics were assessed in two of these trials. Total body clearance of Simulect[®] was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Non-theless, the range of individual Simulect[®] clearance values in the presence of azathioprine (12-57 ml/h) or mycopheno-late mofetil (7-54 ml/h) did not extend outside the range ob-served with dual therapy (10-78 ml/h). The following medi-cations have heen administered [†] in clinical trials with cations have been administered in clinical trials with Simulect[®] with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.

Carcinogenesis/Mutagenesis/Impairment of Fertility

No mutagenic potential of Simulect[®] was observed in the *in* vitro assays with Salmonella (Ames) and V79 Chinese hamutro assays with Samonena (Ames) and Vis Chinese hain ster cells. No long-term of fertility studies in laboratory ani-mals have been performed to evaluate the potential of Simulect[®] to produce carcinogenicity or fertility impair-ment, respectively. Pregnancy Category B

There are no adequate and well-controlled studies in preg-nant women. No maternal toxicity, embryotoxicity, or tera-togenicity was observed in cynomolgus monkeys 100 days post coitum following dósing with basiliximab during the or-ganogenesis period; blood levels in pregnant monkeys were 13-fold higher than those seen in human patients. Immuño-

ार्ग्स् अत्य हर्षे वर्षे Study 3: Triple-therapy Regimen (cyclospo	rine*, corticoste	roids, and aza	thioprine)	ede gi M Storic Carl
and and a second s	Placebo (N=172)	Simulect [®] (N=168)	standa Standard P)-value
Primary endpoint Acute rejection episode (0-6 months)	35%	21%	n an the second s	0.005
Secondary endpoints Death, graft loss or acute rejection episode (0-6 months)	40%	26%		0.008
Biopsy-confirmed rejection episode (0-6 months)	29%	18%		0.023
Patient survival (12 months)	97%	98%	a an	1.000
Patients with functioning graft (12 months)	88%	90%	1. <u>1</u> . 1997 - 1	0.599

barrier, because the IL-2 receptor may play an important role in development of the immune system, and because animal reproduction studies are not always predictive of hu-man response, Simulect[®] should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception before beginning Simulect[®] therapy, during therapy, and for 4 months after completion of Simulect[®] therapy. Nursing Mothers

It is not known whether Simulect[®] is excreted in human milk. Because many drugs including human antibodies are excreted in human milk, and because of the potential for adverse reactions, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

No randomized, placebo-controlled studies have been com-No randomized, placebo-controlled studies have been com-pleted in pediatric patients. In a safety and pharmacoki-netic study, 41 pediatric patients [1-11 years of age (n=27), 12-16 years of age.(n=14), median age.8.1. years] were treated with Simulect[®] via intravenous bolus injection in addition to standard immunosuppressive agents including cyclosporine, USP (MODIFIED), corticosteroids, azathio-prine, and mycophenolate mofetil. The acute rejection rate at ici months was commarable to that in adults in the triple at six months was comparable to that in adults in the triple at six months was comparable to that in adults in the upper therapy trials. The most frequently reported adverse events were hypertension, hypertrichosis, and rhinitis (49% each), urinary tract infections (46%), and fever (39%). Overall, the adverse event profile was consistent with general clinical experience in the pediatric renal transplantation population and with the profile in the controlled adult renal transplantation studies. The available pharmacokinetic data in child-rén and adolescents are described in CLINICAL PHARMA-COLOGY and DOSAGE AND ADMINISTRATION.

It is not known whether the immune response to vaccines, infection, and other antigenic stimuli administered or en-countered during Simulect[®] therapy is impaired or whether such response will remain impaired after Simulect[®]

Geriatric Use

Controlled clinical studies of Simulect[®] have included small number of patients 65 years and older (Simulect[®] 28; placebo 32). From the available data comparing Simulect[®] and placebo-treated patients, the adverse event profile in and patents 265 years of age is not different from patients <65 years of age and no age-related dosing adjustment is re-quired. Caution must be used in giving immunosuppressive drugs to elderly patients

ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

The incidence of adverse events for Simulect[®] was deter-mined in four randomized, double-blind, placebo-controlled Clinical trials for the prevention of renal allograft rejection Two of the studies (Study 1 and Study 2), used a dual main tenance immunosuppressive regimen comprised of cyclosporine, USP (MODIFIED) and corticosteroids, whereas the other two studies (Study 3 and Study 4) used an triple immunosuppressive regimen comprised of cyclosporine, USP (MODIFIED), corticosteroids, and either

azathioprine or mycophenolate mofetil. Simulect[®] did not appear to add to the background of adverse events seen in organ transplantation patients as a consequence of their underlying disease and the concurrent administration of immunosuppressants and other medications: Adverse events were reported by 96% of the patients tions: Adverse events were reported by 50% of the patients in the placeho-treated group. In the four placeho-controlled studies, the pattern of adverse events in 590 patients treated with the recommended dose of Simulect[®] was simple treated with the recommended dose of Simulect[®] was simi-lar to that in 594 patients treated with placebo. Simulect[®] did not increase the incidence of serious adverse events

The most frequently reported adverse events were gastroin-testinal disorders, reported in 69% of Simulact⁶-treated patients and 67% of placebo-treated patients.

The incidence and types of adverse events were similar in Simulect[®] treated and placebo-treated patients. The follow-ing adverse events occurred in ≥10% of Simulect[®] treated ing auverse events occurite in the structure relations of the structure of lemia, hyperglycemia, hypercholesterolemia, hypothóspha-temia, hyperuricemia; *Urinary System*: urinary tract infection; *Respiratory System*: dyspnea, upper respiratory tract infection; Skin and Appendages: surgical wound com-plications, acne; Cardiovascular Disorders-General: hypertension; Central and Peripheral Nervous System: headache; tremor; Psychiatric: insomnia; Red Blood Cell: anemia.

The following adverse events, not mentioned above, were reported with an incidence of $\geq 3\%$ and < 10% in pooled analysis of patients treated with Simulect[®] in the four controlled clinical trials, or in an analysis of the two dual therapy tri-als: Body as a Whole-General: accidental trauma, asthenia, als: Body äs a whole General activated a during assumption chest pain, increased drug level, infection, face édema, fa-tigue, dependent edema, generalized edema, leg edema, malaise, rigors, sepsis; Cardiovascular: ahonrani heart souinds, aggravated hypertension, angina pectoris, cardiac sourice, aggevator in proteinsion; Endocrinie: increased glu-cocorticoids; Gastrointestinal: enlarged abdomen, esophagi-tis, flatulence, gastrointestinal disorder, gastroenteritis, Gl hemorrhage, gum hyperplasia, melena, moniliasis, ulcer-ative stomatitis; *Heart Rate and Rhythm*, arrhythmia, atrial fibrillation, tachycardia; Metabolic and Nutritional: acido-sis, dehydration, diabetes mellitus, fluid overload, hypercalsis, denydraton, dabetes meintas, neu contras, hypocalcemia, cemia, hyperlipemia, hypertriglyceridemia, hypocalcemia, hypoglycemia, hypomagnesemia, hypoproteinemia; weight increase; *Musculo-Skeletal*: arthralgia; arthropathy, back pain, bone fracture, cramps, hernia, myalgia, leg pain; Ner-vous System: dizziness, neuropathy, paraesthesia, hypoes-Vous Systein: Inziness, neuroparis, parasiteria, in portugi thesia; Platelet and Bleeding: hematoma, hemorrhage, pur-pura, thrombocytopenia, thrombosis; Psychiatric: agitation, anxiety, depression; Red Blood, Cell: polycythemia; Reproductive Disorders, Male: genital edema, impotence; Respi-ratory: bronchitis, bronchospasm, abnormal chest sounds, coughing, pharyngitis, pneumonia, pulmonary disorder, pul-monary edema, rhinitis, sinusitis; Skin and Appendages, cyst, herpes simplex, herpes zoster, hypertrichosis, pruritus, rash, skin disorder, skin ulceration; *Urinary*: albuminuria, bladder disorder, dysuria, frequent micturition, hematuria, increased non-protein nitrogen, oliguria, abnormal renal function, renal tubular necrosis, surgery, ureteral disorder, arinary retention; Vascular Disorders: vascular disorder; Vion Disorders: cataract, conjunctivitis, abnormal vision; White Blood Cell: leucopenia. Among these events, leucope nia and hypertriglyceridemia occurred more frequently in the two triple-therapy studies using azathioprine and mycophenolate mofetil than in the dual-therapy studies. Malignancies

Malignancies The overall incidence of malignancies among all patients in the controlled studies was not significantly different be-tween the Simulect[®], and placebo-treatment groups. Over-all, lymphoma/lymphoproliferative disease occurred in 1/590 patients in the Simulect[®] group compared with 3/594 patients in the placebo group. Other malignancies were re-ported among 8/590 patients in the Simulect[®] group com-pared with 9/594 patients in the placebo group. Infections

The overall incidence of cytomegalovirus infection was sim-1ne overall incidence of cytomeganovrus intection was sim-ilar in Simulect⁹. and placebo-treated patients (15% vs. 17%) receiving a dual or triple immunosuppression regi-men. However, in patients receiving a triple immunosup-pression regimen, the incidence of serious cytomegalovirus infection was higher in Simulect⁹-treated patients com-pared to placebo-treated patients (11% vs. 5%). The rates of infections gradient in the series of the series and the series infections and infections are the series infections and infections are the series infections and the series are the series infections and the series infections are the series infections are the series infections and the series are the series infections are the series and the series are the series ar infections, serious infections, and infectious organisms were similar in the Simulect[®] and placebo treatment groups among dual- and triple therapy-treated patients. Post-Marketing Experience

Severe acute hypersensitivity reactions including anaphy-laxis characterized by hypotension, tachycardia, cardiac

edema, respiratory failure, urticaria, rash, pruritus, and/or snezing, as well as capillary leak syndrome and cytokine release syndrome, have been reported during post-marketing experience with Simulet[®].

OVERDOSAGE

A maximum tolerated dose of Simulect® has not been determined in patients. During the course of clinical studies, Simulect[®] has been administered to adult renal transplan-Simulet' has been administered to adult renal transplan-tation patients in single doese of up to 60 mg, or in divided doese over 3.5 days of up to 120 mg, without any associated serious adverse events. There has been one spontaneous re-port of a pediatric renal transplantation patient who received a single 20 mg dose (2.3 mg/kg) without adverse events.

DOSAGE AND ADMINISTRATION

Simulect[®] is used as part of an immunosuppressive regimen that includes cyclosporine, USP (MODIFIED) and cortico-steroids. Simulect[®] is for central or peripheral intravenous administration only. Reconstituted Simulect[®] should be given either as a bolus injection or diluted to a volume of 25 mL (10 mg vial) or 50 mL (20 mg vial) with normal saline or dextrošé 5% and administered as an intravenous infusion over 20 to 30 minutes. Bolus administration may be associ ated with nausea, vomiting and local reactions, including

pain. Simulect[®] should only be administered once it has been determined that the patient will receive the graft and concom-itant immunosuppression. Patients previously adminis-tered Simulect[®] should only be re-exposed to a subsequent course of therapy with extreme caution. Parenteral drug products should be inspected visually for

particulate matter and discoloration before administration. After reconstitution, Simulect[®] should be a clear to opalescent, colorless solution. If particulate matter is present or the solution is colored, do not use

Care must be taken to assure sterility of the prepared solution because the drug product does not contain any antimi-crobial preservatives or bacteriostatic agents.

It is recommended that after reconstitution, the solution should be used immediately. If not used immediately, it can be stored at 2°C to 8°C for 24 hours or at room temperature for 4 hours. Discard the reconstituted solution if not used within 24 hours.

No incompatibility between Simulect[®] and polyvinyl chlo available on the compatibility of Simulect[®] with other intravenous substances. Other drug substances should not be added or infused simultaneously through the same intravenous line.

Adults

In adult patients, the recommended regimen is two doses of 20 mg each. The first 20 mg dose should be given within 2 hours prior to transplantation surgery. The recommended second 20 mg dose should be given 4 days after transplan-tation. The second dose should be withheld if complications such as severe hypersensitivity reactions to $Simulect^{\otimes}$ or graft loss occur.

. Pediatric

In pediatric patients weighing less than 35 kg, the recom mended regimen is two doses of 10 mg each. In pediatric patients weighing 35 kg or more, the recommended regimen is two doses of 20 mg each. The first dose should be given within 2 hours prior to transplantation surgery. The recom-mended second dose should be given 4 days after transplantation. The second dose should be withheld if complications such as severe hypersensitivity reactions to Simulect[®] of graft loss occur.

econstitution of 10 mg Simulect Vial

To prepare the reconstituted solution, add 2.5 mL of Sterile Water for Injection, USP, using aseptic technique, to the vial containing the Simulect[®] powder. Shake the vial gently to dissolve the powder.

The reconstituted solution is isotonic and may be given ei-ther as a bolus injection or diluted to a volume of 25 mL with normal saline or destrose 5% for infusion, When mix-ing the solution, gently invert the bag in order to avoid foaming; DO NOT SHAKE. Reconstitution of 20 mg Simulect Vial

To prepare the reconstituted solution, add 5 mL of Sterile Water for Injection, USP, using aseptic technique, to the vial containing the Simulect[®] powder. Shake the vial gently to dissolve the powder. The reconstituted solution is isotonic and may be given ei-

ther as a bolus injection or diluted to a volume of 50 mL with normal saline or dextrose 5% for infusion. When mixing the solution, gently invert the bag in order to avoid foaming; DO NOT SHAKE.

HOW SUPPLIED

Simulect[®] (basiliximab) is supplied in a single use glass vial.

(2°C to 8°C: 36°F to 46°F).

Do not use beyond the expiration date stamped on the vial REFERENCES

1. Kahan, B.D., Rajagopalan P.R. and Hall M., Transplantation, 67, 276-284 (1999).

2. Nashan, B., Moore R., Amlot P., Schmidt A.-G., Abeywick-

7	T2002-91	no
	REV: January 2003 89007805	me
	US License No. 1244	ba
	Novartis Pharmaceuticals Corporation	br
	East Hanover, New Jersey 07936	lev
	©Novartis	Ca
÷	Shown in Product Identification Guide, page 327	W
-		bo

Ŗ

STALEVO™ 50 STALEVO™ 100 STALEVO™ 150 [stă-lē-vō] (carbidopa, levodopa and entacapone) Tablets Rx only

Prescribing Information

The follow prescribing information is base on official label-ing in effect July 2003.


DESCRIPTION

Stalevo™ (carbidopa, levodopa and entacapone) is a combination of carbidopa, levodopa and entacapone for the treatment of Parkinson's disease.

ment of Parkinson's disease. Carbidopa, an inhibitor of aromatic antino acid decarboxy-lation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as (-)-L-(a-hydrazino-(c-methyl-8-(3.4-dihy-droxybenzene) propanoic acid monohydrate. Its empirical formula is $C_{10}H_{14}N_2O_4\bullet H_2O$, and its structural formula is

• H₂0 OH NHNH₂

Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.3. Levodopa, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-L-aamino- β -(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C₉H₁₁NO₄, and its structural formula is



Entacapone, an inhibitor of catechol-O-methyltransferase (COMT), is a nitro-catechol-structured compound with a molecular weight of 305.3. The chemical name of entace pone is (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N.N-diethyl-2-propenamide, Its empirical formula is C₁₄H₁₅N₃O₅ and its structural formula is

CH ĊN CH3 HO NO.

Stalevo™ (carbidopa, levodopa and entacapone) is supplied

Stalevo¹⁰ (carbidopa, levodopa and entacapone) is supplied as tablets in three strengths: Stalevo 50, containing 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone; Stalevo 100, containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone;

Stalevo 150, containing 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone.

The inactive ingredients of the Stalevo tablet are corn starch, croscarmellose sodium, glycerol 85%, hypromellose, magnesium stearate, mannitol, polysorbate 80, povi-done, sucrose, red iron oxide, titanium dioxide, and yellow iron oxide.

CLINICAL PHARMACOLOGY

Parkinson's disease is a progressive, neurodegenerative dis-order of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Its characteristic features include resting tremor, rigidity, and bradykinetic movements. Mechanism of Action

Levodopa

Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease apparently because it does

ot cross the blood-brain barrier. However, levodopa, the netabolic precursor of dopamine, does cross the blood-brain arrier, and presumably is converted to dopamine in the rain. This is thought to be the mechanism whereby vodopa relieves symptoms of Parkinson's disease. arhidona hen levodopa is administered orally it is rapidly decar-

when levolopa is administered orany it is rapidly decar-boxylated to dopamine in extracerebral lissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits'the decar-boxylation of peripheral levolopa, making more levolopa available for transport to the brain. When coadministered with levole and the source interventions and the solution of available for transport to the brain. When combinistered with levolopa, a carbidopa increases plasma levels of levolopa and reduces the amount of levolopa required to produce a given response by about 75%. Carbidopa prolongs the plasma half-life of levolopa from 50 minutes to 1.5 hours and decreases plasma and urinary dopamine and its major metabolite, homovanilite acid. The $T_{\rm max}$ of levolopa, however, was unaffected by the coadministration. Entacapone

Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT).

In mammals, COMT is distributed throughout various or-gans with the highest activities in the liver and kidney. COMT also occurs in neuronal tissues, especially in glial cells. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of sub-strates that contain a catechol structure. Physiological sub-strates of COMT include DOPA, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).

When entacapone is given in conjunction with levodopa and carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and carbi dopa alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stim-ulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease. The higher levodopa levels may also lead to increased levodopa adverse effects, sometimes requiring a decrease in the dose of levodona

When 200 mg entacapone is coadministered with levodopa/ carbidopa, it increases levodopa plasma exposure (AUC) by 35%-40% and prolongs its elimination half-life in Parkin-son's disease patients from 1.3 to 2.4 hours. Plasma levels of the major COMT mediated dopamine metabolite, 3-methoxy-4-hydroxy_L-phenylalanine (3-OMD), are also markedly de-mand domain and the increased does of the anomalous reased proportionally with increasing dose of entacapone. In animals, while entacapone enters the CNS to a minimal extent, it has been shown to inhibit central COMT activity. In humans, entacapone inhibits the COMT enzyme in peripheral tissues. The effects of entacapone on central COMT activity in humans have not been studied.

Pharmacokinetics The pharmacokinetics of Stalevo™ (carbidopa, levodopa The pharmacokinetics of cataloga, feedback and entacapone) tablets have been studied in healthy sub-jects (age 45-75, years, old). Overall, following administra-tion of corresponding doses of levodopa, carbidopa and entacapone as. Stalevo, or as carbidopa/levodopa.product plus Comtan® (entacapone) tablets, the mean plasma concentrations of levodopa, carbidopa, and entacapone are comparable.

<u>Absorption/Distribution</u>: Both levodopa and entacapone are rapidly absorped and eliminated, and their distribution volume is moderately small. Carbidopa is absorbed and volume is moderately small. (Jaroldopa is absorbed and eliminated slightly more slowly compared with levedopa and entacapone. There are substantial inter- and intra-individual variations in the absorption of levedopa, carbi-dopa and entacapone, particularly concerning its C_{max}. The food-effect on the Stalevo tablet has not been evaluated.

Levodopa

The pharmacokinetic properties of levodopa following the administration of single dose Stalevo^{rm} (carbidopa, levodopa and entacapone) tablets are summarized in Table 1. [See table 1 below]

Since levodopa competes with certain amino acids for trans-port across the gut wall, the absorption of levodopa may be impaired in some patients on a high protein diet. Meals rich in large neutral amino acids may delay and reduce the absorption of levodopa (see *PRECAUTIONS*). Levodopa is bound to plasma protein only to a minor extent

(about 10%-30%). Carbidopa

Following administration of Stalevo as a single dose to healthy male and female subjects, the peak concentration of carbidopa was reached within 2.5 to 3.4 hours on average.

Continued on next page

Table 1 Pharmacokinetic Characteristics of Levodopa With Different Tablet Strengths of Stalevo (mean \pm SD) AUC_{0-∞} (ng•h/mL) C_{max} (ng/mL) T_{max} (h) Tablet Strength 12.5 - 50 - 200 mg 1040 ± 314 470 ± 154 1.1 ± 0.5

Lilly Exhibit 1255, Page 30 of 39

2414/ORTHO BIOTECH

Leustatin-Cont.

		and the second second	
	Dose of LEUSTATIN Injection	Recommended Diluent	Quantity of Diluent
7-day infusion method (use sterile 0.22µ filter when preparing infusion solution)	7 (days) × 0.09 mg/kg	Bacteriostatic 0.9% Sodium Chloride Injection, USP (0.9% benzyl alcohol)	q.s. to 100 mL

Since limited compatibility data are available, adherence to the recommended diluents and infusion systems is ad-vised. Solutions containing LEUSTATIN Injection should not be mixed with other intravenous drugs or additives or infused simultaneously via a common intravenous line. since compatibility testing has not been performed. Prepa-rations containing benzyl alcohol should not be used in neo-nates (see WARNINGS).

nates (see WARNINGS). Care must be taken to assure the sterility of prepared solu-tions. Once diluted, solutions of LEUSTATIN Injection should be administered promptly or stored in the refrigera-tor (2° to 8°C) for no more than 8 hours prior to start of administration. Vials of LEUSTATIN Injection are for single-use only. Any unused portion should be discarded in an appropriate manner (see Handling and Disposal). Parenteral drug products should be inspected visually for particulate matter and discolarction prior to chaining

particulate matter and discoloration prior to administra-tion, whenever solution and container permit. A precipitate may occur during the exposure of LEUSTATIN Injection to In a your during the exposure of LEUSTATIN Injection to low temperatures; it may be resolutilized by allowing the solution to warm naturally to room temperature and by shaking vigorously. DO NOT HEAT OR MICROWAVE. Chemical Stability of Vials:

When stored in refrigerated conditions between 2° to 8°C (36° to 46°F) protected from light, unopened vials of LEUSTATIN Injection are stable until the expiration date indicated on the package. Freezing does not adversely affect the solution. If freezing occurs, thaw naturally to room tem-perature. DO NOT heat or microwave. Once thawed, the vial of LEUSTATIN Injection is stable until expiry if refrig-erated. DO NOT refreeze. Once diluted, solutions containing LEUSTATIN Injection should be administered promptly or stored in the refrigerator (2° to 8°C) for no more than 8 hours prior to administration.

Handling and Disposal: The potential hazards associated with cytotoxic agents are the intervential hazards associated with cytotoxic agents are the intervential hazards and proner precautions should be taken well established and proper precautions should be taken when handling, preparing, and administering LEUSTATIN Injection. The use of disposable gloves and protective gar-ments is recommended. If LEUSTATIN Injection contacts ments is recommended. In ECOSIATIN Injection contacts the skin or mucous membranes, wash the involved surface immediately with copious amounts of water. Several guide-lines on this subject have been published.⁽²⁻⁴⁾ There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate. Refer to your Institution's guidelines and all applicable state/local regula-tions for directoric waste tions for disposal of cytotoxic waste.

HOW SUPPLIED

LEUSTATIN Injection is supplied as a sterile, preservative beto first in its supplied as a sterie, preservative free, isotonic solution containing 10mg (Ing/mL) of cladrib-ine as 10 mL filled into a single-use clear fiint glass 20 mL vial. LEUSTATIN[®] Injection is supplied in 10 mL (1 mg/mL) single-use vials (NDC 59676-201-01) available in a treat-ment set (case) of seven vials.

Store refrigerated 2° to 8°C (36° to 46°F). Protect from light during storage.

REFERENCES

- Santana VM, Mirro J, Harwood FC, et al. A phase I clin-ical trial of 2-Chloro-deoxyadenosine in pediatric patients with acute leukemia J. Clin. Onc., 9: 416 (1991).
- Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For
- Antineopiastic Jrugs. NH Publication No. 83-2621. For sale by the Superintendent of Documents, U. S. Govern-ment Printing Office, Washington, D. C. 20402.
 AMA Council Report. Guidelines for Handling Parenteral Antineoplastics, JAMA March 15 (1965).
 Mational Study Commission on Cytotoxic Exposure-Recommendations for Handling Cytotoxic Agents. Avail-able from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachu-setts College of Pharmary and Miloi Haolth Sciences.
- Study Commission on Cytotoxic Exposure, Massachu-setts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.
 Clinical Oncological Society of Australia: Guidelines and Recommendations for Safe Handling of Antineoplastic Agents, Med. J. Australia 1:425 (1983).
- Agents international in the Construction of Chemotherapeutic Agents: A Report from the Mount Sinai Medical Center. Ca-A Cancer Journal for Clinicians, Sept/Oct. 258-263 (2000) (1983)
- 7. American Society of Hospital Pharmacists Technical As-sistance Bulletin on Handling Cytotoxic Drugs in Hospi-tals. Am. J. Hosp. Pharm., 42:131 (1985).
 OSHA Work-Practice Guidelines for Personnel Dealing with Cvtotoxic (antineoplastic) Drugs Am. J. Hosp.

Rx ONLY

 [†] Viaflex® containers, manufactured by Baxter Healthcare Corporation - Code No. 2B8013 (tested in 1991)
 [‡] MEDICATION CASSETTE™ Reservoir, manufactured by \$IMS Deltec, Inc. - Reorder No. 602100A (tested in 1991)
 ORTHO BIOTECH PRODUCTS, L.P.
 Paritan Num Langua (2024) Raritan, New Jersey 08869

ORTHO BIOTECH ©OBPLP 2000 638-10-940-8 Revised October 2002

ORTHOCLONE OKT®3 STERILE SOLUTION B (muromonab-CD3) For Intravenous Use Only

WARNING:

Only physicians experienced in immunosuppressive therapy and management of solid organ transplant pa-tients should use ORTHOCLONE OKT3 (muromonab-CD3). Patients treated with ORTHOCLONE OKT3 must be managed in a facility equipped and staffed for cardiopulmonary resuscitation and where the patient can be closely monitored for an appropriate period based on his or her health status.

Anaphylactic and anaphylactoid reactions may occur following administration of any dose or course of ORTHOCLONE OKT3. In addition, serious, occasionally life-threatening or lethal, systemic, cardiovascular, and central nervous system reactions have been re ported following administration of ORTHOCLONE OKT3. These have included: pulmo-ORTHOCLONE OKT3. These have included; pulmo-nary edema, especially in patients with volume over-load; shock, cardiovascular collapse, cardiac or respira-tory arrest, seizures, coma, cerebral edema, cerebral herniation, blindness, and paralysis. Fluid status should be carefully-monitored prior to and during ORTHOCLONE OKT3 administration. Pretreatment with methylprednisolone is recommended to minimize sumptoms of Cytokipa Balease Sundramo, (Sac) WAPN symptoms of Cytokine Release Syndrome. (See: WARN INGS: Cytokine Release Syndrome, Central Nervous System Events, Anaphylactic Reactions; DOSAGE AND ADMINISTRATION.)

DESCRIPTION

ORTHOCLONE OKT3 (muromonab-CD3) Sterile Solution is a murine monoclonal antibody to the CD3 antigen of hu-man T cells which functions as an immunosuppressant. It is for intravenous use only. The antibody is a biochemically but intravenous use only the antonony is a monomenatory purified IgCo₂ immunophiloulin with a heavy chain of ap-proximately 50,000 daltons and a light chain of approxi-mately 25,000 daltons. It is directed to a glycoprotein with a molecular weight of 20,000 in the human T cell surface which is essential for T cell functions. Because it is a monoclonal antibody preparation, ORTHOCLONE OKT3 Sterile Solution is a homogeneous, reproducible antibody product with consistent, measurable reactivity to human T cells. Each 5 mL ampule of ORTHOCLONE OKT3 Sterile Solubath o hill ample of OFTHOCHORE OR15 Sterile Soli-tion contains 5 mg (1 mg/mL) of murromonab-CD3 in a clear colorless solution which may contain a few fine translucent protein particles. Each ampule contains a buffered solution (pH 7.0 \pm 0.5) of monobasic sodium phosphate (2.25 mg), dibasic sodium phosphate (9.0 mg), sodium chloride (43 mg), and polysorbate 80 (1.0 mg) in water for injection.

The proper name, muromonab-CD3, is derived from the descriptive term murine monoclonal antibody. The CD3 desig-nation identifies the specificity of the antibody as the Cell Differentiation (CD) cluster 3 defined by the First International Workshop on Human Leukocyte Differentiation

CLINICAL PHARMACOLOGY

ORTHOCLONE OKT3 reverses graft rejection, probably by blocking the function of T cells which play a major role in acute allograft rejection. ORTHOCLONE OKT3 reacts with and blocks the function of a 20,000 dalton molecule (CD3) in the membrane of human T cells that has been associated in the membrane of human T cells that has been associated in vitro with the antigen recognition structure of T cells and is essential for signal transduction. In in vitro cytolytic assays, ORTHOCLONE OKT3 blocks both the generation and func-tion of effector cells. Binding of ORTHOCLONE OKT3 to T lymphocytes results in early activation of T cells, which leads to cytokine release, followed by blocking T cell func-tions. After termination of ORTHOCLONE OKT3 therapy, cell functions usually returns to normal within car unch-Toell function usually returns to normal within one week. In vivo, ORTHOCLONE OKT3 reacts with most peripheral blood T cells and T cells in body tissues, but has not been found to react with other hematopoietic elements or other tissues of the body.

tassues of the body. A rapid and concomitant decrease in the number of circulat-ing CD3 positive cells, including those that are CD2, CD4, or CD8 positive cells, including those that are CD2, CD4, or CD8 positive has been observed in patients studied within minutes after the administration :, of ORTHOCLONE OKT3. This decrease in the number of CD3 positive T cells results from the specific interaction between ORTHOCLONE OKT3 and the CD3 antigen on the surface of all Turmebartor. Teal extinction results in the number of of all T lymphocytes. T.cell activation results in the release of numerous cytokines/lymnhokines, which are fall to be refollowing ORTHOCLONE OKT3 administration. (See: WARNINGS: Cytokine Release Syndrome, Central Nervous System Events.)

While CD3 positive cells are not detectable between days two and seven, increasing numbers of circulating CD2, CD4, and CD8 positive cells have been observed. The presence of these CD2, CD4, and CD8 positive cells has not been shown to affect reversal of rejection. After termination of ORTHOCLONE OKT3 therapy, CD3 positive cells reappear rapidly and reach pre-treatment levels within a week. In some patients however, increasing numbers of CD3 positive cells have been observed prior to termination of ORTHOCLONE OKT3 thrapy. This reappearance of CD3 positive cells has been attributed to the development of neutralizing antibodies to ORTHOCLONE OKT3, which in turn block its ability to bind to the CD3 antigen on T lympho-cytes. (See: PRECAUTIONS: Sensitization.)

Pediatric patients are known to have higher CD3 lympho-cyte counts than adults. Pediatric patients receiving ORTHOCLONE ORT⁹³ therapy often require progressively higher doses of ORTHOCLONE ORT³ to achieve depletion of CD3 positive cells (<25 cells/mm³) and ensure therapeu-tic ORTHOCLONE OKT3 serum concentrations (>800 ng/ mL). (See: DOSAGE AND ADMINISTRATION; PRECAU-TIONS: Laboratory Tests.) Serum levels of ORTHOCLONE OKT3 are measurable us-

ing an enzyme-linked immunosorbent assay (ELISA). Dur-ing the initial clinical trials in renal allograft rejection, in Ing the initial clinical trials in renal allogrant rejection, in patients treated with 5 mg per day for 14 days, mean serum trough levels of the drug rose over the first three days and then averaged 900 ng/mL on days 3 to 14. Serum concentra-tions measured daily during treatment with ORTHOCLONE OKT3 in renal, hepatic, and cardiac allograft recipients revealed that pediatric patients less than 10 years of age have higher levels than patients 10-50 years of years of age have higher levels than patients 10-50 years of age. Subsequent clinical experience has demonstrated that serum levels greater than or equal to 800 ng/mL of ORTHOCLONE OKT3 blocks the function of cytotoxic T cells in vitro and in vitro. Reduced T cell clearance or low plasma ORTHOCLONE OKT3 levels provide a basis for ad-justing ORTHOCLONE OKT3 dosage or for discontinuing therapy. (See: WARNINGS: Anaphylactic Reactions; PRE-CAUTIONS: Laboratory Tests; ADVERSE EVENTS: Hyper-sonitivity Reactions: DOSAGE AND ADMINICTRATION 1. sensitivity Reactions; DOSAGE AND ADMINISTRATION.) Following administration of ORTHOCLONE OKT3 in vivo. leukocytes have been observed in cerebrospinal and perito-neal fluids. The mechanism for this effect is not completely understood, but probably is related to cytokines altering membrane permeability, rather than an active inflamma-tory process. (See: WARNINGS: Cytokine Release Syndrome, Central Nervous System Events.)

CLINICAL STUDIES

Acute Renal Rejection: In a controlled

randomized clinical. trial In a controlled randomized clinical, trial, ORTHOCLONE OKTS was compared with conventional high-dose steroid therapy in reversing acute renal allograft rejection. In this trial, 122 evaluable patients undergoing acute rejection of cadaveric renal transplants were treated either with ORTHOCLONE OKT3 daily for a mean of 14 days, with concomitant lowering of the dosage of azathio-prine and maintenance steroids (62 patients), or with conprime and maintenance steroids (62 patients), or with con-ventional high-dose steroids (60 patients). ORTHOCLONE OKT3 reversed 94% of the rejections com-pared to a 75% reversal rate obtained with conventional high-dose steroid treatment (p=0.006). The one year Kap-lan-Meier (actuarial) estimates of graft survival rates for these patients who had acute rejection were 62% and 45% for ORTHOCLONE OKT3 and steroid-treated patients, re-spectively (p=0.04). At two years the rates were 56% and 42% representively (n=0.06)

42%, respectively (p=0.06). One- and two-year patient survivals were not significantly different between the two groups, being 85% and 75% for ORTHOCLONE OKT3 treated patients and 90% and 85% for steroid-treated patients.

In additional open clinical trials, the observed rate of rever-In additional open chinical trais, the observed rate of reverses of acute renal allograft rejection was 92% (n=126) for ORTHOCLONE OKT3 therapy. ORTHOCLONE OKT3 was also effective in reversing acute renal allograft rejections in 65% (n=225) of cases where steroids and lymphocyte immune globulin preparations were contraindicated or were not successful.

not successful. The effectiveness of ORTHOCLONE OKT3 for prophylaxis of renal allograft rejection has not been established. <u>Acute Cardiac or Hepatic Allograft Rejection</u>: ORTHOCLONE OKT3 was studied for use in reversing acute cardiac and hepatic allograft rejection in patients who are unresponsive to high-doses of steroids. The rate of re-versal in acute cardiac allograft rejection was 90% (n=61) and was 83% for hepatic allograft rejection was 90% (n=61). and was 53% for hepatic allograft rejection (n=124) in pa-tients unresponsive to treatment with steroids. Controlled randomized trials have not been conducted to

evaluate the effectiveness of ORTHOCLONE OKTS com-pared to conventional therapy as first line treatment for acute cardiac and hepatic allograft rejection.

INDICATIONS AND USAGE

ORTHOCLONE OKT3 is indicated for the treatment of acute allograft rejection in renal transplant patients. ORTHOCLONE OKT3 is indicated for the treatment of steroid-resistant acute allograft rejection in cardiac and hepatic transplant patients.

the lowest level compatible with an effective therapeutic response. (See: WARNINGS and ADVERSE EVENTS: Infec-tions, Neoplasia; DOSAGE AND ADMINISTRATION.) CONTRAINDICATIONS

ORTHOCLONE OKT3 should not be given to patients who: • are hypersensitive to this or any other product of murine

- have anti-mouse antibody titers ≥1:1000;
- are in (uncompensated) heart failure or in fluid overload. are in full offensated in the offensate of the set of the set of the set are set of the set are set of the set are set of the set of
- have uncontrolled hypertension;
- have a history of seizures, or are predisposed to seizures; are determined or suspected to be pregnant, or who are breast-feeding. (See: PRECAUTIONS: Pregnancy, Nursing Mothers.).

WARNINGS

SEE BOXED WARNING Cytokine Release Syndrome

Most patients develop an acute clinical syndrome file. Cy tokine Release Syndrome (CRS)] that has been attributed to the release of cytokines by activated lymphocytes or monocytes and is temporally associated with the administration of the first few doses of ORTHOCLONE OKT®3 (particularly, the first two to three doses). This clinical syndrom larly, the infst two to three doess). This clinical syndrome has ranged from a more frequently reported mild, self-limited, "flu-like" illness to a less frequently reported se-vere, life-threatening shock-like reaction, which may in-clude serious cardiovascular and central nervous system manifestations. The syndrome typically begins approxi-mately 30 to 60 minutes after administration of a dose of ORTHOCLONE OKT3 (but may occur later) and may per-sist for several hours. The frequency and severity of this symptom complex is usually greatest with the first dose With each successive dose of ORTHOCLONE OKT3, both the frequency and severity of the Cytokine Release Syn-drome tends to diminish. Increasing the amount of ORTHOCLONE OKT3 or resuming treatment after a hiatus may result in a reappearance of the CRS. Common clinical manifestations of CRS may include: high

fever (often spiking, up to 107°F), chills/rigors, headache tremor, nausea/vomiting, diarrhea, abdominal pain, malaise, muscle/joint aches and pains, and generalized weak ness. Less frequently reported adverse experiences include minor dermatologic reactions (e.g., rash, pruritus, etc.) and a spectrum of often serious, occasionally fatal, cardiorespiratory and central nervous system adverse experiences.

Cardiorespiratory findings may include: dyspnea, shortness of breath, bronchospasm/wheezing, tachypnea, respiratory arrest/failure/distress, cardiovascular collapse, cardiac ar-rest, angina/myocardial infarction, chest pain/tightness, tachycardia (including ventricular), hypertension, hemody-namic instability, hypotension including profound shock, heart failure, pulmonary edema (cardiogenic and non-cardiogenic), adult respiratory distress syndrome, hypoxemia, apnea, and arrhythmias. (See: BOXED WARNING; PRE-CAUTIONS; ADVERSE EVENTS.)

In the initial studies of renal allograft rejection, potentially fatal, severe pulmonary edema occurred in 5% of the initial 107 patients. Fluid overload was present before treatment in all of these cases. It occurred in none of the subsequent 311 patients treated with first-dose volume/weight restrictions. In subsequent trials and in post-marketing exper-ience, severe pulmonary edema has occurred in patients who appeared to be euvolemic. The pathogenesis of pulmonary edema may involve all or some of the following: volume overload; increased pulmonary vascular permeability; and/or reduced left ventricular compliance/contractility. During the first 1 to 3 days of ORTHOCLONE OKT3 therapy, some patients have experienced an acute and transient specine in the glomerular filtration rate (GFR) and dimin-ighed urine output with a resulting increase in the level of serum creatinine. Massive release of cytokines appears to lead to reversible renal functional impairment and/or delaved renal allograft function. Similarly, transient elevations in hepatic transaminases have been reported following administration of the first few doses of ORTHOCLONE OKT3.

Patients at risk for more serious complications of CRS may include those with the following conditions: unstable an-gina; recent myocardial infarction or symptomatic ischemic heart disease; heart failure of any etiology; pulmonary edema of any etiology; any form of chronic obstructive pul-monary disease; intravascular volume overload or depletion of any etiology (e.g., excessive dialysis, recent intensive di-uresis, blood loss, etc.); cerebrovascular disease; patients with advanced symptomatic vascular disease or neuropa thy, a history of seizures; and septic shock. Efforts should be made to correct or stabilize background conditions prior to the initiation of therapy. (See: PRECAUTIONS.) Prior to administration of ORTHOCLONE OKT3, the pa-

tient's volume (fluid) status and a chest X-ray should be as sessed to rule out volume overload, uncontrolled hypertension, or uncompensated heart failure. Patients should not weigh >3% above their minimum weight during the week prior to injection.

The Cytokine Release Syndrome is associated with in-creased serum levels of cytokines (e.g., $\text{TNF} \cdot \alpha$, IL-2, IL-6, IFN-9) that peak between 1 and 4 hours following adminis-

treatment with 8 mg/kg of methylprednisolone (i.e., highdose steroids), given 1 to 4 hours prior to administration of the first dose of ORTHOCLONE OKT3, and by closely fol-lowing recommendations for dosage and treatment dura-tion. (See: DOSAGE AND ADMINISTRATION.) It is not known if corticosteroid pretreatment decreases organ dam-age and sequelae associated with CRS. For example, increased intracranial pressure and cerebral herniation have occurred despite pretreatment with currently recommended doses and schedules of methyprednisolone.

If any of the more serious presentations of the Cytokine Release Syndrome occur, intensive treatment including oxygen, intravenous fluids, corticosteroids, pressor amines, an tihistamines, intubation, etc., may be required.

Central Nervous System Events

Sciarces, encephalopathy, cerebral edema, aseptic meningi-tis, and headache have been reported, even following the first dose, during therapy with ORTHOCLONE OKT®3. Seizures, some accompanied by loss of consciousness or cardiorespiratory arrest, or death, have occurred independently or in conjunction with any of the neurologic syndromes desembod below

A few cases of fatal cerebral herniations subsequent to cerebral edema have been reported. All patients, particularly pediatric patients, must be carefully evaluated for fluid retention and hypertension before the initiation of ORTHOCLONE OKT3 therapy. Close monitoring for neurologic symptoms must be performed during the first twenty-four (24) hours following each of the first few doses of ORTHOCLONE OKT3 injection.

Patients should be closely monitored for convulsions and manifestations of encephalopathy, including: impaired cog-nition, confusion, obtundation, altered mental status, dis-orientation, auditory/visual hallucinations, psychosis (delirium, paranoia), mood changes (e.g., mania, agitation combativeness, etc.), diffuse hypotonus, hyperreflexia, myo clonus, tremor, asterixis, involuntary movements, major motor seizures, lethargy/stupor/coma, and diffuse weak-ness. Approximately one-third of patients with a diagnosis of encephalopathy may have had coexisting aseptic menin gitis syndrome.

Signs and symptoms of the aseptic meningitis syndrome de-scribed in association with the use of ORTHOCLONE OKT3 have included: fever, headache, meningismus (stiff neck), and photophobia. Diagnosis is confirmed by cerebrospinal fluid (CSF) analysis demonstrating leukocytosis with pleo-cytosis, elevated protein and normal or decreased glucose with negative viral, bacterial, and fungal cultures. The pos-sibility of infection should be evaluated in any immunosuppressed transplant patient with clinical findings suggesting meningitis. Approximately one-third of the patients with a diagnosis of aseptic meningitis had coexisting signs and symptoms of encephalopathy. Most patients with the aseptic meningitis syndrome had a benign course and recovered without any permanent sequelae during therapy or subse quent to its completion or discontinuation. However, be cause meningitis is a frequent infection encountered in pediatric allograft recipients, and the immunosuppression associated with transplantation increases the risk of opporassociated with transparated in increases the risk of oppor-tunistic infection, pediatric patients with signs or symptoms suggestive of meningeal irritation while receiving ORTHOCLONE OKT3 should have lumbar punctures per-formed to rule out an infectious etiology. (See: PRECAU-TIONS: Pediatric Use.)

Signs or symptoms of encephalopathy, meningitis, seizures, and cerebral edema, with or without headache, typically have been reversible. Headache, aseptic meningitis, sei zures, and less severe forms of encephalopathy resolved in most patients despite continued treatment with ORTHOCLONE OKT3. However, some events resulted in permanent neurologic impairment.

The following additional central nervous system events have each been reported: irreversible blindness, impaired vision, quadri- or paraparesis/plegia, cerebrovascular accident (hemiparesis/plegia), aphasia, transient ischemic at-tack, subarachnoid hemorrhage, palsy of the VI cranial nerve, hearing decrease, and deafness.

Patients who may be at greater risk for CNS adverse experiences include those; with known or suspected CNS disorders (e.g., history of seizure disorder, etc.); with cerebrovas-cular disease (small or large vessel); with conditions having associated neurologic problems (e.g., head trauma, uremia, infection, fluid and electrolyte disturbance, etc.); with un-derlying vascular diseases; or who are receiving a medication concomitantly that may, by itself, affect the central ner-vous system. (See: WARNINGS, PRECAUTIONS and ADVERSE EVENTS: Cytokine Release Syndrome.) Anaphylactic Reactions

Serious and occasionally fatal, immediate (usually within 10 minutes) hypersensitivity (anaphylactic) reactions have ormatics) personal in patients treated with ORTHOCLONE OKT3. Manifestations of anaphylaxis may appear similar to manifestations of the Cytokine Release Syndrome (described above). It may be impossible to determine the mechanism responsible for any systemic reaction(s). Reactions attributed to hypersensitivity have been reported less frequently than those attributed to cytokine release. Acute hypersensitivity reactions may be character-ized by: cardiovascular collapse, cardiorespiratory arrest loss of consciousness, hypotension/shock, tachycardia, tingling, angioedema (including laryngeal, pharyngeal, or fa-

Serious allergic events, including anaphylactic or anaphylactoid reactions, have been reported in patients re-exposed to ORTHOCLONE OKT3 subsequent to their initial course of therapy. Pretreatment with antihistamines and/or steroids may not reliably prevent anaphylaxis in this setting. Possible allergic hazards of retreatment should be weighed against expected therapeutic benefits and alternatives. If a patient is retreated with ORTHOCLONE OKT3, it is particularly important that epinephrine and other emergency life-support equip should be immediately available.

If hypersensitivity is suspected, discontinue the drug immediately; do not resume therapy or re-expose the patient to ORTHOCLONE OKT3. Serious acute hypersensitivity re-actions may require emergency treatment with 0.3 mL to 0.5 mL aqueous epinephrine (1:1000 dilution) subcutane ously and other resuscitative measures including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated. (See: PRECAUTIONS: Cytokine Release Syndrome vs. An-aphylactic Reactions; ADVERSE EVENTS: Hypersensitivity Reactions)

Consequences of Immunosuppression

Serious and sometimes fatal infections and neoplasias have been reported in association with all immunosuppressive therapies, including those regimens containing ORTHOCLONE OKT 3.

Infections: ORTHOCLONE OKT3 is usually added to iming the degree of immunosuppression. This is used any augment-ing the degree of immunosuppression. This increase in the total amount of immunosuppression may alter the spectrum of infections observed and increase the risk, the severity, and the morbidity of infectious complications. During the first month post-transplant, patients are at greatest risk for Into instant post-transplant, patients are a greatest risk for the following infections: (1) those present prior to trans-plant, perhaps exacerbated by post-transplant immunosup-pression; (2) infection conveyed by the donor organ; and (3) the usual post-operative urinary tract, intravenous line related, wound, or pulmonary infections due to bacterial pathogens. (See: ADVERSE EVENTS: Infections.)

Approximately one to six months post-transplant, patients are at risk for viral infections [e.g., cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), etc.] which produce serious systemic disease and which also in-crease the overall state of immunosuppression.

Reactivation (1 to 4 months post-transplant) of EBV and CMV has been reported. When administration of an antilymphocyte antibody, including ORTHOCLONE OKT3, is followed by an immunosuppressive regimen including cyclosporine, there is an increased risk of reactivating CMV cyclosporine, there is an increased risk of reactivating CMV and impaired ability to limit its proliferation, resulting in symptomatic and disseminated disease. EBV infection, ei-ther primary or reactivated, may play an important role in the development of post-transplant lymphoproliferative disorders. (See: WARNINGS and ADVERSE EVENTS: Neoplasia.)

In the pediatric transplant population, viral infections often include pathogens uncommon in adults, such as varicella zoster virus (VZV), adenovirus, and respiratory syncytial vi-rus (RSV). A large proportion of pediatric patients have not been infected with the herpes viruses prior to transplanta-tion and, therefore, are susceptible to developing primary infections from the grafted organ and/or blood products.

Anti-infective prophylaxis may reduce the morbidity associated with certain potential pathogens and should be consid-ered for pediatric and other high-risk patients. Judicious use of immunosuppressive drugs, including type, dosage, and duration, may limit the risk and seriousness of some opportunistic infections. It is also possible to reduce the risk of serious CMV or EBV infection by avoiding transplanta-tion of a CMV-seropositive (donor) and/or EBV-seropositive (donor) organ into a seronegative patient.

Neoplasia: As a result of depressed cell-mediated immunity from immunosuppressive agents, organ transplant pa-tients have an increased risk of developing malignancies. This risk is evidenced almost exclusively by the occurrence of lymphoproliferative disorders, squamous cell carcinomas of the skin and lip, and sarcomas. In immunosuppressed patients, T cell cytotoxicity is impaired allowing for transfor-mation and proliferation of EBV-infected B lymphocytes. Transformed B lymphocytes are thought to initiate oncogen-esis, which ultimately culminates in the development of most post-transplant lymphoproliferative disorders. Patients, especially pediatric patients, with primary EBV in-fection may be at a higher risk for the development of EBVassociated lymphoproliferative disorders. Data support an association between the development of lymphoproliferative disorders at the time of active EBV infection and ORTHOCLONE OKT3 administration in pediatric liver al-lograft recipients. (See: ADVERSE EVENTS Infections, Neonlasia)

Following the initiation of ORTHOCLONE OKT3 therapy, patients should be continuously monitored for evidence of lymphoproliferative disorders through physical examination and histological evaluation of any suspect lymphoid tissue. Close surveillance is advised, since early detection with subsequent reduction of total immunosuppression may re sult in regression of some of these lymphoproliferative dis-orders. Since the potential for the development of lymphoproliferative disorders is related to the duration and extent atensity) of total immunosuppression, physicians are ad-

Lilly Exhibit 1255, Page 32 of 39

Orthoclone OKT 3-Cont.

vised: to adhere to the recommended dosage and duration of ORTHOCLONE OKT3 therapy; to limit the number of courses of ORTHOCLONE OKT3 and other anti- T lymphocyte antibody preparations administered within a short period of time; and, if appropriate, to reduce the dosage(s) of immunosuppressive drugs used concomitantly to the lowest level compatible with an effective therapeutic response. (See: DOSAGE AND ADMINISTRATION.)

A recent study examined the incidence of non-Hodgkin's lymphoma (NHL) among 45,000 kidney transplant recipients and over 7,500 heart transplant recipients. This study suggested that all transplant patients, regardless of the immunosuppressive regimen employed, are at increased risk of NHL over the general population. The relative risk was highest among those receiving the most aggressive regimens.

The long-term risk of neoplastic events in patients being treated with ORTHOCLONE OKT3 has not been determined.

PRECAUTIONS

General

When using combinations of immunosuppressive agents the dose of each agent, including ORTHOCLONE OKT[®]2, should be reduced to the lowest level compatible with an effective therapeutic response so as to reduce the potential for and severity of infections and malignant transformations. Fever: If the temperature of the patient exceeds 37.8°C (100°F), it should be lowered by antipyretics before administration of each dose of ORTHOCLONE OKT3. The possibility of infection should be evaluated.

Severe Cytokine Release Syndrome Versus Anaphylactic Re actions: It may not be possible to distinguish between an acute hypersensitivity reaction (e.g., anaphylaxis, angioedema, etc.) and the Cytokine Release Syndrome. Poten tially serious signs and symptoms having an immediate onset (usually within 10 minutes) following administration of ORTHOCLONE OKT3 are probably due to acute hyper sensitivity. If hypersensitivity is suspected, discontinue the drug immediately; do not resume therapy or re-expose the patient to ORTHOCLONE OKT3. Clinical manifestations beginning approximately 30 to 60 minutes (or later) following administration of ORTHOCLONE OKT3 are more likely cytokine-mediated. (See: WARNINGS: Cytokine Release

Syndrome Anaphylactic Reactions.) Central Nervous System Events: Since some seizures (and other serious central nervous system events) following ORTHOCLONE OKT3 administration have been lifethreatening, anti-seizure precautions (e.g., an airway ready for use, if needed) should be taken. (See: WARNINGS and ADVERSE EVENTS: Central Nervous System Events.)

Infection/Viral-Induced Lymphoproliferative Disorders: If infection or a viral induced lymphoproliferative disorder occurs, culture or biopsy as soon as possible, promptly institute anonopriate anti-infective therapy, and (if possible) reduce/discontinue immunosuppressive therapy. (See: WARNINGS, ADVERSE EVENTS.) Low Protein-Binding Filter: Use a low protein-binding 0.2

(See: ADMINISTRATION INSTRUCTIONS.)

See: ADMINISTRATION INSTRUCTIONS) Sensitization: ORTHOCLONE OKTIS is a mouse (immuno-globulin) protein that can induce human anti-mouse anti-body production (i.e., sensitization) in some patients follow-ing exposure; a titer >1:1000 is a contraindication for use. (See: WARNINGS, ADVERSE EVENTS.)

(See: WARNINGS, ADVERSE EVENIS.) In the initial clinical trials using low doses of prednisone and azathioprine during ORTHOCLONE OKT3 therapy for renal allograft rejection, antibodies to ORTHOCLONE OKT3 were observed with an incidence of 21% (n=43) for IgM, 86% (n=43) for IgG and 29% (n=35) for the distribution of the temperature of the distribution of the dist IgE. The mean time of appearance of IgG antibodies was 20 ± 2 days (mean \pm SD). Early IgG antibodies appeared towards the end of the second week of treatment in 3% (n=86) of the patients

Subsequent clinical experience has shown that the dose, du ration, and type of immunosuppressive medications used in combination with ORTHOCLONE OKT3 may affect both the incidence and magnitude of the host antibody response Furthermore, immunosuppressive agents used concom-tantly with ORTHOCLONE OKT3 (i.e., steroids, azathio-prine, prednisone, or cyclosporine) have altered the time course of anti-mouse antibody development and the speci-ficity of the antibodies formed (i.e., idiotypic, isotypic, allotypic). Thrombosis: As with other immunosuppressive therapies

arterial, enous, and capillary thromboses of allografts and other vascular beds (e.g., heart, lungs, brain, bowel, etc.) have been reported in patients treated with ORTHOCLONE OKT3. In addition, microangiopathic changes (e.g., platelet microthrombi) in the renal allograft associated in some patients with microangiopathic hemolytic anemia have been reported. This was observed in 5 of 93 (5%) patients receiving doses above the recommended dose. The relationship to dose remains uncertain; however, the relative risk appears to be greater with doses above the recommended dose. Patients with a history of thrombosis or underlying vascular disease should be given Information for Patients: Patients should be advised:

- of the signs and symptoms associated with the Cytokine Release Syndrome and the potentially serious nature of this syndrome (e.g., systemic, cardiovascular, central nervous system events)
- to seek medical attention for skin rash, urticaria, rapid heart beat, respiratory distress, dysphagia, or any swell-ing suggesting an allergic reaction or angioedema. that ORTHOCLONE OKT3 may impair mental alertness
- and coordination and may effect the ability to operate an automobile or machinery.
- of other risks associated with the use of ORTHOCLONE OKT3 (See: BOXED WARNING; WARN-INGS; PRECAUTIONS; ADVERSE EVENTS.)

Laboratory Tests: The following tests should be monitored prior to and during ORTHOCLONE OKT[®]3 therapy:

Renal: BUN, serum creatinine, etc.;
Hepatic: transaminases, alkaline phosphatase, bilirubin;

- · Hematopoietic: WBCs and differential, platelet count
- · Chest X-ray within 24 hours before initiating ORTHOCLONE OKT3 treatment to rule out heart failure or fluid overload.

 Blood Tests: Periodic assessment of organ system func tions (renal, hepatic, and hematopoietic) should be performed.

During therapy with ORTHOCLONE OKT3: In adults During therapy with ORTHOCLONE ORTS: in adults, per-iodic monitoring to ensure plasma ORTHOCLONE ORT3 levels (>800 ng/mL) or T cell clearance (DB positive T cells <25 cells/mm³) is recommended. In pediatric patients, both plasma ORTHOCLONE ORT3 levels (=800 ng/mL) and T plasma OKTHOCLONE OKT3 levels (2800 ng/ml.) and T cell clearance (CD3 positive T cells <25 cells/nm³) should be monitored daily (See; CLINICAL PHARMACOLOGY.) Carcinogenesis: Long-term studies have not been per-formed in laboratory animals to evaluate the carcinogenic potential of ORTHOCLONE OKT3; however, neoplasia has been reported in patients receiving this product. (See WARNINGS and ADVERSE EVENTS: Neoplasia.)

Pregnancy Category C: Animal reproductive studies have not been conducted with ORTHOCLONE OKT3. It is also not known whether ORTHOCLONE OKT3 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. However, ORTHOCLONE OKT3 is an IgG antibody and may cross the human placenta. The effect on the fetus of the release of cytokines and/or immunosuppression after treatment with ORTHOCLONE OKT3 is not known. ORTHOCLONE OKT3 should be given to a pregnant woman only if clearly needed. If this drug is used preparat woman only in clearly needed. If this drug is used during pregnancy, or the patient becomes pregnant while taking this drug, the patient should be apprised of the po-tential hazard to the fetus. (See: CONTRAINDICATIONS, WARNINGS, and ADVERSE EVENTS.)

Nursing Mothers: It is not known whether ORTHOCLONE OKT3 is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse events/oncogenesis shown for ORTHOCLONE OKT3 in human studies, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See: CONTRAINDICATIONS.)

House: Use: Safety and effectiveness have been estab-lished in infants (1 mo. up to 2 yr.); children (2 yr. up to 12 yr.); and adolescents (12 yr. up to 16 yr.). Use of ORTHOCLONE OKT3 in these age groups is supported by

clinical studies that included adults and pediatric patients. In those studies, the safety and efficacy of ORTHOCLONE OKT3 in pediatric patients receiving renal or hepatic transplants was similar to that in the overall co hort. There were insufficient data to compare the safety and efficacy of ORTHOCLONE OKT3 in pediatric patients in a study of patients receiving cardiac transplants. Additional pharmacokinetic, pharmacodynamic, and clinical studies in infants, children, and adolescents have been reported in published literature.

Pediatric patients are known to have higher CD3 lympho cyte counts than adults; therefore, progressively higher doses of ORTHOCLONE OKT3 are often required to achieve therapeutic levels of lymphocyte clearance. (See: DOSAGE AND ADMINISTRATION.)

Specific Safety Concerns in Pediatric Patients Deaths Due to Cerebral Hernitation: The postmarketing data base indicates that pediatric patients may be at increased risk of developing cerebral edema with or without herniation compared to adults. In the period between 1986 and 1996, twenty-five cases (6 in pediatric patients) of cerebral edema were identified with subsequent cerebral herniation and death in five cases (4 in pediatric patients). Herniation in the pediatric patients and one 19 year old subject occurred within a few hours to one day: after the first dose. (2.5 or 5 mg) of ORTHOCLONE OKT3 administered in the investigational setting for prophylaxis of renal allograft rejection. All pediartic patients and especially those receiving a renal allo graft must be carefully evaluated for fluid retention and hy-pertension before the initiation of ORTHOCLONE OKT3 therapy. (See: WARNINGS: Cytokine Release Syndrome; DOSAGE AND ADMINISTRATION: General.) Patients should be closely monitored for neurologic symptoms during the first twenty four (24) hours following each of the first few doses of ORTHOCLONE OKT3 injection. Other Serious Central Nervous System Adverse Events:

include status epilepticus, cerebral edema, diffuse encephainclude status epilepticus, cerebral edema, diffuse encepha-lopathy, cerebritis, seizures, cortical dysfunction, and intra-cranial hemorrhage. Permanent neurologic impairments (e.g., blindness, deafness, paralysis) have been reported rarely. Because meningitis is a frequent infection encoun-tered in pediatric allograft recipients, and the immunosup-pression associated with transplantation increases the risk of opportunistic infection, patients with meningeal irrita-tion following treatment with ORTHOCLONE OKT3 ther-apy should be evaluated with lumbar puncture as early as possible to rule out an infectious etiology. *Viral Infection:* Viral Infection:

Viral injection: The overall incidence of infections appeared to be similar in pediatric patients compared to the overall population stud-ied. In the pediatric population, viral infections often in-clude pathogens uncommon in adults, such as varicella zoster virus (VZV), adenovirus, enterovirus, parainfluenza virus, and respiratory synoctial virus (RSV). In addition, many viral diseases often manifest differently in pediatric patient than that do in adults. Resource a lorge properties patients that they do in adults. Because a large proportion of pediatric patients have not been infected by herpes vi-ruses (e.g., EBV, HSV, CMV) prior to transplantation they may be more susceptible to acquiring primary infections from the grafted organ and/or blood products when immunosuppressed. Antiviral prophylactic therapy may be partic ularly useful in these high risk pediatric patients. (See: AD-VERSE EVENTS: Infections.) Neonlasia[.]

Neoplasta: Patients with primary EBV infection may be at higher risk for the development of EBV-associated lymphoproliferative disorders. There are data to support an association between the development of lymphoproliferative disorders at the time of active EBV infection and ORTHOCLONE OKT[®]3 administration in pediatric liver allograft recipients. Antiviral prophylactic therapy may be particularly useful in these

high risk pediatric patients. Gastrointestinal Fluid Losses:

Parenteral hydration may be required for gastrointestinal fluid loss secondary to diarrhea and/or vomiting resulting from the "Cytokine Release Syndrome"

Prombosis: Pediatric patients may be at an increased risk of thrombosis. Pediatric patients weighing less than 15 kg are at high-risk for hepatic artery thrombosis. Thrombosis has been reported in pediatric transplant recipients treated with ORTHOCLONE OKT3. A number of factors, including sur-gical technique, the presence of a hypercoaguable state, and great technique, use presence of a hyperconguance scale, and the absence of prior dialysis experience may be relevant to the pathophysiology of the increased risk of thrombosis. (See: BOXED WARNING; WARNINGS; PRECAUTIONS; ADVERSE EVENTS; DOSAGE AND ADMINISTRATION.)

ADVERSE EVENTS

Cytokine Release Syndrome In controlled clinical trials for treatment of acute renal allograft rejection, patients treated with ORTHOCLONE OKT3 plus concomitant low-dose immunosuppressive therapy (primarily azathioprine and cortico-steroids) were observed to have an increased incidence of adverse experiences during the first two days of treatment, as compared with the group of patients receiving azathio-prine and high-dose steroid therapy. During this period the majority of patients experienced pyrexia (90%), of which 19% were 40.0°C (104°F) or above, and chills (59%). In addition, other adverse experiences occurring in 8% or more of the patients during the first two days of ORTHOCLONE OKT3 therapy included: dyspnea (21%), nausea (19%), vomiting (19%), chest pain (14%), diarrhea (14%), tremor (13%), wheezing (13%), headache (11%), tachycardia (10%), rigor (8%), and hypertension (8%). A sim-ilar spectrum of clinical manifestations has been observed in open clinical studies and in post-marketing experience involving patients treated with ORTHOCLONE OKT3 for rejection following renal, cardiac, and hepatic transplanta-

Additional serious and occasionally fatal cardiorespiratory manifestations have been reported following any of the first few doses. (See: WARNINGS: Cytokine Release Syndrome ADVERSE EVENTS: Cardiovascular, Respiratory.)

In the acute renal allograft rejection trials, potentially fatal pulmonary edema had been reported following the first two doses in less than 2% of the patients treated with ORTHO-CLONE OKT3. Pulmonary edema was usually associated with fluid overload. However, post-marketing experience re-vealed that pulmonary edema has occurred in patients who appeared to be euvolemic, presumably as a consequence of cytokine-mediated increased vascular permeability ("leaky capillaries") and/or reduced myocardial contractility/compli ance (i.e., left ventricular dysfunction). (See: WARNINGS: Cytokine Release Syndrome DOSAGE AND ADMINISTRA-TION)

Infection

In the controlled randomized renal allograft rejection trial In the controlled randomized renal alogram rejection trial conducted before cyclosporine was marketed, the most com-mon infections during the first 45 days of ORTHOCLONE OKT3 therapy were due to herpes simplex virus (27%) and cytomegalovirus (19%). Other severe and life-threatening infections were Staphylococcus epidermidis (5%), Pneumocystis carinii (3%), Legionella (2%), Cryptococ-cus (2%), Serratia (2%) and gram-negative bacteria (2%) The incidence of infections was similar in patients treated with ORTHOCLONE OKT3 and in patients treated with high-dose steroids.

In a clinical trial of acute hepatic allograft rejection, refrac-

during the first 45 days of the study were cytomegalovirus (16% of patients, of which 43% of infections were severe), fungal infections <math display="inline">(15% of patients, of which 30% were severe)vere), and herpes simplex virus (8% of patients, of which 10% were severe). Other severe and life-threatening infections were gram-positive infections (9% of patients), gramnegative infections (8% of patients), viral infections (2% of negative infections (5% of patients), what infections (2% of patients), and Legionella (1% of patients). In another trial studying the use of ORTHOCLONE OKT[®]3 in patients with hepatic allografts, the incidence of fungal infections was 34% and infections with the herpes simplex virus was 31%. In a clinical trial studying the use of ORTHOCLONE OKT3 in patients with acute cardiac rejection refractory to conventional treatment, the most common infections in the ORTHOCLONE OKT3 group reported during the first 45 days of the study were herpes simplex virus (5% of patients, of which 20% were severe), fungal infections (4% of patients, of which 75% were severe), and cytomegalovirus (3% of patients, of which 33% were severe). No other severe or lifethreatening infections were reported during this period. In a retrospective analysis of pediatric patients treated for acute hepatic rejection, the most common infections reported in patients treated with ORTHOCLONE OKT3 ther-apy were due to bacterial infections (47%), fungal infections (21%), cytomegalovirus (19%), herpes simpler virus (15%), adenovirus (8%), and Epstein-Barr virus (8%). The overall rates of viral, fungal, and haterial infections were similar in patients treated with ORTHOCLONE OKT3 (n=53) and in patients whose rejection was treated with steroids alone (n=27). In another study of 149 pediatric liver allograft pa-tients where 59 episodes of steroid-resistant rejection were treated with ORTHOCLONE OKT3, the incidence of invasive cytomegalovirus infection was higher in patients re-ceiving ORTHOCLONE OKT3 than in those receiving steroids alone

Clinically significant infections (e.g., pneumonia, sepsis, etc.) due to the following pathogens have been reported: Bacterial: Clostridium species (including perfringens), Cory-

- nebacterium, Enterococcus, Enterobacter aero-genes, Escherichia coli, Klebsiella species, Lactobacillus, Legionella, Listeria monocytogenes, Mycobacteria species, Nocardia asteroides, Pro-teus species, Providencia species, Pseudomonas aeruginosa, Serratia species, Staphylococcus spe-cies, Streptococcus species, Yersinia enterocolitica,
- and other gram-negative bacteria. Fungal.* Aspergillus, Candida, Cryptococcus, Dermatophytes:
- Protozoa: Pneumocystis carinii, Toxoplasma gondii, Viral:
- cytomegalovirus* (CMV), Epstein-Barr virus* (EBV), herpes simplex virus* (HSV), hepatitis viruses, varicella zoster virus (VZV), adenovirus, enterovirus, respiratory syncytial virus (RSV), parainfluenza virus.

As a consequence of being a potent immunosuppressive, the incidence and severity of infections with designated(*) pathogens, especially the herpes family of viruses, may be increased. (See: WARNINGS: Infections.) Neoplasia

In patients treated with ORTHOCLONE OKT3, post-trans-plant lymphoproliferative disorders have ranged from lymphadenopathy or benign polyclonal B cell hyperplasias to malignant and often fatal monoclonal B cell lymphomas. In post-marketing experience, approximately one-third of the lymphoproliferations reported were benign and twothirds were malignant. Lymphoma types included: B cell, large cell, polycional, non-Hodgkin's, lymphocytic, T cell, Burkitt's. The majority were not histologically classified Malignant lymphomas appear to develop early after trans-plantation, the majority within the first four months posttreatment. Many of these have been rapidly progressive. Some were fulminant, involving the allografted organ and were widely disseminated at the time of diagnosis. Carcinomas of the skin included: basal cell, squamous cell, sarcoma, melanoma, and keratoacanthoma. Other neoplasms infrequently reported include: multiple myeloma, leukemia, car-noma of the breast, adenocarcinoma, cholangiocarcinoma,

ant¹ recurrences of pre-existing hepatoma and renal cell car-cinome³. (See: WARNINGS: Neoplasia.) Hypersignsitivity Reactions

Reported adverse reactions resulting from the formation of antibodies to ORTHOCLONE OKT3 have included antigenantibodies to ORTHOCLONE OKT3 have included antigen-antibody (immune complex) mediated syndromes and IgE-mediated reactions. Hypersensitivity reactions have ranged from a mild, self-limited rash or pruritus to severe, lifethreatening anaphylactic reactions/shock or angioedema (including: swelling of lips, eyelids, laryngeal spasm and airway obstruction with hypoxia). (See: WARNINGS: Anaphylactic Reactions.)

Other hypersensitivity reactions have included: ineffective ness of treatment, serum sickness, arthritis, allergic interstitial nephritis, immune complex deposition resulting in glomerulonephritis, vasculitis (including temporal and retinal), and eosinophilia.

Adverse Reactions by Body System

Adverse events reported in greater than or equal to 1% of

lody System	Incidence (%)
Autonomic Nervous System Disorders	
Diaphoresis Tasodilation	7
Body as a Whole, General Disorders	an fairse
Inorexia	4
Asthenia Chills	10 43
Satigue	- 4-0 - 11 91-∞1
ethargy	6
Malaise	5,
Pain, trunk Pyrexia	6 77
Cardiovascular Disorders, General	
Arrhythmia	4
Bradycardia Typertension	4 19
lypotension	25
Pain, chest	9 26
Fachycardia Vascular Occlusion	20
Central & Peripheral Nervous System Disc	orders
Convulsions	1
Dizziness Headache	28
Meningitis	1
Iremor	14
Gastrointestinal System Disorders Diarrhea	37
Nausea	32
Paín, abdominal	6
Pain, GI Vomiting	- 7. 25
Hematopoietic Disorders	277 919
Anemia	2
Leukocytosis Thrombocytopenia	2
Metabolic and Nutritional Disorders	
Edema	12
Musculoskeletal System Disorders Arthralgia	7
Myalgia	1
Psychiatric Disorders	6
Confusion Depression	3
Nervousness	- 5
Somnolence Renal Disorders	2
Renal Dysfunction	3
Respiratory System Disorders	 A 10 A 10
Abnormal Chest Sound Dyspnea	10
Hyperventilation	7
Hypoxia	1
Pneumonia Pulmonary Edoma	1
Pulmonary Edema Respiratory Congestion	4
Wheezing	6
Skin and Appendages Disorders Pruritus	7
Rash	14
Rash Erythematous	2
Special Senses Photophobia	1
Tinnitus	1
White Cell and Reticuloendothelial Syste	
Leukopenia	7
Selected Adverse Events Reported In Cl	inical Trials (<
incidence, n=393): Cardiovascular Disorders, General: An	dina Cardiac
rest, Fluctuation in Blood Pressure, Hear	t Failure, Myoc
dial Infarction, Shock, Thrombosis.	1944 - AN 197
Central and Peripheral Nervous System D	
Encephalopathy, Epilepsy, Hypotonia. Gastrointestinal Disorders: Gastroi	ntestinal Hem
rhage.	a state of a
Hemapoietic Disorders: Coagulation	Disorder, Lym
adenopathy, Lymphopenia: Hepatobiliary: Hepatitis, SGOT Incr	eased, SGPT
creased.	and the state of the state
Psychiatric Disorders: Hallucination	s, Mood Chang
Paranoia, Psychosis. Renal Disorders: Anuria, Oliguria.	алан (талан талан та Эми талан талан талан талан талан талан талан талак
Respiratory System Disorders: Apnea,	Pneumonitis.
Special Senses Conjunctivitis Hearing	Decrease
Worldwide Postmarketing Experience Events Listed Alphabetically: Body as a Whole, General Disorders:	• Body Syster
Body as a Whole, General Disorders:	Fever (includ
spiking temperatures as high as 107°F), Cardiovascular Disorders: Cardiovascu	riu-like Synaro

Central and refupinal Networks System Disorders. Agen-tion, Aphasia, Asterixis, Cerebritis, Cerebral Edema, Cere-bral Herniation, Creebrovascular Accident, CNS Infection, CNS Malignancy, Cranial Nerve VI Paisy, Encephalitis, Hy-perreflexia, Involuntary Movements, Intracranial Hemorrhage, Impaired Cognition, Myoclonus, Obnubilation, Pare-

In a post-marketing survey involving 214 renal transplant patients, the incidence of aseptic meningitis syndrome was 6%. Fever (89%), headache (44%), neck stiffness (14%), and photophobia (10%) were the most commonly reported symp-toms; a combination of these four symptoms occurred in 5% of patients

Between 1987 and 1992, 75 post-marketing reports have described seizures, averaging about 12 per year, and including 23 fatalities. More than two-thirds of these reports (53) were of domestic spontaneous origin, and their age and sex distributions were broad. Post-licensure reports generally provide insufficient data to allow accurate estimation of risk or of incidence. Gastrointestinal Disorders: Bowel Infarction.

Hematopoietic Disorders: Aplastic anemia, Arterial, Venous and Capillary Thrombosis of allografts and other vascular beds e.g., heart, lung, brain and bowel etc., Dissemi-nated Intravascular Coagulation, Microangiopathic Changes (e.g., platelet microthrombi), Microangiopathic Hemolytic Anemia, Neutropenia, Pancytopenia. Hepatobiliary: Hepatitis ör Hepato/splenomegaly, usually

secondary to viral infection or lymphoma. Musculoskeletal Disorders: Arthritis, Stiffness/Aches/ Pains.

Renal Disorders: Azotemia, Abnormal Urinary Cytology including exfoliation of damaged lymphocytes, collecting duct cells and cellular casts, Delayed Graft Function, Renal Insufficiency/Renal Failure, usually transient and reversible and occasionally in association with Cytokine Release

Respiratory System Disorders: Adult Respiratory Disstress Syndrome; Respiratory Arrest, Respiratory Failure. Skin and Appendages: Erythema, Flushing, Stevens-Johnson Syndrome, Urticaria.

Special Senses: Blindness, Blurred Vision, Deafness, Dip-lopia, Otitis Media, Nasal and Ear Stuffiness, Papilledema. OVERDOSAGE

Symptoms of overdosage with ORTHOCLONE OKT[®]3 may include hyperthermia, severe chills, myalgia, vomiting, di-arrhea, edema, oliguria, pulmonary edema, and acute renal arrnea, ecema, oigurta, plumonary ecema, and accue renai failure. A high incidence (5%) of microangiopathic hemolytic anemia/HUS syndrome in patients receiving 10 mg per day of ORTHOCLONE OKT3 was also reported. In the event of acute overdosage with ORTHOCLONE OKT3, the patient should be carefully observed and given symptomatic and supportive treatment.

DOSAGE AND ADMINISTRATION

Adults The recommended dose of ORTHOCLONE OKT3 for the treatment of acute renal, steroid-resistant cardiac, or ste-roid-resistant hepatic allograft rejection is 5 mg per day in a single (bolus) intravenous injection in less than one minute for 10 to 14 days. For acute renal rejection, treatment should begin upon diagnosis. For steroid-resistant cardiac or hepatic allograft rejection, treatment should begin when the treating physician deems a rejection has not been re-versed by an adequate course of corticosteroid therapy. (See: CLINICAL PHARMACOLOGY; PRECAUTIONS: Sensitization, Laboratory Tests.)

Pediatric Patients

Penatric rateens The initial recommended dose is 2.5 mg per day in pediatric patients weighing less than or equal to 30 kg and 5 mg per day in pediatric patients weighing greater than 30 kg in a single (bolus) intravenous injection in less than one minute for 10 to 14 days. Daily increases in ORTHOCLONE OKT3 doses (i.e., 2.5 mg increments) may be required to achieve depletion of CD3 positive cells (<25 cells/mm³) and ensure therapeutic ORTHOCLONE OKT3 serum concentrations (> 800 ng/mL). Pediatric patients may require augmenta-tion of the ORTHOCLONE OKT3 dose. For acute renal rejection, treatment should begin upon diagnosis. For steroid-resistant cardiac or hepatic allograft rejection, treatment should begin when the treating physician deems a rejection has not been reversed by an adequate course of corticoster-oid therapy. (See: CLINICAL PHARMACOLOGY, PRE-CAUTIONS; Laboratory Tests; Pediatric Use.)

General General For the first few doses, patients should be monitored in a facility equipped and staffed for cardiopulmonary resuscita-tion (CPR). Patients receiving subsequent doses of ORTHOCLONE OKT3, should also be monitored in a facil-ity equipped and staffed for CPR. Vital signs should be mon-itored frequently. Patients receiving ORTHOCLONE OKT3 should also be carefully monitored for signs and symptoms of Cutching Relaces Surfavers, next unlayer after the first of Cytokine Release Syndrome, particularly after the first few doses but also after a treatment hiatus with resumption of therapy. The patient's temperature should be lowered to <37.8°C (100°F) before the administration of any dose of ORTHOCLONE OKT3.

ORTHOCLONE ORT3. Prior to administration of ORTHOCLONE OKT3, the pa-tient's volume status should be assessed carefully. It is im-perative, especially prior to the first few doses, that there be no clinical evidence of volume overload, uncontrolled hyper-tension, or uncompensated heart failure. Patients should have a clear chest X-ray and should not weigh more than 3% above their minimum weight during the week prior to injection

To decrease the incidence and severity of Cytokine Release Syndrome, associated with the first dose of ORTHOCLONE OKT3, it is strongly recommended that methylprednisolone sodium succinate 8.0 mg/kg be adminOrthoclone OKT 3-Cont.

istered intravenously 1 to 4 hours prior to the initial dose of ORTHOCLONE OKT3. Acetaminophen and antihistamines given concomitantly with ORTHOCLONE OKT3 may also help to reduce some early reactions. (See: WARNINGS and ADVERSE EVENTS: Cytokine Release Syndrome.) is a solution of the second state of the s ble with an effective therapeutic response in order to reduce the potential for malignancy and infections. Maintenance immunosuppression should be resumed approximately three days prior to the cessation of ORTHOCLONE OKT.⁹³ therapy. (See: WARNINGS and ADVERSE EVENTS: Infect

TIONS: Laboratory Tests; ADVERSE EVENTS: Hypersen sitivity Reactions.)

ADMINISTRATION INSTRUCTIONS

- 1. Before administration, ORTHOCLONE OKT3 should be inspected for particulate matter and discoloration. Be-cause ORTHOCLONE OKT3 is a protein solution, it may develop fine translucent particles (shown not to affect ootency).
- Potency).
 No bacteriostatic agent is present in this product. Adherence to aseptic technique is advised. Once the ampule is
- opened, use immediately and discard the unused portion. 3. Prepare ORTHOCLONE OKT3 for injection by drawing solution into a syringe through a low protein-binding 0.2 or 0.22 micrometer (µm) filter. Detach filter and attach a new needle for a single intravenous (bolus) injection.
- new needed for a single intravenous (bolus) injection. 4. Because no data is available on compatibility of ORTHOCLONE OKT3 with other intravenous sub-stances or additives, other medications/substances should not be added or infused simultaneously through the same intravenous line. If the same intravenous line is used for sequential infusion of several different drugs the line should be flushed with saline before and after in ction of ORTHOCLONE OKT3.
- 5. Administer ORTHOCLONE OKT3 as a single intrave nous (bolus) injection in less than one minute. Do not administer by intravenous infusion or in conjunction with other drug solutions.

HOW SUPPLIED

ORTHOCLONE OKT3 is supplied as a sterile solution in packages of 5 ampules (NDC 59676-101-01). Each 5 mL ampule contains 5 mg of muromonab-CD3. Storage: Store in a refrigerator at 2° to 8°C (36° to 46°F). DO NOT FREEZE OR SHAKE.

REFERENCES

- 1. Adair JC, Woodley SL, O'Connell JB, et al. Aseptic Men-
- Adati 3C, Woldey BJ, Count JD, et al. September ingitis following Cardiac. Transplantation: Clinical Characteristics and Relationship to Immunosuppressive . Regimen. Neurology 41:249–252, 1991. Chatenoud L, Legendre C, Ferran C, et al. Corticoster-oid Inhibition of the OKT3 Induced Cytokine-Related 2.
- Syndrome Dosage and Kinetics Prerequisites. Trans-plantation <u>51</u>:334–338, 1991. Cockfield SM, Preiksaitis J, Harvey E, Jones C, Herbert 3. D, Keown P, and Halloran PF, et al. Is Sequential Use of ALG and OKT3 in Renal Transplants Associated with an Increased Incidence of Fulminant Post Transplant
- Lymphoproliferative Disorders? Transplant. Proc. 23. 1106-1107, 1991.
- 1106-1107, 1991. Ettenger RB, Marik J, Rosenthal JT, et al. OKT3 for Re-jection Reversal in Pediatric Renal Transplantation. Clin. Transplantation 2:180-184, 1988. Gaston RS, Deierhoi MH, Patterson T, et al. OKT3 First-Dose Reaction: Association with T Cell Subsets and Cy-ter and Cyter and
- 5.
- tokine Release. Kid. International 39:141–148, 1991. Goldman M, Abramowicz D, DePauw L, et al. OKT3 6. Induced Cytokine Released Attenuation by High-Dose Methylprednisolone. Lancet 2:802-803, 1989. 7. Ortho Multicenter Transplant Study Group. A Random-
- Ortho Multicenter Transplant Study Group. A Random-ized Clinical Trail of OKT3 Monoclonal Anthibody for Acute Rejection of Cadaveric Renal Transplants. N. Engl. J. Med. 313:337-342, 1985.
 Penn I. The Changing Patterns of Posttransplant Malig-nancies. Transplant. Proc. 23:1101-1103,1991.
- Rubin RH and Tolkoff-Rubin NE. The Impact of Infec-tion on the Outcome of Transplantation. Transplant.
- Proc. 23:2068-2074, 1991.
 10. Schroder TJ, Ryckman FC, Hurtubise PE, et al. Immunological Monitoring During and Following OKT3 Ther-
- apy in Children. Clin. Transplantation 5:191-196, 1991. 11. Goldstein G, Fuccello AJ, Norman DJ, et. al.: OKT3
- Monoclonal Antibody Plasma Levels During Therapy and the Subsequent Development of Host Antibodies to
- and the Subsequent Development of rost Antorones to OKT3. Transplantation 42:607–611, 1986.
 Schroeder TJ, Michael AT, First MR, et al. Variations in Serum OKT3 Concentration Based Upon Age, Sex, Transplanted Organ, Treatment Regimen, and Anti-OKT3 Status. Therapeutic Drug Monitoring 16:861–977. 367, 1994.
- 30(7) 1354. 3. First MR, Schroeder TJ, Hurtubise PE, et al. Immune Monitoring During Retreatment with OKT3: Transplan. Proc. 21:1753-1754, 1989.

U.S.A. ORTHO BIOTECH © OBPLP 2001 Design and State (1) 631-10-191-4 Revised January 2003 0.0.20105<u>9</u> - area. () 1968

and and heater and the second second and the second s **PROCRIT**®

[prō-krif] (epoetin alfa) PROCRIT registered trademark of distributor FOR INJECTION

DESCRIPTION

Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid pro-genitors in the bone marrow. PROCRIT (Epoetin alfa), a 165 genitors in the bone marrow risochtri (byceni anay a rod amino acid glycoprotein marufacturied by recombinant DNA technology, has the same biological effects as endogenous erythropoietin.¹ It has a molecular weight of 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product con-tains the identical amino acid sequence of isolated natural ervthropoietin.

PROCRIT is formulated as a sterile, colorless, liquid in an isotonic sodium chloride/sodium citrate or a sodium chlo (IV) or subcutaneous (SC) administration.

Single-Dose, Preservative-Free Vial: 1 mL (2,000, 3,000) 4,000 or 10,000 Units/mL). Each 1 mL of solution contains 4,000 of 10,000 Unitsmin). Each 1 mb of solution Contains 2,000, 3,000, 4,000 or 10,000 Units of Espectin alfa, 2.5 mg Albumin (Human), 5.8 mg sodium citrate, 5.8 mg sodium chloride, and 0.06 mg citric acid in Water for Injection, USP (pH 6.9±0.3). This formulation contains no preservative. Single-Dose, Preservative-Free Vial: 1 mL (40,000 Units/

mL). Each 1 mL of solution contains 40,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.164 mg sodium phosphate monobasic monohydrate, 1.766 mg sodium phosphate diba-sic anhydrate, 0.696 mg sodium citrate, 5.78 mg sodium chloride, and 6.8 mcg citric acid in Water for Injection, USP (pH 6.9±0.3). This formulation contains no preservative. Multidose, Preserved Vial: 2 mL (20;000 Units, 10;000 Units/mL). Each 1 mL of solution contains 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol as preservative in Water for Injection, USP (pH 6.1±0.3).

Multidoše, Preserved Vial: 1 mL (20,000 Units/mL). Each 1 mL of solution contains 20,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol as preservative in Water for Injection, USP (pH 6.1±0.3). CLINICAL PHARMACOLOGY

Chronic Renal Failure Patients Endogenous production of erythropoietin is normally regu-lated by the level of tissue oxygenation. Hypoxia and anemia generally increase the production of erythropoietin, which in turn stimulates erythropoiesis.² In normal subjects, plasma erythropoietin levels range from 0.01 to 0.03 Units/mL, and increase up to 100 to 1000-fold during hyp-oxia or anemia.² In contrast, in patients with chronic renal failure (CRF), production of erythropoietin is impaired, and this erythropoietin deficiency is the primary cause of their anemia

Chronic renal failure is the clinical situation in which there is a progressive and usually irreversible decline in kidney is a progressive and usually inteversible decline in kioney function. Such patients may manifest the sequelae of renal dysfunction, including anemia, but do not necessarily re-quire regular dialysis. Patients with cmd-stage renal disease (ESRD) are those patients with CmF who require regular dialysis or kidney transplantation for survival.

marysis of kinney transplantation for survival. PROCRIT has been shown to stimulate erythropoiesis in anemic patients with CRF, including both patients on dial-ysis and those who do not require regular dialysis.⁴⁻¹³ The first evidence of a response to the three times weekly (T.I.W.) administration of PROCRIT is an increase in the re-(1.1. w) administration of 1 footh 1 is all interest in the re-ticulacyte count within 10 days, followed by increases in the red cell count, hemoglobin, and hematorit, usually within 2-6 weeks⁴-5 Because of the length of time required for erythropoiesis – several days for erythroid progenitors to be a several days for erythroid progenitors to be the several days for erythroid progenitors to be a several days for erythroid progenitors to b mature and be released into the circulation - a clinically cant increase in hematocrit is usually not observed in less than 2 weeks and may require up to 6 weeks in some patients. Once the hematocrit reaches the suggested target range (30-36%), that level can be sustained by PROCRIT therapy in the absence of iron deficiency and concurrent

The rate of hematocrit increase varies between patients and The rate of hematocrit increase wares between patients and is dependent upon the does of PROCRIT, within a therapeu-tic range of approximately 50-300 Units/kg (T.I.W.)⁴ A greater biologic response if not observed at doese exceeding 300 Units/kg (T.I.W.)⁵ Other factors affecting the rate and extent of response include availability of iron stores, the baseline hematocrit, and the presence of concurrent medical

Zidovudine-Treated HIV-Infected Patients

Zaovudinė-ireateo niv-infecteo ratienis Responsiveness to PROCRIT in HIV-infected patients is de-pendent upon the endogenous serum erythropoietin level prior to treatment. Patients with endogenous serum erythr-ropoietin levels \leq 500 mUnits/mL, and who are receiving a dose of zidovudine \leq 4,200 mg/week, may respond to DECORD

to PROCRIT therapy. In a series of four clinical trials in-volving 255 patients, 60% to 80% of HIV-infected patients treated with zidovudine had endogenous serum erythropoietin levels < 500 mUnits/mL. Response to PROCRIT in zidovudine-treated, HIV-infected

patients is manifested by reduced transfusion requirements

and increased hematocrit. <u>Cancer Patients on Chemotherapy</u> Anemia in cancer patients may be related to the disease it-self or the effect of concomitantly administered chemother-apeutic agents. PROCRIT has been shown to increase he matocrit and decrease transfusion requirements after the first month of therapy (months 2 and 3), in anemic cancer patients undergoing chemotherapy. A series of clinical trials enrolled 131 anemic cancer pa

tients who were receiving cyclic cisplatin- or non-cisplatinterns who were receiving cyclic tashalli or hor-tashadi containing chemotheray. Endogenous baseline serum erythropoietin levels varied among patients in these trails with approximately 75% (N=83/110) having endogenous serum erythropoietin levels ≤ 132 mUnits/mL, and approxinately 4% (N=4/110) of patients having endogenous serum erythropoietin lévels > 500 mUnits/mL. In general, patients with lower baseline serum erythropoietin levels responded more vigorously to PROCRIT than patients with higher baseline erythropoietin levels. Although no specific serum erythropoietin level can be stipulated above which patients would be unlikely to respond to PROCRIT therapy, treatment of patients with grossly elevated serum erythropoietin levels (e.g., > 200 mUnits/mL) is not recommended.

Pharmacokinetics Intravenously administered PROCRIT is eliminated at a Intravenously administered FAOCAT is semiminated at a rate consistent with first order kinetics with a circulating half-life ranging from approximately 4 to 13 hours in adult and pediatric patients with CRF.¹⁴⁻¹⁸ Within the therapeu-tic dose range, detectable levels of plasma erythropoietin are maintained for at least 24 hours. After subcutaneous administration of PROCRIT to patients with CRF, peak serum levels are achieved within 5-24 hours after administration and decline slowly thereafter. There is no apparent differ-ence in half-life between adult patients not on dialysis whose serum creatinine levels were greater than 3, and adult patients maintained on dialysis

In normal volunteers, the half-life of intravenously adminin contract volume s, the name of increases a contract of the second sec adolescents appears to be similar to that of adults. Limited data are available in neonates.¹⁷

It has been demonstrated in normal volunteers that the 10,000 U/mL citrate-buffered Epoetin alfa formulation and the 40,000 U/mL phosphate-buffered Epoetin alfa formula-tion are bioequivalent after subcutaneous administration of then are blocknown at the substantiate automatical automatical automatical states in the substantiate automatical states and the phosphate biffered Epoetin alfa formulation were 1.80 ± 0.7 U/mL and 19.0 ± 5.9 hours (mean \pm SD), respectively. The corresponding mean \pm SD values for the citrate-buffered Epoetin alfa formulation were $2.\pm 0.9$ U/mL and 16.3 ± 3.0 hours. There was minimal accumulation in serum after two weekly 750 Units/kg subcutaneous doses of Epoetin alfa.

INDICATIONS AND USAGE

Treatment of Anemia of Chronic Renal Failure Patients PROCRIT is indicated in the treatment of anemia associated with chronic renal failure, including patients on dialysis (end-stage renal disease) and patients not on dialysis. PROCRIT is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need to transfusions in these patients.

Non-dialysis patients with symptomatic anemia considered

for therapy should have a hematocrit less than 30%. PROCRIT is not intended for patients who require immedi-ate correction of severe anemia. PROCRIT may obviate the need for maintenance transfusions but is not a substitute for emergency transfusion.

Prior to initiation of therapy, the patient's iron stores should we evaluated. Transferrin saturation should be at least 20% and ferritin at least 100 ng/mL. Blood pressure should be adequately controlled prior to initiation of PROCRIT therapy, and must be closely monitored and controlled durin $_{\rm ag}$ processes.

PROCRIT should be administered under the guidar acc qualified physician (see "DOSAGE AND ADMINISTRA-TION")

Treatment of Anemia in Zidovudine-Treated HIV-Infected Patients

PROCRIT is indicated for the treatment of anemia related to therapy with zidovudine in HIV-infected patients. PROCRIT is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients. PROCRIT is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis or gastrointestinal bleeding, which should be managed appropriately.

PROCRIT, at a dose of 100 Units/kg three times per week, is effective in decreasing the transfusion requirement and in-creasing the red blood cell level of anemic, HIV-infected patients treated with zidovudine, when the endogenous serum

Lilly Exhibit 1255, Page 35 of 39

WHAT TO DO DURING THE MONTH

1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.

Do not skip pills even if you are spotting or bleeding be-tween monthly periods or feel sick to your stomach (nausea

2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND

WHEN YOU FINISH A WAY TO ANY TAKEN ANY TO ANY TAKEN ANY TAKEN'YA TAKEN ANY TAKEN'YA TAKEN'YA TAKEN'YA TAKEN'YA TAKEN'YA TAKENY TAKEN ANY TAKEN'YA TAKEN'YA TAKEN'YA TAKEN'YA TAKEN'YA TAKEN

WHAT TO DO IF YOU MISS PILLS

The pill may not be as effective if you miss white "active" pills, and particularly if you miss the first few or the last few white "active" pills in a pack. If you MISS 1 white "active" pill: 1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day. 2. You do not need to use a back-up birth control method if you bace say

Jou have sex. If you MISS 2 white "active" pills in a row in WEEK 1 OR WEEK 2 of your pack: 1. Take 2 pills on the day you remember and 2 pills the next

Then take 1 pill a day until you finish the pack.
 You MAY BECOME PREGNANT if you have sex in the 7

days after you miss pills. You MUST use another birth con-trol method (such as condoms, spermicide, or sponge) as a back-up for those 7 days.

back-up for those 7 days. If you MISS 2 white "active" pills in a row in THE 3rd WEEK: The Day 1 Starter instructions are for the 21-day pill pack only. The 28-day pill pack does not accommodate a DAY 1 START dosage regimen. The Sunday Starter instructions are for either the 21-day or 28-day pill pack. 1. If you are a Day 1 Starter: THROW OUT the rest of the pill pack and start a new pack that come day.

that same day. If you are a Sunday Starter:

Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a

new pack of pills that same day

2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth con-trol method (such as condoms, spermicide, or sponge) as a back-up for those 7 days.

If you MISS 3 OR MORE white "active" pills in a row (during the first 3 weeks):

The Day 1 Starter instructions are for the 21-day pill pack The Day i Stater institutions are no the Zirvay pin pack only. The Zs-day pill pack does not accommodate a DAY 1 START dosage regimen. The *Sunday Stater* instructions are for either the 21-day or 28-day pill pack.

1. If you are a Day 1 Starter:

THROW OUT the rest of the pill pack and start a new pack that same day.

If you are a Sunday Starter:

Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.

1. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or clinic because you might be pregnant. 3. You MAY BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms, spermicide, or sponge) as a back-up for those 7 days.

A REMINDER FOR THOSE ON 28-DAY PACKS

If you forget any of the 7 pink "reminder" pills in Week 4: THROW AWAY the pills you missed. Keep taking 1 pill each day until the pack is empty. You do not need a back-up method if you start your next pack on time.

FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO

ABOUT THE PILLS YOU HAVE MISSED Use a BACK-UP METHOD anytime you have sex. KEEP TAKING ONE PILL EACH DAY until you can reach your doctor or clinic. Pregnancy due to pill failure

Tremainly use to put faiture The incidence of pill faiture resulting in pregnancy is ap-proximately less than 1.0% if taken every day as directed, but average failure rates are 5%. If you do become pregnant, the risk to the fetus is minimal, but you should stop taking your pills and discuss the pregnancy with your doctor. Pregnancy after stopping the pill There may be some delay in becoming pregnant after you

stop using oral contraceptives, especially if you had irregu-lar menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy. There does not appear to be any increase in birth defects in

Overdosage Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your health-care provider or pharmacist. Other information Your health-care provider will take a medical and family

Your health-care provider will take a medical and family history before prescribing oral contraceptives and will ex-amine you. The physical examination may be delayed to an-other time if you request it and the health-care provider be-lieves that it is appropriate to postpone it. You should be reexamined at least once a year. Be sure to inform your health-care provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your health-care provider, because this is a time to determine if there are early signs of side effects of oral-contracentive use

This drug of a start of the sta control pills. HEALTH BENEFITS FROM ORAL CONTRACEPTIVES

HEALTH BENEFITS FROM ORAL CONTRACEPTIVES In addition to preventing pregnancy, use of oral contracep-tives may provide certain benefits. They, are: • Menstrual cycles may become more regular. • Blood flow during menstruation may be lighter, and less iron may be lost. Therefore, anemia due to iron deficiency

is less likely to occur.

· Pain or other symptoms during menstruation may be en-

- Countered less frequently.
 Ovarian cysts may occur less frequently.
 Ectopic (tubal) pregnancy may occur less frequently.
 Noncancerous cysts or lumps in the breast may occur less frequently.
- · Acute pelvic inflammatory disease may occur less frequently. • Oral-contraceptive use may provide some protection

against developing two forms of cancer: cancer of the ova-ries and cancer of the lining of the uterus.

If you want more information about birth-control pills, ask your doctor or pharmacist. They have a more technical leaf-let called the Professional Labeling which you may wish to read.

Wyeth Laboratories

A Wyeth-Ayerst Company Philadelphia, PA 19101

CI 4259-7

Revised November 30, 2001 Shown in Product Identification Guide, page 339

MYLOTARG® [mĩ 'lō-tărg]

(gemtuzumab ozogamicin for Injection) FOR INTRAVENOUS USE ONLY

WARNINGS

Mylotarg should be administered under the supervision of physicians experienced in the treatment of acute leu-kemia and in facilities equipped to monitor and treat leukemia patients.

There are no controlled trials demonstrating efficacy and safety using Mylotarg in combination with other chemotherapeutic agents. Therefore, Mylotarg should only be used as single agent chemotherapy and not in combination chemotherapy regimens outside clinical trials.

Severe myelosuppression occurs when Mylotarg is used at recommended doses.

HYPERSENSITIVITY REACTIONS INCLUDING ANAPHY-LAXIS, INFUSION REACTIONS, PULMONARY EVENTS Mylotarg administration can result in severe hypersensitivity reactions (including anaphylaxis), and other in-fusion-related reactions which may include severe pulmonary events. Infrequently, hypersensitivity reactions and pulmonary events have been fatal. In most cases, infusion-related symptoms occurred during the infusion or within 24 hours of administration of Mylotarg and re-solved. Mylotarg infusion should be interrupted for pasolved mylotary musion should be interrupted for pa-tients experiencing dyspnea or clinically significant hypotension. Patients should be monitored until signs and symptoms completely resolve. Discontinuation of Mylotary treatment should be strongly considered for patients who develop anaphylaxis, pulmonary edema, or

acute respiratory distress syndrome. Since patients with high peripheral blast counts may be at greater risk for pulmonary events and tumor lysis syndrome, physi-cians should consider leukoreduction with hydroxyurea or leukapheresis to reduce the peripheral white count to below 30,000/µL prior to administration of Mylotarg. (See WARNINGS.)


HEPATOTOXICITY:

Hepatotoxicity, including severe hepatic veno-occlusive disease (VOD), has been reported in association with the use of Mylotarg as a single agent, as part of a combination chemotherapy regimen, and in patients with-out a history of liver disease or hematopoietic stem-cell-transplant (HSCT). (See WARNINGS and ADVERSE REACTIONS sections.) Patients who receive Mylotarg either before or after HSCT nationts with underlying

erapy may be at increased risk for developing severe VOD. Death from liver failure and from VOD has been reported in patients who received Mylotarg. Physicians should monitor their patients carefully for symptoms of hepatotxicity, particularly VOD. These symptoms of hepatotxicity, particularly VOD. These symptoms can incl^{3 ev} rapid weight gain, right upper quadrant pain, hepatomegaly, ascites, elevations in bilirubin and/or liver enzymes. However, careful monitoring may not identify all patients at risk or prevent the complications of hepatetmisity. of hepatotoxicity.

DESCRIPTION

Mylotarg[®] (gemtuzumab ozogamicin for Injection) is a chemotherapy agent composed of a recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora ssp. calichensis. The antibody portion of Mylotarg binds specifically to the The antibody portion of Mylotarg binds specifically to the CD33 antigen, a sialic acid-dependent adhesion protein found on the surface of leukemic blasts and immature nor-mal cells of myelomonocytic lineage, but not on normal hem-atopoietic stem cells. The anti-CD33 hP67.6 antibody is pro-duced by mammalian cell suspension culture using a myeloma NS0 cell line and is purified under conditions which remove or inactivate viruses. Three separate and in-dependent steps in the hP67.6 antibody purification process achieves retrovirus inactivation and removal. These include low pH treatment, DEAE-Sepharose chromatography, and viral filtration. Mylotarg contains amino acid sequences of viral filtration. Mylotarg contains amino acid sequences of which approximately 98.3% are of human origin. The con-stant region and framework regions contain human sequences while the complementarity-determining regions are derived from a murine antibody (p67.6) that binds CD33. This antibody is linked to N-acetyl-gamma calicheamicin via a bifunctional linker. Gentuzumab ozgamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody. The re-maining 50% of the antibody is not linked to the calicheamicin derivative. Gemtuzumab ozogamicin has a molecular weight of 151 to 153 kDa.



Mylotarg (gemtuzumab ozogamicin for Injection) is a ster-ile, white, preservative-free lyophilized powder containing 5 mg of drug conjugate (protein equivalent) in a 20 mL am-ber vial. The drug product is light sensitive and must be protected from direct and indirect sunlight and unshielded fluorescent light during the preparation and administration of the infusion. The inactive ingredients are: dextran 40; sucrose; sodium chloride; monobasic and dibasic sodium phosphate.

CLINICAL PHARMACOLOGY

General

₽¢

Gemtuzumab ozogamicin binds to the CD33 antigen. This antigen is expressed on the surface of leukemic blasts in more than 80% of patients with acute myeloid leukemia (AML). CD33 is also expressed on normal and leukemic myeloid colony-forming cells, including leukemic clonogenic

eloid colony-forming cells, including leukemic chonogenic precursors, but it is not expressed on pluripotent hemato-poietic stem cells or on nonhematopoietic cells. **Mechanism of Action**: Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is inter-nalized. Upon internalization, the calicheamicin derivative ir released inside the lyssemes of the mylocid cell. The reis released inside the lysosomes of the myeloid cell. The re-leased calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death

Gemtuzumab ozogamicin is cytotoxic to the CD33 positive HL-60 human leukemia cell line. Gemtuzumab ozogamicin produces significant inhibition of colony formation in cultures of adult leukemic bone marrow cells. The cytotoxic ef-fect on normal myeloid precursors leads to substantial myelosuppression, but this is reversible because pluripotent hematopoietic stem cells are spared. In preclinical animal studies, gemtuzumab ozogamicin demonstrates antitumor effects in the HL-60 human promyelocytic leukemia xeno graft tumor in athymic mice. Human Pharmacokinetics

After administration of the first recommended 9 mg/m² dose After administration of the first recommended 9 mg/m² dose of gemtuzumab ozgamicin, given as a 2 hour infusion, the elimination half lives of total and unconjugated calicheami-cin were about 45 and 100 hours, respectively. After the sec-ond 9 mg/m² dose, the half life of total calicheamicin was increased is about 20 hours and the sec-

Lilly Exhibit 1255, Page 36 of 39

WYFTH/3437

Mylotarg-Cont.

tration-time curve (AUC) was about twice that in the first dose period. The pharmacokinetics of unconjugated calicheamicin did not appear to change from period one to two. Metabolic studies indicate hydrolytic release of the calicheamicin derivative from gemtuzumab ozogamicin. Many metabolites of this derivative were found after *in vitro* incu-bation of gemtuzumab ozogamicin in human liver mi crosomes and cytosol, and in HL-60 promyelocytic leukemia cells. Metabolic studies characterizing the possible isozymes involved in the metabolic pathway of Mylotarg have not been performed.

CLINICAL STUDIES

Claritical structures of Mylotary as a single agent have been evaluated in 142 patients in three single arm open-label studies in patients with CD33 positive AMU in first relapse. The studies included 65, 40, and 37 patients. In studies 1 and 2 patients were \geq 18 years of age with a first remission duration of at least 6 months. In Study 3, only patients ≥ 60 were enrolled and their first remission had to have lasted for at least 3 months. Patients with secondary leukemia or white blood cell (WBC) counts $\geq 30,000/\mu L$ were excluded. Some patients were leukoreduced with hydroxyurea or leukapheresis to lower WBC counts below 30,000/µL in order to minimize the risk of tumor lysis syndrome. The treatment course included two 9 mg/m² doses around. The treatment curve included low-up after the last separated by 14 days and a 28-day follow-up after the last dose. Although smaller doses had élicited responses in ear-lier studies, the 9 mg/m² was chosen because it would be expected to saturate all CD33 sites regardless of leukenic burden. A total of 80 patients were 60 years of age and older. The primary endpoint of the three clinical studies was the rate of complete remission (CR), which was defined as

a) leukemic blasts absent from the peripheral blood; b) $\leq 5\%$ blasts in the bone marrow, as measured by mor-

- c) being studies;
 c) hemoglobin (Hgb) ≥ 9 g/dL, platelets ≥ 100,000/µL, absolute neutrophil count (ANC) ≥ 1500/µL; and
- d) red cell and platelet-transfusion independence (no red
- cell transfusions for 2 weeks; no platelet transfusions for 1 week).

In addition to CR, a second response category, CRp, was defind as patients satisfying the definition of CR, including platelet transfusion independence, with the exception of platelet recovery $\geq 100,000$ /µL. This category was added because Mylotarg appears to delay platelet recovery in some patients. Most of these patients (18/19) achieved platelet counts of at least 25,000/µL and about two-thirds (13/19) achieved platelet counts of at least 50,000/µL, before any additional therapy was administered. It is not yet clear whether CR and CRp responses are clinically equivalent; but survival in the two groups appeared similar.

All patients were pre-medicated with acetaminophen 650-1000 mg and diphenhydramine 50 mg to decrease acute infusion-related symptoms. Growth factors and cyto-kines were not permitted. Use of prophylactic antibiotics was not specified.

Response Rate

The overall response (OR) rate for the three pooled monotherapy studies was 30% (42/142) consisting of 16% (23/142) of patients with CR and 13% (19/142) of patients with CR p. The median time to remission was 60 days for both CR and CRp. Remission rates in the individual studies are shown in Table 1.

[See table 1 above]

Two of the most important determinants of response following relapse are age and duration of first remission. Remission rates by prognostic category are outlined in Table 2; the impact of age and duration of first remission in these patients was minimal: [See table 2 above]

Among patients < 60 years of age the overall response rate was 34%; among patients ≥ 60 years of age the overall re-sponse rate was 26%. The overall response rates were similar for females and males: 31% of females and 29% of males achieved remission.

The majority of patients (94%) in the Phase 2 clinical trials were white, only 6% were non-white. All 42 of the respond ing patients were white.

Relapse-Free Survival

Relapse-free survival was calculated from the date of initial therapy (Table 3).

[See table 3 above] **Overall Survival**

Median duration of overall survival for the 142 patients was 5.9 months and 55/142 patients were alive as of the data cutoff date

Post-Remission Therapy

Fifteen (15/42, 36%) OR patients (8 CRs and 7 CRps) received hematopoietic stem cell transplantation. The survival of these 15 patients ranged from 3.5 to 26.9 months as of the data cut-off date. Nine OR patients (4 CR and 5 CRp) had an overall survival of >12 months as of the data cut-off date.

Repeat Courses

Five patients have received a second treatment course of Mylotarg (gentuzumab ozogamicin for Injection) in clinical trials. These nationts were initially treated with Mulotarg

FRIGIUANO/DEON DEFENSIVES		PHYSICIANS'/DESK REFERENCE®
---------------------------	--	-----------------------------

TABLE 1: PERCENTAGE OF PATIENTS BY REMISSION CATEGORY				
Study 1	2 Study 3ª	All Studies		
Type of Remission $n = 65$ $n = 40$	$\frac{1}{n} = \frac{1}{37} \frac{1}{n} = \frac$	n = 142		
CR 17 (95% CI) (9,36)	(3, ² 25) ²⁵	16 (11, 23)		
CRp ⁺ 13 (95% CI) (8, 26) (4, 27)	(3, 25)	13 (8, 20)		
OR (CR + CRp) 32 33 (95% CI) (21, 45) (19, 49)) (10, 38)	, 30 (22, 38)		
a: Patients 60 years of age or greater	n andre alle en andre andre An andre a	International		

10. 940	PERCENTAGE OF PATIEN	ITS BY REMISSION CATE	GORY AND PROGNOST	C GROUP
na produkci na poslavaju na seri Poštaž produkci na poslavaju na seri Poštaž poslava poslavaju na serie serie.	Age < 60 years	Age ≥ 60 years	First Remission ≥ 1 yr	First Remission < 1 yr
Type of Remission	n = 62	n = 80	n = 62	n = 80
CR (95% CI)	18	15	21	13
	(9, 30)	(8, 25)	(12, 33)	(6, 22)
CRp	16	11	11 (5, 22)	15
(95%°CI)	(8, 28)	(5, 20)		(8, 25)
OR (CR + CRp)	34	26	32	28
(95% CI)	(22, 47)	(17, 37)	(21, 45)	(18, 39)

TABLE	3: SUMMARY OF RELAK	PSE-FREE SURVIVAL* FO	R PATIENTS WITH CR AN	
Remission Group	, n	No. Relapsed	Median months	months ^b
ĊR	23	14	7.2	0.5-24.8
CRp	n and a 19 19 - 55 ⁷ M	9	4.4	0.33 ^b -21.5
OR¢	42	23		0.33 ⁶ -24,8

a: Number of months after achieving CR or CRp. b: Data are limited by data cut-off date; first event occurred in 0.83 months for CRp and in 0.5 months for OR. c: Six OR patients (1 CR and 5 CRp) had a relapse-free survival of > 12 months.

after receiving the second course of Mylotarg. Prolonged severe myelosuppression was observed in four patients receiv-ing a third dose.

Overview of Clinical Data

Available single arm trial data do not provide valid compari-sons with various cytotoxic regimens that have been used in relapsed acute myeloid leukemia. Response rates are in the range of rates reported with such regimens only if the CRp responses are included. Nevertheless, treatment with Mylotarg can provide responses, including some of reason able duration. The data support its use in patients for whom aggressive cytotoxic regimens would be considered unsuit able, such as many patients 60 years of age or older.

INDICATIONS AND USAGE

Mylotarg is indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. The safety and ef-ficacy of Mylotarg in patients with poor performance status

and organ dysfunction has not been established. The effectiveness of Mylotarg is based on OR rates (see **CLINICAL STUDIES** section). There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival, compared to any other treatment.

CONTRAINDICATIONS

Mylotarg is contraindicated in patients with a known hypersensitivity to gentuzumab ozogamicin or any of its compo-nents, anti-CD33 antibody (hP67.6), calicheamicin derivitives, or inactive ingredients.

WARNINGS

Mylotarg should be administered under the supervision of physicians experienced in the treatment of acute leukemia and in facilities equipped to monitor and treat leukemia patients.

There are no controlled trials demonstrating efficacy and safety using Mylotarg in combination with other chemotherapeutic agents. Therefore, Mylotarg should only be used as single agent chemotherapy and not in combination chemo-therapy regimens outside clinical trials.

Myelosuppression: Severe myelosuppression will occur in all patients given the recommended dose of this agent. Careful hematologic monitoring is required. Systemic infections should be treated.

Hypersensitivity Reactions Including Anaphylaxis, Infusion Reactions, Pulmonary, Events: Mylotarg administration can result in severe hypersensitivity reactions (including anaphylaxis), and other infusion-related reactions which may include severe pulmonary events. Infrequently, hypersensitivity reactions and pulmonary events have been fatal. In most cases, infusion related symptoms occurred during rred de

Mylotarg (gemtuzumab ozogamicin for Injection) infusion should be interrupted for patients experiencing dyspnea or shown by interrupted to patients experienting displace of clinically significant hypotension. Patients should be moni-tored until signs and symptoms completely resolve. Discon-tinuation of further Mylotarg treatment should be strongly considered for patients who develop anaphylaxis, pulmonary edema, or acute respiratory distress syndrome. Since patients with high peripheral blast counts may be at greater risk for such reactions, physicians should consider leukoreduction with hydroxyurea or leukapheresis to re-duce the peripheral white count to below 30,000/µL prior to

administration of Mylotarg. Infusion Reactions: Mylotarg.can produce a post-infusion symptom complex of fever and chills, and less commonly hypotension and dyspnea that may occur during the first 24 hours after administration. Grade 3 or 4 non-hematologic infusion-related adverse events included chills, fever, hypotension, hypertension, hyperglycemia, hypoxia, and dysp-nea. Most patients, received the following prophylactic medinea. Most patients, received the knowing projection index in cations before administration: diphenhydramine 50 mg po and acetaminophen 650–1000 mg po; thereafter, two addi-tional doses of acetaminophen 650–1000 mg po, one every 4 hours as needed. Vital signs should be monitored during in-fusion and for the four hours following infusion.

Inclinical studies, these symptoms generally occurred after the end of the 2-hour intravenous infusion and resolved af-ter 2 to 4 hours with a supportive therapy of acetamino-phen, diphenhydramine, and IV fluids. Fewer infusionrelated events were observed after the second dose.

Pulmonary Events: Severe pulmonary events leading to death have been reported infrequently with the use of Mylotarg in the postmarketing setting. Signs, symptoms and clinical findings include dyspnea, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, and acute respiratory distress syndrome. These events occur as sequelae of infu-sion reactions; patients with WBC counts > 30,000/µL may be at increased risk. (See Infusion Reactions section of WARNINGS.) Physicians should consider leukoreduction with hydroxyurea or leukapheresis to reduce the peripheral white count to below 30,000 µL prior to administration of Mylotarg. Patients with symptomatic intrinsic lung disease may also be at greater risk of severe pulmonary reactions. Hepatotoxicity: Hepatotoxicity, including severe VOD, has been reported in association with the use of Mylotarg as a single agent, as part of a combination chemotherapy regi men, and in patients without a history of liver disease or HSCT. (See **ADVERSE REACTIONS** section.) Patients who receive Mylotarg either before or after HSCT, patients with underlying hepatic disease or abnormal liver function, and patients receiving Mylotarg in combinations with other chemotherapy may be at increased risk for developing se-tors VOD Dooth from liver failure and from VOD has been

Lilly Exhibit 1255, Page 37 of 39

WYFTH/3439

atotoxicity, particularly VOD. These symptoms can include: rapid weight gain, right upper quadrant pain, hepatomeg-aly, ascites, elevations in bilirubin and/or liver enzymes. However, careful monitoring may not identify all patients at risk or prevent the complications of hepatotoxicity.

Use in Patients with Hepatic Impairment: Mylotarg has not been studied in patients with bilirubin > 2 mg/dL. Extra caution should be exercised when administering Mylotare in patients with hepatic impairment (see ADVERSE REACTIONS section).

Tumor Lysis Syndrome (TLS): TLS may be a consequence of leukemia treatment with any chemotherapeutic agent including Mylotarg. Renal failure secondary to TLS has been reported in association with the use of Mylotarg. Appropriate measures, (e.g. hydration and allopurinol), must be taken to prevent hyperuricemia. Physicians should consider leukoreduction with hydroxyurea or leukapheresis to reduce the peripheral white blood count to < 30,000/uL prior to administration of Mylotarg (see CLINICAL STUDIES section).

Pregnancy: Mylotarg may cause fetal harm when admin isteréd to a pregnant woman. Daily treatment of pregnant rats with gentuzumab ozogamicin during organogenesis caused dose-related decreases in fetal weight in association with dose-related decreases in fetal skeletal ossification be-ginning at 0.025 mg/kg/day. Doses of 0.060 mg/kg/day (approximately 0.04 times the recommended human single dose on a mg/m² basis) produced increased embryo-fetal mortality (increased numbers of resorptions and decreased numbers of live fetuses per litter). Gross external, visceral and skeletal alterations at the 0.060 mg/kg/day dose level included digital malformations (ectrodactyly, brachydactyly in one or both hind feet, absence of the aortic arch, wavy ribs, anomalies of the long bones in the forelimb(s) (short/ thick humerus, misshapen radius and ulna, and short/thick ulna), misshapen scapula, absence of vertebral centrum and fused sternebrae. This dose was also associated with maternal toxicity (decreased weight gain, decreased food consumption). There are no adequate and well-controlled studies in pregnant women. If Mylotarg is used in pregnancy, or if the patient becomes pregnant while taking it, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Mylotarg.

PRECAUTIONS

DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS

General Treatment by Experienced Physicians: Mylotarg should be administered under the supervision of physicians experi-enced in the treatment of acute leukemia and in facilities equipped to monitor and treat leukemia patients.

Laboratory Monitoring: Electrolytes, tests of hepatic func-tion, complete blood counts (CBCs) and platelet counts should be monitored during Mylotarg therapy.

Drug Interactions: There have been no formal drug-inter-action studies performed with Mylotarg. Laboratory Test Interactions: Mylotarg is not known to in-

terfere with any routine diagnostic tests. Carcinogenesis, Mutagenesis, Impairment of Fertility: No Iong-term studies in animals have been performed to eval-uate the carcinogenic potential of Mylotarg. Gemtuzumab orogamicin was clastogenic in the mouse *in vivo* micronu-cleus test. This positive result is consistent with the known ability of calicheamicin to cause double-stranded breaks in DNA. Gemtuzumab ozogamicin adversely affected male, but not female, fertility in rats. Following daily administration of gentuzumab ozogamicin to male rats for 28 days at doses of 0.02 to 0.16 mg/kg/day (approximately 0.01 to 0.11 times the human dose on a mg/m² basis) gentuzumab ozogamicin caused: decreased fertility rates, epididymal sperm counts, and sperm motility; increased incidence of sperm abnormal-ities; and microscopic evidence of decreased spermatogonia and spermatocyte count. These findings did not resolve fol-

lowing a 9-week recovery period. Pregnancy Category D: See WARNINGS section. Nursing Mothers: It is not known if Mylotarg is excreted in human milk. Because many drugs, including immuno-globulins, are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Mylotarg, a decision should be made whether to dis-continue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: The safety and effectiveness of Mylotarg (gemtuzumab ozogamicin for Injection) in pediatric patients have not been studied. Use in Patients with Renal Impairment: Patients with re-

nal impairment were not studied. ADVERSE REACTIONS

Mylotarg has been administered to 142 patients with re-lapsed AML at 9 mg/m². Mylotarg was generally given as two intravenous infusions separated by 14 days. Acute Infusion-Related Events (Table 4)

TABLE 4: PERCENTAGE OF PATIENTS REPORTED TO HAVE ACUTE INFUSION-RELATED ADVERSE EVENTS

Adverse Event	(%) Any Severity	(%) Grade 3 or 4
Chills	62	11
Fever	61	7
Nausea	38	, , , ≤1
Vomiting	32	<1
Headache	12	°° <1
Hypotension	1. 1899	4
Hypertension	6	3
Hypoxia	6	2
Dyspnea	4	1
Hyperglycemia	2 	2 at 1 1.1.1 at 1.1.1 at 1.1

These symptoms generally occurred after the end of the 2-hour intravenous infusion and resolved after 2 to 4 hours with a supportive therapy of acetaminophen, diphenhydra-mine, and IV fluids (see WARNINGS section). Fewer infusion-related events were observed after the second dose Antibody Formation: Antibodies to gentuzumal Antibody Formation: Antibodies to gentizumab ozogamicin were not detected in a total of 142 patients in the Phase 2 clinical studies. Two patients in a Phase 1 study developed "antibody titles" antibidy titles" developed antibody titers against the calicheamicin calicheamicin-linker portion of gentuzumab ozogamicin af-ter three doses. One patient experienced transient fever,

ter three doses. One patient experienced transient lever, hypotension and dyspnear, the other patient had no clinical symptoms. No patient developed antibody responses to the hP67.6 antibody portion of Mylotarg. Myelosuppression: Severe myelosuppression is the major toxicity associated with Mylotarg. During the treatment phase, 137/140 (98%) patients experienced Grade 3 or Grade 4 neutropenia. Responding patients recovered ANCs to 500/µL by a median of 40.5 days after the first dose of Mylotarg. Aniemia, Thrombocytopenia: During the treatment phase,

139/141 (99%) patients experienced Grade 3 or Grade 4 thrombocytopenia. Responding patients recovered platelet counts to 25,000/µL by a median of 39 days after the first dose of Mylotarg. 66/141 (47%) patients experienced Grade 3 or Grade 4 anemia.

Infection: During the treatment phase, 40/142 (28%) pa-tients experienced Grade 3 or Grade 4 infections, including opportunistic infections: The most frequent Grade 3 or Grade 4 infection-related treatment-emergent adverse events (TEAEs) were sepsis (16%) and pneumonia (7%). Herpes simplex infection was reported in 22% of the patients.

Bleeding: During the treatment phase, 21/142 (15%) pabreeding, During the treatment place, 20142 (10%) par-tients experienced Grade 3 or Grade 4 bleeding. The most frequent severe TEAE was epistaxis (3%). There were also reports of cerebral hemorrhäge (2%), disseminated intra-vascular coagulation (2%), intraciranial hemorrhage (2%), and hematuria (1%).

Transfusions: "During the treatment phase, more transfu-sions were required in the NR and CRp patients compared with the CRs (Table 5):

[See table 5 below]

Mucositis: A total of 50/142 (35%) patients were reported to have a TEAE consistent with oral nucositis or stomatitis. During the treatment phase, 5/142 (4%) patients experienced Grade 3 or 4 stomatitis/ mucositis after the first dose.

964

and the second s	TABLE 5: NUMBER	OF TRANSFUSIONS BY	RESPONSE GROUP	lan fall i generation. Network to be bet 6 morenet
Transfusions	All Patients	CR CR	CRp	NR are free
and the second s	n = 142	n = 23	n = 19	ni≒ 100 – .≊
Platelet transfusions	an an an tao ang tao an Tao ang tao ang	and and the second s	tor ordere Ballettar discription av	ne supranya ya 1230 Kabusanja ang Ka
Mean (SD)	14 (23)	5.4 (6)	14.8 (12)	15,8 (27)
(95% CI)	(10.2, 17.8)	(3, 7.8)	(9.3, 20.4)	(10.6, 21.1)
RBC transfusions	a are too 17 al ar ev Eestop - 19 al 1943	an an ann an Anna Anna An An an Anna Anna	l avernji namers ave kritev,vjude	10), 7242 (* 144) at 910(3):54, 14, 45)
Mean	8.2 (26)	2.6 (2)	6.2 (5)	9.9 (31)

The mucositis events for the remaining 45/142 (32%) pa-tients were categorized as Grade 1 or 2. Hepatotoxicity: Abnormalities of liver function were tran-sent and generally reversible. In clinical studies, 33/141 (23%) patients experienced Grade 3 or Grade 4 hyperbiliru-(23%) patients experienced Grade 3 or Grade 4 hyperbilitri-binemia. Nine percent (12/141) of patients experienced Grade 3 or Grade 4 abnormalities in levels of ALT, and 24/141 (17%) patients experienced Grade 3 or Grade 4 ab-normalities in levels of AST. Thirteen patients had concur-rent elevations of transaminases (grade 3 to 4) and bilitri-bin. One patient died with liver failure in the setting of tumor lysis syndrome and multisystem organ failure 22 days after treatment. Another patient died after an episode of persistent jaundice and hepatosplenomegaly 156 days after treatment. Among 27 patients who received hemato-noietie, stem cell transalantation following Wylotarg poietic stem cell transplantation following Mylotarg (gemtuzumab ozogamicin for Injection), three (2 NRs and 1 CR) died of hepatic veno-occlusive disease (VOD) 22 to 35 lays following transplantation.

Skin: No patients experienced alopecia. A nonspecific rash was reported in 22%.

Retreatment Events: Five (5) patients have received more than one course of Mylotarg, 4 of these patients at 9 mg/m². The adverse event profile for retreated patients was similar to that following their initial treatment. One of the repeat to dose patients was in a Phase I study and received a first course of 3 doses at 1 mg/m² and 2 doses of a second course at 6 mg/m^2 . This patient was discontinued from further dose administration as a result of an immune response to the calicheamicin/calicheamicin-linker portion of gemtuzumab ozogamicin. The 4 other retreated patients did not exper-

ience an immune response. Dose Relationship for Adverse Events: Dose-relationship data were generated from a small dose-escalation study The most common clinical adverse event observed in this study was an infusion-related symptom complex of fever and chills. In general, the severity of fever, but not chills, increased as the dose level increased. Only one dose level of Mylotarg was studied in the Phase 2 clinical trials in relapsed AML

Treatment-Emergent Adverse Events (TEAE): TEAEs (Grades 1-4) that occurred in $\geq 10\%$ of the patients regardless of causality are listed in Table 6.

TABLE 6: NUMBER (%) OF PATIENTS REPORTING TREATMENT-EMERGENT ADVERSE EVENTS^a-ALL GRADES (INCIDENCE ≥ 10%^b)

		Safety Studies
Adverse Event	All Patients	Age ≥ 60
en territor per a	(n = 142)	(n = 80)
Body as a whole		
Abdomen enlarged	13 (9)	9 (11)
Abdominal pain	52 (37)	23 (29)
Asthenia	63 (44)	36 (45)
Back pain	22(15)	14 (18)
Chills	104 (73).	53 (66)
Fever	121 (85)	64 (80)
Headache	13 (9) 52 (37) 63 (44) 22 (15) 104 (73) 121 (85) 50 (35)	21 (26)
Neutropenic lever	00(21)	10(20)
Pain Sepsis	30 (21)	20 (25)
Sepsis	36 (25)	19 (24)
Cardiovascular system		
Hemorrhage	14 (10)	· · · 6 (8)
Cardiovascular system Hemorrhage Hypertension Hypotension	29 (20)	16 (20)
Hypotension	28 (20)	13 (16)
Tachycardia	15 (11)	8 (10)
Digestive system		
Anorexia	41 (29)	$\begin{array}{c} 25 \ (31) \\ 22 \ (28) \\ 30 \ (38) \\ 9 \ (11) \\ 51 \ (64) \\ 20 \ (25) \\ 44 \ (55) \end{array}$
Constipation	36 (25)	22 (28)
Diarrhea	54 (38)	30 (38)
Diarrhea Dyspepsia	16(11)	9(11)
Nausea	100 (70)	51 (64)
	45 (32)	20 (25)
Stomatitis Vomiting	89 (63)	44 (55)
Hemic and lymphatic system		
Ecchymosis	18 (13)	
Metabolic	10 (10)	/ ////
Hypokalemia	44 (31)	24 (30)
Hypomagnesemia	14 (10)	24 (30) 3 (4)
Lactic dehydrogenase	11(10)	
increased	19(13)	14 (18)
Musculoskeletal system		14 (18) 8 (10)
Arthralgia	12 (8)	8(10)
Nervous system	10,	
Nervous system Depression Dizziness	13(9)	8 (10)
Dizziness	22 (15)	9 (11)
Reeniratory system	2014 J. 1994	dine tech
Cough increased Dyspnea Epistaxis	28 (20)	15 (19)
Dyspnea	46 (32)	29 (36)
Enjetavie	44 (31)	23 (29)
Pharmaitie	20 (14)	11 (14)
Pharyngitis Pneumonia	14 (10)	8 (10)
Pulmonary physical finding	° 16 (11)	10(13)
Rhinitia	14 (10)	8(10)
Rhinitis of the second second		
Harnos simplor	91:(99)	19 (15)
Herpes simplex the state of the Rash alternative for the state of the	31 (22)	18 (23)
Docal reaction	200 (20) 3	17 (91)
Peripheral edemä Petechiae	20 (10)	17 (21)
refectinger and a solida	20 (20)	. 11(41)

Lilly Exhibit 1255, Page 38 of 39

Mylotarg-Cont.

Urogenital system^d Hematuria 14 (10) 8 (10) Vaginal hemorrhage 7 (12) 2(7)

a: Does not include changes in laboratory values reported as adverse events for events included in the NCI common toxicity scale.

b: $\geq 10\%$ limit specifies the minimum percentage threshold from at least 1 column for an event to be displayed in the table

c: Includes rales, rhonchi, and changes in breath sounds. d: Percentages for sex-specific adverse events are based on the number of patients of the relevant sex.

TEAE with a Grade 3 or 4 severity are listed in Table 7.

TABLE 7: PERCENT (%) OF PATIENTS REPORTED TO HAVE SEVERE OR NCI GRADE 3 OR 4 TREATMENT-EMERGENT ADVERSE EVENTS^a (INCIDENCE $\geq 5\%^{b}$)

Body System		Efficacy and Safety Studies Grades 3–4		
Adverse Event	All Patients (n = 142)	Age ≥ 60 (n = 80)		
Any adverse event	129 (91)	70 (88)		
Body as a whole				
Asthenia	10 (7)	8 (10)		
Chills	18 (13)	12 (15)		
Fever	21 (15)	11 (14)		
Neutropenic fever	10 (7)	4 (5)		
Sepsis	23 (16)	12 (16)		
Cardiovascular system				
Hypertension	13 (9)	9 (11)		
Hypotension	11 (8)	6 (8)		
Digestive system				
Nausea	13 (9)	6 (8)		
Metabolic				
Hypokalemia	4 (3)	4(5)		
Lactic dehydrogenase	- 16 - E			
increased	6 (4)	6 (8)		
Respiratory system				
Dyspnea	13 (9)	10(13)		
Pneumonia	10(7)	5 (6)		
-		and the second second		

a: Does not include changes in laboratory values reported as adverse events for events included in the NCI common toxicity scale

b: \geq 5% limit specifies the minimum percentage threshold from at least 1 column for an event to be displayed in the

Clinically important laboratory abnormalities with a Grade 3 or 4 severity are listed in Table 8.

TABLE 8: NUMBER (%*) OF PATIENTS WITH LABORATORY TEST RESULTS OF GRADE 3 OR 4 SEVERITY⁶

Efficacy and Safety Studies Grades 3–4 All Patients Age ≥ 60				
Test	(n = 142)	(n = 80)		
Hematologic		1997 - 19		
Hemoglobin	66/141 (47)	36/80 (45)		
WBC	136/141 (96)	75/80 (94)		
Total neutrophils, absolute	137/140 (98)	78/79 (99)		
Lymphocytes	130/140 (93)	70/79 (89)		
Platelet count	139/141 (99)	79/80 (99)		
Prothrombin time	2/47 (4)	1/23 (4)		
Partial thromboplastin	1/79 (1)	1/42 (2)		
time	B [*]			
Non-hematologic		5 S. S. S.		
Glucose	17/140 (12)	9/79 (11)		
Creatinine	2/141 (1)	0/80		
Total bilirubin	33/141 (23)	18/80 (23)		
AST	24/141 (17)	12/80 (15)		
ALT	12/141 (9)	7/80 (9)		
Alkaline phosphatase	5/141 (4)	1/80 (1)		
Calcium	17/141 (12)	5/80 (6)		
		0.00.00		

a: Percentage is based on the number of patients receiving a particular laboratory test during the study as is indicated for each test.

b: Severity as defined by NCI common toxicity scale version

There were considered to be no clinically important differ-There were considered to be no clinically important dimer-ences in TEABs between patients < 60 years of age and those patients ≥ 60 . Laboratory parameters associated with hepatic dysfunction (e.g., elevated levels of bilirubin, AST, and ALT) were more consistently observed in patients ≥ 60 years old than in those < 60 years old. There were considered to be no clinically important differ-

ences in TEAEs between female and male patients Other Clinical Experience:

In postmarketing experience and other clinical trials, addi-tional cases of VOD have been reported, some in association

or subsequent HSCT. Renal failure secondary to TLS, hy or subsequent visit reactions, namber secondary to TLC, hy-persensitivity, reactions, namber laws, and pulmonary events, have also been reported in association with the use of Mylotarg (gentuzumab ozogamicin for Injection). (See WARNINGS section).

OVERDOSAGE

No cases of overdose with Mylotarg were reported in clinical experience. Single doses higher than 9 mg/m² in adults were not tested. When a single dose of Mylotarg was adminis-tered to animals, mortality was observed in rats at the dose of 2 mg/kg (approximately 1.3-times the recommended hu-man dose on a mg/m² basis), and in male monkeys at the dose of 4.5 mg/kg (approximately 6-times the recommended human dose on a mg/m² basis). Signs and Symptoms: Signs of overdose with Mylotarg are unknown

äre unknown

Recommended Treatment: General supportive measures should be followed in case of overdose. Blood pressure and blood counts should be carefully monitored. Gemtuzumab ozogamicin is not dialyzable.

DOSAGE AND ADMINISTRATION

The recommended dose of Mylotarg is 9 mg/m^2 , administered as a 2-hour intravenous infusion. Physicians should consider leukoreduction with hydroxyurea or leukapheresis to reduce the peripheral white blood count to below 30,000/µL prior to administration of Mylotarg. Appropriate measures (e.g. hydration and allopurinol) must be taken to prevent hyperuricemia. Patients should receive the following prophylactic medications one hour before Mylotarg ad-ministration: diphenhydramine 50 mg po and acetaminophen $650-1000\,$ mg pc; thereafter, two additional doses of acetaminophen $650-1000\,$ mg pc, one every 4 hours as needed. Vital signs should be monitored during infusion and for four hours following infusion. The recommended treat-ment course with Mylotarg is a total of 2 doses with 14 days between the doses. Full recovery from hematologic toxicities is not a requirement for administration of the second dose. Hepatic Insufficiency: Patients with hepatic impairment were not included in the clinical studies. See WARNINGS section.

Renal Insufficiency: Patients with renal impairment were not included in the clinical studies.

Instructions for Reconstitution

The drug product is light sensitive and must be protected from direct and indirect sunlight and unshielded fluorescent light during the preparation and administration of the infusion. All preparation should take place in a biologic safety hood with the fluorescent light off. Prior to reconstitution allow drug vials to come to room temperature. Reconstitute allow drug vials to come to roum temperature. Reconstitute the contents of each vial with 5 mL Sterile Water for Injec-tion, USP, using sterile syringes. Gently swirl each vial. Each vial should be inspected for complete solution and for particulate. The final concentration of drug in the vial is 1 mg/mL. While in the vial, the reconstituted drug may be stored refrigerated (2-8° C) and protected from light for up to 8 hours.

Instructions for Dilution

Withdraw the desired volume from each vial and inject into a 100 mL IV bag of 0.9% Sodium Chloride Injection. Place the 100-mL IV bag into an UV protectant bag. The resulting drug solution in the IV bag should be used immediately. Administration

DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS

Once the reconstituted Mylotarg is diluted into the IV bag containing normal saline, the resulting solution should be infused over a 2-hour period. A separate IV line equipped with a low protein-binding 1.2-micron terminal filter must be used for administration of the drug. Mylotarg may be given peripherally or through a central line. Premedication, consisting of acetaminophen and diphenhydramine, should be given before each infusion to reduce the incidence of a post-infusion symptom complex (see ADVERSE REAC-TIONS, Acute Infusion-Related Events).

TAUNS, Acute invision-neiated Events). Stability and Storage: Wijolarg should be stored refriger-ated 2° to 8° C (36° to 46° F) and protected from light. Instructions for Use, Handling and for Disposal: Mylotarg should be inspected visually for particulate matter and discoloration, following reconstitution and prior to administra-tion. Protect from light and use an UV protective bag over the IV bag during infusion. Procedures for handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.^{1,2,3}

HOW SUPPLIED

Nylotarg⁶ (gemtuzumab ozogamicin for Injection) is sup-plied as a single-vial package with an amber glass vial con-taining 5 mg of Mylotarg lyophilized powder. Single-unit 5 mg package: each 20 mL vial contains 5 mg of Mylotarg. NDC 0008-4510-01.

REFERENCES

¹Recommendation for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83:2621. For Sale by the Superintendent of Documents, US Govern-

ment Printing Office, Washington, DC 20402. AMA Council Report. Guidelines for Handling Parenteral Antineoplastics. JAMA 1985; 253 (11): 1590–1592.

³ National Study Commission on Cytotoxic Exposure-Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, ScD, Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts Col-

PHYSICIANS' DESK BEFEBENCE®

R

Manufactured by: Wyeth Laboratories Division of Wyeth-Ayerst Pharmaceuticals Inc. Philadelphia, PA 19101 CI 7407-4 Revised May 28, 2002

Shown in Product Identification Guide, page 339

NEUMEGA® [nu-meg<a] (oprelvekin) B/ ONLY

BOXED WARNING

Allergic Reactions Including Anaphylaxis Neumega has caused allergic or hypersensitivity reac-tions, including anaphylaxis. Administration of Neumega should be permanently discontinued in any patient who develops an allergic or hypersensitivity re-action (see WARNINGS, CONTRAINDICATIONS, ADVERSE REACTIONS and ADVERSE REAC-TIONS Immunogenicity). TIONS, Immunogenicity).

DESCRIPTION

Interleukin eleven (IL-11) is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. IL-11 is a member of a family of human growth factors which includes human growth hormone, granulocyte colony-stimulating factor (G-CSF), and other growth

Derelvekin, the active ingredient in Neumega, is produced in *Escherichia coli (E. coli)* by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length and differs from the 178 amino acid length of native IL-11 only in lacking the amino-terminal proline residue. This alteration has not resulted in measur-

able differences in bioactivity either *in vitro* or *in vivo*. Neumega is formulated in single-use vials containing of oprelvekin (specific activity approximately 8 x 10^6 Units/ mg) as a sterile, lyophilized powder with 23 mg Glycine, USP, 1.6 mg Dibasic Sodium Phosphate Heptahydrate, USP, and 0.55 mg Monobasic Sodium Phosphate Monohydrate, USP When reconstituted with 1 mL of Sterile Water for Injection, USP, the resulting solution has a pH of 7.0 and a concentration of 5 mg/mL.

CLINICAL PHARMACOLOGY

The primary hematopoietic activity of Neumega is stimulation of megakaryocytopoiesis and thrombopoiesis. Neumega has shown potent thrombopoietic activity in animal models has snown potent thromboporeut activity in similar income of compromised hematopoiesis, including moderately to se-verely myelosuppressed mice and nonhuman primates. In these models, Neumega improved platelet nadirs and accel-erated platelet recoveries compared to controls.

Preclinical trials have shown that mature megakaryocytes which develop during *in vivo* treatment with Neumega are ultrastructurally normal. Platelets produced in response to Neumega were morphologically and functionally normal and possessed a normal life span.

IL-11 has also been shown to have non-hematopoietic activ-In-11 mas also been shown to have non-nemanopoiete activ-ties in animals including the regulation of intestinal epi-thelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute-phase protein synthesis, inhibition of pro-inflammaacute-phase protein synthesis, inhibition of pro-inflamma-tory cytokine production by macrophages, and the stimula-tion of osteoclastogenesis and neurogenesis. Non-hemato-poietic pathologic changes observed in animals include fibrosis of tendons and joint capsules, periosteal thickening, papilledema, and embryotoxicity (see PRECAUTIONS, <u>Pe-diatric Use</u> and **PRECAUTIONS**, <u>Pregnancy Category C</u>). IL-11 is produced by bone marrow stromal cells and is part of the cytoking family test shares the en130 signal transof the cytokine family that shares the gp130 signal trans-ducer. Primary osteoblasts and mature osteoclasts express mRNAs for both IL-11 receptor (IL-11R alpha) and gp130 Both bone-forming and bone-resorbing cells are potential targets of IL-11.⁽¹⁾

Pharmacokinetics

The pharmacokinetics of Neumega have been evaluated in studies of healthy, adult subjects and cancer patients receivstudies of heatiny, addit subjects and cancer patients receiving chemotherapy. In a study in which a single 50 µg/kg sub-cutaneous dose was administered to eighteen healthy men, the peak serum concentration (C_{max}) of 17.4 ± 5.4 µg/mL (mean ± 5.0) was reached at 3.2 ± 2.4 hrs (T_{max}) following dosing. The terminal half-life was 6.9 ± 1.7 hrs. In a second study, in which single 75 µg/kg subcutaneous and intrave-nous doses were administered to twenty-four healthy subjects, the pharmacokinetic profiles were similar between men and women. The absolute bioavailability of Neumega was >80%. In a study in which multiple subcutaneous doses of both 25 and 50 µg/kg were administered to cancer pa-tients receiving chemotherapy, Neumega did not accumu-late and clearance of Neumega was not impaired following multiple doses.

In a dose escalation Phase 1 study, Neumega was also a ministered to 43 pediatric (ages 8 months to 18 years) and 1 adult patient receiving ICE (ifosfamide, carboplatin, etopo-side) chemotherapy. Administered doses ranged from 25 to